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Abstract  
Although the central nervous system (CNS) was once considered an 
immunologically privileged site, in recent years it has become increasingly 
evident that cross talk between the immune system and the CNS does occur. As 
a result, patients with chronic inflammatory diseases such as rheumatoid 
arthritis, inflammatory bowel disease or psoriasis are often further burdened 
with neuropsychiatric symptoms such as depression, anxiety and fatigue. Despite 
the recent advances in our understanding of neuroimmune communication 
pathways, the precise effect peripheral immune activation has on neural 
circuitry remains unclear. Therefore, the primary aim of this thesis was to 
develop a better understanding of the bidirectional relationship, and 
communication pathways, that exist between the immune system and the 
nervous system.  
By utilising transcriptomics in a well-characterised murine model of systemic 
inflammation, I have investigated the molecular mechanisms by which 
inflammation originating in the periphery can induce transcriptional modulation 
in the brain. Systemic inflammation was induced in male C57BL/6 mice via 
intraperitoneal injection of lipopolysaccharide (LPS).  After 48 hours, whole 
brain transcriptional profiles were assessed, and compared to that of a vehicle-
treated control group, using Affymetrix GeneChip microarrays. Target gene 
induction, identified by microarray analysis was validated independently using 
QPCR. Expression of the same panel of target genes was then investigated, in 
the brains of mice, following the induction of different sterile, and TLR-
dependent, models of peripheral inflammation.  
Microarray analysis of whole brains collected 48hr after LPS challenge revealed 
increased transcription of a range of interferon-stimulated genes (ISGs) in the 
brain, including a significant upregulation of the classic interferon-induced 
chemokine CXCL10. This transcriptional profile could not be reproduced by the 
systemic administration of TNFα, or following lipoteichoic acid-induced systemic 
inflammation. However, target genes remained induced in the brain following 
daily LPS injections, in the absence of a detectable inflammatory cytokine 
response in the periphery. 
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The central induction of CXCL10 suggests that acute exposure to LPS in the 
periphery may prime the brain for T cell infiltration. This prompted an 
investigation into whether leukocytes infiltrated the brain following daily 
systemic LPS injections. First, the inflammatory chemokine repertoire in the 
brains of LPS treated mice was systematically characterised. In addition to 
Cxcl10, repeated injection of LPS in the periphery triggered a transient increase 
in the transcription of a number of other inflammatory chemokines in the brain. 
Chemokine induction was associated with an influx of leukocytes from the 
periphery, and an increase in mRNA encoding the relevant chemokine receptors. 
Therefore, chemokine induction in the brain following daily systemic LPS 
injections may mediate the recruitment of leukocytes from the periphery.  
The transcriptional response in the brain following systemic LPS challenge is 
indicative of a peripherally triggered inflammatory response in the brain. The 
data described in this thesis highlight a potential mechanism of gene modulation 
in the brain which may be dependent on a TLR-induced type I interferon 
response. Considerable evidence links type I interferons to psychiatric disorders, 
and consequently, interferon production in the brain could represent an 
important mechanism linking peripheral TLR-induced inflammation with 
behavioural changes. In addition, the data described in this thesis demonstrate 
that chronic exposure to LPS in the periphery may remotely modulate the 
recruitment of leukocytes to the brain. This highlights a potential protective 
mechanism that could prevent a chronic bacterial infection from spreading from 
the periphery to the brain. 
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1 Introduction 
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1.1 The Immune Response 
Our bodies are constantly under threat from a multitude of opportunistic 
microorganisms which occupy every square inch of our environment, our skin and 
our mucosal surfaces. Fortunately, we are shielded from this potentially 
pathogenic environment by physical epithelial barriers. However, these barriers 
can be breached and consequently our bodies must be armed with effective 
counter-defence strategies in order to rapidly deter invading pathogens and heal 
damage so that we don’t succumb to infection. To this end, the immune system 
acts as our internal armed forces. Fortified with an arsenal of inflammatory 
mediators and anti-microbial agents, it is well equipped to combat the vast 
majority of threats it encounters in a lifetime. It is constantly vigilant. Some 
leukocyte populations act as sentinels, continuously surveying the extracellular 
environment for any signals alluding to danger. Others act as scouts, circulating 
between lymphoid organs in their search for foreign antigen. Upon detection of 
damage or pathogenic invasion, waves of leukocytes are rapidly recruited to the 
site of injury whilst reinforcements are deployed from the bone marrow. The 
first battalion of leukocytes that arrive at an inflamed site are those affiliated 
with the innate immune system. The innate immune system constitutes the 
immediate and non-specific arm of the immune response. During an infectious 
insult, whilst it battles to control the spread of pathogens, an antigen-specific 
adaptive response is primed in nearby lymph nodes (LNs). Not only do leukocytes 
of the adaptive immune system act as reinforcements in the attack against 
pathogens but they generate immunological memory which protects the host 
from subsequent infections of the same nature. The immune system is intricate, 
dynamic and extremely well coordinated. A complex interplay exists between 
the innate and adaptive arms of the immune response, and the antigen-specific 
host-defence mechanisms, utilized by the adaptive immune system, very much 
complement the highly specialised effector functions of the innate immune 
response. Innate and adaptive immunity will now be discussed in more detail, 
with particular emphasis on some of the key effector mechanisms adopted by 
both systems to provide host protection.  
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1.1.1 Innate Immunity 
Activation of the innate immune system is promptly triggered with the generic 
release of a multitude of inflammatory signalling molecules following any 
physical or pathogenic insult to the body. However, in order to execute an 
appropriate counter-offensive, the innate immune system must first recognise 
when it is injured or under attack. To this end, the innate immune system has 
evolved a myriad of cellular receptors which enable it to recognise different 
pathogenic components, termed pathogen-associated molecular patterns 
(PAMPs), or endogenous molecules that are associated with cell death or injury, 
termed damage-associated molecular patterns (DAMPs). These receptors, 
referred to as pattern-recognition receptors (PRRs), are highly specific for 
different molecular patterns from different sources. They therefore allow 
immune cells to tailor their effector responses according to different types of 
infection or injury. The best characterised of the PRRs are the members of the 
Toll-like receptor (TLR) family which reside within cellular membranes. TLRs can 
therefore recognise PAMPs or DAMPs that are present in either the extracellular 
environment or within membrane-bound vesicles. Humans and mice have 10 and 
13 functioning TLRs respectively1. Although TLRs 1-9 each have a distinct 
specificity, the ligands for human TLR10 and murine TLRs 11-13 have yet to be 
defined. TLR ligation triggers an intracellular signalling cascade which 
culminates in the transcription of numerous genes encoding relevant 
inflammatory mediators such as cytokines and chemokines1. Complementing the 
action of TLRs, Nod-like receptors (NLRs) reside within the cytoplasm where they 
are strategically positioned to recognise intracellular PAMPs and DAMPs and, 
depending on the receptor, generate an appropriate transcriptional response or 
activate the inflammasome1,2. Activation of the inflammasome contributes to 
the inflammatory response by cleaving certain cytokines, including IL-1β; 
transforming them to an active state. Like NLRs, Rig-like receptors (RLRs) also 
reside in the cytoplasm. This family of PRRs predominantly recognise virally-
derived PAMPS and therefore their ligation is typically associated with the 
induction of anti-viral mediators such as interferons (IFNs)1,2. The broad-
spectrum release of inflammatory mediators that occurs as a result of PRR 
ligation is one of the initiating steps in a cascade of events which shapes innate 
and adaptive immune responses and triggers the four cardinal features of acute 
inflammation; heat, redness, swelling and pain. 
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Amongst their various actions, inflammatory mediators induce activation and 
vasodilation of nearby blood vessels3. Not only does this increase blood flow to 
the site of injury, but activated endothelial cells upregulate cellular adhesion 
molecules which facilitate interactions between circulating leukocytes and the 
endothelium. Activation of the vasculature also stimulates the release of clotting 
factors and platelet aggregation which, depending on the nature of the injury, 
can either minimise blood loss or prevent the spread of pathogens to the blood 
stream3. The induction of an acute inflammatory insult promptly triggers a wave 
of innate leukocyte populations to infiltrate and accumulate within the inflamed 
site3. Leukocyte infiltration is initiated, coordinated and maintained by 
inflammatory mediators such as cytokines (Section 1.1.4) and chemokines 
(Section 1.1.6). Inflammatory mediators also play a role in blood vessel dilation3. 
Within dilated blood vessels, although blood flow increases, its velocity 
decreases. This leads to an increased number of leukocytes passing slowly 
through the inflamed vasculature and is therefore the cause of two of the 
classical features of acute inflammation; redness and heat3. Interactions 
between chemokines and their receptors enable leukocytes to adhere to 
activated endothelial cells and extravasate from the blood to the inflamed tissue 
(Section 1.1.6). During acute inflammatory responses, the permeability of the 
vasculature increases resulting in swelling, or oedema3. In addition to permitting 
the ingress of protective plasma proteins from the circulation, this expedites the 
infiltration of leukocytes. Neutrophils, a short-lived population of innate 
granulocytes, are the first leukocytes to arrive on the scene3. Due to their 
multifaceted approach to host defence, neutrophils play a pivotal role in acute 
inflammatory responses. They have numerous strategies for clearing pathogens 
from an infected site. Not only are they skilled at phagocytosis, but they are 
armed with a battery of cytokines, chemokines and highly-reactive anti-
microbial peptides contained within intracellular granules4. These granules are 
rapidly deployed to the plasma membrane and their contents released following 
neutrophil activation. Within the cell, phagosomes containing engulfed 
microorganisms fuse with granules to form phagolysosomes5. This triggers the 
formation of the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
enzyme complex, subsequently generating reactive oxygen species (ROS) within 
phagolysosomes5. Pathogens are therefore exposed to anti-microbial agents 
within a highly-oxidative environment which culminates in their inactivation and 
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their subsequent death. When activated, neutrophils can also rapidly release 
ROS into the extracellular environment6. Although this can contribute to 
pathogen clearance, it may also lead to bystander tissue damage and therefore 
amplify local inflammation. Moreover, neutrophils release structures known as 
neutrophil extracellular traps (NETs)5. Composed of a web-like complex of 
nuclear components and anti-microbial granular proteins, these NETs trap, 
neutralise and destroy extracellular microorganisms. Neutrophils can also be 
activated to produce a number of inflammatory cytokines and chemokines which 
amplify local inflammatory responses and promote further leukocyte infiltration, 
particularly the infiltration of ‘inflammatory’ monocytes7 (Section 1.1.6.2). Once 
in the tissue, monocytes rapidly differentiate into macrophages and monocyte-
derived dendritic cells (DCs). Therefore, not only are neutrophil effector 
functions important for pathogen clearance, but they drive the immune response 
forward by attracting macrophages and monocyte-derived DCs to the site. 
Like neutrophils, macrophages are proficient phagocytes. During steady state 
conditions, their basal duty is to clear cell debris, erythrocytes and apoptotic 
cells8. This they do efficiently. However, macrophages are equipped with a 
whole spectrum of PRRs2 which makes them one of the primary sensors of 
pathogenic insults or mechanical injuries to the host. Macrophages are a highly 
plastic population of leukocytes. Upon recognition of danger signals, they rapidly 
change morphology and differentiate into classically-activated (M1) 
macrophages8. By secreting an abundance of cytokines, chemokines and 
inflammatory agents, these can both contribute to innate host defence and 
shape adaptive immune responses. One of the main characteristics of M1 
macrophages is their ability to activate NADPH oxidase and to produce the 
inducible form of nitric oxide synthase (iNOS)9. These result in the synthesis of 
ROS and nitric oxide (NO), which both play an integral role in host defence, 
allowing M1 macrophages to mount an effective antimicrobial defence. ROS and 
NO can function within the cell, to combat intracellular pathogens, or may be 
released into the extracellular environment along with other microbicidal agents 
that contribute to host defence10. During the resolution of inflammatory 
responses, macrophages differentiate into alternatively activated macrophages 
and contribute to would healing and suppression of the inflammatory milieu8. 
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As DCs can also phagocytose microbes and produce inflammatory cytokines, they 
too contribute to innate immune responses. However DCs are best known for 
their key role in transporting antigen to the lymph nodes (LNs) where they can 
present it to naïve lymphocytes in order to prime and shape adaptive immune 
responses (Section 1.1.2). Another cell population that plays a role in innate 
immune responses are natural killer (NK) cells. NK cells are rapidly recruited to 
sites of inflammation where they become activated by inflammatory cytokines 
and other danger signals11. During infection they live up to their name by 
targeting and killing infected cells. Furthermore they produce inflammatory 
cytokines that enhance the microbicidal actions of macrophages8. Therefore, a 
number of innate effector cells are sequentially recruited to sites of infection or 
injury. Via a complex interplay, these cell populations cooperate in the 
induction, maintenance and resolution of inflammatory responses and in the 
clearance of invading pathogens. In addition, a number of these innate 
leukocytes contribute to inducing and shaping the appropriate adaptive immune 
response (Section 1.1.2). 
Amongst the repertoire of inflammatory agents that are produced during acute 
inflammatory responses are complement components and lipid mediators such as 
prostaglandins. The complement system is integrally involved in host defence. 
Complement components bind to pathogenic or apoptotic cell surfaces to trigger 
a cascade of proteolytic events which ultimately lead to opsonisation of their 
targets12. Opsonised cells or pathogens can be readily cleared from the 
environment by phagocytosis. Prostaglandins are immune modulators which are 
involved both in the induction phase and in the resolution phase of immune 
responses13. They can be rapidly synthesised from membrane-released 
arachidonic acid by a number of cell types following a pathogenic insult or 
trauma. This requires the sequential induction of cyclooxygenase (COX) enzymes 
followed by prostaglandin synthases13. Prostaglandins have a diverse range of 
functions. They contribute to the inflammatory response by promoting 
vasodilation, vascular permeability and subsequent oedema14. In addition, 
prostaglandins play a role in inducing fever (Section 1.4.2.2) and pain15, one of 
the cardinal features of inflammation. During the course of an inflammatory 
response, prostaglandins gradually induce the expression of anti-inflammatory 
lipid mediators which promote the resolution of inflammation16. 
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Inflammation also leads to systemic effects that contribute to host defence. 
Inflammatory chemokines can recruit mature leukocytes from the bone marrow 
thus increasing their numbers in the circulation17,18. In addition, an acute phase 
response is stimulated in the liver. A vast number of acute phase proteins can be 
secreted from the liver into the circulation19. These have an assortment of 
functions which collectively promote host defence. Acute phase proteins 
include: opsonins, such as C-reactive protein, serum amyloid A and various 
complement components; coagulation factors, such as fibrinogen and von 
Willebrand factor; and factors such as ferritin and transferrin, which sequester 
free iron19. In summary, following a pathogenic insult or mechanical trauma, the 
concerted action of a host of inflammatory mediators, innate leukocytes and 
antimicrobial peptides function both locally and systemically to aid host 
defence. 
1.1.2 Adaptive Immunity 
Adaptive immunity is a lymphocyte-dependent antigen-specific response to 
invading pathogens. Antigen uptake in the presence of danger signals causes 
tissue-resident DCs to alter their surface marker expression and migrate through 
lymphatic vessels to the draining LNs3. Free antigen can also travel to draining 
LNs through the lymphatics20. It then filters through the subcapsular sinus and, 
depending on its size, into the LN conduit system. In the T cell zones of LNs, 
small antigen is continuously sampled from conduits by LN-resident DCs20. To 
initiate adaptive immune responses, mature antigen-loaded DCs must first 
present their antigen to T cells and provide the relevant signals required for T 
cell priming3,21. Once they encounter DCs bearing their cognate antigen, T cells 
undergo clonal expansion and differentiate into an assortment of effector T 
cells, memory T cells and follicular helper cells. Effector T cells promptly 
migrate to the site of infection to carry out their appropriate host-defence 
functions, whereas follicular helper cells remain in the LN and travel to the 
follicle/T cell zone boundary to prime antigen-specific B cell responses22. 
Simultaneously, within the follicles of the LN, B cells can acquire certain kinds 
of antigen from a specialised population of subcapsular sinus macrophages which 
scavenge particulate antigen from the lymph23,24. Following specific antigen 
uptake, B cells migrate towards the T cell zones and present antigen to follicular 
helper cells25. Only when an antigen-experienced T cell encounters its cognate 
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antigen on the B cell surface will full B cell priming occur. Primed B cells then 
clonally expand, differentiating into memory B cells or antibody-secreting 
plasma cells, which migrate to the spleen and bone marrow and secrete large 
amounts of antibodies into the circulation. 
The effector T cell population that is generated during an adaptive immune 
response is diverse. Depending on the cytokine repertoire present during T cell 
priming, effector CD4+ T cells can adopt one of a variety of possible phenotypes. 
For example, Th1 cells, primed in response to interleukin (IL)-12, produce vast 
amounts of IFNγ and contribute to the immune response against intracellular 
bacterial infection26, whereas Th2 cells, primed in response to IL-4, produce IL-
4, IL-5 and IL-13 and contribute to the host-response against helminths26. In 
addition to these well characterised CD4+ T cell populations are Th9 cells, Th17 
cells and Th22 cells27. Whilst Th17 cells have been associated with the immune 
response against extracellular pathogens, such as bacteria and fungi, both Th9 
cells and Th22 cells are newly described and any roles these cell populations 
might have, outside a general contribution to tissue inflammation, have yet to 
be established27. In contrast, the phenotypic outcome for a primed CD8+ T cell is 
less ambiguous. Once activated, CD8+ T cells transform into cytotoxic killing 
machines which target infected, cancerous or damaged cells for programmed 
cell death3,28. 
In addition to producing an antigen-specific effector response, the priming of 
adaptive immunity generates immunological memory. Following a primary 
exposure to antigen, the frequency of lymphocytes that are specific for this 
antigen increases dramatically. Although the majority of these lymphocytes are 
short-lived effector cells, a proportion of them, known as clonally expanded 
memory lymphocytes, can persist in the body for a lifetime29. Different 
populations of memory lymphocytes include CD8+ memory T cells, CD4+ effector 
memory T cells (TEM), CD4+ central memory T cells (TCM) and memory B cells. 
Aside from TEM cells, all of these memory cells express lymphoid tissue homing 
molecules, such as CCR729,30 (Section 1.1.6.2). Like naïve lymphocytes, these cell 
populations circulate between secondary lymphoid organs scouting for antigen. 
However, during recall responses, they expand much more rapidly than naïve 
lymphocytes following an initial pathogen encounter31. In contrast, TEM cells do 
not retain a lymphoid tissue homing phenotype. Instead they express 
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inflammatory chemokine receptors and integrins which enable them to rapidly 
infiltrate inflamed tissues29. In addition to a faster response, memory 
lymphocytes respond to antigen with greater potency than naïve or effector 
lymphocytes31. Therefore due to their long lifespan, their enrichment in the 
circulation and their heightened ability to respond to pathogens, memory 
lymphocytes protect the host against subsequent infections with the same 
pathogen following an initial exposure.  
1.1.3 Cytokines: an intercellular communication system 
The cytokine superfamily encompasses a large number of small protein moieties 
which collectively provide a network of communication between virtually every 
cell type of the body. These cellular communication molecules have a highly 
diverse range of physiological functions. Amongst their multitude of roles in 
immune system communication, cytokines are critically involved in the 
organogenesis of secondary lymphoid organs, the induction and resolution of 
inflammation, the modulation of host defence mechanisms and the coordination 
of leukocyte migration (Section 1.1.6). As this thesis is exclusively focused on 
immune and nervous system responses during experimental inflammatory 
models, only the cytokines that are relevant to this work are discussed in more 
detail below. These include cytokines which have a role in modulating 
inflammation and host defence, such as IFNs and inflammatory cytokines, and 
chemokines, which coordinate leukocyte migration. 
1.1.4 Inflammatory cytokines 
‘Inflammatory cytokines’ is an umbrella term covering a range of inducible 
cytokines which are known to amplify inflammatory responses. Three 
prototypical inflammatory cytokines released early after infection or tissue 
damage are tumour necrosis factor-α (TNFα) and two members of the interleukin 
(IL) family, IL-1β and IL-6. The release of these proteins is triggered following a 
physical or pathogenic insult to the body. By acting in an autocrine and 
paracrine manner, inflammatory cytokines stimulate a cascade of events leading 
to local inflammation. IL-1β, IL-6 and TNFα share the capacity to induce 
activation, vasodilation and permeablisation of nearby blood vessels3. This 
increases blood flow to the site of injury, contributes to the influx of plasma 
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proteins to the tissue and enhances the release of clotting factors from the 
endothelium3. In addition, inflammatory cytokines, particularly TNFα, are potent 
activators of tissue macrophages2. By inducing further cytokine and NO 
production, this amplifies the local inflammatory response. Thus inflammatory 
cytokines are rapidly induced in response to tissue damage or pathogen 
detection. As part of a protective host response, these cytokines act locally to 
contribute to the four characteristic hallmarks of inflammation: heat, redness, 
swelling and pain. 
IL-1β, IL-6 and TNFα also function in an endocrine manner. Acting at sites distal 
to their production, these inflammatory cytokines trigger a number of systemic 
effects that augment the host response to infection. For example, they can 
stimulate the production of acute phase proteins from hepatocytes in the liver, 
thus contributing to the acute phase response3. Furthermore, inflammatory 
cytokines induce fever and a number of behavioural symptoms that are 
associated with sickness (Section 1.4.1). There are several ways in which fever 
can aid host defence. As some pathogens are thermosensitive, an increase in 
body temperature may help curtail their replication32. Furthermore, 
hyperthermia can enhance many metabolic processes involved in the effector 
mechanisms of both the innate and the adaptive immune response32-34. 
Inflammatory cytokine-induced behavioural changes, such as fatigue and social 
withdrawal, are also beneficial to the host as they promote energy conservation 
and reduce the risk of exposure to further dangerous stimuli35. Therefore 
inflammatory cytokines, such as IL-1β, IL-6 and TNFα, have a combination of 
local and systemic effects which ultimately promote leukocyte migration to the 
site of injury, aid pathogen clearance and prevent the spread of infection. 
1.1.5 Interferons 
First named for their ability to interfere with viral replication, IFNs comprise a 
panel of cytokines that are integrally involved in host defence. IFNs can bind to 
one of three types of IFN receptor and are therefore classified accordingly. 
Those that bind to the ubiquitously expressed IFN-α/β receptor (IFNAR) are 
termed type I IFNs. In mammals there are approximately 20 members of this IFN 
subfamily. These include, but are not limited to, various types of IFNα (13 in 
humans and 14 in mice) and usually a single IFNβ. The recently discovered type 
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III IFNs engage the IFNλ receptor (IFNLR)36. To date, there are 3 known members 
of this subfamily; IFNλ1 (IL-29), IFNλ2 (IL-28A) and IFNλ3 (IL-28B)37. Unlike the 
type I IFNAR, the type III IFN receptor is expressed predominantly by epithelial 
cells in certain tissues, such as the kidney and the brain38. The only known type 
II IFN, IFNγ, binds to the widely distributed IFNγ receptor (IFNGR). Through 
similar signal transduction pathways, the ligation of these IFN receptors can 
induce the expression of thousands of IFN-stimulated genes (ISGs)39 (Figure 1.1).  
Up until relatively recently, the general dogma regarding type I and II IFN 
responses stated that ISGs induced by type I IFNs had a prominent role in 
combating viral infections, whereas those induced by type II IFNs were part of 
the host response against intracellular microbes. This view is supported by a 
battery of evidence to suggest that antiviral and antimicrobial responses are 
profoundly impaired in IFNAR- and IFNγ-deficient rodents respectively40-48. 
Furthermore, ISGs associated with type I IFNs often encode proteins with 
antiviral properties. For example, their induced protein repertoire includes a 
number of 2’,5’ oligoadenylate synthases (OAS), which block the spread of 
infections by degrading viral RNAs49. They also induce members of the Mx family 
of GTPases, which suppress replication by inhibiting the intracellular transport 
of viral proteins (Reviewed in Ref 50). In contrast, type II ISGs often encode 
proteins with microbicidal properties, such as iNOS51, a crucial enzyme involved 
in the synthesis of NO. These reports confirm a pivotal role for type I and type II 
IFNs in mediating antiviral and antimicrobial responses respectively. Like type I 
IFNs, the type III IFN subfamily are also inducible following viral infections52. 
Although less is known about this particular IFN category, they have been shown 
to activate similar signalling pathways to type I IFNs36,52,53 (Figure 1.1), and thus 
induce a similar ISG expression profile. Furthermore, type III IFNs can modulate 
host responses to certain viral infections in vivo52,54.  
Taken together, the data above have led to the general view that type I and 
type III IFNs induce an antiviral immune response whereas type II IFNs mediate 
responses to intracellular bacteria. However, whilst this may be true, to 
distinguish IFN subfamilies purely based on these physiological functions is too 
simplistic. In fact, there is a considerable degree of overlap between the ISG 
repertoires that are induced by these different classes of IFNs39. It is likely this is 
at least partially due to the ability of type I and type III IFNs to stimulate 
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transcription of type II ISGs55 (Figure 1.1). The similar transcriptional profile 
shared by the three IFN subtypes, suggests that type I and/or type III IFNs may 
share some of the same physiological functions as the type II IFN subfamily. In 
support of this, type II IFNs are produced during certain viral infections. Studies 
using IFNγ-deficient mice have demonstrated the involvement of type II IFNs in 
modulating a proportion of antiviral responses43,56-58. Furthermore, the induction 
of type I and type III IFNs has been described during a number of intracellular 
bacterial infections59-63. By suppressing bacterial growth or replication, type I 
IFNs appear to have a supportive role in host defence during a variety of 
intracellular microbial infections60,62-65. However, the role of type I IFNs in 
antimicrobial immunity is not clear-cut. By suppressing the innate immune 
system and sensitising infected cells to bacterial-induced apoptosis, the 
production of type I IFNs can have a deleterious effect during certain other 
bacterial infections, such as Listeria monocytogenes and Francisella tularensis66-
69. Due to the similarities in the signalling pathways utilized by both type I and 
type III IFNs, it could be predicted that type III IFNs also have similar complex 
roles in modulating specific antimicrobial responses. However, as this cytokine 
subfamily has only recently been described, their role in bacterial infection is 
yet to be established in vivo. In summary, these findings imply that it may be 
inaccurate to pigeonhole IFN subfamilies as being either antiviral or 
antimicrobial. IFNs of all categories are produced in response to a wide array of 
pathogenic stimuli and depending on the cell populations involved, or the nature 
of these stimuli, specific IFN subtypes might function cooperatively or 
individually to induce the relevant host defence mechanisms. 
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Figure 1.1 IFN receptor signalling pathways. 
Interferons (IFNs) bind to one of three heterodimeric IFN receptors. The only known type II IFN, 
IFNγ, binds to the IFNγ receptor. This receptor is composed of an IFNGR1- and an IFNGR2-chain 
which associate intracellularly with the Janus activated kinases (JAKs), JAK1 and JAK2. Receptor 
ligation leads to the downstream phophorylation and homodimerisation of signal transducer and 
activator of transcription (STAT) 1 molecules. Activated STAT1 homodimers form a transcription 
factor known as the IFNγ-activated factor (GAF). GAF subsequently translocates to the nucleus 
and stimulates the transcription of IFN-stimulated genes (ISGs) that contain an IFNγ-activated site 
(GAS) in their promoter region. The type I IFN receptor, which consists of the two subunits; 
IFNAR1 and IFNAR2, and the type III IFN receptor, which is comprised of IFNLR1 and IL-10R2, 
both associate with JAK1 and tyrosine kinase (TKY) 2. Ligation of either receptor triggers the 
phophorylation of STAT1 and STAT2. This results in the formation of the IFN-stimulated gene 
factor 3 (ISGF3), a transcription factor complex which comprises a STAT1:STAT2 heterodimer and 
an associated IFN regulatory factor, IRF9. ISGF3 stimulates the transcription of ISGs by binding to 
the IFN-stimulated response element (ISRE). In addition to activating ISGF3, ligation of either the 
type I or the type III IFN receptor can lead to the formation of GAF and the subsequent transcription 
of GAS-associated ISGs. 
 
1.1.6 Chemokines 
Chemokines, or chemotactic cytokines, are small, diverse proteins with a key 
role in inducing the directed migration of target leukocytes. They can be 
categorised into four subfamilies: CXC/α chemokines, CC/β chemokines, XC/γ 
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chemokines and CX3C/δ chemokines70. Intramolecular di-sulphide bonds between 
conserved cysteine residues dictate both the tertiary structure of chemokines 
and their subsequent nomenclature70,71 (Figure 1.2). With 28 and 16 members 
respectively, CC- and CXC-chemokines represent the largest of the chemokine 
families. Both XC- and CX3C-chemokine sub-groups contain only a single member 
known to-date71. Although chemokines have a multitude of functions in vivo, 
their best characterised role is to orchestrate leukocyte migration, both during 
homeostasis and inflammation.  
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Figure 1.2 Conserved Structures of the Four Chemokine Families. 
Chemokines are classified according to the assembly of cysteine residues located near the amino-
terminus (-NH2). (A) The sole member of the XC chemokines, XCL1, has one cysteine residue near 
the amino terminus. (B) CC chemokines have two adjacent cysteine residues near the amino 
terminal. (C) CXC chemokines have two cysteine residues at the amino-terminus which are 
separated by a non-conserved amino acid residue. (D) The only known member of the CX3C 
family, CX3CL1 (fractalkine), has two cysteine residues at the amino-terminus which are separated 
by three non-conserved amino acid residues. CX3CL1 and CXC family member CXCL16, have an 
adhesive mucin-like domain, a membrane-spanning hydrophobic α-helix and a short cytoplasmic 
tail. CX3CL1 and CXCL16 are the only transmembrane chemokines that have been discovered.   
 
Chemokines exert their functions by binding to 7 transmembrane-spanning G 
protein-coupled receptors (GPCRs), activating a cascade of downstream 
signalling pathways. These chemokine receptors are classified according to the 
chemokine ligands to which they bind. There are 10 known CC receptors and 6 
known CXC receptors72. CX3C and XC receptor families both consist of one known 
member72. Leukocytes express specific chemokine receptor profiles which will 
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depend on each cell’s lineage and activation state73. This receptor profile will 
dictate where each cell has the capacity to migrate to in vivo. The majority of 
CC chemokine receptors and 3 out of the 6 known CXC receptors have more than 
one chemokine ligand (Table 1.1). Likewise, many of the CC and CXC chemokines 
can bind to more than one receptor71,72. Not only does this promiscuity allow 
many of the chemokine systems to adopt an element of redundancy74, but it 
enable chemokines to finely tune immune responses. 
Receptors Ligands 
  
CC Receptors  
CCR1 CCL3, CCL3L1, CCL5, CCL7, CCL8, CCL13, CCL14, CCL15, CCL16, CCL23 
CCR2 CCL2, CCL7, CCL8, CCL13, CCL16 
CCR3 CCL5, CCL7, CCL8, CCL11, CCL13, CCL15, CCL24, CCL26, CCL28 
CCR4 CCL17, CCL22 
CCR5 CCL3, CCL3L1, CCL4, CCL4L1, CCL5, CCL8 
CCR6 CCL20 
CCR7 CCL19, CCL21 
CCR8 CCL1 
CCR9 CCL25 
CCR10 CCL27, CCL28 
  
CXC Receptors  
CXCR1 CXCL6, CXCL8 
CXCR2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 
CXCR3 CXCL9, CXCL10, CXCL11 
CXCR4 CXCL12 
CXCR5 CXCL13 
CXCR6 CXCL16 
  
CX3C Receptor  
CX3CR1 CX3CL1 
  
XC Receptor  
XCR1 XCL1 
Table 1.1 Chemokine receptors and their specific ligands. 
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1.1.6.1 Coordinating leukocyte migration 
Chemokines are best known for their role in inducing chemotaxis, the process 
whereby the directed migration of cells is dictated by a chemical gradient. By 
ligating chemokine receptors and thus activating G protein-mediated signalling 
pathways, these chemotactic cues trigger a series of conformational and 
molecular changes within leukocytes to promote their directed mobility75. 
Despite the fact that leukocytes migrate towards soluble chemokine gradients in 
vitro, the evidence to suggest that this phenomenon occurs in vivo is sparse. 
A prototypical example of chemokine function in vivo is their role in facilitating 
leukocyte recruitment to tissues. Rather than involving a chemokine gradient, 
this particular function is dependent on immobilised chemokines, presented on 
the surface of the endothelium76. All leukocytes express a specific combination 
of cellular adhesion molecules and chemokine receptors. This combination of 
surface molecules forms a site-specific molecular “postcode” which governs 
leukocyte entry to tissues both in homeostasis and inflammation. To enter a 
tissue from the circulation, leukocytes must first cross the vascular wall. 
Leukocyte recruitment is a complex and tightly controlled process which, for the 
sake of simplicity, can be broken down into a series of generalised stages 
(depicted in Figure 1.3). Leukocytes begin by rolling along the endothelium. 
Initial contact is generally mediated by transient interactions between selectins 
on the endothelial surface and glycosylated ligands on the leukocyte 
membrane77. If they express the appropriate chemokine receptor, leukocytes 
will receive signals from immobilised chemokines that are presented on the 
surface of the vascular endothelial cells. Via G protein mediated signalling 
pathways, chemokine receptor ligation triggers conformational changes within a 
leukocyte to induce integrin clustering and activation77. Activated integrins bind 
to cellular adhesion molecules from the Ig superfamily with high affinity, thus 
triggering the firm arrest of leukocytes to vascular endothelial cells. This is 
followed by their diapedesis across endothelial cell junctions and into tissues77. 
Therefore, the recruitment of circulating leukocytes to tissues follows a specific 
sequence of tightly controlled events that is dependent on the expression of 
adhesion molecules, by both leukocytes and endothelial cells, and the 
presentation of chemokines on the surface of the endothelium. 
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Much less is known about how chemokines control the migration of leukocytes 
once they have entered a tissue. Studies using chemokine receptor deficient 
rodents have highlighted the fundamental role of specific chemokine systems in 
the positioning and retention of leukocytes within tissues. An example of this is 
the role of the CCR7 ligands, CCL19 and CCL21, and the CXCR5 ligand, CXCL13, 
in the positioning of lymphocytes within specific LN microenvironments 
(discussed in Section 1.1.6.2). In 2005, Okada et al. demonstrated a CCL21 
gradient in the LN, extending from the T cell zone towards the follicles25. This 
was the first time a chemokine gradient had been visualised in vivo. Using 
intravital microscopy, Okada et al. also showed that B cells migrated in a 
random manner within LN follicles. Following antigen encounter, B cells 
upregulated the CCL21 receptor, CCR7, which promoted their directed migration 
towards the follicle/T cell zone boundary25. This indicates that a functional 
CCL21 gradient may exist within the LNs. Due to the constitutive movement of 
fluids within tissues, a soluble chemokine gradient would be difficult to maintain 
in vivo. Chemokines are often bound and “presented” by sulphated residues on 
cell surfaces or within the extracellular matrix76. It therefore remains to be 
established whether chemokine receptor ligation induces the random motility of 
leukocytes (chemokinesis), or whether the directed migration of leukocytes is 
triggered by immobilised chemokine gradients (haptotaxis). In support of the 
latter, Weber et al. demonstrated that interstitial gradients of immobilised 
CCL21 extend from the lymphatic endothelium into the skin78. This gradient was 
shown to be functional as it was essential for the directed migration of DCs into 
lymphatic vessels, as demonstrated using intravital microscopy. Thus, leukocytes 
respond to chemokines in vivo, but it is unclear whether their movement is 
dictated by a process of chemotaxis, chemokinesis or haptotaxis. What is clear is 
that chemokines and their receptors are crucially involved in inducing leukocyte 
motility and in the strategic positioning of leukocytes within tissues. 
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Figure 1.3 Leukocyte recruitment to tissues. 
Migration of leukocytes to tissues occurs in a series of stages. (1) Transient interactions between 
selectins and glycosylated ligands facilitate the rolling of leukocytes along the activated 
endothelium. (2) Chemokines (ChKs), displayed on the surface of the endothelium, bind to 
leukocyte chemokine receptors (ChK Rs) to activate integrins. (3) Activated integrins bind to 
cellular adhesion molecules (CAM) to induce firm adhesion of leukocytes to the endothelial surface. 
This is followed by diapedesis (4) across inter-endothelial junctions. Once in the tissues, 
chemokines govern the directed migration of leukocytes to their target location. This may be 
facilitated by chemokine gradients. 
1.1.6.2 Chemokines during homeostasis and inflammation 
Chemokines coordinate leukocyte migration during doth homeostatic and 
inflammatory conditions. Thus, depending on their role in vivo, chemokines can 
be classified as being ‘homeostatic’ or ‘inflammatory’. However, it is important 
to note that this rule is not absolute. A degree of overlap exists between these 
sub-categories. For example, the production of a number of ‘homeostatic’ 
chemokines can be enhanced during inflammatory conditions and many of the 
chemokines considered ‘inflammatory’ have a key role during homeostasis71. 
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Under steady state conditions, ‘homeostatic’ chemokine production is 
constitutive and strictly regulated. These chemokines are expressed in discrete 
regions within specific tissues to facilitate the targeted migration of patrolling 
leukocytes throughout the body. An ideal example of this cell- and tissue-
specific phenomenon is the highly synchronised action of the homeostatic 
chemokines, CCL19, CCL21 and CXCL13. CCL19 and CCL21 function through the 
chemokine receptor CCR779,80. CCR7 ligation is involved in the recruitment of 
naïve T cells to the LNs and in the targeting of T cells to specific LN 
microenvironments81. Furthermore, CCR7 and its ligands play a role in the 
homing of DCs through the lymphatics to T zones of the LNs, where they will 
encounter patrolling T cells21,81. B cells also utilise CCR7 to enter the LN. 
However, upon entering the LN, B cells migrate to specific B cell follicles. This is 
dependent on interactions between CXCR5, expressed on the surface of B cells, 
and its ligand CXCL13 which is produced within follicles82. Thus, in the steady 
state, CCL19, CCL21 and CXCL13 collectively coordinate a finely tuned series of 
events leading to the specific positioning of leukocytes within specialised LN 
microenvironments.  
One of the most important homeostatic chemokines, particularly in terms of 
development, is CXCL12 which functions primarily by binding to CXCR4. CXCL12 
was the first chemokine to evolve. It is highly conserved across many species, 
including lower vertebrates83,84 and is hence considered the ‘primordial 
chemokine’. Moreover, both CXCL12- and CXCR4- deficiencies have proven to be 
perinatally lethal in mice due to abnormalities, particularly in haematopoiesis 
and cerebellar formation85-87. Thus CXCL12 is crucial for both immune system 
and brain development. The CXCL12/CXCR4 axis also plays a number of 
prominent roles during adult life. For example CXCL12 is intrinsically involved in 
the homing to and retention of haematopoietic stem cells in the bone marrow88. 
In addition, CXCL12 may have a number of roles in the central nervous system 
(CNS) during steady-state conditions. These are described in detail in Section 
1.3.2.1. 
As the name suggests, ‘inflammatory’ chemokines are highly inducible following 
virtually any pathogenic insult. Their primary function is to recruit the 
appropriate leukocyte populations to sites of inflammation. Many inflammatory 
chemokines exist. As they are of particular relevance to this thesis, the actions 
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of CCL2, CCL3, CCL5, CXCL1, CXCL2, CXCL9 and CXCL10 will now be discussed. 
Both CXCL1 and CXCL2 are rapidly induced during acute inflammatory responses. 
These molecules exert their chemotactic functions by ligating CXCR2, a receptor 
predominantly expressed by neutrophils89-91. In addition to promoting 
chemotaxis, CXCR2 ligation is thought to contribute to other aspects of 
neutrophil activation, including degranulation and cytokine production92. By 
activating endothelial cells in nearby blood vessels, proteins released during 
degranulation can induce the secretion of CCL2 from the endothelium90. CCL2 is 
a potent chemoattractant for circulating ‘inflammatory’ monocytes which 
express CCR293,94. Thus, neutrophil recruitment to inflamed tissues generally 
precedes the infiltration of ‘inflammatory’ monocytes.  
In addition to CCR2, ‘inflammatory’ monocytes have been reported to express 
CCR193. Like CCR5 (discussed below), CCR1 responds to the chemokines CCL3 and 
CCL5. However, the ability of CCL3 to attract ‘inflammatory’ monocytes in vitro 
has been shown to be considerably weaker than that of CCL2, suggesting that 
CCR2 may be the predominant chemokine receptor involved in the recruitment 
of this monocyte subpopulation95. Circulating monocytes can rapidly 
differentiate into macrophages once they reach an inflamed tissue. This is 
associated with an upregulation of chemokine receptors CCR1 and CCR5 and a 
downregulation of CCR295,96. As both CCR1 and CCR5 respond to the shared 
ligands, CCL3 and CCL5, this paradigm shift means that differentiated 
macrophages are more susceptible to the chemoattracting actions of both of 
these chemokines, and less susceptible to CCL295. CCL3 and CCL5 also have the 
capacity to attract ‘resident’ monocytes, which are known to express CCR594.  
CXCLs9-11 are IFN-inducible chemokines which are commonly induced during Th1 
cell-mediated immune responses97-99. Whilst their shared receptor, CXCR3, is 
expressed mainly by activated T cells, it can also be found on a number of other 
leukocyte populations, including NK cells99-101. In addition to CXCR3, activated T 
cells, particularly Th1 cells and TEM cells, also generally express CCR1 and CCR5, 
enabling them to migrate towards both CCL3 and CCL5. Thus, relevant leukocyte 
populations can be rapidly recruited to inflamed tissues following the elevated 
secretion of specific combinations of inflammatory chemokines. 
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1.2 Immune Components of the CNS 
The brain and the spinal cord collectively make up the CNS. Under normal 
homeostatic conditions, these organs are largely isolated from the peripheral 
immune system. The CNS lacks conventional lymphatic drainage102, contains very 
few ‘professional’ antigen presenting cells (APCs)103 and is separated from the 
periphery by seemingly impenetrable cellular barriers fortified by complex tight 
junctions104. The blood-cerebrospinal fluid barrier (BCSFB) separates the 
circulation from the cerebrospinal fluid (CSF) while the blood-brain barrier (BBB) 
and blood-spinal cord barrier (BSCB) demarcate the vasculature feeding the 
brain and spinal cord parenchyma respectively. These barriers serve to protect 
the CNS parenchyma from plasma components and inflammatory leukocytes. As 
a result of this apparent isolation from the peripheral immune system, until very 
recently the CNS was considered to be an ‘immune-privileged’ site.  
Within the CNS a number of different, highly specialised cell populations 
harmoniously coexist. Ensheathed in myelin, neurons relay sensory information 
to discrete brain regions which subsequently command the appropriate motor 
response. Oligodendrocytes provide the myelin-rich membrane which insulates 
neuronal axons. This sheath speeds up action potential propagation along each 
axon. Further protection and support is provided by astrocytes and microglia 
(discussed below). Collectively these cell types constitute a crucial and vastly 
complicated cellular network. Neurons are postmitotic and are therefore not 
capable of self-renewal105. Thus, a degree of separation between the immune 
system and the CNS is an evolutionarily advantageous strategy as it protects 
these critical and non-renewable neuronal circuits from the collateral damage 
that could arise as a result of peripheral inflammation. However, the notion that 
the CNS is completely isolated from the immune system is too simplistic. The 
brain and spinal cord are important organs, and in fact many immunological 
mechanisms, both innate and adaptive, act in parallel to enable the CNS to 
mount an appropriate response to infection. Thus the term ‘immune-specialised’ 
is arguably a more apt description of the immune-components that protect the 
CNS. The mechanisms that mediate innate and adaptive immunity in the CNS will 
now be discussed. As it is of particular relevance to this thesis, this discussion 
will predominantly focus on immune responses in the brain. 
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1.2.1 Innate components 
Microglia and astrocytes constitute the principal innate responders of the CNS. 
Both cell types are endowed with a number of PRRs and so can respond to 
pathogenic insults with the induction of numerous inflammatory mediators106-115. 
However, whereas microglial exposure to pathogenic stimuli culminates in the 
production of many inflammatory cytokines, chemokines and reactive oxygen 
species, astrocyte stimulation results in a more finely tuned chemokine response 
which may lead to the selective recruitment of appropriate leukocyte 
populations to sites of CNS injury.  
1.2.1.1 Microglia   
Microglial cells are generally considered the tissue macrophages of the CNS 
parenchyma. Their haematopoietic origin differentiates them from other CNS-
derived cells. Microglia are generated from yolk sac-derived myeloid precursors 
early in development116 and constitute between 5 and 20% of the glial cell 
population in the CNS117. Rather than being continually replenished from bone 
marrow-derived myeloid progenitor cells, as was once proposed, their 
population is sustained by the self-renewal of the CNS-resident progenitor cells 
that enter the brain during embryogenesis116.  
Microglia have a number of functions and differ in morphology depending on 
their activation state. Under physiological conditions, ‘resting’ microglia 
perpetually extend, retract and remodel highly motile cellular processes118. 
These dynamic processes continuously sample the extracellular space scouting 
for pathogens. Microglial processes are also known to interact with neuronal 
synapses but the functional significance of this remains unclear119. Microglia are 
the principle innate effector cells of the CNS. During steady state, their 
morphology closely resembles that of immature myeloid cells120. However, 
microglia have the capacity to respond to a large array of pathogens and 
inflammatory agents. Consequently, microglial activation is a classic hallmark of 
virtually all CNS pathologies. Microglia express numerous cytokine receptors and 
PRRs. In addition to the TLRs discussed below, they have been reported to 
express the mannose receptor and mRNA encoding the cytoplasmic NLRs, NOD1 
and NOD2121-123. These receptors are involved in the phagocytosis of pathogens 
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and the intracellular recognition of bacterial components respectively. This 
receptor profile allows microglia to sense and respond to cytokines, PAMPs and 
DAMPS. Following pathological stimuli, microglia rapidly transform into activated 
effector cells. Now capable of enhanced phagocytosis124,125, antigen presentation 
(Section 1.2.2.3) and inflammatory mediator production108,109,126,127, ‘activated’ 
microglia are more akin in morphology to mature myeloid cells such as activated 
macrophages.    
Several studies have been carried out to characterise the full repertoire of PRRs 
that are expressed by microglial cells and their functional significance. Of the 13 
known TLRs, TLRs 1-9 are expressed by primary microglial cells, isolated from 
humans, primates and rodents106-109. A number of these receptors have been 
shown to be functional in vitro. For example, treating primary cultured 
microglia with ligands specific for TLR2, TLR3, TLR4 and TLR9 induce the 
expression of a host of inflammatory mediators108,109,126,127. TLR3 recognises viral 
double-stranded RNA and TLR9 recognises CpG motifs from both viral and 
bacterial DNA, whereas TLR2 and TLR4 respond to gram-positive and gram-
negative bacterial components respectively1. Therefore, microglia have the 
capacity to respond to viral and bacterial pathogens. Stimulating microglia using 
PAMPS induces a similar inflammatory response regardless of the nature of the 
pathogenic insult. For example, following ligation of either antiviral or 
antimicrobial TLRs, microglia have been shown to upregulate the expression of a 
wide variety of inflammatory cytokines, including IFNβ, IL-1β, IL-6, IL-12 and 
TNFα108,109,126,127. Furthermore, they produce reactive oxygen species, such as NO 
via the upregulated expression of iNOS109,126. TLR2-, TLR3- or TLR4-ligation of 
microglia also upregulates the expression of inflammatory chemokines, including 
CCL2, CCL3, CCL5 and CXCL10108,109,127 enabling the potential recruitment of 
activated CD4+ Th1 cells, TEM cells, CD8+ cytotoxic T cells and NK cells, as well 
as monocytes and macrophages. Collectively, the above leukocyte populations 
are well equipped to respond to either a viral or a bacterial infection. 
Therefore, microglial cells, stimulated by TLR ligands in vitro, produce a large 
number of inflammatory cytokines in addition to various chemokines. Although 
potent, this inflammatory response is more generalised when compared to that 
of astrocytes (Section 1.2.1.2), as microglia produce inflammatory mediators 
that are comparable regardless of the immune stimuli.  
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Although microglia are therefore capable of initiating a wide range of 
inflammatory responses in vitro, they are maintained in a quiescent state in the 
normal CNS in vivo through neuronal interactions. Neurons express both the 
glycoprotein CD200, and the chemokine CX3CL1 which interact with their 
corresponding receptors, CD200R and CX3CR1, found on the surface of 
microglia128-130. These interactions exert a potent restraining influence and their 
disruption leads to elevated microglial activation and neurotoxicity128-130. 
Therefore, the absence of these in situ interactions needs to be considered 
when interpreting the effects of activating isolated microglia with TLR ligands in 
vitro. There have however been some investigations into microglial TLR 
responses in vivo. Intraperitoneal injection of lipopolysaccharide (LPS), a TLR4 
agonist, leads to an upregulation of TLR2 and CD14 mRNA by microglial cells in a 
TLR4-dependent manner131. Furthermore, microglial TLR4 expression is 
necessary for leukocyte recruitment to the cerebral vasculature following 
intracerebral LPS injection132. These results suggest that microglial cells do 
express functional TLR4 in vivo. TLR2 and TLR3 may also be functional on 
microglial cells in vivo as a number of groups have demonstrated that microglial 
responses are impaired in TLR2- and TLR3-deficient rodents133-135. Therefore, 
TLR-expression by microglia may play important roles in vivo.  
1.2.1.2 Astrocytes 
Astrocytes are the most abundant cell type in the CNS. Their primary functions 
include maintenance of the BBB, uptake and metabolism of excess glutamate 
and γ-aminobutyric acid (GABA), regulation of extracellular potassium levels and 
the production of several trophic and survival factors (reviewed in Ref 136). 
However, they also play a part in innate immune responses of the CNS.  
Like microglia, primary cultured astrocytes have been reported to express a 
number of PRRs and can respond to a variety of PAMPs by producing 
inflammatory mediators. However they may not possess as wide a repertoire of 
TLRs as microglia and there are conflicting data on the precise TLR profile they 
may express. This may be due to species-specific differences in TLR expression. 
Indeed, a report by McKimmie et al. demonstrated a differential TLR repertoire 
in the CNS of three different mouse strains137. As most reports show that 
astrocytes express TLR3110-113, astrocytes have been implicated in antiviral 
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responses110,113. However, as will be discussed below, astrocytes also appear to 
express a number of functional antimicrobial PRRs and therefore express the 
appropriate receptors to recognise either viral or bacterial pathogens.  
Stimulation of astrocytes with the TLR3 ligand, polyinosinic:polycytidylic acid 
(poly(I:C)), results in the upregulation of TNFα and a number of chemokines, 
particularly CXCL10, CCL5, and to a lesser extent, CCL2110,112,113. One report also 
noted the upregulation of IFNα and IFNβ113. A similar response is seen following 
TLR9 activation of astrocytes using CpG, which leads to the production of 
inflammatory cytokines and the chemokines CCL2, CCL3, CCL4 and CXCL10114,115. 
CCL5 and CXCL10 attract activated T cell populations and NK cells which are 
integral in the host response against viral infection. Monocyte recruitment is also 
a common feature in the virus-infected brain, and accordingly, the chemokine 
profile expressed by astrocytes following poly(I:C) or CpG stimulation includes 
the expression of a number of monocyte chemoattractants, namely CCL2, CCL3, 
CCL4 and CCL5. Therefore, by expressing inflammatory and antiviral cytokines 
and by producing the chemokines necessary to attract the relevant antiviral 
leukocyte populations to the site of injury, astrocytes may play a pivotal role in 
modulating antiviral responses in the CNS. 
There is increasing evidence to suggest that astrocytes may also be able to 
respond to bacterial PAMPs in vitro as they have been reported to express TLR2, 
TLR4 and the cytosolic NLR, NOD2. Although the expression of TLR4 is not 
detected consistently110,138, many reports show that astrocytes are capable of 
responding to LPS in vitro111,113,139,140. The astrocytic response to either TLR2 or 
TLR4 ligation is remarkably similar, involving a production of the monocyte 
chemoattractants, CCL3, CCL5 and in particular, CCL2112,113,141,142. Both TLR2 and 
TLR4 ligands also induce a potent upregulation of TNFα. In addition, LPS has also 
been reported to induce iNOS expression and the production of neutrophil 
chemoattractants, such as CXCL1 and CXCL2112,113,141. Thus, the chemokine 
profile that is induced in astrocytes in response to TLR2 and TLR4 ligation is 
ideally suited to attract an influx of neutrophils and monocytes into the CNS. As 
these cell types play a pivotal role in antimicrobial responses, this would 
undoubtedly contribute to the host response against bacterial infection in the 
CNS. Furthermore, the upregulation of iNOS may lead to enhanced NO synthesis. 
NO is crucial in the host response against a number of bacterial infections 
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(reviewed in Ref 143). Although NOD2 expression has also been shown to 
contribute to inflammatory cytokine induction in astrocytes144; its role in 
chemokine induction has yet to be established. Consequently, by attracting 
antimicrobial effector cells from the periphery and by inducing the expression of 
antimicrobial agents, astrocytes may also play a role in the central immune 
response against bacterial pathogens. 
The ability of astrocytes to modulate innate immune responses in the CNS, may 
depend on the extracellular milieu. In inflammatory conditions or following TLR 
ligation, astrocytes can upregulate the expression of a number of TLRs, making 
them more efficient in their ability to recognise and respond to 
pathogens111,113,139. In addition, inflammatory cytokines have been shown to 
trigger the induction of intracellular adhesion molecule-1 (ICAM-1) and vascular-
associated adhesion molecule-1 (VCAM-1) on astrocytes113. As astrocytic 
processes ensheath the cerebral vasculature to form the glia limitans, which 
constitutes a barrier to restrict the exchange of cells and molecules between the 
CNS and the periphery145, enhanced adhesion molecule expression at this 
location may facilitate the ingress of infiltrating inflammatory leukocytes to the 
CNS parenchyma from the perivascular spaces.  
Although the role of astrocytes in pathogen recognition has been relatively 
unexplored in vivo, it is apparent that astrocytes have the potential to 
contribute to innate immune responses in the CNS by recognising a combination 
of viral and microbial pathogens and inducing an appropriate inflammatory 
response. Furthermore, by upregulating adhesion molecule expression and 
tailoring their chemokine induction, astrocytes may attract the relevant 
leukocyte populations into the brain to suit the pathological stimuli. 
1.2.2 Adaptive components in the CNS 
Recent evidence suggests that the CNS can mount successful adaptive responses 
against local antigens. As will be discussed below, antigen can be transported 
from the brain to the cervical LNs where it can be presented by APCs to naïve T 
cells. A proportion of the T cells which are primed in the cervical LNs home to 
the brain146, possibly by adopting a specific brain-homing phenotype. These may 
enter the CNS across one of the cellular barriers that protect it from the 
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periphery. Once in the CNS, T cells encounter strategically positioned APCs 
which may propagate a CNS-targeted immune response.  
1.2.2.1 Antigen drainage 
Although the CNS is devoid of conventional lymphatic vessels, there is evidence 
to suggest that CNS-derived antigen in the CSF and interstitial fluid of the 
parenchyma can drain from the brain to the cervical LNs. These pathways have 
been determined using radiolabelled and fluorescently labelled antigen. CSF 
passes through the subarachnoid space where it drains to the cervical LNs via the 
nasal lymphatics147. Interstitial fluid appears to drain from the brain along 
perivascular pathways, flowing along the basement membranes of capillaries and 
arteries sequentially until reaching the cervical LNs102. Although antigen can 
travel to the cervical LNs, whether or not brain-derived APCs can travel to LNs 
to present antigen remains controversial. The evidence for this will be discussed 
in Section 1.2.2.3. 
Once antigen reaches the LNs, it is presented by LN-resident APCs to elicit an 
adaptive immune response. A well established animal model of CNS 
autoimmunity is the immunisation of rodents with myelin-derived antigens 
emulsified in adjuvant to induce experimental autoimmune encephalomyelitis 
(EAE)148. This is generally associated with an infiltration of leukocytes across the 
BSCB and the subsequent development of inflammatory, demeylinating lesions in 
the spinal cord. Focally damaging the cerebral hemisphere seven days post-
inoculation has been shown to cause a 6-fold increase in cerebral 
inflammation149. The importance of this pathway for the initiation of immune 
responses in the brain is shown by the fact that the cerebral lesions occurring 
during EAE are markedly reduced by the removal of the cervical LNs150. 
The cervical LNs have also been implicated in driving brain-specific B cell 
responses. Injecting human albumin into the brain or CSF of rats has been shown 
to induce an antibody response in the cervical LNs; an effect that was abolished 
by cervical LN obstruction147. Together these observations suggest that antigen is 
drained from the brain to cervical LNs where it can induce antibody responses 
and activate brain-homing lymphocytes. 
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1.2.2.2 Immune Surveillance 
In the steady state, a limited number of leukocytes constitutively patrol the 
CNS; a phenomenon known as immune surveillance. Leukocytes entering the CNS 
to sample brain-derived antigen must first combat either the BCSFB, the BBB or 
BSCB. The best characterised route of leukocyte entry to the healthy brain is via 
the choroid plexus, a richly vascularised site on the ventricles of the brain where 
CSF is secreted and where endothelial fenestrations and intercellular gaps 
facilitate an easy migration of molecules and cells into the perivascular space151. 
The CSF of healthy individuals contains approximately 150 000 T cells152, the 
majority of which are TCM cells that have presumably been recruited from the 
bloodstream152,153. P-selectin recruits circulating T cells to the choroid plexus 
stroma whilst epithelial cells constitutively express leukocyte extravasation-
associated adhesion molecules P- and E-selectin, ICAM-1 and VCAM-1 on their 
apical surface153,154. Not only is T cell entry to the CNS impaired in P-selectin 
null mice155 but P-selectin glycoprotein ligand-1 (PSGL-1), a ligand for both P- 
and E-selectin, is expressed by all CD4+ TCM cells in the CSF of patients with non-
inflammatory neurological conditions156. Once across the BCSFB, TCM cells 
circulate in the CSF for several hours, scanning the surface of central APCs for 
antigen before returning to the bloodstream152,153. However, upon encounter 
with their cognate antigen in the CNS, TCM cells initiate a massive inflammatory 
response that often culminates in the invasion of inflammatory leukocytes.  
TCM cells may also cross the BBB to patrol the perivascular regions of the brain 
parenchyma where they will potentially encounter antigen displayed by 
perivascular macrophages (PVMs). Due to a network of tight junctions, trans-
endothelial migration across the BBB is severely restricted and occurs only at 
post-capillary venules152. The adhesion molecules involved in facilitating this 
migration in the steady state have not been clearly defined. It is known 
however, that non-inflamed BBB endothelium expresses CD34, ICAM-2 and to a 
lesser extent ICAM-1, but not P-selectin, E-selectin or VCAM-1157. As a result, the 
initial adherence of leukocytes to the vasculature may involve interactions 
between CD34 on the endothelium and L-selectin on the surface of TCM cells. 
Thus by a series of interactions with the highly specialised barriers that separate 
the CNS from the periphery, peripherally activated T cells with varying 
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specificities continuously enter central compartments to sample CNS-derived 
antigen. 
1.2.2.3 Professional and ‘amateur’ APCs of the CNS 
The non-inflamed brain contains relatively few professional APCs, although 
monocyte-derived DCs have been reported in the choroid plexus and the 
meninges103,158. The presence of BBB-associated DCs has also been reported in 
the healthy mouse brain159. These APCs may act as sentinels, strategically 
localised to interact with and present antigen to surveying T cells as they enter 
the CNS. Observations made by Greter et al. support this hypothesis. When T 
cells enter the CNS during EAE, they require reactivation signals from MHC class 
II-expressing APCs to induce pathology159. By crossing MHC class II-deficient mice 
with mice that express MHC class II under the control of the CD11c promoter 
(CD11c-H2-Ab1/H2-Ab1-/-), Greter et al. demonstrated that MHC class II-
expressing CD11c+ DCs were sufficient to restore pathology to mice that lacked 
all other MHC class II-expressing cell types159. As only activated T cells can enter 
the brain160, CNS-derived DCs may be intrinsically involved in restimulating T 
cells as they enter from the periphery. Following this response, a wave of 
leukocytes can rapidly infiltrate the CNS from the periphery. This leukocyte 
infiltrate has been reported to include blood-derived DCs which, once in the 
CNS, can potentiate the presentation of brain-derived antigen to infiltrating T 
cells161.  
An additional role for CNS-resident DCs may be the transportation of antigen 
from the CNS to the draining LNs. DCs in the cervical LNs have been shown to 
present myelin-derived antigen during EAE and the demyelinating autoimmune 
disease, multiple sclerosis (MS)162. It is not clear whether these DCs migrated to 
the LNs from the brain, or whether free antigen was taken up by LN-resident DCs 
after draining through the lymphatic system. However, following microinjection 
of the protein antigen ovalbumin (OVA) into the brain, labelled DCs rapidly 
accumulate at the injection site before migrating to the cervical LNs to induce a 
robust T cell response146. The resulting fully primed, OVA-specific T cells then 
adopted a CNS-homing phenotype and subsequently travelled to the brain. These 
studies suggest that DC trafficking from the brain to the cervical LNs should not 
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be ruled out as a possible mechanism of priming adaptive CNS-specific cellular 
responses. 
In addition to the classical APCs of the CNS, microglia, PVMs and astrocytes all 
share the capacity to upregulate MHC class II molecules in an inflamed 
environment. Thus, these cell types may also have a role in activating T cell 
responses in vivo. Encapsulated by the basement membrane on the abluminal 
side of the BBB, PVMs constitutively express MHC class II molecules and the 
costimulatory molecules required for antigen presentation and T cell 
activation163. Due to their strategic location these macrophages may be able to 
restimulate activated T cells as they cross the BBB. Selective depletion of PVMs 
after an intraventricular injection of chlodronate liposomes resulted in a delayed 
onset of EAE accompanied by a reduction of disease severity, suggesting a role 
for PVMs in antigen presentation in vivo164. 
The role of microglia in antigen presentation in vivo has long been debated. In 
addition to upregulating MHC class II molecules109,165, activated microglia 
upregulate costimulatory molecules, such as CD40, CD80 and CD86109,165. As 
described in Section 1.2.1.1, they also produce a number of cytokines and 
chemokines, which could shape T cell effector functions. Many studies have 
described the ability of activated microglia to prime naïve T cells and to 
reactivate effector T cells165-168. However, these studies focus on microglial 
functions in vitro. Activated microglia have also been shown to be able to cross-
present exogenous antigen in vivo after naïve CD8+ T cells were injected into 
the brain167. There is evidence to suggest that naïve T cell priming by microglia 
may be atypical. For example, although microglial-activated T cells upregulate 
the activation marker CD25 and target cells in an antigen-specific manner, they 
do not proliferate169,170. In fact, antigen presentation by microglia may act as a 
method of limiting T cell responses in the CNS by inducing the apoptosis of 
antigen-specific T cells169. The in vitro studies are limited as removing microglia 
from the constraints of their microenvironment can have a profound impact on 
their behaviour (see Section 1.2.1.1). In addition, naïve T cells are not known to 
enter the CNS. As a consequence, it is unclear whether these reports are 
biologically relevant. Nevertheless, microglia expressing MHC class II and 
costimulatory molecules have been detected in inflammatory lesions during MS 
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and EAE171-173 and therefore these cells may have a role in the secondary 
activation of effector T cells during pathology.  
Unlike microglia and PVMs, astrocytes are generally considered to be poor 
activators of T cell responses. Although they typically express very low levels of 
MHC class I, MHC class II and costimulatory molecules, several reports 
demonstrate that these surface molecules are inducible following IFNγ-
stimulation in vitro174-176. These reports, however, are not always consistent as 
some studies note a lack of costimulatory molecule (CD80 or CD86) induction 
following IFNγ treatment165,177. Furthermore in mice that overexpressed IFNγ, 
the induction of MHC class I or class II molecules could be detected in microglia 
but not astrocytes178. It has been demonstrated in vitro, that the induction of 
MHC molecules can be inhibited by the presence of other cytokines, such as 
TNFα or IL-1α179,180. Therefore, the induction of these molecules in vivo may 
depend on the exogenous cytokine milieu. Many studies have attempted to 
investigate whether IFNγ-treated astrocytes are capable of priming T cell 
responses. These studies have yielded highly variable results and almost 
exclusively focus on cultured astrocytes. For example, Constantinescu et al. 
demonstrated the capacity of cultured, IFNγ-stimulated astrocytes to induce the 
proliferation of myelin-specific T cells181. In contrast, in a similar set of 
experiments, Weber et al. showed an induction of cytotoxic T cell activity but 
an absence of proliferation181. Taken together, these studies show that whilst 
IFNγ may endow astrocytes with the ability to prime T cell responses in vitro, 
their ability to do so in vivo requires further clarification. It is unlikely that 
antigen presentation by astrocytes plays a major role in driving CNS-specific T 
cell responses.  
 
1.3 Chemokines in the CNS 
It is becoming increasingly clear that chemokines play a role in CNS responses. 
Not only are they induced in the CNS following injury or pathogenic insult, but a 
limited repertoire of chemokines and their receptors are constitutively 
expressed in discrete regions of the CNS and thus may be involved in neuronal 
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and/or glial cell communication. The involvement of relevant chemokine 
systems in homeostasis and inflammation will now be discussed below. 
1.3.1 Chemokines in CNS disorders 
Chemokines are induced in the brain following several CNS disorders. Often this 
is accompanied by the infiltration of leukocytes from the periphery. Although 
leukocyte infiltration can be beneficial to the host, for example in the clearance 
of pathogens from the CNS, it can also be detrimental. Infiltrating leukocytes 
produce a variety of inflammatory mediators which can lead to tissue damage 
and enhanced morbidity. Also, during autoimmune diseases such as MS, 
autoreactive lymphocytes can directly target CNS-derived self antigen resulting 
in demyelinating lesions and neuronal damage. Understanding the functional 
relevance of the chemokine systems that are induced in the brain during 
different CNS disorders is highly important in order to delineate those that are 
pivotal to host defence and those which contribute to pathogenesis. 
1.3.1.1 Chemokines in viral encephalitis 
Viral encephalitis is typically associated with a substantial induction of 
chemokines within the CNS. These chemokines recruit leukocytes from the 
periphery which mount an antiviral immune response. Although this is often 
required for viral clearance, as mentioned above, the effects can also be 
deleterious. Two examples of viruses that can cause encephalitis in rodents are 
West-Nile virus (WNV) and mouse hepatitis virus (MHV). The key chemokine 
systems that are involved in host defence and neuropathology following CNS 
infection with either of the aforementioned viruses have been well characterised 
and as a result, the involvement of the relevant chemokine systems has been 
described below. 
WNV is a mosquito-borne arbovirus. Due to its global distribution, it is now 
considered an endemic pathogen. Fortunately, patients who contract WNV are 
often asymptomatic and the vast majority of patients who do experience 
symptoms are merely burdened with flu-like symptoms. However, a small 
proportion of patients experience severe neurological symptoms, such as 
meningitis or encephalitis, as a result of CNS infection182. This can be lethal and 
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the majority of survivors of neuroinvasive WNV experience persistent 
neurological deficits for months to years after the infection resolves. Several 
studies using mouse models of WNV indicate that survival of WNV-induced CNS 
disease is largely dependent on the chemokine-mediated recruitment of 
leukocytes to the CNS. This is at least partially translatable to human pathology. 
For example, it has been well established that CCR5 plays a key role in 
modulating anti-viral responses in both humans and mice infected with WNV. 
Leukocyte recruitment to the CNS is fundamental for viral clearance and 
survival183-185. Genetic depletion of CCR5 is associated with a significant 
reduction of CD4+ and CD8+ T cells, NK cells and macrophages and increased 
viral load in the CNS following WNV infection183. Moreover, all CCR5-deficient 
mice succumbed to infection, compared with only 35% of wild-type mice, 
suggesting that CCR5-dependent leukocyte infiltration of the CNS is fundamental 
for successful anti-viral defence in this model. This can be reversed by the 
adoptive transfer of CCR5+ splenocytes183. Interestingly, the fraction of 
leukocytes expressing CCR5 in the CNS of wild-type mice was not large enough to 
account for the substantial reduction of leukocytes observed in the CNS of CCR5-
deficient mice. Therefore, the accumulation of CCR5-bearing leukocytes in the 
CNS may trigger further leukocyte recruitment in a CCR5-independent manner. 
This is likely to be at least partially dependent on interactions between CXCR3 
and one of its ligands CXCL10, which is highly upregulated in the CNS of WNV-
infected mice186-188. Blocking the effects of CXCL10, either using neutralising 
antibodies, CXCL10- or CXCR3-deficient mice, led to impaired CD8+ T cell 
trafficking to the CNS, failure to control viral replication and subsequently 
reduced survival rates187,188. The CCL2/CCR2 axis also appears to play a role in 
anti-viral CNS responses to WNV as a reduction in infiltrating monocytes was 
noted in the CNS of virally-infected CCR2-deficient mice186. However, this 
observation was shown to be a result of monocytopenia in the blood rather than 
a defect in monocyte recruitment to the CNS. Impaired monocyte accumulation 
in the CNS was associated with increased viral burden and mortality. Therefore, 
chemokines, produced in the brain and in the periphery, are pivotal in 
coordinating leukocyte levels in the blood and their subsequent recruitment to 
the CNS. Chemokine-mediated accumulation in the CNS is required for the host 
to mount a successful anti-viral response following WNV infection. 
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Complimenting the data derived from the murine models of WNV, a role for 
CCR5 has also been established in human pathology. This was determined by 
genotyping cohorts of Caucasian patients with symptomatic WNV to compare the 
frequency of the CCR5 loss-of-function allele, CCR5Δ32, with that of the general 
population. Unsurprisingly, the frequency of individuals homozygous for the 
CCR5Δ32 allele was markedly higher in symptomatic WNV patients than in the 
general population189. In one cohort, homozygosity for this allele was 
significantly linked to fatality. Therefore, consistent with the data from murine 
models, CCR5 deficiency is a major risk factor for symptom presentation 
following WNV infection. 
Chemokines are also required for mice to successfully clear MHV infection in the 
CNS. However, in some cases, chemokine production in the CNS can lead to 
excessive tissue damage. MHV is a corona virus. When injected intracranially, 
neurotropic strains of MHV trigger an acute encephalomyelitis followed by 
chronic demyelinating disease that is phenotypically similar to the human 
autoimmune disease, MS190. One of the chemokine axes shown to be pivotal in 
coordinating the host response against MHV is the CCL2/CCR2 axis. CCL2 is 
rapidly induced in the brain following MHV infection191. In the absence of its 
receptor, CCR2, mice were unable to clear the virus from the CNS and therefore 
all succumbed to infection191. This was associated with a significant decrease in 
CD4+ T cell and macrophage infiltration and a reduction in IFNγ production in 
the CNS. Therefore, CCL2 induction in the CNS, and the subsequent recruitment 
of CCR2-expressing macrophages, is required for the successful clearance of MHV 
from the CNS. 
Within a day of viral administration, CXCL10 can be detected in the brain 
colocalised with viral infection192. As the infection disseminates throughout the 
CNS parenchyma, so does the expression of CXCL10, produced predominantly by 
astrocytes. CXCL10 plays a major role throughout the course of the disease. In 
the acute stages of MHV infection, this role is beneficial. CXCL10 is involved in 
recruiting CD4+ and CD8+ T cells to the CNS, both of which are required for anti-
viral defence. In the absence of CXCL10, this process is markedly reduced, 
resulting in impaired viral clearance and increased mortality193,194. CXCL10 
expression is also required for the induction of CXCL9 and CCL5 in the CNS190,193. 
The majority of T cells infiltrating the brain during MHV infection express the 
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chemokine receptor CXCR3, and unsurprisingly, CXCL9 has also been shown to 
contribute to T cell recruitment to the CNS195. Although they are crucial for 
survival, infiltrating T cells contribute to a progressive accumulation of 
macrophages in the CNS. Macrophages are the end-stage effector cells in 
demyelinating diseases. By producing inflammatory mediators which generate 
bystander tissue damage, macrophages amplify demyelination. One of the key 
chemokine axes responsible for their recruitment is the CCL5/CCR5 axis. CCL5 
expression is triggered by the CXCL10-induced infiltration of CD4+ T cells190. This 
has no benefit to the host as blocking the effects of this axis using CCR5-
deficient mice had no effect on viral clearance196. In fact, blocking the 
CCL5/CCR5 axis, either using CCL5-specific neutralising antibodies or CCR5-
deficient mice, led to a clear reduction of macrophage infiltration, 
demyelination and subsequent disease severity197,198. Therefore, by recruiting 
virus-specific CD4+ and CD8+ T cells to the brain during MHV infection, the acute 
induction of CXCL10, followed by CXCL9 plays a crucial role in anti-viral 
defence. However, one caveat to the induction of CXCL10 in the brain is that 
recruited CD4+ T cells trigger CCL5 production, inevitably leading to the 
destructive infiltration of CCR5-expressing macrophages. 
Thus, a number of chemokines are induced in the CNS following viral infection. 
The data described above suggest that the induction of chemokines targeting the 
receptors CXCR3, CCR2 and CCR5 play an important role in the recruitment of T 
cells, NK cells and macrophages from the circulation. Depending on the nature 
of the insult, the infiltration of these cell populations can be beneficial to the 
host, promoting viral clearance from the CNS, or deleterious, leading to 
bystander tissue damage. 
1.3.1.2 Chemokines in MS and EAE 
MS is a chronic, inflammatory autoimmune disease of the CNS. It is characterised 
by accumulation of autoreactive and inflammatory leukocytes which form 
demyelinating lesions within the CNS parenchyma. Many studies have attempted 
to analyse and interpret the involvement of specific chemokine systems in MS 
pathology and much of our current understanding of these systems is derived 
from observations made using rodent models of demyelinating diseases, like EAE. 
In terms of immune cell components, MS is primarily a T cell- and macrophage-
53 
mediated pathology. Three chemokine receptors that are considered highly 
important in mediating the recruitment of these leukocyte populations to the 
CNS during multiple other pathologies are CCR2, CCR5 and CXCR3183,186-
188,191,193,194,197,198. Interestingly, CCR5 expression has been described on 
monocytes and lymphocytes in the CSF and lesions of MS patients156,199-201, and 
elevated levels of CCL3 and CCL5 have been observed both in lesions and in the 
CSF of MS patients during relapse202-204. In addition, increased expression of CCL3 
and CCL5 has been reported in the CSF of animals with EAE205-207. However, 
neither CCL3- or CCR5-deficient mice are resistant to EAE208, nor is there an 
association with CCR5Δ32 allele homozygosity and protection against MS209. This 
suggests that CCR5 is not essential for MS or EAE pathogenesis, possibly as a 
result of the high level of redundancy in chemokine systems. In the absence of 
CCR5, the chemokines CCL3 and CCL5 may recruit CCR1-expressing leukocytes to 
the CNS. In support of this, CCR1-deficient mice exhibit a reduction in both 
severity and incidence of EAE210. Furthermore, CCR1 antagonism ameliorated 
disease phenotype in a rat model of EAE211. As a result, CCR1 blockade was 
considered a potential treatment target in MS patients. Disappointingly, the 
CCR1 antagonist did not prove beneficial in clinical trials212. 
The majority of CD4+ T cells that patrol the CSF of patients with MS and non-
inflammatory neurological diseases express CXCR3156,213. However, the same is 
true for T cells in the CSF of patients with no neurological diseases214. 
Therefore, although CXCR3 may mediate T cell entry to the CSF, this does not 
appear to require neuroinflammation. Interestingly, during MS relapses, an 
increased proportion of CD4+ T cells have been reported to express CXCR3 in 
both peripheral blood and CSF compared to that of patients in remission202,213. In 
both studies, this was associated with increased disease activity. In addition, 
proximal to demyelinating lesions, the majority of T cells in perivascular cuffs 
were reported to express CXCR3214.  Moreover, CXCL10 expression was shown to 
be elevated both in demyelinating lesions214 and in the CSF of MS patients during 
attacks200. Although these observations suggest that CXCR3 ligands may be 
involved in recruiting T cells to the brain during MS, the involvement of this 
chemokine axis has been difficult to confirm in EAE models. Blocking the actions 
of either CXCL10 or its receptor CXCR3 using neutralising antibodies has had 
variable effects on the incidence and severity of EAE215-218. However, studies 
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using CXCL10- or CXCR3-deficient rodents consistently suggest that this 
chemokine axis is not essential for the recruitment of mononuclear cells to the 
CNS216,218-220. In fact, most studies agree that EAE is exaggerated in animals 
lacking either molecule216,218,220. It has been reported that glial cells produce 
CXCR3 ligands in response to IFNγ221. Therefore, during MS and EAE, the 
expression of CXCR3 on infiltrating T cells and the induction of CXCR3 ligands in 
the CNS may represent an epiphenomenon that occurs as a result of IFNγ-
producing encephalitogenic T cells accumulating in the CNS in response to other 
mediators. 
The CCL2/CCR2 axis has a fundamental role in the induction of EAE and is 
therefore likely to contribute to MS pathology. In MS patients, CCL2 is highly 
expressed by reactive astrocytes within demyelinating lesions and in the 
surrounding parenchyma204,222. Surprisingly, the concentration of CCL2 is 
consistently depleted in the CSF of MS patients compared to patients with other 
inflammatory diseases200,223. This has been hypothesised to occur as a result of 
increased CCL2 uptake by infiltrating CCR2+ monocytes224. Although central CCL2 
production is assumed to facilitate the specific recruitment of CCR2-expressing 
mononuclear cells from the periphery, an explicit role for this chemokine and its 
receptor in contributing to MS pathology has not yet been verified. In addition to 
being expressed in MS lesions, CCL2 is also expressed by astrocytes nearby 
inflammatory foci in the CNS of animals with EAE225,226. Confirming a major 
involvement of this chemokine system in EAE pathogenesis, it has been reported 
that EAE is either markedly attenuated or completely absent in mice lacking 
either CCL2 or CCR2227-229. Although this provoked the development of CCR2 
antagonists for the treatment of MS, these inhibitors failed to show any 
improvements in clinical trials230.  
These studies highlight a number of chemokines and chemokine receptors that 
play a role in the recruitment of mononuclear cells to the CNS during MS and 
EAE. However, these represent only a few of the many chemokine systems that 
are potentially involved. For example, CCR7 is expressed on the majority of TCM 
cells in the CSF of MS patients and on infiltrating DCs in MS lesions. Its ligands, 
CCL19 and CCL21 have also been characterised on the luminal surface of the BBB 
during EAE231,232. In addition, there may be a role for the CCL20/CCR6 axis in the 
trafficking of T cells to the CNS across the choroid plexus epithelium during the 
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initial stages of EAE233. A number of other chemokine systems have also been 
implicated in MS and EAE pathogenesis. These have been reviewed extensively in 
Ref 234. Despite the characterisation of the chemokine profile present in lesions 
and CSF of MS patients and the identification of the chemokine systems that are 
crucial for the induction of EAE, the key chemokines responsible for MS 
pathogenesis remain poorly defined. This is at least partially because the 
knowledge gained from EAE models does not always accurately translate across 
species. Another major issue in deciphering the involvement of specific 
chemokine axes in MS is that the therapeutic use of chemokine receptor 
antagonists has so far failed to show any benefits in clinical trials. It is unclear 
whether the observed lack of improvement in these trials is due to chemokine 
redundancy or a failure in the efficacy of the receptor antagonists. As a result, 
there have been very few advances in this field in the past decade. 
1.3.1.3 Central chemokine induction in response to systemic inflammation 
Very little has been published relating to chemokine induction in the brain 
following systemic inflammation. The majority of the research in this area 
focuses on central chemokine responses following the systemic administration of 
TLR ligands in experimental rodent models of inflammation. In these models, 
systemic LPS-induced inflammation is commonly associated with a central 
upregulation of the neutrophil chemoattractants, CXCL1 and CXCL2, and a 
number of CC and other CXC chemokines235-238. These include CCL2, CCL5 and 
CXCL10, which are known for their role in the infiltration of leukocytes to the 
CNS during viral encephalitis (Section 1.3.1.1). A similar chemokine repertoire 
has also been reported following peripheral administration of poly(I:C)239,240. 
However these studies are primarily focused on transcriptional data. Thus, 
systemically stimulating mice with certain TLR ligands can lead to an induction 
of chemokines in the brain. 
Although many different chemokines are induced in the brain following systemic 
TLR3- or TLR4-induced inflammation, the function of these chemokines remains 
largely unexplored. The upregulation of CXCL1 and CXCL2 in the brain following 
high systemic doses of LPS has been associated with an influx of neutrophils to 
the CNS236,237. Although it is not required for neutrophil rolling and adhesion to 
the cerebral vasculature, CXCR2 expression was shown to be necessary for 
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neutrophils to invade the brain parenchyma237. The remainder of the 
chemokines, induced in the brain in response to LPS, are known to recruit T 
cells, NK cells and monocytes/macrophages to sites of inflammation (Section 
1.1.6). However, to my knowledge, there have been no reports of any of these 
cell populations infiltrating the brain following systemic LPS challenge. Although 
a similar phenomenon has yet to be described during systemic LPS-induced 
inflammation, the central upregulation of CCL2 has been shown to recruit 
monocytes to the brain in an experimental murine model of hepatic 
inflammation241. Therefore, depending on the context, central chemokine 
expression triggered in response to systemic inflammation can result in the 
recruitment of inflammatory leukocytes to the brain. 
The chemokines CCL3 and CCL5 have been described as endogenous pyrogens. 
Both are induced in the brain in response to systemic LPS challenge238, thus their 
production in the brain may play a contributing role in the development of 
fever. In rats, microinjection of CCL5 into the hypothalamus induced a febrile 
response242,243. This was ameliorated by pretreating rats with either a 
microinjection of CCR5-specific monoclonal antibodies into the same site or an 
intravenous injection of the CCR1/CCR5 antagonist, Met-CCL5. Met-CCL5 also 
suppressed the febrile response in rats following intravenous LPS injection243, 
suggesting that CCR1 and/or CCR5 ligands contribute to LPS-induced fever in 
rats. In addition to the de novo expression of inflammatory chemokines in the 
brain, it has been recently demonstrated that systemic LPS-induced 
inflammation results in the reduced expression of CX3CR1244; a chemokine 
receptor which plays a prominent role in maintaining CNS homeostasis (1.3.2.2). 
This effect, which is particularly pronounced in aged mice, results in microglial 
hyperactivation. In a study using CX3CR1-deficient mice, overt microglial 
activation following systemic LPS challenge lead to prolonged social 
withdrawal245. This was associated with elevated microglial expression of IL-1β 
and indoleamine 2,3 dioxygenase (IDO), both of which are implicated in the 
development of inflammation-induced behavioural changes (Section 1.4.3). 
These data suggest that, in response to systemic inflammation, the central 
modulation of chemokines and their receptors may have downstream 
implications on neuroinflammation and the subsequent development of sickness 
behaviours. 
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1.3.2 Chemokines in CNS homeostasis 
In addition to their role in CNS disorders, it has been suggested that chemokines 
may be intrinsically involved in CNS homeostasis. Both neurons and glial cells 
constitutively express a number of chemokines and their receptors in spatially 
specific regions of the adult brain. However, the functional significance of this 
expression remains largely unclear. Often, the neuroanatomical distribution of 
chemokines and their specific receptors overlap giving rise to the hypothesis 
that these chemokines may have a role in basal communication between neurons 
and glia.  
1.3.2.1 Chemokines as neuromodulators 
It has been suggested that chemokines may function as a class of 
neuromodulator; being released at nerve endings and having pre- and post-
synaptic effects, both directly and indirectly by modulating the activity of 
‘classical’ neurotransmitters. The chemokines that have been most widely 
studied in this field are CXCL12 and CCL2. The involvement of these chemokines 
and their receptors in CNS homeostasis will be summarised below, including any 
evidence supporting the potential involvement of chemokines in modulating 
synaptic transmission. 
CXCL12 and its receptor, CXCR4, are highly expressed throughout the brain 
during emryogenesis and the CXCL12/CXCR4 axis is a critical component in 
orchestrating brain development. However, high levels of constitutive 
expression, of both ligand and receptor, persevere into adulthood in highly 
regionalised areas of the brain246,247. As well as being expressed by microglia and 
astrocytes, both ligand and receptor are expressed by neurons. Anatomically 
mapping CXCL12 and CXCR4 expression in the adult rat brain revealed that 
serotonergic neurons in the dorsal raphe nucleus, cholinergic neurons in the 
substantia innominata and dopaminergic neurons in the substantia nigra 
expressed both receptor and ligand246-248. CXCL12 and CXCR4 are also both 
expressed in hypothalamus and the prosterior pituitary247,249. Interestingly, in 
the latter sites, both CXCL12 and CXCR4 were colocalised with vasopressin in 
presynaptic nerve terminals indicating the possibility that CXCL12 may be 
released at neuronal synapses249.  
58 
Although it is generally considered to be an inflammatory chemokine, animal 
studies have shown that CCL2 is also constitutively expressed in the brain, along 
with its receptor, CCR2250,250-252. As with CXCL12 and CXCR4, neuroanatomical 
mapping of CCL2 and CCR2 has demonstrated the presence of both receptor and 
ligand on cholinergic, dopaminergic and vasopressin-expressing neurons250,252. As 
a result, several studies have attempted to investigate the potential involvement 
of CXCL12/CXCR4 axis and the CCL2/CCR2 axis in modulating neuronal 
transmission. 
Electrophysiological recordings, using whole cell patch clamp, have 
demonstrated that exposing neuronal subtypes from the relevant brain regions 
to CXCL12 can modulate neuronal membrane potential, often triggering action 
potentials. For example, CXCL12 has been shown to have depolarising effects on 
serotonergic neurons from the dorsal raphe nucleus248. This was attributed to the 
presynaptic release of both glutamate and GABA. CXCL12 also enhanced GABA-
induced inhibitory currents in dopaminergic neurons from the substantia nigra253. 
In contrast, CXCL12 was shown to have an inhibitory effect on the firing of 
vasopressin neurons249. Electrophysiological experiments have also demonstrated 
that CCL2 can affect neuronal membrane potential. CCL2 was shown to enhance 
the excitability of hippocampal neurons and dopaminergic neurons in the 
substantia nigra254,255. The subsequently increased neuronal firing that was 
observed in the hippocampus was attributed to elevated glutamatergic 
transmission. CCL2 can also induce calcium (Ca2+) transients in primary cultured 
neurons isolated from a number of other different brain regions250. Chemokine-
induced changes in membrane potential may have downstream consequences on 
the release of neurotransmitters or neurohormones. Indeed following-up the 
electrophysiological experiments with in vivo studies have shown that injecting 
CXCL12 into the third ventricle inhibits the release of vasopressin into the 
blood249. Moreover, injecting either CXCL12 or CCL2 into the substantia nigra 
stimulated a rapid release of dopamine into the striata255,256. In either case this 
was accompanied by enhanced locomotor function. Collectively, these data 
suggest that chemokines may have the capacity to modulate neuronal 
transmission. This appears to occur indirectly through the modulation of 
neurotransmitter release, specifically glutamate and/or GABA. 
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Although intriguing, these studies are limited as they invariably involve exposing 
the brain, or brain slices, to high concentrations of the relevant chemokines. 
There is no literature to suggest that this is representative of what occurs under 
physiological conditions in vivo. From the described experiments, it is unclear 
whether CXCL12 or CCL2 act directly on neurons to modulate the release of 
neurotransmitters or whether they function primarily on glial cells to govern 
neurotransmitter uptake. Moreover, it is worth noting that chemokines, 
particularly inflammatory chemokines such as CCL2, induce the expression of a 
number of other mediators. Thus, when interpreting observations derived from 
injecting a chemokine into the brain, it is difficult to delineate between the 
direct effect of the chemokine and the potential indirect effects of inducible 
agents. Taken together, these observations demonstrate that, under 
experimental conditions, chemokines have the capacity to indirectly impact 
neuronal membrane potential resulting in altered neuronal transmission. By 
doing so, chemokines may be able to modulate neuroendocrine functions and 
neurotransmitter release in steady state conditions. However, this remains to be 
clarified in vivo. 
1.3.2.2 Maintaining microglial quiescence 
CX3CL1 is the exclusive member of the CX3C chemokine family. It is 
constitutively expressed by neurons in spatially specific regions of the 
brain257,258. Although the exact function of CX3CL1-expressing neurons remains to 
be established, the CX3CL1 receptor, CX3CR1, is constitutively expressed 
throughout the brain by microglial cells257,258. As a result, much research has 
gone into elucidating the role of the CX3CL1/CX3CR1 axis in the brain. A 
fundamental tool that has been widely beneficial in accelerating these studies 
has been the replacement of Cx3cr1 with a green fluorescent protein (GFP) 
reporter gene. Creating a CX3CR1 null locus, the generation of CX3CR1gfp mice 
has enabled phenotypic comparisons between CX3CR1+/+, CX3CR1gfp/+ and 
CX3CR1gfp/gfp mice259. Analyses of these mice have identified a number of 
phenotypes resulting from the lack of CX3CR1 signalling. For example, CX3CL1 
has been shown to exert a potent restraining influence on microglia in vivo. 
Using CX3CR1 deficient mice, several groups have described elevated microglial 
activation, often accompanied with increased cytokine production following the 
induction of CNS diseases or systemic LPS challenge128,245,260-262 (Section 1.3.1.3) 
60 
Although these observations relate to microglial responses during 
neuroinflammatory and neurodegenerative disorders, microglia are 
constitutively exposed to CX3CL1. Therefore, CX3CR1 ligation may have a 
physiological role in maintaining microglial quiescence in steady state 
conditions. 
Supporting the concept described above, impaired signalling through CX3CR1 has 
been shown to enhance microglial activation in the hippocampus of healthy 
rodents130,263. In the adult brain, microglia have been shown to shape 
hippocampal neurogenesis through the phagocytosis of apoptotic neuroblasts264. 
Two separate studies have demonstrated that disrupting CX3CL1-mediated 
signalling in rodents, by either administering CX3CR1-specific monoclonal 
antibodies or using CX3CR1-deficient animals, resulted in impaired hippocampal 
neurogenesis130,263. In both studies, reduced neurogenesis was accompanied by 
enhanced hippocampal microglial activation and elevated levels of hippocampal 
IL-1β. Rodgers et al. also noted impaired synaptic plasticity and cognitive 
function in CX3CR1 deficient rodents130. Interestingly, the described deficits 
could be reversed in either study by infusion of the IL-1 receptor antagonist (IL-
1ra)130,263. Not only do these studies highlight a potential role for IL-1β in 
modulating adult neurogenesis, but they implicate the CX3CL1/CX3CR1 axis in 
suppressing microglial activation and inflammatory cytokine production during 
physiological conditions. 
 
1.4 Peripheral inflammation and behaviour 
Although the immune system was once considered autonomous, there is now 
considerable evidence to suggest that immune responses are in part conducted 
by the sympathetic nervous system and the hypothalamic-pituitary-adrenal 
(HPA) axis (reviewed in Ref 265). The immune system responds in kind. Through 
the release of inflammatory mediators, the immune system rapidly alerts the 
brain to peripheral inflammation, ultimately invoking an appropriate behavioural 
response. Thus the immune system and the nervous system are intimately 
interlinked. This bi-directional interplay is essential in mounting a successful 
response to pathogens. 
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1.4.1 Evidence of inflammation-induced behavioural changes 
It is well established that systemic infection or inflammation can have marked 
effects on mood and behaviour. These behavioural changes, termed sickness 
behaviours, include fever, somnolence, loss of appetite, social withdrawal, 
anhedonia, malaise and impaired motor and cognitive function266,267. Sickness 
behaviours are highly conserved, occurring in many mammalian species as a 
result of numerous types of infection268. By promoting energy conservation and 
minimising heat loss, they represent a sound strategy designed help an organism 
overcome infection. As will be described below, sickness behaviours also occur 
during chronic inflammatory diseases. In these instances, what should be a 
beneficial, self-limiting system can become dysregulated. This can lead to a 
maladaptive behavioural response characterised by prolonged depression and 
anxiety. In the remainder of this section, the evidence backing the immune 
system as a key contributor to the behavioural symptoms of sickness will be 
discussed, as will the routes of immune-to-brain communication and the 
potential mechanisms of inflammation induced sickness behaviours. 
1.4.1.1 Cytokine-induced behavioural changes 
Acute or chronic exposure to cytokines or potent inflammatory agents, such as 
LPS, induces a variety of behavioural symptoms in both humans and rodents. 
Thought to be mediated by the actions of inflammatory cytokines TNFα, IL-1β 
and IL-6, these behavioural phenotypes often markedly resemble symptoms of 
major depression.  
In the last 15 years, a number of human studies have been aimed at investigating 
the impact of peripheral endotoxin-induced inflammation on mood and 
cognition. In a study using healthy volunteers, the administration of LPS elicited 
an acute behavioural response characterised by significantly elevated depression 
and anxiety within the first few hours following treatment269. These behavioural 
phenotypes were significantly correlated with elevated plasma levels of TNFα 
and IL-6. Furthermore, inducing low-grade inflammation by injecting healthy 
volunteers with a Salmonella typhi vaccination has been shown to negatively 
affect mood and cognitive function270-272. These symptoms correlated with 
elevated levels of circulating IL-6. Thus, in humans, elevated levels of 
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circulating cytokines may guide the behavioural response by transmitting 
peripheral inflammatory signals to the brain. 
Although intriguing, the findings described above are limited as they focus on a 
highly acute inflammatory insult. Under physiological conditions, most 
inflammatory pathologies will be more chronic in nature. In addition the 
correlation between depression and elevated peripheral cytokines may represent 
an epiphenomenon. There are however several lines of evidence linking chronic 
inflammatory stimulus and specific cytokines to profound changes in mood and 
behaviour. The manifestation of major depressive disorders is a common 
comorbidity associated with chronic inflammatory diseases. Strikingly, 
approximately 50% of patients with multiple sclerosis will present with a 
psychiatric illness during their lifetime, with major depression being the most 
common273. This association is not limited to inflammatory diseases of the CNS. 
Patients with peripheral chronic inflammatory disorders, such as rheumatoid 
arthritis, psoriasis and inflammatory bowel disease, are also at a greater risk of 
developing major depression than the general population274-276.  
Although once considered of psychosocial aetiology, the manifestation of major 
depressive disorders in patients with chronic inflammatory diseases may occur 
through the direct effects of peripheral inflammatory cytokines. Supporting this 
hypothesis are the results of a phase III clinical trial in which patients with 
moderate to severe psoriasis were treated with soluble TNFα receptor 
Etanercept. Neutralisation of TNFα caused a reduction in depression which 
preceded a reduction in disease severity276. Further supporting the notion of 
cytokine-induced depression; patients receiving chronic IFNα or IL-2 therapy face 
a significant risk of experiencing neuropsychiatric side effects during 
treatment277,278. Both recombinant cytokines are used therapeutically to treat 
chronic hepatitis C and various malignancies. Occurring in approximately one 
third of patients279, IFNα-induced depressive symptoms markedly resemble 
symptoms of idiopathic major depression. Moreover, these symptoms can be 
prevented by pre-treatment with anti-depressant medication277,278. Less 
predictable are the neuropsychiatric side effects induced by IL-2 which have 
been reported to include belligerence, gross disorientation and possible 
psychosis280. 
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Supporting these clinical data, it is well established that injecting rodents with 
inflammatory cytokines or cytokine-inducing agents induces a myriad of sickness 
behaviours. Using animal models to investigate sickness behaviours and 
depression-like behaviours has been widely beneficial in developing our 
understanding of the underlying mechanism behind inflammation-induced 
behavioural changes. Specifically it has confirmed the importance of specific 
inflammatory cytokines in transmitting information to the brain. For example, 
injecting rodents systemically with LPS, a potent inducer of IL-1β, IL-6 and 
TNFα, triggers the full spectrum of sickness behaviours, including fever, 
anorexia, decreased motor activity and activation of the HPA axis281-285. 
Inflammatory cytokines are thought to be the principle mediators of LPS-induced 
sickness behaviours as similar behavioural symptoms occur in response to 
centrally or systemically administered recombinant IL-1β or TNFα286-291. Indeed 
blocking IL-1β signalling, either using IL-1 receptor deficient mice or by 
administering IL-1ra, can ameliorate many of the behavioural phenotypes 
induced by LPS292-295.  
It is worth noting that a number of LPS- or cytokine-induced sickness behaviours 
strikingly resemble the clinical symptoms of depression, such as anhedonia and 
social withdrawal266. In addition, a number of LPS-induced sickness behaviours 
can be treated with conventional antidepressants296-298. These observations have 
led to attempts to form a distinction between sickness behaviours and so-called 
depression-like behaviours. This is no easy task. The idea that rodents 
experience “depression” is controversial. Moreover considerable overlap exists 
between sickness and depression-like behaviours. Despite these complexities, a 
study by Frenois et al. demonstrated that 24 hours following systemic LPS 
injection, long after mice had recovered from the potentially confounding 
influence of reduced motor activity and loss of appetite, mice presented with 
behaviours resembling depressive symptoms299. These were characterised by a 
prolonged duration of immobility during the forced-swim test, understood to 
represent behavioural despair, and a decreased preference for sucrose which is 
thought to be a sign of anhedonia. Thus, although symptoms of sickness and 
depression may be difficult to distinguish in rodents it is possible that, in the 
hours following LPS injection, a distinct fraction of depressive-like behaviours 
persevere after other sickness behaviours resolve. 
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Overall, the evidence to suggest that cytokines can have a negative impact on 
mental wellbeing is compelling. The mechanisms by which cytokines, and 
cytokine inducing agents such as LPS, transmit signals to the brain and the 
downstream effect this is thought to have on neural circuitry will be discussed in 
detail in Sections 1.4.2 and 1.4.3. 
1.4.1.2 Depression and inflammatory cytokines 
Not only have inflammatory cytokines been shown to contribute directly to 
symptoms of depression but medically healthy patients with major depression 
often present with elevated levels of inflammatory mediators in their 
circulation. These include inflammatory cytokines, such as IL-1β, IL-2, IL-6, IFNγ 
and TNFα, the soluble IL-6 receptor, sIL-6R and the IL-1 receptor antagonist300. 
Although the specific association of individual cytokines, and soluble cytokine 
receptors/receptor antagonists, with major depression has been variable 
between reports, the underlying theme of enhanced immune activation has been 
constant. To combat the variability between individual reports, a meta-analysis, 
performed by Dowlati et al. confirmed the significant elevation of both IL-6 and 
TNFα in patients with major depression300. Thus major depression is consistently 
associated with enhanced immune activation and the inflammatory cytokines IL-
6 and TNFα may be reliable biomarkers in pathology. 
The immune dysfunction that accompanies major depression is likely to be of 
clinical importance as inflammatory mediators may contribute to pathology 
(Section 1.4.3). As described above, anti-inflammatory agents have proven 
beneficial in ameliorating depressive symptoms in patients with chronic 
inflammatory diseases. Furthermore, several studies have shown that treating 
medically healthy depressed patients with immune-targeted therapy, specifically 
COX inhibitors, in combination with antidepressants showed greater efficacy in 
combating depression than antidepressants alone301-303. In a study by Mendlewich 
et al. patients treated with COX inhibitors in combination with antidepressants 
showed remission despite being initially unresponsive to antidepressant therapy 
alone303. Cyclooxygenases are the rate-limiting enzymes in the synthesis of 
prostaglandins. Prostaglandins have a role in modulating inflammatory responses 
in the periphery (Reviewed in Ref13) and are implicated in the transmission of 
immune signals across the BBB (see Section 1.4.2.2). As a result, the beneficial 
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effects of COX inhibition are likely due to the subsequent impairment of these 
processes. Thus, prostaglandin-induced responses are likely to contribute to the 
pathogenesis of major depression. 
1.4.2 Routes of immune-to-brain communication 
Under normal homeostatic conditions, the CNS is protected from the changeable 
and potentially pathogenic milieu of the periphery by the BCSFB and the BBB. 
Due to the delicacy of the CNS and the danger of intrathecal swelling, the entry 
of immune cells and inflammatory mediators is tightly regulated. However, the 
brain must be able to respond to changes in the peripheral inflammatory 
environment otherwise the behavioural phenotypes that accompany infection, 
chronic peripheral inflammation and cytokine therapy would not be seen. The 
precise mechanisms by which these peripheral immune challenges are 
communicated to the brain to induce sickness behaviours remain to be fully 
clarified. Several pathways, which will be discussed below, have been 
implicated in this immune-to-brain interplay. These are assumed to primarily 
involve the intermediary action of inflammatory cytokines and cytokine-induced 
secondary messengers, such as prostaglandins. Using animal models, it has been 
demonstrated that most sickness behaviours can be induced by peripheral or 
central administration of either IL-1β or TNFα286-291. Furthermore, a number of 
the central responses to peripheral inflammation, and the resulting behavioural 
phenotypes, can be attenuated by blocking the effects of IL-1β (discussed in 
Section 1.4.3). Although not a requisite for any of the psychiatric symptoms, IL-6 
is required for the induction of a fever response281. Thus, from these studies it is 
abundantly clear that cytokines may play a crucial role in immune-to-brain 
communication and sickness behaviour induction. 
1.4.2.1 Active cytokine transport 
The BBB is an endothelial lining of the cerebral vasculature. Its specialised 
transport systems severely restrict the transcellular exchange of molecules 
between the periphery and the CNS. Inflammatory cytokines, such as IL-1α, IL-
1β, IL-6 and TNFα, are amongst the repertoire of proteins and peptides that can 
be actively transported across the BBB304-307. Several studies have demonstrated 
that peripherally administered radiolabelled cytokines have the capacity to 
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enter the CNS304-307, even when the BBB remains intact. This unidirectional influx 
can be inhibited by the administration of excess unlabelled cytokines, indicating 
the presence of cytokine-specific, saturable active transport systems. The 
function of these receptors may be modulated in pathological settings. For 
example, activity of the TNFα transporter is increased following spinal cord 
injury or stroke307,308. Interestingly, LPS has been shown to modulate the active 
transport of insulin and amyloid-β across the BBB309,310. However, the effect of 
LPS on the transport of inflammatory cytokines remains to be established. 
Cytokine transporters function at a low capacity and are quickly saturated. 
Whilst a role for active cytokine transport in the induction of sickness 
behaviours, particularly in memory processing, has been inferred311, the 
evidence supporting active transport as a key route of immune-to-brain 
communication is minimal.  
1.4.2.2 Humoral routes of communication 
Peripheral inflammatory mediators and cytokine inducers, such as LPS, can 
signal to the brain via several humoral routes of communication. Both cytokines 
and LPS can activate the brain endothelium, thus relaying signals across the BBB. 
In addition, blood-borne inflammatory agents may activate certain brain regions 
directly.  
In general, the BBB protects the brain from the periphery. However, there are 
small specialised brain regions surrounding the margins of the cerebral 
ventricles, termed the circumventricular organs (CVOs), which lack a 
conventional BBB. In these regions, which possess a fenestrated endothelium, 
neurons and microglia may be exposed to circulating inflammatory mediators. 
Supporting this, the expression of the immediate-early gene c-Fos, a classic 
indicator of neuronal activation, is induced in sensory CVOs of the rat brain 
following the intraperitoneal administration of LPS or the intravenous injection 
of IL-1β, IL-6 or TNFα312-314. Furthermore, IL-1β, IL-6 and TNFα mRNA is rapidly 
induced in these regions in response to systemic LPS, but not in response to the 
intravenous injection of inflammatory cytokines312,313,315. This suggests that LPS 
may have a direct role activating cells in the CVOs, as well as an indirect role via 
the induction of inflammatory cytokines. Indeed, TLR4 is widely expressed 
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throughout the CVOs316. In addition to neuronal activation, characterised by c-
Fos induction, systemic administration of LPS triggers a wave of microglial 
activation that is dependent on the paracrine effects of TNFα317-319. Beginning 
mainly in the CVOs, but also in the choroid plexus and the leptomeninges, this 
response extends to adjacent brain structures and after high doses of LPS, 
spreads throughout the parenchyma. Thus, circulating cytokines and LPS have 
the capacity to induce neuronal activity in the CVOs. In addition, systemic LPS 
challenge can induce local inflammation and microglial activation in the CVOs. 
Via the paracrine effects of TNFα, this culminates in the activation of microglia 
throughout the parenchyma.  
A more defined route of immune-to-brain communication is the activation of the 
BBB by blood-borne inflammatory agents. Via a complex interplay between 
endothelial cells and perivascular macrophages (PVMs), this leads to the 
synthesis of prostaglandins. In turn, prostaglandins can freely diffuse into the 
parenchyma and activate discrete brain regions. In fact, a number of brain 
responses to peripheral inflammation, such as fever and HPA axis activity, are at 
least partially dependent on prostaglandins, particularly prostaglandin E2 (PGE2) 
320,321. This demonstrates the pivotal role of BBB activation in transmitting 
peripheral immune signals to the brain.  
Cytokines stimulate cells associated with the BBB endothelium by signalling 
through cytokine receptors to activate the inflammatory transcription factor 
NFκB. In support of this, intravenous IL-1β or TNFα administration triggers a 
rapid and transient induction of IκB-α throughout both large and small vessels of 
the brain vasculature and in scattered parenchymal microglia312,320. Not only is 
NFκB a potent inducer of IκB-α but it is also a positive regulator of COX-2 
transcription322. Indeed, COX-2 is highly induced throughout the vasculature in 
response to either cytokine312,323. Co-staining for COX-2 protein and specific cell 
markers revealed that, in response to IL-1β, COX-2 was produced predominantly 
by PVMs324. As it is the rate-limiting enzyme in prostaglandin synthesis, enhanced 
COX-2 production could potentially result in the elevated release of these 
soluble mediators from cells associated with the endothelium. The terminal 
enzyme in the synthesis of PGE2, microsomal prostaglandin E synthase (mPGES), 
is also induced in the cerebral vasculature following intravenous IL-1β 
challenge324,325. COX-2 and mPGES are typically expressed in a concomitant 
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manner326 and unsurprisingly, virtually all COX-2 positive vascular cells co-
expressed mPGES325. Thus, cytokine-mediated activation of the cerebral 
vasculature and associated PVMs leads to the rapid induction of the necessary 
enzymatic components required for PGE2 synthesis. Subsequently, PGE2 was 
shown to be synthesised in PVMs following IL-1β challenge324. 
In a similar manner to inflammatory cytokines, intraperitoneal LPS injection 
induces the transcription of IκB-α, COX-2 and mPGES mRNA in the BBB 
endothelium. In addition, IκB-α expression extended to microglial cells of the 
parenchyma327. Again, COX-2 and mPGES were co-localised328. The induction of 
these genes occurs rapidly. However, in contrast to the transient response that 
is induced by circulating cytokines, induction of IκB-α, COX-2 and mPGES 
following LPS injection is comparatively prolonged320,323. As expected, the 
enhanced expression of COX-2 protein and mPGES mRNA was accompanied by 
increased PGE2 production; this time by both endothelial cells of the cerebral 
vasculature and associated PVMs324. Using brain endothelial monolayers, Moore 
et al. demonstrated that four times more PGE2 was released from the abluminal 
side of a cultured endothelial cell layer than the luminal side329. Therefore, PGE2 
would appear to be released into the parenchyma in a polarised fashion. In 
addition to inducing inflammatory cytokine production in the periphery, which in 
itself contributes to endothelial cell activation, LPS can activate the BBB 
vasculature directly. In support of this, inducing tissue specific, sterile 
inflammation using intramuscular turpentine injection, induced a similar pattern 
of BBB activation as injecting inflammatory cytokines327. This was completely 
blocked in IL-1β-deficient mice; however, BBB activation in response to systemic 
LPS injection remained intact327. Consequently, although IL-1β is capable of 
activating cells associated with the cerebral endothelium, it is not essential for 
BBB activation in response to LPS. 
The distinct action of IL-1β and LPS on the cerebral vasculature is highlighted in 
an elegant study by Serrats et al. This group demonstrated that ablation of 
PVMs, using chlodronated liposomes, completely abolished COX-2 and mPGES 
expression by cells associated with the cerebral vasculature in response to 
intravenous IL-1β injection324. In contrast, PVM ablation markedly potentiated 
the expression of both molecules in response to intraperitoneal LPS injection, 
leading to heightened PGE2 production in the brain324. This implies a bi-
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directional interaction between endothelial cells and PVMs whereby, in response 
to IL-1β, activation of PVMs and subsequent PGE2 production occurs downstream 
of endothelial cell activation. However, PVMs would appear to exert a potent 
inhibitory effect on endothelial cell activity which is partially overcome by LPS 
leading to the production of PGE2 by endothelial cells. Whether produced in 
response to IL-1β or LPS, elevated PGE2 production was associated with 
enhanced activation of the HPA control circuitry, characterised by increased c-
Fos expression in the catecholaminic neurons that project onto the 
hypothalamus. HPA axis activation subsequently leads to the increased 
production of stress hormones324. This is likely to be mediated by PGE2 as intra-
cerebral PGE2 injection is sufficient to induce the same response330. The impact 
that enhanced HPA axis activity has on behaviour will be discussed in Section 
1.4.3.1. 
Activated endothelial cells may also perpetuate the immune response by 
secreting cytokines into the brain and into the periphery. In support of this, LPS 
has been shown to stimulate cytokine production, including IL-6 and TNFα, in 
brain endothelial monolayers331. Whilst cytokines were secreted from both the 
luminal and abluminal sides of the monolayers, IL-6 production was 2-fold 
greater on the abluminal side, suggesting that IL-6 might be released into the 
brain in a polarised manner. In addition to enhanced cytokine production, 
activated endothelial cells upregulate cytokine receptor expression in response 
to intravenous inflammatory cytokine administration or intraperitoneal LPS 
injection. This has been documented for both TNFα receptor subtypes, TNFR1 
(p55) and TNFR2 (p75), and both components of the IL-6 receptor, IL-6R and 
gp130312,313. Upregulation of cytokine receptor expression is likely to enhance 
the ability of endothelial cells to respond to circulating cytokines. This may 
result in increased activation of the cerebral vasculature and thus enhanced 
transduction of immune signals into the brain.  
Taken together these reports suggest that, via different mechanisms, LPS and 
inflammatory cytokines, particularly IL-1β, can activate cells associated with the 
cerebral vasculature. By inducing COX-2 and mPGES expression, this leads to 
elevated PGE2 production. In turn, PGE2 activates the HPA axis, thus mediating 
the transduction of inflammatory signals across the BBB. In parallel, activated 
endothelial cells of the BBB produce cytokines whilst simultaneously increasing 
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cytokine receptor expression. This is likely to perpetuate endothelial cell 
activation and enhance immune signal transduction from the periphery to the 
brain. 
1.4.2.3 Leukocyte infiltration 
As described in Section 1.2.2.2, a steady flow of leukocytes migrate from the 
blood to patrol the brain. To do this they must cross one of the two cellular 
barriers that protect the brain from the periphery; the BBB or the BCSFB. During 
homeostatic conditions, this process is highly exclusive (briefly described in 
Section 1.2.2.2). However, following inflammatory insult, either peripheral or 
central, the restrictions that govern leukocyte entry to the brain become more 
relaxed. The consequences, which range from enhanced adhesion of leukocytes 
to the cerebral vasculature to mass immune cell invasion of the CNS, depend on 
the nature of the inflammatory insult. 
Following an inflammatory insult to the CNS, the expression of adhesion 
molecules is upregulated by cerebral vasculature endothelial cells. This 
phenomenon is best characterised in neuroinflammatory disorders in which 
leukocyte infiltration of the CNS plays a prominent role, such as ischemic stroke 
and MS. Ischemic stroke triggers an inflammatory response in the brain. The 
central production of cytokines and chemokines results in the activation of the 
cerebral vasculature and the subsequent recruitment of neutrophils and 
monocytes from the peripheral blood. Amongst the adhesion molecules that are 
upregulated by the cerebral vasculature in response to ischemic stroke are P- 
and E- selectin and Ig superfamily member, ICAM-1332. These adhesion molecules 
play a crucial role in pathology as their neutralisation leads to a reduction in 
infarct volume, and mortality rate, whilst improving neurological outcome332. 
ICAM-1 induction is thought to be mediated by IL-1β. In support of this, ICAM-1 
expression following cerebral ischemia is reduced in mice which overexpress IL-
1ra333. The firm adhesion of ICAM-1 to integrins, present on the surface of 
leukocytes, requires chemokine-mediated Gαi signalling pathway activation. The 
presence of a number of chemokines on the BBB endothelium has been well 
documented in response to ischemic stroke. Of note is the presence of CXCL8, 
CCL2 and CCL3 which have all been implicated in the recruitment of monocytes 
and neutrophils to the brain during pathology332. Thus, stroke-induced 
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inflammation leads to elevated adhesion molecule expression and chemokine 
presentation by the cerebral vasculature.  
Leukocyte infiltration of the brain is also a cardinal feature of both MS and EAE. 
Current dogma suggests that MS is initiated by autoreactive T cells which enter 
the immune-specialized CNS under the pretext of 
immunosurveillance153,156,232,332. As described in Section 1.2.2.3, these T cells 
most likely encounter their cognate antigen displayed by APCs in the CSF. This 
leads to a robust inflammatory response which subsequently facilitates T cell 
infiltration across the BCSFB and the BBB. PSGL-1 is expressed by most 
encephalitogenic T cells in the CNS of mice with EAE. It has the capacity to bind 
to P-, E- or L-selectin334 thus may be involved in lymphocyte tethering to the BBB 
during MS. In support of this, immunohistochemical analysis has identified the 
expression of E selectin in the cerebral vasculature associated with MS lesions332. 
In addition, CD4+ T cells from MS patients express elevated levels of PSGL-1 and 
have an enhanced ability to cross an in vitro model of the inflamed BBB332. ICAM-
1 and VCAM-1 are also associated with MS lesions335. Moreover, the ligands for 
these adhesion molecules, integrins lymphocyte function-associated antigen 1 
(LFA-1) and very late antigen 4 (VLA-4) respectively, are expressed by 
infiltrating inflammatory leukocytes335. Activation of these integrins undoubtedly 
involves interactions between chemokine receptors on the leukocyte cell surface 
and one of the many chemokines that are upregulated in the brain during 
pathology. A brief outline of some of the chemokine systems that have been 
implicated in MS pathology has been given in Section 1.3.1.2. During MS, 
inflammatory leukocytes also infiltrate the CSF across the BCSFB. The precise 
mechanisms governing this recruitment remain to be defined. However, within 
the choroid plexus, inflammatory conditions have been shown to upregulate 
epithelial expression of both ICAM-1 and VCAM-1 and also to induce de novo 
mucosal addressin cellular adhesion molecule (MadCAM-1) expression151. 
Therefore central inflammation, induced by autoreactive T cells, leads to 
elevated adhesion molecule expression on both the BCSFB and the BBB. This, 
coupled with a massive central induction of inflammatory chemokines leads to 
immune cell invasion of the CSF and the brain parenchyma. 
Elevated adhesion molecule expression and enhanced recruitment of leukocytes 
to the BBB endothelium can often be a feature of CNS disorders. However, the 
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same has been reported following peripheral inflammatory insults. Systemic 
administration of LPS can activate the BBB endothelium leading to an 
upregulation of ICAM-1 and P- and E-selectin336-338. This enhances the rolling and 
tethering of activated lymphocytes to the vasculature339,340. Activation of the 
BBB endothelium, characterised by enhanced expression of VCAM-1, has also 
been documented in a mouse model of hepatic inflammation241. BBB activation 
was associated with enhanced rolling and adhesion of monocytes to the cerebral 
vasculature and subsequent parenchymal invasion. Thus, activation of the BBB 
endothelium and recruitment of leukocytes to the brain is not a phenomenon 
that is limited to CNS disorders. 
Inflammatory cytokines are implicated at various stages of leukocyte 
recruitment to the brain. As described above, IL-1β induces ICAM-1 expression 
during cerebral ischemia. In addition, intraventricular IL-1β injection has been 
shown to induce ICAM-1 protein, and CCL2 mRNA expression, in the cerebral 
vasculature which lead to the central recruitment of monocytes and 
neutrophils341. Adhesion molecules such as ICAM-1 and VCAM-1, and 
inflammatory chemokines, can also be induced by TNFα. As described in Section 
1.3.1.3, following the induction of hepatic inflammation, TNFα was shown to 
play a role in central CCL2 production and subsequent monocyte recruitment241. 
Furthermore, inflammatory cytokines, such as TNFα, IL-1β and IL-6, have been 
shown to disrupt BBB integrity241. Thus, cytokines have an intrinsic role in 
enhancing adhesion molecule expression, increasing chemokine production and 
increasing BBB permeability. These effects relax the conditions required for 
leukocyte recruitment to the brain.  
By enhancing the production of inflammatory mediators, infiltration of 
leukocytes into the CNS will likely potentiate the central inflammatory response. 
This may have downstream implications on behaviour. In support of this, Pollack 
et al. demonstrated that the transient sickness behaviours that are associated 
with EAE preceded neurological deficits but coincided with the leukocyte 
infiltration of the brain, the central induction of inflammatory cytokines and the 
hypothalamic production of PGE2342. Furthermore, blocking leukocyte 
recruitment to the brain prevented the induction of sickness behaviours that are 
associated with hepatic inflammation241. The mechanisms by which inflammatory 
cytokines impact behaviour are described in Section 1.4.3. Taken together, 
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these reports demonstrate that during inflammatory CNS diseases, and some 
peripheral inflammatory diseases, adhesion molecules are upregulated by 
endothelial cells of the cerebral vasculature. This, in association with the 
enhanced production of chemokines in the CNS, culminates in leukocyte 
recruitment across the BBB. Furthermore, the elevated production of cytokines 
in the brain that accompanies inflammatory cell invasion may have a potent 
impact on behaviour. 
1.4.2.4 Neuronal transmission 
The vagus nerve extends from the brain and innervates the viscera. Not only 
does it play an integral role in modulating responses in the periphery, but 
afferent projections carry information from the viscera to the nucleus of the 
solitary tract266. Secondary projections in turn relay this information to a number 
of different brain regions. Secondary projection sites include regions of the brain 
that are relevant to behaviour, including the paraventricular nucleus of the 
hypothalamus, which has a role in the activation of the HPA axis (see Section 
1.4.3.1), and the central amygdala which has a role in fear conditioning and 
social behaviour266,343. The role of the vagus nerve in transmitting immune 
signals to the brain became apparent when it was demonstrated that 
intraperitoneal administration of LPS led to neuronal activation, characterised 
by activation of the transcription factor Fos (protein product of c-Fos), in both 
primary and secondary projection areas of the vagus nerve266. Since then a 
number of studies have been aimed at identifying the functional significance of 
this peripherally-induced neuronal activation, with particular relevance to its 
effect on sickness behaviours. 
Vagotomy experiments have been repeatedly used to determine the role of the 
vagus nerve in LPS or IL-1β-induced sickness behaviours. Several groups have 
reported that the fever response to IL-1β or LPS is attenuated in vagotomised 
rodents287,344,345. However, the results of these studies have been highly variable 
with a number of other groups reporting that the LPS- or IL-1β-induced fever 
response is unaffected in vagotomised rodents289,346,347. General dogma suggests 
that the effect of vagotomy on IL-1β- or LPS-induced fever may be dose-
dependent. In IL-1β- or LPS-challenged mice, vagotomy has been shown to 
attenuate the monophasic fever induced by low doses of either stimulus, 
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whereas the biphasic fever induced by high doses was unaffected345,346. 
However, this rule has not been consistent as a separate study demonstrated 
that vagotomy had no effect on fever regardless of the administered dose of IL-
1β289. Several other consequences of vagotomy have been described, such as an 
attenuation of hyperalgesia348 and activation of the HPA axis349 following 
peripheral LPS or cytokine challenge, despite having no effect on central IL-1β 
production350. Moreover, the reduction of social exploration that occurs 
following peripheral IL-1β administration was attenuated in vagotomised rats289. 
To summarise, by relaying immune signals to the brain, the vagus nerve plays a 
role in mediating LPS- or cytokine-induced CNS responses. However, this role 
appears to be partial and most likely occurs in parallel to other routes of 
immune-to-brain communication. 
1.4.3 Mechanisms of cytokine-induced behavioural changes 
Once peripheral immune signals are transmitted to the brain, they can have a 
profound effect on neural circuitry, leading to activation of the neuroendocrine 
system and altered neural transmission and plasticity. Individually, each of these 
actions has the capacity to impact mood and behaviour, as will be discussed 
below. However, in reality, these actions are likely to occur in parallel. In 
addition, to a certain extent, each of the effects described below will have an 
impact on each other. The relative induction of each will probably depend on 
the nature and duration of the inflammatory insult. Thus, a number of 
mechanisms exist whereby peripheral inflammation can alter brain function to 
promote sickness behaviours or in extreme cases, depression or anxiety.  
1.4.3.1 HPA axis activation 
The complex network of interactions between the hypothalamus, the pituitary 
gland and the adrenal glands collectively constitute the HPA axis. By modulating 
a major part of the neuroendocrine system, the HPA axis coordinates the body’s 
response to stress. Both physical and ‘psychological’ stress trigger the 
production of corticotrophin releasing factor (CRF) from the paraventricular 
nucleus (PVN) of the hypothalamus351. CRF subsequently stimulates the release 
of adrenocorticotrophic hormone (ACTH) from the anterior pituitary gland into 
the circulation. In turn, circulating ACTH induces the secretion of glucocorticoids 
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(cortisol in humans or corticosterone in rodents) from the adrenal glands351. By 
binding to glucocorticoid receptors (GRs), situated in various tissues throughout 
the body, these hormones exert a multitude of effects on the periphery and the 
brain. Not only do glucocorticoids control metabolism, modulate the growth of 
bone and muscle and suppress the immune system but they also act as 
neuromodulators, impacting neuronal survival, proliferation, excitability and 
signalling351. GRs are widely expressed throughout the brain, particularly in 
regions which are known to govern mood, behaviour and cognition, such as the 
dorsal raphe nucleus, the hippocampus and other regions of the limbic system351. 
It is therefore unsurprising that aberrant activation of the HPA axis is associated 
with neuropsychiatric disorders like depression and anxiety.  
Under steady state conditions, the HPA response is rapid and short-lived. Various 
feedback mechanisms exist which dampen HPA axis activity. Not only do 
glucocorticoids exert potent anti-inflammatory effects on the immune system 
but they reduce further CRF release from the PVN and subdue ACTH secretion 
from the pituitary352. When these negative feedback mechanisms are impaired, 
it can lead to an exaggerated HPA axis response. This is assumed to occur in a 
proportion of patients with major depression who consistently present with 
elevated levels of cortisol in their plasma, urine and CSF352. Interestingly, a 
significant literature indicates that GR expression and function is impaired in 
depressed patients353,354. Furthermore, cortisol production could not be 
suppressed by the administration of a GR agonist, dexamethasone354. These data 
suggest that this group of depressed patients develop glucocorticoid resistance 
as a consequence of altered GR function and expression. By leading to impaired 
negative feedback of the HPA axis, this is at least partially responsible for the 
exaggerated HPA axis responses that are associated of major depression. 
In a proportion of depressed individuals, antidepressant therapy has been shown 
to restore GR expression and function353,354. In doing so, antidepressants restore 
the intrinsic negative feedback mechanisms of the HPA axis, thus normalising its 
activity. This has led to the hypothesis that hyperactivation of the HPA axis may 
in fact contribute to pathology. Ridder et al. have subsequently corroborated 
this using genetically manipulated mice which underexpress the glucocorticoid 
receptor. Mimicking the impaired receptor function observed in depressed 
individuals, these mice are significantly more prone to depressive-like symptoms 
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than their wild type littermates when exposed to environmental stressors355. 
Therefore, as well as being associated with depression, hyperactivation of the 
HPA axis might also play a role in pathology. 
Inflammatory cytokines are strongly implicated in influencing various stages of 
HPA axis activation in response to either physical or psychological stress. There 
is evidence demonstrating that immune challenge, whether as a result of 
bacterial or viral infection or exposure to recombinant cytokines or LPS, triggers 
the activation of the HPA axis in both patients and rodents356. Ultimately, this 
leads to elevated levels of ACTH and glucocorticoids in the circulation. Although 
many cytokines have been implicated in inducing HPA activity, IL-1β is generally 
considered to be the most potent. Unlike other inflammatory cytokines, IL-1β 
activates the HPA axis consistently across models and species356. In fact, in many 
cases, immune-induced activation of HPA axis can be abrogated in IL-1 receptor 
(IL-1R)-deficient mice, or by administration of IL-1ra357. However, blocking IL-1β 
activity has variable effects on HPA axis activation in rodents following systemic 
LPS injection. For example, numerous reports suggest that IL-1β has a pivotal 
role in triggering the HPA response to endotoxin284,356-358. However, Dunn et al. 
and Ebusui et al. demonstrated that blocking the effects of IL-1β, using IL-1ra, 
had no significant effect on HPA axis activation following the systemic 
administration of LPS359,360. Furthermore, Kozak et al. showed a normal rise in 
circulating corticosterone in IL-1β-deficient mice in response to LPS282. Thus, IL-
1β may not be the sole, or indeed the principle mediator of HPA responses 
following LPS injection. These conflicting findings are likely dependent on a 
number of variables, such as; the species or strain of rodent used in the 
experimental model, the dose and strain of LPS that was administered, the route 
of LPS administration or the time elapsed following injection. For example, 
Perlstein et al. demonstrated that, following LPS challenge, IL-1β, IL-6 and TNFα 
acted synergistically to activate the HPA axis361. However, the predominance of 
each cytokine in triggering an ACTH response depended on the dose of LPS 
administered and the time point at which ACTH concentrations were assessed 
following LPS injection. Taken together, these reports suggest that, although 
cytokines have a fundamental role in activating the HPA axis following 
inflammatory insult, the precise involvement of individual cytokines may depend 
on the nature of the immune challenge.  
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Cytokines, particularly IL-1β, also play a role in modulating HPA axis activation 
in response to psychological stress. Numerous rodent stress models have been 
shown to induce IL-1β expression and subsequent protein production in a variety 
of brain regions (Reviewed in Ref 357). Included in these brain regions are the 
hypothalamus and the pituitary where IL-1β secretion has been shown to occur 
rapidly following inescapable footshock362. IL-1β is also implicated in the stress 
response in humans. Many studies utilising various forms of stressful stimuli have 
demonstrated that IL-1β production in the periphery is enhanced in response to 
stress357. The importance of this cytokine in modulating the body’s stress 
circuitry has been defined by blocking its action in rodent stress models. For 
example, Shintani et al. established that central administration of IL-1ra prior to 
the induction of immobilisation stress led to a dampening of the HPA 
response363. Moreover, Goshen et al. demonstrated that activation of the HPA 
axis was impaired in IL-1RI-deficient mice following exposure to mild stress364. In 
contrast, following the induction of severe stress, HPA axis activation in IL-1RI-
deficient mice was comparable to that in wild-type mice364. Consequently, 
although signalling through the type I IL-1R plays a key role in modulating the 
HPA axis in response to certain stressors, it is not the sole mediator of HPA axis 
activation following severe stress. 
The main mechanism of inflammatory cytokine-induced HPA axis activation is 
arguably the hypothalamic induction of CRF. Intraperitoneal IL-1β-injection has 
been shown to enhance the secretion of both CRF from the hypothalamus and 
ACTH from the pituitary. However, IL-1β-induced ACTH production has been 
shown to be dependent on hypothalamic CRF as it can be ameliorated by 
administering CRF-specific antibodies365,366. HPA activation may also be partially 
mediated by the direct effect of cytokines on the pituitary gland. Although there 
have been conflicting reports regarding the ability of pituitary cells to secrete 
ACTH in response to cytokines in vitro365-367, an in vivo study by Kariagina et al. 
demonstrated that systemic LPS injection could induce ACTH and corticosterone 
production in CRF deficient mice368. This response was coupled with increased 
IL-1β, IL-6 and TNFα expression in the pituitary and thus may have been initiated 
by the action of these cytokines on ACTH-secreting pituitary cells. A direct 
effect of inflammatory cytokines on the adrenal glands has also been 
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proposed356. Although this has been substantiated by in vitro studies, it is not 
clear to what extent this occurs in vivo.  
Finally, cytokines have been shown to affect the negative feedback mechanisms 
of the HPA axis. Via a number of different inflammatory signalling pathways, 
various cytokines have been shown to interfere with the function of the 
glucocorticoid receptor and its translocation to the nucleus369. In doing so, these 
cytokines can contribute to glucocorticoid resistance which, as described above, 
may have an impact on behaviour and depressive symptoms. Thus, not only do 
cytokines induce activation of the HPA axis but they can also impair the negative 
feedback mechanisms that are employed by glucocorticoids. By leading to an 
exaggerated HPA axis response, prolonged exposure to cytokines could 
potentially contribute to depressive symptoms. 
1.4.3.2 Neurotransmitter modulation 
Monoamine neurotransmitters, such as serotonin and dopamine, play a pivotal 
role in modulating emotion, behaviour and cognition. Consequently, 
dysregulated monoamine transmission is proposed as a component of the 
pathophysiology of neuropsychiatric disorders. Both serotonin and dopamine 
have been linked to major depression. As a result, selective serotonin reuptake 
inhibitors (SSRIs), which modulate serotonin transmission, are the most common 
and effective drugs used to combat depression. In addition to major depression, 
altered serotonin transmission is also associated with anxiety and obsessive 
compulsive disorder (Reviewed in Ref 370), whereas altered dopamine 
transmission is commonly associated with attention-deficit hyperactivity 
disorder, schizophrenia and psychosis371-373. Indeed the majority of anti-
psychotic drugs target dopamine receptors372. Intriguingly, monoamine 
transmission can be modulated on a number of levels by inflammation. As a 
result, through its impact on both the serotonergic and dopaminergic systems, 
the central upregulation of inflammatory cytokines, which occurs as a result of 
peripheral inflammation, may have a profound impact on mood and behaviour.  
A number of mechanisms control monoamine transmission, one of which involves 
high affinity monoamine reuptake at neuronal synapses. With regards to 
serotonin and dopamine, this is mediated by the serotonin transporter (SERT) 
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and the dopamine transporter (DAT) respectively. Inflammation is one of many 
factors which can regulate the activity and expression of these transporters. 
Treatment of both neurons and astrocytes with inflammatory cytokines, such as 
IL-1β and TNFα, results in elevated SERT expression and significantly enhanced 
reuptake activity374,375. This is thought to occur through cellular activation of the 
p38 mitogen-activated protein kinase (MAPK) signalling pathway. In a proof of 
concept study, directly linking peripheral immune activation to elevated SERT 
activity, Cavanagh et al. used single positron emission computed tomography to 
demonstrate that blocking TNFα in patients with rheumatoid arthritis led to a 
20% reduction in SERT activity376. Furthermore, injecting mice systemically with 
LPS has been shown to increase both DAT and SERT activity377,378. The latter 
effect led to enhanced symptoms of behavioural despair in an IL-1RI-dependent 
manner378. Increased DAT expression has also been reported in patients with 
major depression373. Thus, peripheral inflammation has been shown to modulate 
the activity of monoamine transporters; an effect that may have a direct impact 
on behaviour. 
In parallel to their effect on SERT and DAT activity, inflammatory cytokines can 
also impact the biosynthesis of monoamines. This occurs indirectly. Dopamine 
biosynthesis is impaired as a result of IFNα-induced NO production in the 
brain379. The effects of inflammatory cytokines on serotonin biosynthesis occur 
via activation of IDO, the rate-limiting enzyme in the degradation of tryptophan 
(Figure 1.4). Not only is tryptophan an essential amino acid, but it is a precursor 
for the biosynthesis of serotonin. Both LPS and IFNγ have been shown to activate 
IDO. LPS-induced IDO activation is dependent on the p38 MAPK signalling 
pathway and involves the intermediary and synergistic effects of inflammatory 
cytokines IL-1β, IL-6 and TNFα380. However, IFNγ enhances IDO expression and 
activity in a manner dependent on the transcription factors, signal transducer 
and activation of transcription (STAT)-1 and IFN regulatory factor (IRF)-1381. By 
converting the available tryptophan into kynurenine, IDO activation is thought to 
have a negative impact on the levels of serotonin biosynthesis and may thus 
impact mood. Indeed blocking IDO has been shown to attenuate LPS-induced 
depression-like behaviours in mice381.  
In addition to reducing tryptophan availability, cytokine-induced IDO activation 
leads to the generation of a number of neuroactive metabolites which may also 
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contribute to depressive symptoms. In support of this, peripheral administration 
of kynurenine, the breakdown product of IDO-induced tryptophan catabolism, 
was sufficient to induce depression-like behaviours in mice381. In the CNS, 
kynurenine will either be converted to quinolinic acid (QUIN) by microglia or 
kynurenic acid (KA), by astrocytes (Figure 1.4). QUIN and KA agonise and 
antagonise N-methyl-D-aspartate (NMDA) receptors respectively and thus have 
opposing effects on glutamate release (for review see Ref 382). QUIN is 
excitotoxic, stimulating glutamatergic activity whilst simultaneously inducing 
oxidative stress. Cytokine-induced excitotoxicity may have an impact on neural 
plasticity. This will be discussed in more detail in Section 1.4.3.3. In contrast, by 
inhibiting glutamate release, KA is neuroprotective382. However, as dopamine 
release is partially regulated by glutamate383, elevated KA may lead to a 
dampening of dopamine transmission.  
Although QUIN-mediated excitotoxicy can be neurotoxic, a defined link between 
neurotoxicity and depressive symptoms has yet to be established. However, 
recent clinical evidence suggests that glutamate may have a role to play in the 
pathophysiology of depression. Elevated levels of glutamate have been observed 
in the serum of depressed patients, and in regions of the brain associated with 
the limbic system384,385. This may be due to enhanced glutamate release386, 
decreased metabolism387 or reduced uptake388. Importantly, targeting 
glutamatergic transmission, either using the NMDA antagonist ketamine389,390, or 
riluzole which inhibits glutamate release391, can have potent and rapid 
antidepressive effects. Therefore QUIN-mediated glutamate production, as a 
result of increased IDO activity, may play a role in inflammation-induced 
behavioural deficits. However, the putative behavioural effects of enhanced IDO 
activation may be dependent on the relative induction of neuroprotective KA 
versus the neurotoxic QUIN. 
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Figure 1.4 The kynurenine pathway. 
Tryptophan (TRP), the essential amino acid precursor for serotonin (5-HT), is oxidised through the 
enzymatic action of indoleamine 2,3 dioxygenase (IDO). This process can be modulated by 
inflammatory cytokines, which induce the activity of IDO. By enhancing TRP oxidation, cytokine-
induced IDO activity may limit 5HT biosynthesis. Furthermore, enhanced IDO activity will increase 
levels of kynurenine (KYN), the major metabolite of TRP degradation. KYN can be further 
metabolised in glial cells to generate one of two neuroactive metabolites; kynurenic acid (KA) in 
astrocytes or quinolinic acid (QUIN) in microglia. KA is an N-methyl-D-aspartate (NMDA) receptor 
antagonist and is thus neuroprotective. However, as an NMDA receptor agonist, QUIN can induce 
glutamatergic activity. In addition, the breakdown of KYN to QUIN is associated with reactive 
oxygen species. Glutamatergic activity and oxidative stress can collectively lead to CNS 
excitotoxicity making QUIN neurotoxic.  
 
Taken together, these reports suggest that inflammatory cytokines, produced in 
the brain in response to systemic inflammation, can affect both the biosynthesis 
of monoamines and their reuptake at the synapse. By leading to impaired 
monoamine transmission, these collective effects are likely to adversely affect 
mood and behaviour.  
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1.4.3.3 Cytokines modulate neural plasticity 
Like chemokines, inflammatory cytokines, such as IL-1β, IL-6 and TNFα, and 
their receptors are constitutively expressed at low levels in the brain. However, 
following a pathogenic insult, the levels of cytokines in the brain increase 
dramatically. Under homeostatic conditions, these cytokines are thought to play 
a role in modulating synaptic plasticity by regulating neurotrophic support, 
regulating neurogenesis and controlling the balance of excitatory glutamatergic 
activation and inhibitory GABAergic activation. Through these actions, 
alterations to central cytokine concentrations as a result of inflammation, may 
impact neuronal firing patterns causing behavioural anomalies.  
The hippocampus is part of the limbic system and plays a major role in memory 
formation392. It is one of two regions of the brain where neurogenesis persists 
into adulthood. A proportion of patients with major depression have reduced 
hippocampal volume393. Moreover, antidepressants have been shown to enhance 
neurogenesis both in humans and in animal models394-396. This has led to the 
hypothesis that impaired hippocampal neurogenesis may contribute to the 
pathophysiology of depression. In agreement with this, hippocampal 
neurogenesis was required for the behavioural effect of antidepressants in 
mice397. Many factors are thought to influence the rate of neurogenesis, 
including stress and inflammation. For example, reports have demonstrated that 
systemic administration of IFNα or LPS markedly reduced hippocampal 
neurogenesis in rodents, as did exposure to chronic stressors398-401. These effects 
can be ameliorated by blocking the effects of inflammatory cytokines. 
Decreased neurogenesis induced by IFNα or chronic stress was attenuated by 
blocking the effects of IL-1β398,400. Following systemic LPS injection, 
neurogenesis was restored via the administration of a non-steroidal anti-
inflammatory agent, indomethacin399. These reports suggest a causative role of 
inflammatory cytokines in reducing hippocampal neurogenesis. 
A number of mechanisms have been proposed to account for the observed 
cytokine-induced reduction in neurogenesis. Not only is the IL-1RI expressed by 
hippocampal neurons in vivo, but hippocampal neural progenitor cells proliferate 
in vitro in response to IL-1β398. This suggests a potential direct effect of IL-1β on 
hippocampal neurons. IL-1β can also dampen neurogenesis indirectly via 
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activation of the HPA axis (Section 1.4.3.1). There is considerable evidence 
linking HPA axis activation and impaired neurogenesis. For example, Goshen et 
al. demonstrated that the elevated HPA axis activation and simultaneous 
reduction in neurogenesis that typically occurs in response to stress, does not 
occur in IL-1RI-deficient mice401. Moreover, the administration of corticosterone 
was sufficient to cause a reduction in neurogenesis in both wild type and IL-1R 
deficient mice. This implies that IL-1 at least partially mediates its effects on 
neurogenesis via activation of the HPA axis. Contrary to the inhibitory effects 
that HPA axis activation has on neurogenesis, suppressing neurogenesis in animal 
models has been shown to result in increased activation of the HPA axis402. Thus, 
a negative feedback mechanism may occur, which perpetuates the simultaneous 
enhancement of HPA axis activation and reduction of neurogenesis. Increased 
activation of the HPA axis could account for the proposed impact that reduced 
neurogenesis may have on behaviour (Section 1.4.3.1). 
Another mechanism that may contribute to a cytokine-induced reduction in 
neurogenesis is reduced levels of hippocampal brain-derived neurotrophic factor 
(BDNF). BDNF is a neurotrophic regulatory factor which is downregulated in the 
hippocampus of rodents in response to IL-1β or LPS administration403 and in the 
circulation of patients treated with IFNα404. BDNF has a multitude of functions. 
In addition to controlling neuronal survival, differentiation, transmission and 
plasticity, BDNF has a role in promoting neurogenesis405. Therefore, 
inflammatory cytokines or LPS may adversely affect neurogenesis by causing a 
decrease in hippocampal BDNF production.  
Due to its pleiotropic nature, a sustained decrease in BDNF levels might 
negatively affect neuronal function in a number of ways other than 
neurogenesis. As BDNF promotes survival, neuronal viability may be impaired. 
Supporting this, the loss of dopaminergic neurons in response to peripheral LPS 
injection was prevented by BDNF infusion into the striatum406. It is unclear what 
impact, if any, these effects have on behaviour. Patients treated with IFNα 
presented with reduced circulating BDNF levels regardless of whether they 
developed depression404. However, an allelic variant of the BDNF gene, that 
causes reduced BDNF production, is associated with depression levels following 
IFNα-therapy404. Consequently, a cytokine-induced reduction in BDNF levels can 
84 
affect neural plasticity via a number of different mechanisms and this, in turn, 
may have a downstream impact on behaviour.  
Inflammatory cytokines have been shown to elevate the expression of glutamate 
receptors whilst at the same time reduce the expression of GABA receptors at 
the synapse407. In addition, cytokines can further enhance glutamatergic activity 
by increasing glutamate release and decreasing glutamate reuptake via the 
downregulation of glutamate transporter expression in a manner that would 
appear to be dependent on NO production408-410. Thus, prolonged or excessive 
inflammation could tip the excitatory/inhibitory balance in favour of excitatory 
glutamatergic transmission. In combination with an IDO-induced breakdown of 
kynurenine to QUIN (Section 1.4.3.2), these effects could potentially induce CNS 
excitotoxicity. Damage to highly sensitive neurons and oligodentrocytes in 
regions of the brain associated with emotions, behaviour and cognitive function 
may contribute to some of the effects of cytokine-induced psychiatric disorders. 
To summarise, inflammatory cytokines, induced in the brain in response to 
systemic inflammation, can impact neural plasticity through a number of 
mechanisms. These effects which lead to dampened neurogenesis, diminished 
neurotrophic support and elevated glutamatergic transmission, may collectively 
increase activation of the HPA axis, reduce neurogenesis, adversely effect 
neuronal viability and trigger CNS excitotoxicity. However, the downstream 
impact that altered neural plasticity has on mood and behaviour following 
peripheral inflammation remains to be fully established. 
1.5 Thesis aims 
The immune system and the nervous system are not as distinct as was once 
thought. Both systems utilise cytokines and chemokines as a method of 
communication and they appear to interact in a bidirectional manner. 
Inflammation in the periphery has been shown to have an impact on mood and 
behaviour. Furthermore, there is evidence to suggest that depressive disorders 
could influence the levels of inflammatory mediators in the periphery.  
As described above, the brain can become sensitised to the occurrence of a 
peripheral inflammatory response by a number of mechanisms which act in 
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parallel. However, the biological pathways that culminate in the onset of 
neuropsychiatric symptoms remain to to fully defined. The overall aim of this 
thesis was to establish a more indepth understanding of the bidirectional 
relationship, and communication pathways, that exist between the immune 
system and the nervous system. In doing so, I sought to identify potential 
mechanisms that could account for inflammation-induced behavioural changes. 
1. The aim of Chapter 3 was to determine what impact an acute exposure to 
systemic LPS had on neurological transcriptional modulation. 
2. The aim of Chapter 4 was to use different sterile, and TLR-dependent, 
models of peripheral inflammation to investigate the molecular 
mechanisms involved in modulating of gene expression in the brain 
following peripheral LPS injection.  
3. Employed by both the immune system and the nervous system, 
chemokines are prime candidates for orchestrating inter-system 
communication. Thus the aim of Chapter 5 was to establish whether 
chemokine transcription was induced in the brain following a series of 
systemic LPS injections. Due to their well characterised role in 
coordinating leukocyte migration, an additional aim of this chapter was to 
determine whether chemokine induction triggered an influx of leukocytes 
to the brain following systemic LPS exposure. 
4. Having highlighted a number of chemokines that could potentially 
mediate leukocyte recruitment to the brain following systemic LPS 
challenge, the aim of Chapter 6 was to optimise a protocol that would 
enable these chemokine systems to be compared to those involved in MS. 
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2 Materials & Methods 
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2.1 General Reagents & Buffers 
2.1.1 Materials & Reagents 
Unless otherwise specified, all chemicals, kits and reagents were purchased from 
Life Technologies. 
All plastics were purchased from BD Biosciences unless stated otherwise. 
2.1.2 Buffers 
0.5M EDTA (pH8): 186.1g ethylenediaminetetraacetic acid (EDTA) (Sigma 
Aldrich) and 20g NaOH (Sigma Aldrich) was dissolved in 900ml distilled H20 
(dH20), adjusted to pH8 using HCl (Sigma Aldrich) and then made up to 1L using 
dH20. 
MACS Buffer: 500ml phosphate-buffered saline (PBS), 2ml 0.5M filter sterilised 
EDTA and 10ml foetal calf serum. 
PEA Buffer: 500ml PBS, 1ml 0.5M filter sterilised EDTA and 2.5ml 4.5% human 
albumin (Bio Products Laboratory). 
Tris-acetate EDTA (TAE) Buffer: A 50x stock solution of TAE buffer was made by 
dissolving 242g Tris base (Sigma Aldrich) in 750ml dH20. 57.1ml glacial acetic 
acid (Sigma Aldrich) and 100ml 0.5M EDTA was then added and the buffer was 
made up to 1L with dH20. Before use, stock buffer was diluted 1:50 in dH20. 
10mM Tris-EDTA (TE) Buffer: 1M Tris-EDTA buffer (Sigma Aldrich) was diluted 
1:100 with nuclease-free H20 before use. 
2.2 In Vivo Procedures 
2.2.1 Animal welfare 
All animals were housed within the Biological Services Central Research Facility 
and Joint Research Facility at the University of Glasgow. Animals were 
maintained in specific pathogen-free conditions and given access to food and 
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water ad libitum. All experiments received ethical approval and were performed 
under the auspices of a UK Home Office Licence. 
2.2.2 Mice 
6-7 week old, male C56BL/6 mice were purchased from Harlan laboratories. 
Before experimental procedures were carried out, mice were given a week to 
acclimatise. After procedures, mice were culled using a recognised schedule 1 
technique.  
2.2.3 Induction of systemic inflammation using LPS 
2.2.3.1 Acute model 
Systemic inflammation was induced in 8 week old C57BL/6 mice by 
intraperitoneal (I.P.) injection of LPS (Escherichia Coli, serotype 055:B5; Sigma 
Aldrich). 100µl of 1mg/ml LPS, or an equivalent volume of vehicle (sterile PBS), 
was injected into the peritoneal cavity. Mice were culled 6 hours, 12 hours or 48 
hours after LPS, or vehicle, challenge. 
2.2.3.2 ‘Chronic’ endotoxin tolerance model 
To induce endotoxin tolerance, C57BL/6 mice were injected (I.P.) with a single 
100µl dose of 0.5mg/ml LPS, or an equivalent volume of vehicle (sterile PBS), 
daily for 2, 5 or 7 consecutive days. Mice were culled 24 hours after final 
injection.  
2.2.4 Induction of systemic inflammation using TNFα 
Systemic inflammation was induced in 8 week old C57BL/6 mice by intravenous 
(I.V.) injection of recombinant murine TNFα (Peprotech). 100µl of 10µg/ml 
TNFα, or the equivalent volume of vehicle (sterile dH2O), was injected into the 
tail vein at 0 and 24 hours. Mice were culled 6 hours or 24 hours after final 
injection. 
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2.2.5 Induction of systemic inflammation using LTA 
Systemic inflammation was induced in 8 week old C57BL/6 mice by I.V. injection 
of lipoteichoic acid (LTA) derived from Staphylococcus aureus (Sigma-Aldrch). 
100µl of 5mg/ml LTA, or the equivalent volume of vehicle (sterile dH2O) was 
injected into the tail vein at 0 and 24 hours. Mice were culled 6 hours or 24 
hours after final injection. 
2.3 Ex Vivo Procedures 
2.3.1 Perfusion 
Mice were perfused using a syringe and 23G needle to inject 20ml of PBS 
(warmed to 37°C) through the left ventricle. Blood and PBS were drained 
through an incision in the right atrium. 
2.3.2 Brain dissection 
Perfused mice were decapitated. Surgical scissors were used to cut through the 
skin to reveal the scull. By sliding scissors carefully along the interhemispheric 
fissure, the scull was cut open and then pulled aside with forceps, allowing the 
brain to be dissected from scull. Brainstems and olfactory bulbs were removed 
from the brains with a scalpel. The meninges were also removed from brains 
that were to be used for gene expression analysis. 
2.3.3 Preparation of brain samples for histological analysis 
2.3.3.1 Tissue Processing 
Whole brains were immersed in approximately 4ml of 10% buffered formalin 
(CellPath) and incubated for 48 hours at room temperature. After fixation, brain 
tissue was dehydrated in an automatic tissue processor (Citadel 1000, Thermo 
Scientific). Using the following program, brains were sequentially immersed in 
increasing concentrations of ethanol (EtOH) (VWR) followed by Xylene (Leica 
Biosystems) and then paraffin wax (Leica Biosystems): 
1. 70% EtOH   1 hour 
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2. 90% EtOH   1 hour 
3. 95% EtOH   1 hour 
4. 100% EtOH   3 x 2 hours 
5. Xylene   3 x 2 hours 
6. Paraffin wax   2 x 4 hours 
2.3.3.2 Tissue embedding 
Processed brain tissue was divided into 3 coronal sections using a brain slicer. 
Coronal sections were orientated appropriately and embedded into wax blocks 
using the Histocentre 3 (Thermo Scienific, Massachusetts, US). Blocks were 
stored at room temperature until required for further sectioning. 
2.3.3.3 Tissue sectioning 
Embedded tissue blocks were cut into 5µm sections using a microtome. Sections 
were mounted onto charged frosted microscope slides (Superfrost Plus, VWR) 
and stored at room temperature until required for histological analysis. 
2.3.4 Preparation of brain samples for gene expression analysis 
Brains were dissected from mice as described above and cut in half (sagittally) 
through the interhemispheric fissure using a scalpel. Right hemispheres were 
placed in cryovials (Alpha Laboratories) and snap frozen in liquid nitrogen. 
Frozen tissue was stored at -80°C to maintain RNA integrity until required for 
RNA purification. 
2.3.5 Isolation of plasma from peripheral blood 
Mice were culled by a recognised schedule 1 technique. Blood was collected 
from the right atrium, in 20µl EDTA, with a 1ml syringe. Blood was transferred to 
1.5ml eppendorf tubes (Greiner) and plasma was separated from blood cells by 
centrifugation for 10 minutes at 300g. The plasma was then transferred to 1.5ml 
eppendorf tubes and centrifuged at 3000g for 5 minutes to pellet remaining 
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platelets. Platelet-free plasma was collected as the supernatant and stored at -
80°C until required for protein expression analysis. 
2.3.6 Isolation of leukocytes from peripheral blood 
Mice were culled by a recognised schedule 1 technique. Blood was collected 
from the right atrium in 20µl EDTA with a 1ml syringe. Blood was transferred to 
1.5ml eppendorf tubes and blood cells were pelleted by centrifugation for 10 
minutes at 300g. After removing the plasma, pelleted blood cells were added to 
a 15ml falcon tube with 5ml 1x red blood cell lysis buffer (Miltenyi) and 
incubated for 7 minutes at room temperature. 10ml of PBS was added to each 
sample and the cells were pelleted by centrifugation for 7 minutes at 300g. The 
supernatant was decanted and pelleted cells were washed with 15ml PBS. Cells 
were centrifuged as before, resuspended in 1ml PBS and transferred to 1.5ml 
eppendorf tubes. Cells were pelleted by centrifugation for 5 minutes at 600g. 
The supernatant was aspirated and the cell pellets were lysed in 700µl RLT 
buffer (Qiagen). Lysed samples were homogenised by centrifugation through a 
Qiashredder column (Qiagen) for 2 minutes at 13 000g and stored at -80°C to 
maintain RNA integrity until required for RNA purification. 
2.3.7 Isolation of bone marrow 
Mice were culled by a recognised schedule 1 technique and perfused. Skin, 
tendons and muscle tissue were stripped from the hind legs and the tibia and 
femur were dissected from mice by cutting through the connective tissue above 
the tibia and below the femur at the ankle joint. The bones were cleaned of 
excess muscle tissue then cut at the top and the bottom using surgical scissors. 
Using a 23G needle and a syringe, Bone marrow was flushed from the bones with 
PBS and then pushed through a 70µm cell strainer, using the plunger from a 5ml 
syringe, to create a single cell suspension. Cell number and viability was 
determined by staining cells with Trypan blue and counting them using a 
haemocytometer. Cells were pelleted by centrifugation for 7 minutes at 300g. 
The cell pellet was washed in PBS and then centrifuged as before. Cells were 
resuspended to a concentration of 5x106 cells/ml. 1ml of each cell sample was 
transferred to 1.5ml eppendorf tubes. Cells were pelleted by centrifugation for 5 
minutes at 600g. Cell pellets were lysed in 700µl RLT buffer. Lysed samples were 
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homogenised by centrifugation through a Qiashredder column for 2 minutes at 13 
000g and stored at -80°C to maintain RNA integrity until required for RNA 
purification. 
2.3.8 Generation of single-cell suspension from brain digests 
Mice were culled by a recognised schedule 1 technique and perfused. Brains 
were dissected from the mice as described above and then kept on ice in HBSS 
prior to digestion. Brain tissue was finely diced using a scalpel and then each 
brain was digested in 10ml of digestion cocktail, pre-warmed to 37°C. The 
cocktail consisted of; 6µg/ml Liberase TM (Roche), 5U/ml DNaseI and 25mM 
Hepes buffer diluted in HBSS. Samples were shaken at 750rpm for 45 minutes at 
37°C. Following digestion, cell suspensions were passed through a 70µm cell 
strainer. Cells were washed twice with 2mM EDTA in HBSS and centrifuged after 
each wash at 300g for 10 minutes at 4°C. Cell pellets were then washed in MACS 
buffer and resuspended in 1.8ml MACS buffer. 200µl of Myelin removal beads 
(Miltenyi) was added to each sample and samples were incubated at 4°C for 15 
minutes. Cells were then washed in MACS buffer, centrifuged as before and 
resuspended in 2ml MACS buffer. Myelin was removed using the AutoMACS 
(Miltenyi) programme, DepleteS. Meylin-depleted cells were eluted from the 
AutoMACS columns in 4ml MACS buffer. Cells were pelleted as before and 
resuspended in 1ml MACS buffer. Cell number and viability was determined by 
staining cells with Trypan blue and counting them using a haemocytometer.   
2.4 Human Primary Cell Procedures 
2.4.1 Patients & clinical samples 
Buffy coats were obtained from the NHS as surplus from Scottish National Blood 
Transfusion Service. All donors gave informed consent and ethics were obtained 
from the relevant local ethics committee.  
2.4.2 Isolation of mononuclear cells from peripheral blood 
PBMCs were separated from buffy coats using a density gradient. Blood taken 
from buffy coats was diluted 1:1 with PEA buffer. 10ml of the diluted mixture 
was layered on top of 4ml histopaque 1077 (Sigma Aldrich) in a 15ml falcon tube. 
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Tubes were spun for 20 minutes at 500g with no brake, separating the blood into 
4 distinct phases. Peripheral blood mononuclear cells (PBMCs) which collect at 
the interphase between the plasma and the histopaque were transferred into a 
15ml falcon tube using a sterile pasteur pipette. Cells were washed twice with 
ice-cold PEA, centrifuging for 5 minutes at 350g and decanting the supernatant 
after each wash. Washed cells were resuspended in PBS to a concentration of 
1x106 cells/ml. 
PBMCs were serially diluted 10-fold to get concentrations of 1x105 and 1x104 
cells/ml. These were transferred to 1.5ml eppendorf tubes into aliquots of 500, 
1x103, 5x103, 1x104, 5x104 and 5x105 cells. PBMCs were pelleted by 
centrifugation at 600g for 5 minutes. The supernatant was removed and the 
PBMCs were lysed in RLT buffer. Cells were vortexed in RLT to aid lysis and then 
stored at -80°C to maintain RNA integrity until required for RNA purification. 
2.5 Gene Expression Analysis 
2.5.1 RNA purification 
2.5.1.1 RNA extraction from cells using silica-membrane technology 
RNA was extracted following the RNeasy Mini Kit protocol (Qiagen) and the 
RNeasy Micro Kit protocol (Qiagen) as described by the manufacturers.  
As described previously, cells were lysed in RLT buffer, homogenised using a 
Qiashredder and stored at -80ºC until required for RNA purification. The volume 
of RLT buffer used depended on cell number: 
<1x105 cells    70µl RLT 
1x105 to 5x106 cells   350µl RLT 
>5x106 cells    600µl RLT 
Where specified, 200ng E. coli transfer RNA (Sigma Aldrich) was added to the 
RLT prior to cell lysis.  
RNA was precipitated by adding 1 volume of 70% EtOH in nuclease-free H2O. RNA 
from each sample was collected by centrifugation through an RNeasy spin 
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column (Mini Kit) or an RNeasy MinElute spin column (Micro Kit). Spin columns 
were washed several times to remove any protein impurities and then air dried. 
Unless specified otherwise, genomic DNA was digested on-column between 
washes as described in the protocol. RNA was eluted from the RNeasy spin 
columns into 1.5ml nuclease-free eppendorf tubes (Life Technologies) in 30-
100µl nuclease-free H2O and in approximately 12µl from the RNeasy MinElute 
spin columns. This was quantified using a nanodrop (Nanodrop 1000, Thermo 
Scientific) and stored at -80°C to maintain RNA integrity until required for cDNA 
synthesis. 
2.5.1.2 RNA extraction from cells using Trizol 
Cells were lysed by vortexing with 800µl of Trizol reagent and the lysate 
incubated for 5 minutes at room temperature. Where specified, 200ng E. coli 
total RNA was added to the lysate. 160µl of chloroform:Isoamyl alcohol (1:24) 
(Sigma-Aldrich) was added to each sample, vortexted and incubated for 3 
minutes at room temperature. Samples were then spun at 13 000g for 15 
minutes at 4°C to separate the mix into 3 distinct phases. The upper aqueous 
phase of each sample was transferred into 1.5ml nuclease-free eppendorf tubes 
and the RNA precipitated with 400µl 100% isopropanol (VWR). Samples were 
incubated for 2 hours at -20°C before being centrifuged at 13 000g for 10 
minutes at 4°C. The RNA pellet was then washed with 75% EtOH in nuclease-free 
H2O. This was centrifuged at 13 000g for 5 minutes at 4°C and the supernatant 
discarded. RNA pellets were air-dried and then dissolved in 12µl nuclease-free 
H2O. 
2.5.1.3 RNA extraction from tissues using Trizol 
‘Snap-frozen’ brain tissue was disrupted using a Qiagen TissueLyser. Brain tissue 
was shaken in 2ml nuclease-free eppendorf tubes, containing 1ml Trizol and a 
5mM stainless steel bead (Qiagen), for 10 minutes at 50 oscillations per second. 
The disrupted tissue and Trizol mixture was then divided between 2x 2ml 
nuclease-free eppendorf tubes. 500µl Trizol was added to each eppendorf tube. 
Samples were vortexed and incubated for 5 minutes at room temperature. 200µl 
of chloroform:Isoamyl alcohol was added to each eppendorf tube, vortexted and 
incubated at room temperature for 3 minutes. Samples were then spun at 13 
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000g for 15 minutes at 4°C to separate the mix into 3 distinct phases. The upper 
aqueous phase of each sample was transferred into 1.5ml nuclease-free 
eppendorf tubes and the RNA precipitated with 500µl 100% isopropanol. Samples 
were incubated for 10 minutes at room temperature before being centrifuged at 
13 000g for 10 minutes at 4°C. The RNA pellet was then washed with 75% EtOH 
in nuclease-free H2O. This was centrifuged at 13 000g for 5 minutes at 4°C and 
the supernatant aspirated. RNA pellets were air-dried and then dissolved in 50µl 
nuclease-free H2O. RNA from each sample was re-combined to give a final 
volume of 100 µl. 
2.5.1.4 Genomic DNA digest using DNA-freeTM 
Where specified, contaminating genomic DNA was removed from RNA samples 
using a DNA-freeTM kit, as described by the manufacturers. Briefly, 1µl of 10x 
DNase I buffer and 1µl recombinant DNase I was added to 10µl of RNA sample. 
Reactions were incubated for 20 minutes at 37°C. 1.2µl of DNase Inactivation 
Agent was added to stop the reactions. Samples were centrifuged and the RNA 
was then aspirated from pelleted genomic DNA and stored at -80°C until 
required for cDNA synthesis.  
2.5.1.5 RNA clean-up 
RNA extracted from tissue was purified using a Qiagen RNeasy Mini kit as 
described by the manufacturers. 350µl RLT buffer was added to each 100µl 
sample and mixed by inverting. RNA was precipitated by adding 250µl of 100% 
EtOH. RNA from each sample was collected by centrifugation through an RNeasy 
spin column. Spin columns were washed several times to remove impurities and 
then air dried. Genomic DNA was digested on-column between washes as 
described in the protocol. RNA was eluted from the RNeasy spin columns in 
approximately 100µl nuclease-free H2O. This was quantified using a nanodrop 
(Nanodrop 1000, Thermo Scientific) and stored at -80°C to maintain RNA 
integrity until required for cDNA synthesis. 
2.5.2 Assessment of RNA integrity 
The quality of RNA was assessed by the University of Glasgow Polyomics Facility. 
Assessment was performed using a 2100 Bioanalyzer (Agilent) on a Nano chip or 
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Pico chip in accordance with manufacturer’s instructions. All chips and reagents 
used were supplied in the RNA 6000 Nano kit (Agilent) or the RNA 6000 Pico kit 
(Agilent). 
RNA was diluted in nuclease-free H2O to the required concentration.  
Pico chip 
Total RNA    50-5000 pg/ml 
mRNA     250-5000 pg/ml 
Nano chip 
Total RNA    5-500 ng/ml 
mRNA     25-250 ng/ml  
65µl of gel matrix was mixed with 1µl of a nucleotide-specific dye. To prime the 
chips, 9µl of the gel-dye mix was applied to the appropriate wells. Pressure was 
applied using a priming syringe (supplied) to disperse the gel-dye mix throughout 
the microfluidics of the chip. 9µl was also applied to an additional 2 wells as 
described in the protocol. 
After priming, 5µl of RNA 6000 marker was applied to each of the sample wells 
and also the ladder well of each chip. 1µl of ladder was then pipetted into the 
ladder well and 1µl of each diluted RNA sample was added to each of the sample 
wells. Chips were vortexed briefly to mix contents and then RNA was separated 
in a microchannel according to size using the 2100 Bioanalyzer. 
2.5.3 Microarrays 
Microarrays were run at the University of Glasgow Polyomics Facility. Prior to 
array, the quality of purified RNA was verified as described above. Purified RNA 
was sent to the Glasgow Polyomics Facility where it was amplified by in vitro 
transcription (IVT) and converted to sense-strand cDNA using an Ambion WT 
Expression kit (Life technologies).  cDNA was then fragmented and labelled using 
a GeneChip WT Terminal Labelling kit (Affymetrix). Fragmented cDNA was then 
loaded and run on GeneChip mouse gene 1.0 ST arrays (Affymetrix). All 
procedures were carried out as described by the manufacturers. 
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2.5.4 Microarray analysis 
Raw data from the microarray study were provided by the University of Glasgow 
Polyomics Facility and analysed using Parkek Genomics Suite v6.5 and 
Genespring GX software v10. Details of the analyses are described in detail in 
the text (Chapter 3). 
2.5.4.1 DAVID Bioinformatics 
Gene ontology terms were assigned to differentially expressed genes using the 
Database for Annotation, Visualization and Integrated Discovery (DAVID) 
Bioinformatics Resources v6.7 (http://david.abcc.ncifcrf.gov/). Analysis was 
performed in accordance with two protocols outlined by Huang et al.411,412.  
Significance of enrichment was determined using a modified Fisher’s Exact test 
and a Benjamini-Hochberg multiple testing correction was used to correct for 
the rate of type I errors. Co-expression of a gene cluster was considered 
significant if it satisfied a p-value cut-off of 0.05. 
2.5.4.2 Ingenuity pathway analysis 
Genes were grouped into canonical pathways using Ingenuity Pathway Analysis 
software (Ingenuity® Systems, www.ingenuity.com). Significance of 
differentially altered pathways was determined using a Fisher’s Exact test and a 
Benjamini-Hochberg multiple testing correction was used to correct for the rate 
of type I errors. Enrichment of a pathway was considered significant if it 
satisfied a p-value cut-off of 0.05. 
2.5.4.3 Interferon signature analysis 
The potential of different IFN subtypes to regulate differentially expressed ISGs 
was determined using the Interferome database v1.0 
(http://interferome.its.monash.edu.au/interferome/home.jspx). Interferome is 
a database of ISGs, established from a compilation of data from microarray and 
proteomic experiments in which cells or tissues have been treated with different 
types of IFNs413. 
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2.5.5 cDNA Synthesis 
Unless otherwise stated, cDNA was synthesised using Quantitect Reverse 
Transcription kit (Qiagen). cDNA required for applications involving TaqMan gene 
expression assays was synthesised using the High Capacity RNA-to-cDNA kit. 
When stated, the SuperScript III Reverse Transcription kit was used as a 
potential alternative to the High Capacity kit.  
Regardless of the method used, for each experimental group, cDNA synthesis 
reactions were accompanied by 2 control reactions: 
1. –RT control: Reverse transcriptase (RT) was substituted for nuclease-free 
H2O to control for genomic DNA contamination. 
2. No template control: Template RNA was substituted for nuclease-free H2O 
to control for contamination of reagents. 
2.5.5.1 Quantitect 
To first eliminate contaminating genomic DNA (gDNA) from the RNA template, 
the following DNase-digests were set up in 0.2ml nuclease-free PCR tubes: 
Template RNA (≤1µg)  ≤12µl 
7x gDNA Wipeout Buffer  2µl 
Nuclease-free H2O* 
Total volume    14µl 
*Reaction made up to 14µl in H20. 
The contents were mixed by pulse centrifugation. To eliminate gDNA, reactions 
were incubated at 42°C for 2 minutes before being placed on ice to stop the 
reaction. 
To perform the reverse transcription reaction, the following master mix was 
assembled and then added to the contents of each tube to give a final reaction 
volume of 20µl: 
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Quantiscript RT*   1µl 
5x Quantiscript RT Buffer  4µl 
RT Primer Mix   1µl 
Total volume    6µl 
*Substituted with 1µl nuclease-free H2O in –RT control reactions. 
Tubes were pulse centrifuged to mix. The RT reaction was carried out in a 
thermocycler set for the following programme: 
1. 42°C  15 minutes 
2. 95°C  3 minutes 
3. 4°C  Forever 
cDNA was diluted 1:5 in nuclease-free H2O and stored at -20°C until required for 
gene expression studies. 
2.5.5.2 High Capacity RNA-to-cDNA 
To perform reverse transcription using the High Capacity RNA-to-cDNA kit, the 
following components were assembled in 0.2ml nuclease-free PCR tubes: 
Template RNA (≤2µg)   ≤9µl 
2x RT Buffer    10µl 
20x RT Enzyme Mix*  1µl 
Nuclease-free H2O† 
Total Volume   20µl 
*Substituted with 1µl nuclease-free H2O in –RT control reactions. 
†Reaction made up to 20µl in H20. 
Contents were mixed by pulse centrifugation. Reverse transcription was carried 
out in a thermocycler set for the following programme: 
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1. 37°C  60 minutes 
2. 95°C  5 minutes 
3. 4°C  Forever 
cDNA was stored neat at -20°C until required for gene expression studies. 
2.5.5.3 SuperScript III 
Prior to reverse transcription, the following reactions were set up in 0.2ml 
nuclease-free PCR tubes: 
Template RNA (<500ng)  ≤8µl 
Random Hexamers (50 ng/µl) 1µl 
dNTP Mix (10mM)   1µl 
Nuclease-free H2O* 
Total volume    10µl 
*Reaction made up to 10µl in H20. 
After mixing contents by pulse-centrifugation, tubes were incubated at 65°C for 
5 minutes in a thermocycler, to denature RNA, and then placed on ice for at 
least 1 minute.  
A master mix was prepared, containing the following reagents: 
10x First Strand Buffer  2µl 
MgCl2 (25mM)   4µl 
DTT (0.1M)    2µl 
RNaseOUT (40 U/µl)  1µl 
SuperScript III RT (200 U/µ l) 1µl 
Total Volume   10µl 
*Substituted with 1µl nuclease-free H2O in –RT control reactions. 
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10µl of master mix was added to each reaction to create a total reaction volume 
of 20µl. Contents were mixed by pulse centrifugation. Reverse transcription 
occurred in a thermocycler set for the following programme: 
1. 25°C  10 minutes 
2. 50°C  50 minutes 
3. 85°C  5 minutes 
4. 4°C   Forever 
cDNA samples were collected by pulse centrifugation. After the addition of 1µl 
RNaseH (2 U/µl), samples were incubated for 20 minutes at 37°C in a 
thermocycler. 
 cDNA was stored neat at -20°C until required for gene expression studies. 
2.5.6 Polymerase chain reactions 
Polymerase chain reactions (PCRs) were performed using pre-made red PCR 
master mix (Rovalab) as described below: 
Red PCR mastermix   45µl 
Forward primer   0.5µl 
Reverse primer   0.5µl 
Template cDNA   1-2µl 
Nuclease-free H2O* 
Total Volume   50µl 
*Reaction made up to 10µl in H20. 
 
PCR reactions were run in a thermocycler set for the following programme: 
1. 95°C  3 minutes 
102 
2. 95°C  15 seconds 
3. 60°C  15 seconds  35-40x cycles 
4. 72°C  45 seconds 
5. 72°C  5 minutes 
6. 4°C   Forever 
2.5.6.1 Electrophoresis of PCR products 
Electrophoresis was used to separate the PCR products according to size through 
a 2% agarose gel containing ethidium bromide. To form a 2% agarose gel, the 
appropriate weight of agarose (Sigma-Aldrich) was added to TAE buffer and 
heated in the microwave until dissolved. Ethidium bromide was then added and 
the melted agarose was poured into a gel cassette. Combs were inserted into the 
cassette and the agarose gel was left to cool and set. Gels containing PCR 
products were run in TAE buffer for 45-60 minutes at 100 volts. To verify that 
the products were the correct size, they were compared to a DNA ladder. 
Hyperladder IV (Bioline) was used for products <1000 bp whereas Hyperladder I 
(Bioline) was used for products <10kb. The visualisation of PCR products was 
performed under UV light using an Alpha 2200 Digital UV-Visphoto Imager (Alpha 
Innotech). 
2.5.7 Quantitative real-time PCR 
2.5.7.1 Primer design 
To perform quantitative real-time PCR (QPCR), a set of specific primers had to 
be designed to amplify each target gene. The design of these primers had to 
adhere to a stringent set of conditions to ensure the accuracy and efficiency of 
the reaction. In addition to designing primers for use in the QPCR reaction, an 
additional set of primers had to be designed in order to create PCR products to 
act as standard templates. 
All primers were designed using Primer3 Input software version 0.4.0 
(http://frodo.wi.mit.edu/).  
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Specification for QPCR primers: 
Primer size    18 to 24 base pairs (bp) (20 bp optimal) 
Melting temperature (Tm)  59.5°C to 61°C (60°C optimal) 
GC content    40% to 65% (50% optimal) 
Max self complementarity  3 (≤2 optimal)   
Max 3’ complementarity  1 
Amplicon size   ≤150bp 
To create standard templates for each target gene, standard primers were 
designed that would amplify the region in which the QPCR primers would bind. 
These primers were designed using similar parameters as outlined above; 
however, the size of the amplicon could vary between 100bp and 2000bp and if 
the software did not return any suitable results, the maximum self 
complementarity could be increased to 5. Standard primers were designed to 
flank the amplicon targeted by the relevant QPCR primers and the adjacent 20bp 
on either side. 
All primers were synthesised by Integrated DNA Technologies. The specificity of 
the primer sequences (Table 2.1 & Table 2.2) was first assessed using the free 
online bioinformatics resource, Basic Local Alignment Search Tool 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Following acquisition of the primers, 
their specificity was confirmed by running a PCR reaction using any cDNA 
containing the transcript of interest. Primers were considered specific if they 
amplified a single product of the appropriate size. 
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Gene Name Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) 
Apobec3 TTC ACC CGT CTC CCT TCA AGC GTG GAT GTT GTC CTT GT 
C4 TGA CTG CCT TCG TGC TGA TGC TCT GTG GAT GAC TGG AC 
Ccl2 CTC ACC TGC TGC TAC TCA TTC A CCA TTC CTT CTT GGG GTC A 
Ccl3 CAG CCA GGT GTC ATT TTC CT CAG GCA TTC AGT TCC AGG TC 
Ccl5 CTA CTG CTT TGC CTA CCT CT ACA CAC TTG GCG GTT CCT T 
Ccr1 GCC CTC ATT TCC CCT TCA A CGG CTT TGA CCT TCT TCT CA 
Ccr3 GAT TGC CTA CAC CCA CTG CT CGG AAC CTC TCA CCA ACA A 
Ccr5 TTT GTC CTG CCT TCA GAC C TTG GTG CTC TTT CCT CAT CTC 
Ctsc AGG CCA CAC AGC TAT CAG TT TTG CCA ACA AAG CAA GCC CA 
Cxcl1 GCT TGC CTT GAC CCT GAA TGT CTT CTT TCT CCG TTA CTT GG 
Cxcl2 AAG TTT GCC TTG ACC CTG AA TCT CTT TGG TTC TTC CGT TG 
Cxcl10 GCT CAA GTG GCT GGG ATG GAG GAC AAG GAG GGT GTG G 
Cxcr2 TGT CTG CTC CCT TCC ATC TT CCA TTT CCT CTC CTC CAC CT 
Cxcr3 AGT GCT TGT CCT CCT TGT AGT TG GGT GTT GTC CTT GTT GCT GA 
Fcgr4 CGT GGC ATC AAA TCA CAT TC CCG CAC AGA GAA ATA CAG CA 
Gbp2 CCA AGC GAG ATG CCT TTA TC TTC TTC TTC CAG GGG TCC A 
Gbp3 AGT TCC AGA AGA AGC TGG TGG TCA AGT TCA GCC TGG CAG TGA CGA ATA 
Gbp4 CCT CCT TCC TCT TTC TTC TTC CTT T GTG TTT CTA TGG GGG TGT GG 
Gbp6 AAA CAC ACT CCC TCT CCC AGT TGA AGC CAG TCA ACA TCC AG 
Ifit1 GAC AAG GCA ATC ACC CTC TAC T TCT TTC AGC CAC TTT CTC CAA 
Ifitm3 CGC TCC ATC CTT TGC CCT TCA GTG GCC CCC ATC TCA GCC ACC TCA T 
Igrm1 AGT TCA GCA GGT AGC CCA GA TCA GCC TCA GTT TCC ACT CC 
Il1b CGC TCA GGG TCA CAA GAA AC GAG GCA AGG AGG AAA ACA CA 
Il2rg CGG AAG CCT GAA CAT CAA TC CCA AGG TGA GTA GGG GAG GT 
Il6 TTC CAT CCA GTT GCC TTC TT ATT TCC ACG ATT TCC CAG AG 
Irf7 GAA GAG GCT GGA AGA CCA ACT AGA TAA AAC GCC CTG TGC TG 
Lcn2 TGA ATG GGT GGT GAG TGT GGC TGA TCC TTG GTA TGG TGG CTG GTG GG 
Lgals3bp ATT CCT GTG TCC CCT CCT TC GTG AGT GCT GGC TGA AAC CT 
Ly6a ACC TCC ACC CTT GTC CTT TT GAG CAC CTA CCT ACC CAG CA 
Oasl2 AGC GAG CGA GGG ATG TTC AGG T TGG GGC TGT AGG GGT TTG TCC AG 
Pglyrp TCT GGA ATG TGG GGG TGT CTC TTT GGA TGA CCT GAT AGA GTT GG 
Rtp4 GCA TCT TTG GGT GAG AAG AT ATG GGG AGG AAC TCT TTG GT 
Saa3 TCT TCC TGT TGT TCC CAG TCA CCC AGT AGT TGC TCC TCT TCT C 
Serpina3n ACA GCC TGG AGG ATG TCC TTT CAA TGG TTC CTG TGA TTG CAG ACA GGT 
Sp100 CAT CAT TTT CCT TGG CTG GT CAT TTT GGT TGG TCC TTG CT 
Stat1 GAA AAA CGC TGG GAA CAG AA CGA CAG GAA GAG AGG TGG TC 
Tbp TGC TGT TGG TGA TTG TTG GT AAC TGG CTT GTG TGG GAA AG 
Tnfa CAC CAC CAT CAA GGA CTC AA GAG GCA ACC TGA CCA CTC TC 
Table 2.1 QPCR primer sequences 
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Gene Name Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) 
Apobec3 GGA CCA TTC TGT CTG GGA TG GGA GGG TGA GGG GAG ATA AA 
C4 GAG CCC TTC TTG TCC TGT TG AGT TTG CCT TGG TGA TGG AG 
Ccl2 CAC CAG CAC CAG CCA ACT GCA TCA CAG TCC GAG TCA CA 
Ccl3 CCA CGC CAA TTC ATC GTT TAT GCA GGT GGC AGG AAT GT 
Ccl5 CCC TCA CCA TCA TCC TCA CT TCA GAA TCA AGA GGC CCT CTA TCC 
Ccr1 ACT TTG GCA TCA TCA CCA G CTC AGA TTG TAG GGG GTC CA 
Ccr3 GCC ATC CGT CTT ATT TTT GTT G ATT TCT TGC TCC CCA GTT GA 
Ccr5 ACC CAT TGA GGA AAC AGC AA CTT CTG AGG GGC ACA ACA AC 
Ctsc GCT TTC TCT GCC ATC TGC TC CTT CCA CCA CCC CAA AAT C 
Cxcl1 CTG GGA TTC ACC TCA AGA ACA CTT TTC GCA CAA CAC CCT TC 
Cxcl2 CGC CCA GAC AGA AGT CAT AG ACT CAC CCT CTC CCC AGA AA 
Cxcl10 CGA TGG ATG GAC AGC AGA GAG CCT GAC AAG GAG GGT GTG GGG AGC A 
Cxcr2 CGG GGT TCC TTC TTG TCT TT TGC TAT GTT CCT GTG TGA GG 
Cxcr3 TGG GGT CTC TGT CTG CTC TT TTT GCC TCT CCC TCT TCT CA 
Fcgr4 AAC GGC AAA GGC AAG AAG T TGG GGC AGA GAA AGT GTA AAA 
Gbp2 TTT GTG GGC TTC TTT CCA AC CTT TGC TGC CTC TGT GAG TG 
Gbp3 CCC CAG AGA GGA CAA AGT GA ACC CCC CAG GAA CAG AGA AAG 
Gbp4 TTG GTT TTG TGA GGG CAT TT ATC CAG TAA GGG GAG GCA GT 
Gbp6 GTC TTC TCT TCC CCC ACC TC GGC TCC CAA TAA AAC CGC AC 
Ifit1 GCA AGA GAG CAG AGA GTC AAG GCA  GCA GGG TTC ATT TCC CCA GTG AGC 
Ifitm3 TCT GAG AAA CCG AAA CTG CCG CA TGT AGG GAG GGG CAA GGA GGG A 
Igrm1 CTG CTC CAC TAC TCC CAA C CTC TCC AGC CCA AAA ACA AA 
Il1b CAC TCA TTG TTG CTG TGG AG ATG TGC TGG TGC TCA TTC A 
Il2rg CCA GAG AAA GAA GAG CAA GCA GAA AGA GGG CAA GGG ACA C 
Il6 TCC AGA AAC CGC TAT GAA GT CTC CAG AAG ACC AGA GGA AA 
Irf7 CTG TGA CCC TCA ACA CCC TAA GAG CCC AGC ATT TTC TCT TG 
Lcn2 TTC CGG GGC AGG TGG TAC GTT AAG ACA GGT GGA TGG GGA GTG CTG 
Lgals3bp TGG TCA TAC GCC CCT TCT AC CAC AGG AAA TCC CAC AGG AC 
Ly6a GGA GGC AGC AGT TAT TGT GG ACT CAA CAG GGG GAC ATT CA 
Oasl2 AGA AAG GGA TGG GAA CAG GTG GCT GGG TCG GGG ACT AAG CAG GGT T 
Pglyrp TGT TGT TTG CCT GTG CTC TC CTG AGT CTT TGT TGG GGG TCA A 
Rtp4 AGA CAG TGC TTG GCA GGT TC CTA TGG GGA AGG GCA TTT TT 
Saa3 ACC ACT TCC GAC CTG CTG GCA CAT TGG GAT GTT TAG GG 
Serpina3n TGA CAA TGG GAC ACA ACT GG AGG GGT AGG GGA CAA GAC AA 
Sp100 CCG AAT GGG TCA TCC TTA GA TCT TTT TCT GCG TCG TTG TG 
Stat1 CCT ATG AGC CCG ACC CTA TT GGA AGC AGG TTG TCT GTG GT 
Tbp GAG TTG CTT GCT CTG TGT GCT G ATA CTG GGA AGG CGG AAT GT 
Tnfa TCT GTG AAG GGA ATG GGT GT GGC TGG CTC TGT GAG GAA 
Table 2.2 Standard primer sequences 
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2.5.7.2 Generation of standard templates 
In order to quantify expression levels of target genes, a standard curve 
consisting of PCR signal versus known DNA copy numbers was generated. This 
was done by performing a PCR reaction using the standard primers to amplify a 
region of cDNA containing the amplicon of interest. PCR products were 
separated by gel electrophoresis. The appropriately sized products were cut 
from the gel and purified using a QIAquick Gel Extraction kit (Qiagen) in 
accordance with the manufacturer’s instructions. The quantity of DNA present in 
the purified standards was assessed using the nanodrop 1000.  
The absolute number of amplicon copies present in each standard was 
determined using the following calculation: 
Copies perµl    =  (Concentration (g/µl) X Avogadro’s Constant) 
 Molecular weight of amplicon 
Molecular weight = Size of amplicon (bp) X 660* (Daltons) 
*Average molecular weight for 1 base paired nucleotide. 
Purified standards were diluted 1 x 10-2 in TE buffer and stored at -20°C until 
required for QPCR. 
2.5.7.3 QPCR 
cDNA was synthesised as described previously. QPCR amplifications were 
performed on each cDNA sample in triplicate within wells of either a 96-well PCR 
plate (Star Lab) or a 384-well PCR plate (Star Lab). A standard curve was 
generated by serially diluting the purified standards 10-fold in nuclease-free H2O 
to obtain dilutions of between 1 x 10-5 and 1 x 10-9. Each dilution was included 
on QPCR plates in triplicate. 
A master mix containing the following reagents was prepared for each primer 
pair: 
96-Well PCR Plate 
SYBR® Green FastMix*  7.5µl 
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Nuclease-free H2O   5.7µl 
Forward Primer   0.15µl 
Reverse Primer   0.15µl 
Total volume    13.5µl 
384-Well PCR Plate 
SYBR® Green FastMix*  5µl 
Nuclease-free H2O   3.8µl 
Forward Primer   0.1µl 
Reverse Primer   0.1µl 
Total volume    9µl 
*Purchased from Quanta Bioscience. 
Master mix was applied to PCR plates using a multi-channel pipette. 1.5µl of 
cDNA was added to each well of 96 well PCR plates to create a final reaction 
volume of 15µl. Alternatively, 1µl of cDNA was added to each well of 384 well 
PCR plates to create a final reaction volume of 10µl.  
QPCR was performed using a Prism® 7900HT Sequence Detection System (Life 
Technologies) set for the following programme: 
1. 95°C  20 seconds 
Then 40 cycles of: 
2. 95°C  3 seconds 
3. 60°C  30 seconds  
To confirm the specificity of the QPCR primers a dissociation curve was 
generated using the following programme: 
4. 95°C  15 seconds 
5. 60°C  1 minute  
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6. 95°C  15 seconds 
7. 60°C  15 seconds 
2.5.7.4 Determining relative gene expression 
Following QPCR, the absolute copy number of QPCR amplicons present in each 
reaction was calculated from the standard curve. To control for variations in the 
concentration of RNA used in reverse transcription reactions, data were 
normalised to the reference gene, TATA binding protein (TBP), as follows: 
Normalised copy number = copy number of target gene / copy number of TBP  
Fold change values were calculated by comparing the normalised copy number 
of individual samples to the mean of the control samples. 
2.5.7.5 Determining relative transcript expression 
When RNA was too low to quantify, relative RNA abundance was assessed by 
comparing the cycle threshold (CT) values from QPCR amplifications of the 
reference gene Glyceraldehyde 3-phosphate dehydrogenase (GAPHD). The 
relative transcript expression (RTE) of GAPDH in each sample was calculated by 
the following equations:  
RTE = 2χ; χ= CTBaseline – CTGAPDH  
As even slight variations in GAPDH expression levels would skew the results, this 
method of comparison could only be used when RNA was extracted from the 
same population of cells. 
2.5.8 TaqMan low density array 
TaqMan low density arrays (TLDA) were performed using a Prism® 7900HT 
Sequence Detection System in accordance with manufacturer’s guidelines. Array 
cards were custom-made by Life Technologies to each contain 4 identical panels 
of 32 different TaqMan assays. 
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cDNA was synthesised using the High Capacity RNA-to-cDNA kit as described 
previously. A master mix containing the following reagents was assembled for 
each sample: 
TaqMan Universal Master Mix 100µl 
H2O      90µl 
cDNA*     10µl 
Total volume    200µl 
*cDNA reversed transcribed from 1µg RNA. 
Using a micropipette, 100µl of sample-specific master mix was loaded into each 
reservoir of the TLDA cards. Array cards were centrifuged twice at 300g for 1 
minute before being sealed using a TLDA sealer provided with the assays. ‘Fill 
reservoirs’ were cut from the cards using scissors. The QPCR reactions were then 
carried out using the following programme: 
1. 95°C  10 minutes 
Then 40x cycles of: 
2. 97°C  30 seconds 
3. 59.7°C 1 minute 
2.5.8.1 Determining relative gene expression 
The relative gene expression of each target gene was then quantified relative to 
the reference gene TBP using Prism® SDS2.2 software. 
The relative gene expression analysis was performed using Prism® SDS2.2 
software. The expression of each target gene was first normalised to the 
reference gene TBP as follows:  
ΔCT = CTTarget gene – CTTBP  
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Then the normalised gene expression in each sample was compared to that of a 
randomly picked control sample, or calibrator: 
ΔΔCT = ΔCTSample – ΔCTCalibrator  
Finally the fold change in gene expression, or relative quantification (RQ) value, 
for each sample, compared to the calibrator, was calculated as follows: 
RQ = 2-ΔΔCT 
2.5.9 RNA amplification 
RNA was isolated from cells, as described above, and amplified following the 
SuperScriptTM RNA Amplification System protocol, as described by the 
manufacturers. 
First-strand cDNA synthesis 
Reactions were set up in 200µl PCR tubes as follows: 
Total RNA    <9µl 
T7-Oligo(dT) Primers  1µl 
DEPC-treated H2O    
Total Reaction Volume  10µl 
 
Contents were mixed by pulse centrifugation. RNA was then denatured by 
incubating in a thermocycler for 10 minutes at 70ºC and then cooled on ice. The 
following components were then added to each reaction at room temperature: 
5X First-Strand Buffer  4µl 
0.1M DTT    2µl 
10mM dNTP    1µl 
RNaseOUTTM    1µl 
SuperScriptTM III RT (200 U/µl) 2µl 
Total Reaction Volume  20µl 
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The tubes were incubated in the thermocycler at 46ºC for 2 hours, 70ºC for 10 
minutes and then placed on ice. 
 
Second-strand cDNA synthesis 
The contents from the first strand reaction tubes were added to a 1.5ml 
microcentrifuge tube along with the following components: 
 
DEPC-treated H2O   91µl 
5X Second-Strand Buffer  30µl 
10mM dNTP Mix   3µl 
DNA Polymerase I (10 U/µl) 4µl 
DNA Ligase (10 U/µl)  1µl 
Rnase H (2 U/µl)   1µl 
Total Reaction Volume  150µl 
 
Tubes were incubated in a refridgerated water bath at 16ºC for 2 hours, cooled 
on ice, then stored at -20ºC until required for cDNA purification. 
cDNA purification 
cDNA was precipitated by adding 500µl of cDNA Loading Buffer and then 
collected on a silicone membrane by centrifugation through provided spin 
cartridges. cDNA was then washed with cDNA Wash Buffer, air-dried and then 
eluted in 100µl DEPC-treated H2O. The volume of eluate was then reduced to 
less than 20µl by evaporation using a speed-vacuum centrifuge. 
In vitro transcription 
DEPC-treated H2O was added to the purified cDNA to bring the total volume to 
23µl. The following components were then added at room temperature: 
100mM ATP    1.5µl 
100mM CTP    1.5µl 
100mM GTP    1.5µl 
100mM UTP    1.5µl 
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10X T7 Reaction Buffer  4µl 
T7 Enzyme Mix   7µl 
Total Reaction Volume  40µl 
 
After a 16 hour incubation at 37ºC, 2µl DNase I was added to each tube. The 
tubes were then incubated for a further 30 minutes to digest template cDNA. 
aRNA purification 
Amplified RNA (aRNA) was precipitated by adding 160µl of RNA Binding Buffer 
followed by 100µl of 100% EtOH. It was then collected on a spin cartridge silicon 
membrane by centrifugation. RNA was then washed twice with 500µl RNA Wash 
Buffer, air-dried and eluted in 100µl DEPC-treated H2O. Purified aRNA was stored 
at -80ºC. 
2.6 Protein Analysis 
2.6.1 ELISA 
Murine plasma cytokines were analysed using DuoSet enzyme-linked 
immunosorbent assay (ELISA) Development System kits (R&D Systems). As ELISA 
reactions were performed in half-area 96 well ELISA plates, all the volumes of 
samples and reagents used were half of the recommended volumes. Otherwise, 
ELISAs were performed as described in the manufacturer’s instructions. All 
reactions were performed in duplicate. 
2.6.2 Flow Cytometry 
The relative proportion of cell populations was determined by staining cells for 
relevant surface antigen. The expression of surface antigen was assessed using a 
MACSQuant Analyzer (Miltenyi). 
A single cell suspension was generated from mouse brains as described in Section 
2.3.8. PBL were isolated from whole blood (Section 2.3.6), and strained through 
nitex mesh. Cells were counted using a haemocytometer. 1x106 cells from each 
sample were transferred to FACS tubes and washed in 2ml MACS buffer. These 
were then resuspended in 100µl MACS buffer and labelled with fluorochrome-
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conjugated antibodies. To prevent non-specific binding, Fc receptors were first 
blocked by adding 1µl FcR block (Miltenyi) per 1x106 sample. Cells were 
incubated for 10 minutes on ice. To label surface antigen, fluorochrome-
conjugated antibodies, as described in Table 2.3, were added to each sample. 
Antigen Fluorochrome Clone Dilution Company 
CD3 PE 145-2C11 1/25 eBioscience 
CD8 FITC 53-6.7 1/100 BioLegend 
CD11b APC M1/70 1/100 eBioscience 
F4/80 PerCP BM8 1/100 BioLegend 
CD45* VB 30/F11 1/100 BioLegend 
CD45** AF450 30/F11 1/100 eBioscience 
Table 2.3 Fluorescently-conjugated antibodies used for flow cytometry 
*Used to identify CD45-expressing cells on days 2 and 5 of LPS time course.       
**Used to identify CD45-expressing cells on days 2 and 5 of LPS time course. 
5µl of each antibody was added to the cells and cell samples were incubated on 
ice for 20 minutes in the dark. Labelled cells were washed in 3ml MACS buffer 
and pelleted by centrifugation at 300g for 10 minutes. Supernatant was 
decanted and the cells resuspended in 200µl MACS buffer. To discern live from 
dead cell populations, 1µl of Draq7 (Abcam) was added to each sample. 
The surface antigen expression of individual cells from each sample was 
immediately assessed using a MACSQuant analyzer (Miltenyi) as described by the 
manufacturers. 
2.6.3 Histology 
Histology was performed on brain tissue sections by the Veterinary Diagnostic 
Services Laboratory, a core facility within the University of Glasgow. The 
primary antibodies used are listed in Table 2.4. These were used with 
horseraddish peroxidase-conjugated anti-rabbit and anti-mouse secondary 
antibodies from Envision+ System-HRP labeled polymer kits (DAKO). 
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Antigen Host Species Clone Dilution Company 
CD3 Rabbit  SP7 1/30 Vector 
MPO* Rabbit GA511 1/1000 Dako 
Calprotectin Mouse MAC387 1/500 Dako 
Table 2.4 Primary antibodies used for immunohistochemistry. 
*MPO: Myeloperoxidase 
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3 Transcriptional profiling of CNS following 
systemic inflammation 
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3.1 Introduction and aims 
As previously described, systemic infection or inflammation can have a profound 
effect on the CNS, manifesting in a number of autonomic and behavioural 
adaptations and increased neuroendocrine activation. These behavioural 
phenotypes, termed sickness behaviours, occur during acute bacterial or viral 
infections, but also during chronic inflammatory diseases274-276. In the latter 
case, what would be a beneficial, self-limiting system can become dysregulated. 
The prolonged depression and anxiety that ensues represents a major burden to 
patients, not least because these detrimental co-morbidities lead to a poorer 
clinical outcome. 
It is becoming increasingly evident that inflammatory cytokines play a pivotal 
role in triggering a number of sickness behaviours. This has been discussed in 
detail in Section 1.4.1. Moreover patients with major depressive disorders, that 
are otherwise medically healthy, often present with elevated levels of 
inflammatory cytokines both in their circulation and their CSF276. Thus it would 
appear that a bi-directional interplay exists between the immune system and the 
nervous system. The extent to which this inter-system communication impacts 
the normal functioning of the brain is currently under much scrutiny and a great 
deal of progress has been made into deciphering neuroimmune communication 
pathways. However, the precise effect immune activation has on neural circuitry 
remains unclear. One well characterised model of systemic inflammation which 
has been used repeatedly to explore routes of neuroimmune communication, 
involves injecting mice, intraperitoneally, with LPS. Renowned for inducing a 
multitude of sickness behaviours, LPS-induced inflammation has become a key 
model in establishing how the brain responds to changes in the peripheral 
inflammatory milieu.  
In the immediate hours following a single injection of LPS, the response in the 
brain is well characterised. Therefore, the main aim of this chapter was to 
establish what prolonged impact LPS-induced systemic inflammation had on 
transcriptional modulation in the brain. To this end, C57BL/6 mice were injected 
intraperitoneally with a high dose of LPS. Whole brain RNA profiles, 48 hours 
after injection, were compared to a vehicle injected control group using 
Affymetrix microarrays. This is a novel approach as most studies focus on the 
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events in the brain that occur within the initial 12 hours following LPS injection. 
Microarray analysis generated a list of genes that were differentially modulated 
in the brain in response to systemic LPS. To determine the biological relevance 
of this, these genes were subsequently grouped into functional categories and 
pathways. Therefore, in this chapter, transcriptomics were used to investigate 
the molecular mechanisms by which inflammation originating in the periphery 
can induce transcriptional modulation in the brain. 
3.2 Acute model of systemic LPS-induced inflammation 
To induce inflammation systemically, 8 week old male C57BL/6 mice were 
injected I.P. with 100 µg of LPS or 100µl of vehicle (sterile distilled H20). Mice 
were terminally anesthetised, and then perfused, either 6 hours, 12 hours or 48 
hours after injection.  
3.2.1 Model validation 
To confirm peripheral inflammation following systemic LPS challenge, the 
concentration of inflammatory cytokines in the circulation was measured using 
ELISAs. ELISAs were performed on plasma samples isolated from LPS- and 
vehicle-injected mice; 6 hours, 12 hours and 48 hours post-injection. Plasma 
from all mice injected with LPS displayed significantly elevated levels of IL-1β 
and IL-6, 6 hours following injection (Figure 3.1). Levels IL-1β returned to 
baseline between 6 and 12 hours following injection and IL-6 levels remained 
elevated until 48 hours. Although TNFα could not be detected in the circulation 
at any of the timepoints assayed, it has previously been shown that TNFα levels 
peak in the circulation of C57BL/6 mice 2 hours following LPS injection (100 µg 
i.p.) and then rapidly decline414. Therefore, injecting LPS systemically initiates 
an inflammatory response in the periphery, with elevated levels of inflammatory 
cytokines in the plasma for up to 48 hours. 
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Figure 3.1 Plasma concentration of inflammatory cytokines following systemic LPS injection 
Plasma was isolated from the whole blood of mice; 6 hours, 12 hours and 48 hours following 
injection with either 100 µg LPS (I.P.) or an equivalent volume of vehicle. Concentrations of (A) IL-
1β, (B) IL-6 and (C) TNFα in the plasma were determined using ELISA. Data represent the mean 
+/- SEM. Significance was determined using two-way ANOVA. n = 4/group. 
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3.2.2 Processing of RNA samples 
RNA was extracted from the right brain hemispheres of mice, 48 hours after 
systemic LPS or vehicle injection. Prior to the microarray analysis, the integrity 
of extracted RNA samples was assessed using an Agilent 2100 Bioanalyzer. This is 
a microfluidics-based platform in which nucleotide fragments are separated 
according to size and evaluated qualitatively using an electropherogram. Using 
the electropherogram, RNA integrity can be both visually and mathematically 
assessed using the RNA integrity number (RIN) algorithm. The RIN algorithm 
screens the electrophoretic trace of each RNA sample and assigns it a RIN score 
between 1 and 10. This scale, where 10 is perfectly intact and 1 is entirely 
degraded, is based on the presence or absence of degraded RNA products and 
the ratio of 28S:18S ribosomal subunit RNA.  
Figure 3.2 is an example of an electropherogram exhibiting completely intact 
RNA. The characteristics of high quality RNA include three distinct peaks; the 
RNA marker, ribosomal RNA subunit 18S and ribosomal RNA subunit 28S. These 
are denoted in the electropherogram (Figure 3.2A) by numbers 1, 2 and 3 
respectively. Otherwise, there should be very little background noise on the 
graphs. RNA samples extracted for the microarray study were qualitatively 
assessed and representative electropherograms from the vehicle-injected and 
the LPS-injected groups are displayed in Figure 3.2B and Figure 3.2C 
respectively. The RIN of each sample is listed in Table 3.1. It is recommended 
that for a sample to be deemed of suitable quality, it should have a RIN of 8 or 
above. All RNA analysed was of sufficient quality to be used for the microarray 
study, as exemplified by the high RIN, the clear peaks and the low molecular 
weight noise visible in the electropherograms. 
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Figure 3.2 Quality of RNA samples and efficiency of DNA fragmentation 
RNA was isolated from whole brains, 48 hours after injection with 100µg LPS or an equivalent 
volume of vehicle. Samples were processed for microarray analysis, converted to sense-strand 
cDNA and then fragmented. Both the quality of the RNA samples and the efficiency of DNA 
fragmentation were determined using an Agilent 2100 Bioanalyzer. Data are displayed as 
fluorescence units [FU] over time. (A) Example of high quality total RNA with an RNA integrity 
value of 10. (B-C) Integrity of whole brain total RNA extracted from; (B) vehicle-injected and (C) 
LPS-injected mice. (D-E) Fragmented DNA samples from; (D) vehicle-injected and (E) LPS-
injected mice. (B-E) Data shown are one representative sample from each group. n = 3/group. 
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Sample Ribosomal 28S:18S Ratio RIN Score 
Vehicle 1 1.5 8.9 
Vehicle 2 1.4 8.8 
Vehicle 3 1.6 9.3 
LPS 1 1.7 9.5 
LPS 2 1.9 9.5 
LPS 3 2.1 9.7 
Table 3.1 Integrity of RNA samples 
RNA was isolated from whole brains, 48 hours after injection with 100µg LPS or vehicle. The 
ribosomal 28S:18S ratio of each sample was calculated using an Agilent 2100 Bioanalyzer and 
used to calculate the RNA integrity number (RIN). 
Having verified the RNA quality, samples were amplified by in vitro transcription 
(IVT) and reverse transcribed. The resulting sense-strand cDNA was fragmented 
and labelled prior to hybridisation. In addition to RNA sample integrity, the 
efficiency of fragmentation was also checked on the Agilent 2100 Bioanalyzer; 
this time using a DNA chip. As with the RNA chip, the fragmented DNA was 
fluorescently labelled and then separated in a microchannel according to size. 
Fluorescence intensity was measured over time and representative 
electropherograms from the vehicle-injected and the LPS-injected groups are 
displayed in Figure 3.2D&E. Each graph exhibits one peak, just adjacent to the 
DNA marker, suggesting that all DNA fragments, contained in the samples, were 
of a relatively similar size. It was also apparent that both samples consisted of 
small DNA fragments, as demonstrated by the short speed at which the 
fragments moved through the microchannel. Altogether, these data indicate that 
the RNA samples were of high quality and the fragmentation of the 
corresponding sense-strand cDNA was successful. 
3.3 Determining how systemic LPS injection affects the 
transcriptional profile of the brain 
In order to establish how systemic LPS challenge affects neurological 
transcriptional modulation, the transcriptional profiles of the brains of three 
LPS-injected mice were compared to those of three vehicle-injected mice using 
Affymetrix GeneChip Mouse Gene 1.0 ST arrays. Comprising 764 885 distinct 
probes, which equates to 28 869 well-annotated gene transcripts, these 
GeneChips have complete genome coverage. The transcriptome of each sample 
is interrogated using 25-mer oligonucleotide probes which are specifically 
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distributed across the entire length of each transcript. Probes are designed for 
each exon, with a median of 26 probes being specific to each gene transcript. As 
this system uses probes that anneal to various regions along the length of each 
gene, these whole-transcript GeneChips are more accurate that the traditional 
system in which probes localize to the far 3’ end of each transcript. As a result, 
they were an ideal choice of array to use for this study.  
3.3.1 Pre-processing of Affymetrix chip data using Partek 
Microarrays were performed by the Glasgow Polyomics facility 
(http://www.polyomics.gla.ac.uk/). Data, provided by this core facility, were 
analysed using Partek Genomics Suite 6.5 software. Prior to analysis, the raw 
data must be assessed qualitatively and then pre-processed. This occurs in a 
series of stages, each of which will be described below.  
1. Background correction: This corrects for the level of background noise that 
occurs as a result of non-specific hybridisation. 
2. Normalisation: Performed in order to unify the distribution of signal 
intensities of each chip, thus enabling the comparison and coordinated 
analysis of data from multiple chips. 
3. Summarisation: This first summarises the signal intensities of individual probe 
sets to exons and then to the corresponding genes; giving each entity a 
normalised intensity value. 
Pre-processing is carried out using an appropriate summarisation algorithm. 
Although many different summarisation algorithms have been developed, Partek 
offers only two options; Robust Multi-array Average (RMA) or GCRMA (RMA 
adjusted for GC content). RMA is considered the most sensitive and specific of 
the summarisation algorithms and GCRMA is a modified form of RMA. The 
difference between these two algorithms, which will now be discussed, lies in 
the background correction step.  
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3.3.1.1 Background correction of the Affymetrix chips 
Background signal intensity is corrected on a chip-by-chip basis. For every set of 
probes, the observed signal intensity consists of the true intensity, caused by 
specific hybridisation, and a certain level of background noise, caused by non-
specific hybridisation. In order to determine the true intensity, the level of 
background noise must be established.  
The Affymetrix Gene 1.0 ST system uses an innovative design where the 
background can be determined using 17 000 generic background probes; a 
comparatively smaller number than previous Affymetrix designs which contain 
one background probe set to each perfect match (PM) probe set. Instead, these 
anti-genomic background probes are designed to cover the entire range of GC 
content. The GCRMA algorithm uses the signal intensities of these probes to 
determine background. For every transcriptome-interrogating probe set, the GC 
content is calculated. The background signal, defined as the median signal 
intensity of all background probes with an equal GC content, is subsequently 
subtracted from the observed signal of the probe set. The signal that remains is 
the “true” intensity. In contrast, the RMA summarisation uses a PM only system. 
Ignoring the background probe intensities, RMA instead takes into account the 
distribution of the data and applies it to a complex algorithm which models the 
background signal intensity. This noise level, calculated using RMA, is 
subsequently subtracted from the observed intensity to obtain the “true” 
intensity.  
The exclusion of background intensities by RMA is thought to reduce noise, 
however, RMA has the disadvantage that it loses the information that the 
background probe intensities provide. For that reason, GCRMA was selected to 
pre-process the dataset. 
3.3.1.2 Signal histogram of normalised data 
Monitoring of sample hybridisation is an essential step in ensuring the quality of 
the array data. Whether as a result of user error, or differences in chip 
manufacturing, variations can occur that affect the reproducibility of the 
results. Differences in the efficiency of hybridisation can be detected using a set 
of control transcripts. Prior to hybridisation, fragmented cDNA is added to a 
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hybridisation cocktail that contains the controls. These consist of standard 
concentrations of 4 transcripts, bioB, bioC, bioD and cre. BioB is present at a 
1.5pM concentration; the detection limit of most arrays. BioC, bioD and cre are 
present at 5pM, 25pM and 100pM respectively. In order to ensure there are no 
differences in the efficiency of hybridisation from one chip to the next, the 
signal intensities of the control transcripts on each chip are plotted on a 
histogram. Figure 3.3A shows the signal intensities of the 4 hybridisation controls 
on each of the 6 GeneChips used in the array study. The intensity similarities of 
each of the controls would suggest that little variation exists between the 
hybridisation efficiency of each chip. 
In addition, the frequency of the signal intensities detected on each microarray 
chip was also plotted on a signal histogram (Figure 3.3B). After labelled cDNA is 
hybridised to the chip, signal intensities are calculated for each probe set. The 
histogram plots the occurring frequency (Y-axis) of a range of signal intensities 
(X-axis) for all the probe sets on each chip. In addition to controlling for 
hybridisation quality, this signal histogram controls for other sources of non-
biological variation that could affect the results, such as the efficiency of cDNA 
labelling or starting RNA quantity or quality. Each line on the graph represents a 
different array chip and these are coloured according to sample grouping. It is 
clear from the graph that all chips have a similar pattern of signal intensity 
distribution, therefore ruling out non-biological variables.  
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Figure 3.3 Signal histogram of normalised intensity values 
A microarray study was performed to compare gene expression in the brains of mice injected with 
LPS, to a vehicle-injected control group. Labelled sense-strand cDNA was generated from 
amplified RNA samples and hybridised to each chip along with 4 control transcripts at standard 
concentrations. Signal intensities of control and sample hybridization were compared between 
chips using signal histograms. (A) Normalised signal intensities of hybridization controls; bioB, 
bioC, bioD and cre. Each line on the histogram represents an individual GeneChip. (B) The 
occurring frequency of signal intensities for all probe sets on each chip. Each line represents an 
individual GeneChip and thus an individual sample. Lines are coloured according to experimental 
grouping. Blue represents vehicle-injected control samples and red represents samples taken from 
LPS-injected mice. n = 3/group. 
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3.3.1.3 Principle component analysis 
Prior to gene expression analysis, principle component analysis (PCA) was 
performed to check the quality of the data. PCA is a mathematical method of 
reducing the dimensionality of a dataset so that trends in the data can be easily 
visualised. Useful for datasets with large numbers of variables, PCA functions by 
applying a new set of variables to the data. These variables, less in number than 
those of the original dataset, are termed the principle components (PC) and are 
designed to retain as much of the variance of the original variables as possible. 
PC1 represents the variable with the greatest variance and subsequent 
components are numbered in ascending order with decreasing significance. The 
Affymetrix dataset was subject to PCA and each sample was plotted according to 
the top 3 most significant PC components. 
A plot displaying the PCA scores of all of the GeneChip data is shown in Figure 
3.4. When grouped in this manner, samples with a similar transcription profile 
should cluster together. This allows the distinction between different groups of 
data to be visualised and also highlights any outliers in a particular group. The 
points on the graph represent the samples from each group, clustered around an 
additional centroid circle. These are coloured according to their experimental 
grouping. The vehicle-injected mice were more tightly clustered than the LPS-
injected group, suggesting that more transcriptional variation exists between the 
brains of the LPS-injected mice. In spite of this variation, there is a clear 
distinction between the group of LPS-injected mice and the group of control 
mice. 
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Figure 3.4 Principle component analysis of microarray samples 
A microarray study was performed to compare gene expression in the brains of mice injected with 
LPS to a vehicle-injected control group. The 3 largest principle components of the array study were 
compared using a principle component analysis (PCA) plot. Each circle on the graph represents 
data from individual GeneChips, and therefore individual samples, clustered around a centroid 
circle. The more tightly clustered a group of circles are, the more they are transcriptionally similar. 
Samples are coloured according to experimental grouping. Blue represents vehicle-injected control 
samples and red represents samples taken from LPS-injected mice. n = 3/group. 
 
3.3.2 Gene expression analysis of Affymetrix chips using Partek 
The quality control measures, outlined above, have systematically ruled out 
sources of variation, such as differences in RNA quality, the labelling of samples 
or the quality of sample hybridisation. As a result, it can now be assumed that 
any differences observed between the two groups of samples are a result of 
genuine shifts in their transcriptional profiles. In order to determine which of 
the observed transcriptional changes are likely to be biologically meaningful, 
normalised intensity values, established using the GCRMA algorithm, were 
subject to statistical analysis. 
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3.3.2.1 Genes identified by Partek as being differentially expressed in the 
brains of LPS challenged mice 
In order to assess which genes were differentially expressed in the brains of LPS-
injected mice compared to the vehicle-injected controls, a one-way ANOVA was 
performed on the data, along with a Benjamini-Hochberg multiple testing 
correction (MTC) with a false discovery rate (FDR) of 0.1. 
MTCs are a statistical method of reducing the rate of type I errors, i.e. the rate 
of wrongfully rejecting the null hypothesis. The rate of type I errors rises in 
magnitude when multiple hypotheses are simultaneously tested from a single 
dataset. For that reason, accurately testing the hypotheses derived from a 
microarray study, with tens of thousands of variables, can prove problematic. 
Based on a set of observations, the p-value is the probability that the null-
hypothesis is true. The more often a p-value is calculated from a single dataset, 
the greater the probability is of generating a false positive, or type I error. For 
example, in a microarray study, for every 1000 genes that have a p-value of 
0.05, probability suggests that 50 of these (1000 x 0.05) will, by chance, be false 
positives. MTCs increase the stringency of statistical analysis tests, thereby 
reducing the rate of type I errors. Subsequently, MTCs should always be applied 
to datasets containing large numbers of variables, such as those generated from 
microarray studies. 
One of the drawbacks of MTCs is that whilst reducing the occurrence of false 
positives, they increase the chance of false negatives. Benjamini-Hochberg is the 
least stringent of the MTCs utilized by Partek, making it the ideal MTC to use for 
such a small study. The Benjamini-Hochberg method ranks all entities according 
to their p-value; from most to least significant. A corrected p-value is calculated 
from the equation below where N = total numbers of entities and r = rank: 
Corrected p-value = p-value*(N/N-r) 
The stringency of the MTC can be controlled by setting the FDR value. This is the 
expected proportion of incorrect rejections. By setting the FDR to 0.1, every 
entity with a corrected p-value of less than 0.1 was considered significant. This 
set the unadjusted p-value cut-off to 0.00036562. 131 entities satisfied this 
significance threshold. Of these significant entities, those that were 
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differentially expressed by at least 1.5-fold are displayed in Table 3.2. The table 
has been sub-divided into the 55 entities that were upregulated 2-fold or more 
and the additional 30 entities that were differentially expressed by at least 1.5-
fold. Although significant, the remaining 46 entities that were not differentially 
expressed as much as 1.5-fold were not included in further analyses as they are 
unlikely to be biologically relevant.  
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Genbank 
Accession 
Gene 
Symbol 
Gene Name Fold 
Change  
P-value 
 
Fold Change ≥ 2 
NM_008491 Lcn2 Lipocalin 2 29.29  2.61E-05 
NM_011315 Saa3 Serum amyloid A3 11.60 2.56E-04 
NM_016850 Irf7 Interferon regulatory factor 7 6.08 1.1E-04 
NM_011854 Oasl2 2'-5' Oligoadenylate synthetase-like 2 5.44 1.01E-04 
BC150711 AI607873 Interferon activated gene 204 
homologue 
4.93 3.74E-05 
NM_023386 Rtp4 Receptor transporter protein 4 4.75 1.21E-04 
NM_025378 Ifitm3 Interferon induced transmembrane 
protein 
4.22 1.30E-05 
NM_011579 Tgtp1 T-cell specific GTPase 1 3.79 3.64E-04 
NM_008620 Gbp4 Guanylate binding protein 4 3.76 1.39E-04 
 
NM_013563 Il2rg Interleukin 2 receptor, gamma chain 3.71 9.29E-05 
NM_023065 Ifi30 Interferon gamma inducible protein 30 3.64 9.95E-05 
NM_144559 Fcgr4 Fc receptor, IgG, low affinity IV 3.57 4.23E-06 
NM_194336 Gbp6 Guanylate binding protein 6 3.54 5.68E-06 
NM_009252 
 
Serpina3n Serine (or cysteine) peptidase 
inhibitor, clade A 
3.52 3.12E-04 
 
NM_001082960 Itgam Integrin alpha M 3.41 2.45E-04 
 
NM_001033767 Gm4951 Predicted gene 4951 3.36 4.14E-05 
--- N/A* --- 3.35 2.71E-05 
NM_011150 Lgals3bp Lectin, galactoside-binding, soluble, 3 
binding protein 
3.31 7.93E-05 
NM_001001892 H2-K1 Histocompatibility 2, K1, K region 3.24 3.11E-04 
 
NM_008331 
 
Ifit1 Interferon-induced protein with 
tetratricopeptide repeats 
3.23 3.50E-05 
NM_009780 C4b Complement component 4B (Childo 
blood group) 
3.13 2.78E-04 
 
NM_011905 Tlr2 Toll-like receptor 2 3.09 1.74E-05 
--- Rnf213** Ring finger protein 213  3.09 1.22E-04 
AK173199 Rnf213 Ring finger protein 213 3.07 5.21E-06 
NM_010260 Gbp2 Guanylate binding protein 2 3.02 8.62E-05 
NM_013673 Sp100 Nuclear antigen Sp100 3.02 1.8E-04 
NM_145545 Gbp7 Guanylate binding protein 7 2.86 3.04E-05 
--- Rnf213** Ring finger protein 213  2.74 1.15E-04 
NM_010130 Emr1 EGF-like module containing, mucin-
like, hormone receptor-li 
2.72 1.74E-04 
--- Rnf213 Ring finger protein 213  2.69 1E-04 
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--- N/A* --- 2.69 2E-04 
NM_011693 Vcam1 Vascular cell adhesion molecule 1 2.68 1.11E-04 
NM_018734 Gbp3 Guanylate binding protein 3 2.66 6.62E-05 
NM_009402 Pglyrp1 Peptidoglycan recognition protein 1 2.56 1.89E-05 
NM_010738 Ly6a Lymphocyte antigen 6 complex, locus 
A 
2.55 3.80E-05 
NM_009283 Stat1 Signal transducer and activator of 
transcription 1 
2.51 2.41E-04 
NM_009982 Ctsc Cathepsin C 2.47 3.09E-06 
NM_153197 Clec4a3 C-type lectin domain family 4, 
member a3 
2.46 2.91E-04 
AK173199 Rnf213 Ring finger protein 213 2.39 2.53E-04 
NM_008879 Lcp1 Lymphocyte cytosolic protein 1 2.36 1.27E-04 
NM_008326 Irgm immunity-related GTPase family M 
member 1 
2.33 3.25E-04 
--- N/A* --- 2.32 1.42E-04 
NM_001160415 Apobec3 apolipoprotein B mRNA editing 
enzyme 
2.32 1.86E-04 
NM_031195 Msr1 Macrophage scavenger receptor 1 2.29 4.58E-05 
--- Rnf213** Ring finger protein 213  2.26 1.29E-05 
NM_011708 Vwf Von Willebrand factor homolog 2.26 3.89E-05 
NM_031376 Pik3ap1 phosphoinositide-3-kinase adaptor 
protein 1 
2.21 1.41E-04 
NM_021384 Rsad2 Radical S-adenosyl methionine 
domain containing 2 
2.18 2.37E-04 
--- N/A* --- 2.13 1.4E-04 
NM_001163522 Emcn Endomucin 2.12 1.34E-04 
NM_001037713 Xaf1 XIAP associated factor 1 2.09 1.74E-04 
NM_001113356 C1rb Complement component 1, r 
subcomponent B 
2.09 1.99E-04 
NM_013690 Tek Endothelial-specific receptor tyrosine 
kinase 
2.06 1.37E-04 
NM_012054 Aoah Acyloxyacyl hydrolase 2.04 3.06E-04 
NM_001039530 Parp14 Poly (ADP-ribose) polymerase family, 
member 14 
2.02 7.28E-05 
     
Fold Change ≥ 1.5 and <2 
NM_013805 Cldn5 claudin 5 1.97597 8.43E-05 
--- Rnf213** Ring finger protein 213  1.91996 1.46E-04 
NM_172479 Slc38a5 Solute carrier family 38, member 5 1.86936 8.83E-05 
NM_001081215 Ddx60 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 60 
1.8692 1.33E-05 
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NM_010833 Msn Moesin 1.85669 1.59E-04 
NM_010741 Ly6c1 lymphocyte antigen 6 complex, locus 
C1 
1.84075 1.33E-04 
NR_030719 Gm8979 very large inducible GTPase 1 
pseudogene 
1.83413 8.11E-05 
BC023105 BC023105 cDNA sequence BC023105 1.81633 5.22E-05 
NM_025992 Herc5 hect domain and RLD 5 1.80396 2.4E-04 
NM_009868 Cdh5 cadherin 5 1.80082 1.62E-05 
NM_010493 Icam1 intercellular adhesion molecule 1 1.79505 1.36E-04 
--- N/A* --- 1.76818 1.63E-04 
--- Rnf213** Ring finger protein 213  1.763 3E-04 
NR_003507 Oas1b 2'-5' oligoadenylate synthetase 1B 1.75542 1.55E-04 
NM_010104 Edn1 endothelin 1 1.74503 1.66E-04 
NM_028261 Tmem173 transmembrane protein 173 1.73832 2.27E-05 
NM_010225 Foxf2 forkhead box F2 1.71563 7.39E-05 
NM_007609 Casp4 caspase 4, apoptosis-related cysteine 
peptidase 
1.70807 1.29E-04 
NM_031181 Siglece sialic acid binding Ig-like lectin E 1.69006 1.7E-04 
NM_009888 Cfh complement component factor h 1.64032 2.28E-04 
NM_001037298 Fam38a family with sequence similarity 38, 
member A 
1.62396 9.95E-05 
NM_019963 Stat2 signal transducer and activator of 
transcription 2 
1.60841 1.01E-04 
NM_030253 Parp9 poly (ADP-ribose) polymerase family, 
member 9 
1.59804 1.17E-04 
NM_001111059 Cd34 CD34 antigen 1.59774 8.42E-05 
--- N/A* --- 1.58439 1.27E-04 
NM_025659 Abi3 ABI gene family, member 3 1.54831 1.42E-04 
--- N/A* --- 1.52005 3.61E-04 
NM_028195 Cyth4 cytohesin 4 1.5195 1.00E-04 
NM_183168 P2ry6 pyrimidinergic receptor P2Y, G-
protein coupled, 6 
1.51848 3.49E-04 
NM_007705 Cirbp cold inducible RNA binding protein -1.5643 3.09E-04 
Table 3.2 Differentially expressed entities identified using Partek  
Microarrays were analysed using Partek Genomics Suite. These data show the fold change and 
significance of the entities that were upregulated ≥ 2-fold, and additional entities that were 
differentially expressed ≥ 1.5-fold but < 2-fold, in the brains of mice injected with 100µg LPS 
compared to vehicle. Significance was calculated using one-way ANOVA. 
*Probe sets do not map to annotated genes 
**Annotations manually determined using Affymetrix online database, NetAffx 
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3.3.3 Gene ontology clustering 
After a list of differentially expressed genes was generated using Partek 
Genomics Suite, it was then subject Gene ontology clustering. All genes with a 
fold change value of 1.5 or greater were analysed using the database for 
annotation, visualisation and integrated discovery (DAVID) Bioinformatics 
Resources 6.7 (http://david.abcc.ncifcrf.gov/). DAVID is a free online software 
system that systematically maps lists of relevant genes according to their 
biological function. This applies biological relevance to a dataset, by 
determining which groups of functionally related genes are significantly 
enriched. Significance of enrichment is determined using a modified Fisher’s 
Exact test and a Benjamini-Hochberg MTC was used to correct for the rate of 
type I errors involved in performing multiple comparisons. Co-expression of a 
gene cluster was considered significant if it satisfied a p-value cut-off of 0.05. 
The top 10 most significantly enriched processes are shown in Figure 3.5. 
Amongst the most significantly altered biological groups are the Immune 
response, Immunity & defence and Macrophage-mediated immunity. This 
strongly implies the presence of an immune response in the brain following 
systemic LPS. As macrophages and microglia share many similar characteristics, 
it is possible that this immune response is linked to microglial activation. Also 
ranking high in the list of altered processes is Interferon-mediated immunity 
(Figure 3.5). Therefore, injecting mice systemically with LPS induces an immune 
response in the brain that may involve microglial activation and the induction of 
an IFN response. 
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Figure 3.5 Top 10 enriched biological annotations. 
Using DAVID bioinformatics software, gene ontology clustering was performed on the list of genes 
that were identified as being differentially regulated by ≥ 1.5-fold, in the brains of LPS-challenged 
mice, compared to a control group. The co-expression of functionally-related gene clusters was 
rated in order of significance. Significance was calculated using a modified Fisher’s Exact test.  
*External side of plasma membrane. 
 
3.3.4 Ingenuity Pathway Analysis 
To complement and validate the data generated using DAVID, the list of genes 
were grouped into biological pathways. Pathway analysis, such as that carried 
out using Ingenuity Pathway Analysis (IPA) software, focuses on the proteins that 
a list of genes encodes. By investigating the functional relationships and 
annotated physical interactions between these proteins, as described in the 
relevant literature, IPA clusters them into molecular networks associated with 
cellular responses. Rather than providing an accurate representation of which 
pathways are activated in a given cell type or tissue, this form of data-mining 
facilitates hypothesis generation only. IPA pathway analysis was performed on 
significant genes with a fold change of greater-than or equal-to 1.5. Of the 85 
entities that satisfied this cut-off, 70 were defined as being well-annotated and 
“analysis-ready” by the IPA software package. These 70 genes were subsequently 
grouped into pathways. Significance of differentially altered pathways was 
determined using a Fisher’s Exact test and a Benjamini-Hochberg MTC was used 
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to correct for the rate of type I errors. The 10 most significantly altered 
pathways are displayed in Figure 3.6. 
0 1 2 3 4 5
IL-9 signalling
IFN signalling
IL-8 signaling
†Jaks & Tyk2 in IFN signalling
Hepatic fibrosis**
Activation of IRF by cPRR*
Acute phase response signaling
Complement system
Leukocyte extravasation
Dendritic cell maturation
-log (p-value)
 
Figure 3.6 Top 10 significantly altered biological pathways. 
Using Ingenuity Pathway Analysis software, the list of genes that were identified as being 
differentially regulated ≥ 1.5-fold, in the brains of LPS-challenged mice compared to a control 
group, were grouped into biological pathways. Significance was calculated using a Fisher’s Exact 
test and pathways were ranked accordingly.  
*Activation of interferon regulatory factors by cytosolic pattern recognition receptors.  
**Hepatic fibrosis/Hepatic stellate cell activation.  
†Jak1, Jak2 and Tyk2 in interferon signalling. 
 
The most altered biological pathway was Dendritic cell (DC) maturation. 
Expression of this pathway appears enhanced due to the upregulation of; Tlr2, 
H2-K1, Icam1, Fcgr4, Stat1 and Stat2 (Table 3.2), although the enhancement of 
most of these genes could be explained by microglial activation. Many of the 
genes involved in leukocyte extravasation were upregulated in response to 
peripheral LPS injection. This pathway, illustrated in Figure 3.7, involves the 
upregulation of a number of genes implicated in both leukocyte rolling and 
adhesion to the vasculature and subsequent leukocyte transmigration. This may 
explain the entry of leukocytes to the brain; either across the BBB or across the 
BCSFB. 
Also amongst the top most significant pathways are; Activation of IRF by 
cytosolic pattern recognition receptors, Jak1, Jak2 and Tyk2 in IFN signalling and 
IFN signalling. Activation of IRFs by cytosolic pattern recognition receptors, 
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illustrated in Figure 3.8, involves an upregulation of IRF7, a classic feature of an 
IFNβ response, and upregulation of Stat1 and Stat2; genes that are also involved 
in IFN signalling (Figure 3.9). The pathway Jak1, Jak2 and Tyk2 in IFN signalling 
was not shown as it displayed a very similar network of genes as the IFN 
signalling pathway. Although molecules in IFN-related signalling pathways are 
transcriptionally enhanced, this does not necessarily equate to post-translational 
phosphorylation. In addition, it does not appear from the pathway analysis as if 
there is any of the elevated ISG transcription that would be a characteristic 
hallmark of signal transduction. In actual fact, the ISGs included in this pathway 
diagram are only a small fraction of the possible genes that can be modulated by 
IFNs. IFNs induce the expression of thousands of genes by activating 
transcription factor complexes that bind to one of two elements in gene 
promoter regions; the IFNγ-activated site (GAS) or the IFN-stimulated response 
element (ISRE)415. As mentioned in more detail below, a high proportion of the 
genes that are upregulated in the brain in response to LPS are known ISGs. 
Therefore, not only is the IFN signalling pathway transcriptionally enhanced, but 
it is also likely to be activated in the brain in response to systemic LPS. These 
observations provide further evidence of an IFN-response in the brain in response 
to systemic LPS. 
 
137 
 
Figure 3.7 The Leukocyte extravasation signalling pathway 
Following a microarray study, comparing gene expression in the brains of LPS- and vehicle-injected mice, the leukocyte extravasation signalling pathway was identified 
using Ingenuity Pathway Analysis (IPA) software as being significantly enriched. This diagram outlines the genes involved in this pathway. Genes that are highlighted 
red are significantly upregulated by ≥ 1.5-fold in the brain in response to LPS. Figure was taken from IPA.
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Figure 3.8 The Activation of IRF by cytosolic pattern recognition receptors signalling 
pathway 
This diagram outlines the genes involved in the Activation of interferon regulatory factors (IRFs) by 
cytosolic pattern recognition receptors signalling pathway: a pathway that was identified using 
Ingenuity Pathway Analysis (IPA) software as being differentially regulated in response to LPS. 
Genes that are highlighted red are significantly upregulated by ≥ 1.5-fold in the brain in response to 
LPS. Figure was taken from IPA. 
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Figure 3.9 The Interferon signalling pathway 
Using Ingenuity Pathway Analysis (IPA) software, differential regulation of the interferon signalling 
pathway was identified as being a downstream effect of peripheral LPS injection. This diagram 
outlines the genes involved in this pathway, including some of the key interferon stimulated genes 
that are activated in response. Genes that are highlighted red are significantly upregulated by ≥ 
1.5-fold in the brain in response to LPS. IFIT1 has been outlined in red as although it was 
significantly upregulated in the brain, it was not deemed “analysis-ready” by IPA and thus excluded 
from pathway analysis. Figure was taken from IPA. 
 
3.3.5 Re-analysing the Affymetrix data using GeneSpring 
Analysing the Affymetrix dataset using Partek Genomics Suite returned a list of 
55 differentially expressed entities that satisfied a fold change cut-off of 2. To 
further validate the microarray, the upregulation of a selection of genes had 
first to be confirmed using QPCR. With the aim of focusing only on the genes 
that are most likely to be biologically relevant, the Affymetrix dataset was 
reanalysed using GeneSpring GX analysis software so that the resulting list of 
significantly relevant genes could be compared to that generated using Partek.  
The Mouse Gene 1.0 ST array data were analysed in GeneSpring using a modified 
version of RMA, RMA16. This summarisation algorithm conforms to the same 3 
steps as RMA; background correction, normalisation and probe summarisation. 
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However, RMA16 differs from its predecessor in that a value of 16 is added to 
the normalised intensities calculated using the RMA algorithm. This extra step is 
for variance stabilisation.  
As before, a signal histogram was used to visually assess the efficiency of 
hybridisation and the separation between the two groups of samples was viewed 
on a PCA plot. As potential sources of non-biological variability have already 
been ruled out (Figure 3.3) and the transcriptional variation between groups 
already been demonstrated (Figure 3.4), the corresponding graphs, generated 
using GeneSpring, are not shown.  
3.3.6 Analysis of Affymetrix data using GeneSpring 
To establish a list of significantly relevant genes using GeneSpring GX software, 
the normalised intensity values created by the pre-processing of the Affymetrix 
chips were filtered by expression and subject to statistical analysis.  
3.3.6.1 Filtering entities on expression 
Pre-processing the array chips using RMA16 assigns the 28 869 entities on each 
chip with a normalised intensity value. In order to eliminate low level 
background gene expression, each entity had to possess a normalised intensity 
value that fell within the upper 80% of all the normalised intensity values on that 
chip. In addition, to be included, each entity had to satisfy this parameter in all 
three samples of one group. Filtering on expression narrowed the dataset down 
to 22 927 entities (Figure 3.10A). 
3.3.6.2 Genes identified in GeneSpring as being differentially expressed in 
the brains of LPS challenged mice 
To identify differentially expressed genes using GeneSpring, an unpaired t-test 
was performed on the data, along with a Benjamini-Hochberg multiple testing 
correction. A profile plot of the normalised intensity values of entities deemed 
statistically significant is shown in Figure 3.10B. Of the 96 entities that were 
classified as being significantly different, 89 were upregulated in the brain in 
response to LPS and 7 were downregulated. 
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As the aim of reanalysing the array data was to focus only on the genes that 
were most robustly differentially expressed, a fold change cut-off of 2 was 
applied to the dataset. 39 entities satisfied this parameter, all of which were 
upregulated in the brain in response to LPS. The normalised intensity values of 
these entities are displayed in Figure 3.10C and the relative signal intensities 
have been displayed in a heatmap (Figure 3.11). The heatmap allows a visual 
comparison of relative expression to be made; between individual entities, 
individual samples or groups of samples. The fold change, p-value and gene 
name (where applicable) of each entity is listed in Table 3.3. Although 
containing many of the key players that were identified using Partek, this gene 
list differs to that generated using Partek, both in size and content. In spite of 
this, genes encoding acute phase proteins lipocalin 2 and serum amyloid A3 were 
identified in both lists as being the most upregulated (Table 3.2 & Table 3.3). In 
addition, genes common to both lists were shown to be upregulated by a similar 
magnitude using either Partek or GeneSpring. A comparison of the two lists will 
be made below (Section 3.3.7). 
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Figure 3.10 Normalised intensity values of individual entities. 
Affymetrix gene chips, used to compare gene expression in the brains of LPS- and vehicle-injected 
mice, were analysed using GeneSpring GX analysis software. These profile plots display the 
normalised intensity values of (A) all entities after being filtered on expression, (B) all significantly 
regulated entities (C) All differentially expressed entities satisfying a fold change cut-off of 2. 
Normalised intensity values were established using the RMA16 summarisation algorithm. Each 
entity is coloured according to the median normalised intensity value of the LPS-treatment group. n 
= 3/group. 
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Figure 3.11 Heatmap of the signal intensity of individual entities relative to baseline 
This heatmap displays the relative signal intensities of the 39 entities that were classified, by 
GeneSpring GX software, as being differentially expressed in the brains of LPS-challenged mice 
compared to vehicle-injected controls. Only entities with a fold change of 2 or greater have been 
included. Individual entities in each sample are coloured according to their expression level relative 
to baseline. For ease of visualisation, relative expression values were calculated by mathematically 
scaling down the normalised intensity values to fit within the range -1 to 1. 
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Genbank 
Accession 
Gene 
Symbol 
Gene Name Fold 
Change  
P-value 
NM_008491 Lcn2 Lipocalin 2 16.58  8.27E-06 
NM_011315 Saa3 Serum amyloid A3 8.69 1.91E-04 
BC150711 AI607873 Interferon activated gene 204 
homologue 
3.93 7.84E-05 
NM_011854 Oasl2 2'-5' Oligoadenylate synthetase-like 2 3.91 1.25E-04 
NM_025378 Ifitm3 Interferon induced transmembrane 
protein 
3.69 3.91E-05 
NM_009252 
 
Serpina3n Serine (or cysteine) peptidase 
inhibitor, clade A 
3.32 
 
1.65E-04 
NM_009099 Trim30 Tripartite motif-containing 30 3.28 9.56E-05 
NM_008331 
 
Ifit1 Interferon-induced protein with 
tetratricopeptide repeats 
3.12 1.05E-04 
NM_008329 Ifi204 Interferon activated gene 204 3.05 6.68E-05 
NM_133871 Ifi44 Interferon activated gene 44 2.94 1.44E-04 
NM_023386 Rtp4 Receptor transporter protein 4 2.93 4.51E-05 
NM_021274 Cxcl10 chemokine (C-X-C motif) ligand 10 2.91 8.88E-05 
NM_144559 Fcgr4 Fc receptor, IgG, low affinity IV 2.90 2.18E-05 
NM_011150 Lgals3bp Lectin, galactoside-binding, soluble, 3 
binding protein 
2.89 5.40E-05 
NM_194336 Gbp6 Guanylate binding protein 6 2.70 4.41E-06 
NM_013563 Il2rg Interleukin 2 receptor, gamma chain 2.64 4.41E-06 
--- N/A*  2.60 4.42E-05 
NM_00100189
2 
H2-K1 Histocompatibility 2, K1, K region 
 
2.49 4.42E-05 
NM_010260 Gbp2 Guanylate binding protein 2 2.42 1.13E-04 
NM_028595 Ms4a6c Membrane-spanning 4-domains, 
subfamily A, member 6C 
2.40 1.91E-04 
AK173199 Rnf213|LOC6
72511 
Ring finger protein 213 2.34 5.92E-07 
NM_009402 Pglyrp1 Peptidoglycan recognition protein 1 2.36 8.03E-05 
--- Rnf213** Ring finger protein 213 2.33 1.36E-05 
NM_009982 Ctsc Cathepsin C 2.31 5.42E-05 
NM_010738 Ly6a Lymphocyte antigen 6 complex, locus 
A 
2.29 1.60E-05 
NM_018734 Gbp3 Guanylate binding protein 3 2.28 1.60E-04 
NM_172689 Ddx58 DEAD box polypeptide 58 2.27 1.26E-04 
NM_145545 Gbp7 Guanylate binding protein 7 2.27 3.80E-06 
NM_009780 
 
C4b |C4a complement component 4B (Childo 
blood group) | complement 4A 
(Rodgers blood group) 
2.24 
 
1.40E-04 
145 
NM_013673 Sp100 Nuclear antigen Sp100 2.22 4.61E-05 
NM_026835 Ms4a6d Membrane-spanning 4-domains, 
subfamily A, member 6D 
2.21 4.36E-05 
NM_008326 
 
Irgm Immunity-related GTPase family M 
member 1 
2.21 2.56E-05 
NM_013805 Cldn5 Claudin 5 2.10 1.42E-04 
--- Rnf213** Ring finger protein 213 2.08 2.78E-05 
NM_199146 AI451617 Expressed sequence AI451617 2.06 8.85E-05 
NM_009283 Stat1 Signal transducer and activator of 
transcription 1 
2.04 5.75E-06 
--- Rnf213** Ring finger protein 213 2.02 2.69E-06 
NM_153564 GBP5 Guanylate binding protein 5 2.02 5.17E-05 
NM_00116041
5 
Apobec3 Apolipoprotein B mRNA editing 
enzyme 
2.02 2.07E-05 
Table 3.3 Differentially expressed entities identified using GeneSpring  
Microarrays were analysed using GeneSpring GX software. These data show the fold change and 
significance of the 39 entities that were upregulated ≥ 2-fold in the brains of mice injected with LPS 
compared to vehicle. Significance was calculated using an unpaired t-test. 
*Probe sets don’t map to annotated genes 
**Annotations manually determined using Affymetrix online database, NetAffx 
 
3.3.7 Defining the genes commonly identified by both Partek and 
GeneSpring 
As mentioned above, the aim of reanalysing the array data was to focus 
attention on genes that were highlighted by both software packages as being 
differentially expressed, thus maximizing scrutiny. The two lists of differentially 
expressed entities, that satisfied a fold change cut-off of 2, were compared 
(Figure 3.12). Of the 29 entities that were common to both lists, 24 are known 
genes. These are grouped according to biological function in Table 3.4. 
Strikingly, over half of the genes in this list are known ISGs. This supports the 
hypothesis generated from the Ingenuity pathway analysis; that IFN signalling is 
induced in the brain following peripheral LPS injection. In addition, a number of 
genes encoding acute phase reactants are upregulated, as are a variety of genes 
involved in immunity and defence. Due to their consistency in both datasets, the 
sub-list of genes, listed in Table 3.4, has subsequently been focused on for the 
remainder of the study. 
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Figure 3.12 Differentially expressed entities identified using Partek and GeneSpring 
Affymetrix gene chips were analysed using two software packages: Partek Genomics Suite and 
GeneSpring GX analysis software. This Venn diagram compares the 55 entities that were identified 
as being differentially expressed ≥ 2-fold by Partek, to the 39 entities that were identified by 
Genespring using the same parameters.  
 
10 29 27 6
Partek (55) GeneSpring (39) 
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Gene Symbol Gene Name 
Interferon Stimulated  Genes 
Ctsc Cathepsin C 
Gbp2 Guanylate binding protein 2 
Gbp3 Guanylate binding protein 3 
Gbp6 Guanylate binding protein 6 
Gbp7 Guanylate binding protein 7 
Ifit1 Interferon-induced protein with tetratricopeptide repeats 
Ifitm3 Interferon induced transmembrane protein 
Igrm1 Immunity-related GTPase family M, member 1 
Lgals3bp Lectin, galactoside-binding, soluble, 3 binding protein 
Oasl2 2'-5' Oligoadenylate synthetase-like 2 
Rnf213 Ring finger protein 213 
Rtp4 Receptor transporter protein 4 
Sp100 Nuclear antigen Sp100 
Stat1 Signal transducer and activator of transcription 1 
 
Acute Phase Reactants 
Lcn2 Lipocalin 2 
Saa3 Serum amyloid A3 
Serpina3n Serine (or cysteine) peptidase inhibitor, clade A 
 
Immunity System Components 
C4b |C4a Complement component 4B (Childo blood group) | complement 4A (Rodgers 
blood group) 
Fcgr4 Fc receptor, IgG, low affinity IV 
H2-K1 Histocompatibility 2, K1, K region 
Pglyrp1 Peptidoglycan recognition protein 1 
 
Cell Surface Molecules 
Il2rg Interleukin 2 receptor, gamma chain 
Ly6a Lymphocyte antigen 6 complex, locus A 
 
mRNA Editing 
Apobec3 Apolipoprotein B mRNA editing enzyme 
Table 3.4 Functional properties of differentially expressed genes, common to both Table 3.2 
and Table 3.3. 
Affymetrix gene chips were analysed using two software packages: Partek Genomics Suite and 
GeneSpring GX analysis software. These data show the biological functions of the 24 known genes 
that were common to both gene lists and upregulated ≥ 2-fold in the brains of mice injected with 
LPS compared to vehicle. Genes were clustered according to biological function using the 
Database for Annotation, Visualization and Integrated Discovery v6.7 
(http://david.abcc.ncifcrf.gov/). 
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TLR4 ligation is known to result in the increased production of type I and/or type 
II IFNs55,416. To determine whether the ISGs were regulated by type I IFNs, type II 
IFNs or both, the list of ISG was analysed using the Interferome® database. This 
data mining analysis revealed that all 14 of the ISGs that were common to both 
array datasets had the potential to be regulated by type I IFNs (Figure 3.13). 8 of 
these could also be regulated by type II IFNs and 6 of the ISGs could also be 
regulated by type III IFNs. 
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Figure 3.13 Interferon subtype analysis of ISGs induced in the brain 
Interferon subtype analysis of the ISGs from Table 3.4 was performed using the Interferome 
database v1 (http://vera093.its.monash.edu.au/interferome/)  
 
In summary, comparing the transcriptional profile of the brains of mice injected 
with LPS to those injected with vehicle, yielded a list of 85 differentially 
expressed entities with a fold change of at least 1.5. The known genes in this list 
were subject to GO clustering and pathway analysis; both of which highlighted 
the possibility of microglial activation and an IFN response in the brain. In order 
to focus on the genes that were most robustly differentially expressed, the fold 
change cut-off was increased. The list of genes satisfying a fold change cut-off 
of 2 was compared to one generated using a different software package, and 
thus a different summarisation algorithm. Common to both lists, the resulting 
sub-list of differentially expressed genes was assumed to be the most 
meaningful. Determining the biological function of these genes revealed that 
over half are known ISGs. In short, it would appear that LPS-injection in the 
periphery may trigger IFN signalling in the brain and a subsequent induction of 
ISGs. 
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3.4 QPCR analysis of target genes in the brain, blood 
and BM of LPS challenged mice 
The Affymetrix array dataset has provided a list of genes that were differentially 
expressed in the brain following intraperitoneal LPS-injection. These were 
clustered according to biological function and grouped into relevant pathways. 
Using RNA isolated from an independent experiment, transcriptional changes 
were then validated by QPCR. To control for the possibility of a contaminating 
signal coming from the peripheral blood, and to see how the transcriptional 
response in the brain differed from that of the periphery, the expression of 
target genes was compared in the brain, PBL and bone marrow of mice, 48 hours 
after injection with either LPS or vehicle. In addition, QPCR was used investigate 
gene expression at earlier time points, in order to gain a better understanding of 
the kinetics of ISG expression. 
3.4.1 Validation of differential gene expression using QPCR 
In addition to validating the sub-list of genes described in Section 3.3.7, 
upregulated expression of gene encoding the classic interferon-inducible 
chemokine, CXCL10 and interferon regulatory factor (IRF) 7 was also validated 
using SYBR green QPCR, as was the gene encoding the negative regulator of IRF7, 
guanylate-binding protein (GBP) 4. Designing primers specific to H2-K1 proved 
impractical due to the common occurrence of sequence homologies in the MHC 
gene cluster. Consequently, H2-K1 was excluded from validation. In addition, 
due to the relatively high proportion of GBPs in the dataset, Gbp7 and Gbp6 
were arbitrarily excluded. 
With the exception of Sp100 and Stat1, all ISGs assayed were confirmed as being 
significantly upregulated in the brains of mice challenged with systemic LPS 
compared to vehicle controls (Figure 3.14), as were the acute phase reactants 
(Figure 3.15) and all remaining genes aside from Apobec3 and C4 (Figure 3.16). 
Although a few genes, Lcn2, Saa3, Il2rg and Fcgr4, showed a markedly greater 
upregulation when gene expression was measured by QPCR compared to 
microarray, the induction of the majority of target genes correlated well with 
the microarray expression data. Therefore, the confirmation of target gene 
induction using QPCR validates the Affymetrix dataset. 
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3.4.2 Comparison of central response to peripheral response 
With the aim of determining whether the inflammatory response in the brain 
differs from that of the periphery, and to control for the possibility of a 
contaminating signal coming from the peripheral blood, gene expression in the 
brain was compared to that of PBL, 48 hours following systemic LPS challenge. 
As an additional control, gene expression in the brain was also compared to that 
of the bone marrow; a highly vascularised peripheral tissue. The fold change of 
each target gene in both the PBL and the bone marrow was determined using 
SYBR Green QPCR. QPCR analysis showed a distinct pattern of gene expression in 
each of the three tissues analysed. Most of the target genes could be separated 
into three main groups: those that were significantly upregulated in all three 
tissues, those that were upregulated both in the brain and the PBL or those 
upregulated only in the brain.  
A high proportion of genes were upregulated to a similar extent in both the brain 
and the PBL. As a result, the enhanced signal observed in the brain following LPS 
injection, has the potential to be derived from a minute level of blood 
contamination; despite extensive perfusion. However, by examining gene 
modulation in multiple tissues, i.e. the brain, blood and bone marrow, it is 
possible to exclude this possibility. Only two ISGs, Cxcl10 and Ifitm3, were 
significantly upregulated in the brain, PBL and bone marrow (Figure 3.14). Other 
genes falling into this category were acute phase reactants; Lcn2 and Saa3 
(Figure 3.15), and the anti-microbial gene, Pglyrp1 (Figure 3.16). Significantly 
upregulated in both the brain and the PBL were ISGs; Ifit1, Igrm1, Lgals3bp, 
Oasl2 and Rtp4 (Figure 3.14) along with an immune response gene; Fcgr4 (Figure 
3.16). Critically, both Cxcl10 and Fcgr4 were upregulated to a significantly 
greater extent in the brain than either of the extra-neural tissues, implying a 
level of independent modulation in the brain. In contrast, Pglyrp and Saa3 were 
induced in the brain to a lesser extent than in the PBL, suggesting a greater level 
of gene regulation in the blood. The bone marrow is highly vascular. As a result, 
a partial perfusion would likely result in a contaminating signal in all three 
tissues. Although induced to a similar extent in the brain and the blood, Ifit1, 
Ifitm3, Igrm1, Lcn2, Lgals3bp, Oasl2 and Rtp4 were upregulated significantly 
more in the brain than the bone marrow. Taken together, these differences in 
the fold change of target genes in each tissue are indicative of different levels 
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of gene regulation. This implies that the observed fold changes in the brain are 
not a secondary effect of blood contamination.  
In further evidence of independent gene regulation in the brain; Type I IFN-
regulated ISGs; Gbp3, Gbp4 and Irf7 were all significantly upregulated in the 
brain alone (Figure 3.14, Table 3.5), as was cytokine receptor component, Il2rg 
(Figure 3.16). However, Gbp3 showed a slight trend towards an upregulation in 
the bone marrow and as a result, the induction observed in the brain was 
significantly greater than in peripheral blood leukocytes, but not greater than in 
the bone marrow. Similarly, although IFNγ-regulated gene, Gbp2, acute phase 
reactant, Serpina3n and cell surface marker Ly6a were significantly upregulated 
only in the brain (Figure 3.14, Figure 3.15, Figure 3.16 and Table 3.5), these 
genes also showed a trend towards an upregulation in the PBL. Taken together, 
these data demonstrate a differential pattern of gene expression in the brain 
from that of the two peripheral tissues. This is extremely important as it 
provides evidence of a brain-specific inflammatory response as a result of 
systemic LPS injection, thus validating the microarray experiment.  
Gene symbol Mean fold change +/- SEM P-value 
Gbp2 2.41 0.405 0.0160 
Gbp3 1.87 0.231 0.0197 
Gbp4 3.69 0.545 0.0030 
Il2rg 8.95 0.730 < 0.0001 
Irf7 4.93 0.561 0.0004 
Ly6a 2.61 0.215 0.0003 
Serpina3n 2.62 0.439 0.0154 
Table 3.5 List of target genes upregulated specifically in the brain 
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Figure 3.14 Differential ISG expression in the brain, PBL and BM of LPS-treated mice 
compared to vehicle control group.  
RNA was isolated from the brain, peripheral blood leukocytes (PBL) and bone marrow (BM) of 
mice, 48 hours after injection with 100µg LPS or an equivalent volume of vehicle. Gene expression 
analysis of (A) Ctsc, (B) Cxcl10, (C) Gbp2, (D) Gbp3, (E) Gbp4, (F) Ifit1, (G) Ifitm3, (H) Igrm1, (I) 
Irf7, (J) Lgals3bp, (K) Oasl2, (L) Rtp4, (M) Sp100 and (N) Stat1 was performed using QPCR and 
normalised to TBP. Data are expressed as fold change in gene expression in the brain, PBL and 
BM of LPS-injected mice (■) relative to that of vehicle-injected controls (□). Data represent the 
mean +/- SEM. Significance of each fold change was calculated for individual tissues using an 
unpaired t-test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. A statistical comparison was made between the 
fold induction in the brain and the fold induction in both the PBL and the BM using two-way 
ANOVA: #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001. n = 4/group. 
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Figure 3.15 Differential expression of acute phase response genes in the brain, PBL and BM 
of LPS-treated mice compared to vehicle control group. 
RNA was isolated from the brain, peripheral blood leukocytes (PBL) and bone marrow (BM) of 
mice, 48 hours after injection with 100µg LPS or an equivalent volume of vehicle. Gene expression 
analysis of (A) Lcn2, (B) Saa3 and (C) Serpina3n was performed using QPCR and normalised to 
TBP. Data are expressed as fold change in gene expression in the brain, PBL and BM of LPS-
injected mice (■) relative to that of vehicle-injected controls (□). Data represent the mean +/- SEM. 
Significance of each fold change was calculated for individual tissues using an unpaired t-test: *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001. A statistical comparison was made between the fold induction in the 
brain and the fold induction in both the PBL and the BM using two-way ANOVA: #P ≤ 0.05, ##P ≤ 
0.01, ###P ≤ 0.001. n = 4/group. 
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Figure 3.16 Differential expression of remaining target genes in the brain, PBL and BM of 
LPS-treated mice compared to vehicle control group. 
RNA was isolated from the brain, peripheral blood leukocytes (PBL) and bone marrow (BM) of 
mice, 48 hours after injection with 100µg LPS or an equivalent volume of vehicle. Gene expression 
analysis of (A) Apobec3, (B) C4, (C) Fcgr4, (D) Il2rg, (E) Ly6a and (F) Pglyrp was performed using 
QPCR and normalised to TBP. Data are expressed as fold change in gene expression in the brain, 
PBL and BM of LPS-injected mice (■) relative to that of vehicle-injected controls (□). Data 
represent the mean +/- SEM. Significance of each fold change was calculated for individual tissues 
using an unpaired t-test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. A statistical comparison was made 
between the fold induction in the brain and the fold induction in both the PBL and the BM using 
two-way ANOVA: #P ≤ 0.05, ##P ≤ 0.01, ###P ≤ 0.001. n = 4/group. 
 
 
156 
3.4.3 Determining kinetics of ISGs expression in the brain 
In the immediate hours following a single injection of LPS, the response in the 
brain is well characterised. Largely encompassing an acute phase response, the 
majority of reported effects in the brain are known to peak within 12 hours 
following injection315,324,417. To determine whether the upregulation of ISGs, 
observed 48 hours after LPS injection, is merely a remnant of an earlier 
response, we looked at expression levels of a selection of ISGs in the brain 6 
hours and 12 hours following injection and compared them to the expression 
levels at 48 hours. With the exception of Cxcl10, the expression levels of which 
are significantly reduced at 48 hours, no significant differences were observed 
(Figure 3.17). However, in the case of Gbp4 and Irf7, there is a noticeable trend 
towards a reduction in expression between 12 hours and 48 hours. These data 
suggest that an IFN response has been initiated in the brain by 6 hours following 
LPS injection. This response persists until 48 hours after injection, retaining it’s 
potency until at least the 12 hour time point. 
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Figure 3.17 Temporal expression of ISGs in the brains of LPS-injected mice 
RNA was isolated from the brain, 6, 12 and 48 hours after injection with 100µg LPS or an 
equivalent volume of vehicle. Relative ISG expression was determined using QPCR and 
normalised to TBP. Data are expressed as fold change in gene expression in the brain of mice, 6 
hours (□), 12 hours (■) and 48 hours (■) following LPS-injection relative to vehicle-injected controls 
mouse brains. Data represent the mean +/- SEM. A statistical comparison was made between the 
fold induction at different time points using two-way ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n 
= 4/group. 
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3.5 Discussion and conclusions 
In order to assess what influence LPS-induced systemic inflammation has on gene 
expression in the brain, microarrays were utilised to compare the transcriptional 
profile of the brain 48 hours after injection with either LPS or vehicle. The data 
were subjected to several levels of analysis. A number of transcripts were 
significantly elevated in the brain 48 hours following LPS injection. These were 
clustered according to biological function and then grouped into pathways. QPCR 
analysis was then used to validate the dataset and to compare gene expression 
in the brain, the PBL and the bone marrow. These further analyses identified a 
number of key points, the most important being that an innate inflammatory 
response occurs in the brain in response to LPS. Although this has been 
characterised previously in the immediate hours following LPS-injection, it is 
generally assumed that the response resolves within 24 hours324,417,418. From this 
dataset however, it is apparent that injecting mice with high doses of LPS 
induces an immune response that lasts in the brain for at least 48 hours. 
Differing in kinetics and magnitude, this response is distinct from that of the PBL 
and the bone marrow. This crucial observation supports the validity of the 
dataset; ruling out the possibility of a contaminating signal coming from the 
peripheral blood.  
The occurrence of an LPS-dependent immune response in the brain was 
demonstrated when genes were clustered according to their biological function. 
This method of categorisation revealed that many of the upregulated genes are 
associated with the “Immune response” and “Immunity and defence”. 
“Interferon-mediated immunity” and “Macrophage-mediated immunity” also 
ranked highly in the list of significantly enriched biological processes. Microglia 
have long been considered the macrophage-like cells of the CNS. They have 
motile processes which survey the extracellular environment for pathogens or 
signs of cell damage. Responding accordingly, they play a pivotal role in the 
innate immune system of the CNS419. This response is akin to that of tissue 
macrophages. As microglia also share many structural similarities with their 
peripheral myeloid-derived counterparts, it can be very hard to distinguish one 
from the other: so much so that, until recently, it was thought that microglia 
were derived from the same myeloid precursors as macrophages419. As a result, 
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the enrichment of “Macrophage-mediated immunity” could well be an indication 
of microglial cell-mediated immunity. 
Enhanced transcription of genes involved in “Interferon-mediated immunity” is 
indicative of an IFN-response in the brain. This is certainly backed up by the 
pathway analysis which shows significant upregulation of the “Activation of IRFs 
by cytosolic pattern recognition receptors”, “Jak1, Jak2 and Tyk2 in IFN 
signalling” and the “IFN Signalling” pathways. IFN signalling leads to the 
downstream activation of an abundance of ISGs. In further support of an IFN 
response in the brain, the differential transcriptional profile following LPS 
injection is largely monopolised by the induction of this gene family; with ISGs 
encompassing over half of the genes believed to be most biologically 
meaningful.  
Crucially, the expression profile in the brain differed from that of peripheral 
blood leukocytes and from the bone marrow. Target genes were modulated to a 
different extent in the three tissues analysed. Importantly, ISGs encoding GBP-3, 
GBP-4 and IRF7 were upregulated independently in the brain, as was the gene 
encoding the cytokine receptor component, IL-2Rγ. In addition, although the 
genes encoding the interferon-inducible chemokine, CXCL10, and the 
immunoglobulin receptor, FCγRIV, were also induced in the periphery, they were 
upregulated to a significantly greater extent in the brain. Altogether, these data 
identify a brain-specific response to systemic LPS-induced inflammation. This is 
extremely important. By ruling out contaminating blood as being a source of the 
gene expression signal, these observations confirm the brain specificity of the 
Affymetrix dataset. 
Although the mechanism by which ISGs are induced in the brain remains to be 
examined, the temporal expression patterns of a selection of these genes were 
demonstrated using QPCR. All ISGs assayed were induced by 6 hours following 
LPS injection and remained elevated until 48 hours, after the bulk of the acute 
phase response is known to have resolved420. This implies that early events 
following peripheral LPS challenge may be responsible for the initiation of ISG 
expression. 
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The list of ISGs that are upregulated in response to LPS consists of an assortment 
of type I, type II and type III IFN-response genes. As IFNγ, the only type II IFN, is 
known to induce an anti-microbial response55, enhanced expression of IFNγ-
regulated genes would certainly be expected in the periphery following LPS 
injection. However, there is no evidence, as yet, to suggest that LPS can enter 
the brain. Although TLR4 is expressed in the brain, a study with radiolabelled 
LPS suggested that negligible levels cross the BBB421, therefore, it is unclear 
what has induced the expression of these IFNγ-response genes. IFNγ is known to 
simulate anti-microbial immunity in a cell-autonomous manner so, although no 
elevated transcripts encoding IFNγ were detected by the array study, it is 
possible that IFNγ was produced in the brain at an earlier time point. Certainly 
in the periphery, IFNγ is thought to be produced approximately 6 hours following 
intraperitoneal LPS injection316,422. Likewise, the array study detected no 
elevation of type I IFNs suggesting that any enhanced production of this cytokine 
family must have also occurred prior to the array if it occurred in the brain at 
all. Another possibility might be that peripherally produced IFNs have a direct 
effect on the brain. This will be discussed in more detail below. 
The enrichment of type I and type III IFN-regulated genes was a surprising finding 
as these responses are more readily associated with viral clearance55. In spite of 
this dogma, LPS, and other gram negative bacterial components, can induce 
IFNβ expression downstream of the non-canonical TRIF-dependent signalling 
pathway55. However, for this to be the mechanism accounting for the observed 
ISG induction either LPS, or LPS-induced IFNβ, would have to gain access to the 
brain. In summary, although both type I and type II ISGs were upregulated in the 
brain following LPS-injection, the mechanism of their induction remains to be 
clarified. Further work will be required in order to decipher whether IFN 
production in the brain occurs following LPS injection and if so, whether 
systemic LPS can have a direct role in central IFN induction.  
If Banks et al. are correct in their hypothesis that LPS does not access the 
brain421 one possible explanation, accounting for the central induction of ISGs, is 
the direct effect of systemic IFNs. A study by Wang et al. showed that the brain 
was highly sensitive to systemic IFNα, delivered by intraperitoneal injection423. 
The brain rapidly responded to the recombinant cytokine by increasing ISG 
transcription. In spite of this, no induction of IFNα1 or IFNβ was detectable in 
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the brain. Wang et al. argue that the direct action of systemic IFNα must 
therefore be responsible for the central elevation of ISG transcription. Amongst 
the genes induced in the brain were Stat1, and Gbp3, both of which appear in 
the list of target genes that were upregulated in response to systemic LPS. 
Cxcl10 transcripts, however, were undetectable following systemic IFNα 
injection. This conflicts with a previous report by the same group which revealed 
Cxcl10 as being one of the main genes to be over-expressed when neurons, 
either in vitro or in vivo, were exposed to IFNα424. Therefore, if systemic IFNα 
has the capacity to directly access the brain, Cxcl10 should be detectable 
following a systemic injection. However, if correct, the hypothesis proposed by 
Wang et al. could account for the induction of ISGs following systemic LPS 
injection; but only if IFNβ and IFNγ also shared the capacity to directly access 
the brain. Although attractive, this hypothesis requires further evidence to 
demonstrate that IFNα crossed one of the brain’s barriers, or that another IFNα-
subtype was not produced in the brain to account for the ISG induction observed 
by Wang et al. An alternative mode of action could be indirect action of 
peripherally produced IFNs on the CNS, via stimulation of the BBB or afferent 
nerves.  
Of the ISGs upregulated in the brain in response to LPS, CXCL10 had the highest 
fold change. It was also one of the few genes to be upregulated to a greater 
extent in the brain than the PBL. CXCL10 has been shown to be induced in the 
brain following stroke425, West Nile Virus187,188 or HIV-associated CNS disease426. 
It has also been shown to be upregulated by neurons in response to IFNα; both in 
vitro and in vivo424. CXCL10 is an interferon-inducible chemokine which binds 
CXCR3 to promote leukocyte chemotaxis427. Induction of CXCL10 in the brain 
following systemic LPS challenge may result in the chemoattraction and 
subsequent infiltration of CXCR3+ leukocytes. Although there have been previous 
reports of increased CXCL10 expression in the brain following systemic LPS 
injection428, CXCR3-mediated leukocyte infiltration to the brain is not a 
phenomenon that has been reported after peripheral LPS injection. However, 48 
hours following LPS injection, CXCL10 is upregulated almost 10-fold, as are a 
number of genes involved in the leukocyte extravasation pathway. Therefore, 
leukocyte infiltration is worth investigating as a potential downstream effect of 
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injecting high doses of LPS peripherally. Chapter 5 will address whether 
leukocytes infiltrate the brain in response to systemic LPS challenge.   
ISGs were not the only genes to remain induced 48 hours after LPS injection. 
Genes encoding acute phase reactants lipocalin (LCN) 2, serum amyloid A3 
(SAA3) and serine-protease inhibitor 3N (Serpin A3N) were all amongst the most 
altered. As a result, “Acute phase response signalling” was highlighted as one of 
the most significantly enhanced biological pathways. Responsible for activation 
of the HPA axis and fever, the acute phase response is one of the key features of 
LPS challenge. Although the liver is considered the principle production site of 
acute phase proteins, LPS has previously been shown to induce the expression of 
acute phase reactants in choroid plexus epithelial cells. Utilizing 
transcriptomics, a study by Marques et al. reported a significant induction of a 
number of genes in the choroid plexus following intraperitoneal LPS injection420. 
In particular, between 3 and 24 hours, Lcn2, Saa3 and Serpina3n were amongst 
the most upregulated. Therefore, induction of these genes in the choroid plexus 
is likely to be a contributing factor to the enhanced expression that was 
detected in the brain 48 hours after systemic LPS injection. Strategically 
positioned within the cerebral ventricles, the choroid plexus is responsible for 
cerebrospinal fluid (CSF) production. In addition, it manages molecular and 
cellular trafficking across the blood-CSF-barrier; acting as an interface between 
the blood and the CSF. The extra-hepatic release of acute phase proteins into 
the CSF, in response to the peripheral inflammatory milieu, may represent a 
defence mechanism employed by the choroid plexus to protect the brain.  
In summary, systemic LPS-induced inflammation triggers an immune response in 
the brain. Observed 48 hours after challenge, the brain has a specific 
transcriptional signature; characterised by increased ISG expression. ISGs are 
induced in the brain by 6 hours post-injection and retain their potency for at 
least 48 hours. However, it has yet to be established whether this induction is a 
direct effect of central IFN production, or whether peripherally produced IFNs 
can travel to, or interact with, the brain. Of the ISGs induced in the brain in 
response to LPS, Cxcl10 was upregulated most. It was also upregulated to a 
greater extent in the brain than in the blood. This transcriptional response is 
indicative of peripherally triggered, interferon-mediated brain inflammation and 
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the induction of CXCL10 suggests that the brain may be being primed for T cell 
infiltration.  
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4 Defining mechanisms of target gene induction in 
the CNS following systemic LPS challenge 
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4.1 Introduction and aims 
In Chapter 3, it was demonstrated that systemic administration of LPS alters the 
gene expression profile in the brains of C57BL/6 mice; triggering the induction of 
a number of inflammatory genes. However, the precise mechanisms accounting 
for target gene induction in the brain remains to be clarified.  
Current dogma suggests that the brain can become sensitised to systemic LPS 
challenge by a number of mechanisms which act in concert. Described in detail 
in Section 1.4.2, these comprise neural transmission along with various humoral 
routes. Circulating inflammatory cytokines, induced in response to LPS, can 
activate blood vessel endothelial cells to enhance prostaglandin release and thus 
transmit inflammatory signals across the BBB323-325,327. Supplementing this 
humoral pathway, afferent neurons innervating regions of inflammation respond 
to the inflammatory cytokine milieu and relay this information to the brain 
(Section 1.4.2). Thus, by propagating inflammatory signals from the periphery to 
the brain, inflammatory cytokines may play a major role in immune-to-brain 
communication following systemic LPS injection. As a consequence, the initial 
aim for this chapter was to establish whether elevated circulating inflammatory 
cytokines were sufficient or indeed necessary to induce a similar transcriptional 
response as that induced by a single, systemic injection of LPS. To this end, 
target gene expression was assessed in the brain and matched PBL samples 
following systemic TNFα-induced inflammation or during LPS-induced endotoxin 
tolerance, when inflammatory cytokine production is known to be ameliorated in 
the periphery429,430. Following TNFα-induced inflammation, or LPS-induced 
endotoxin tolerance, the respective induction or amelioration of circulating 
cytokines was confirmed by ELISA. Target gene expression in the brain and PBL 
was then compared to a vehicle injected control group using SYBR Green QPCR. 
LPS binds to TLR4 and exerts its effects via one of two downstream signalling 
pathways (Figure 4.1): activation of the classical MyD88-dependent pathway 
resulting in inflammatory cytokine induction, or IRF3 activation through the 
TRIF-dependent pathway triggering IFNβ production. The literature surrounding 
immune-to-brain communication pathways following LPS-induced inflammation 
almost exclusively focuses on the downstream effects of NFκB activation as a 
result of the classical MyD88-dependent pathway. For example, NFκB activation 
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is responsible for the induction of inflammatory cytokines which, as described 
above, can activate the vagus nerve and the BBB endothelium. Furthermore, 
circulating LPS can activate the brain vasculature directly by ligating TLR4 
expressed on the surface of the endothelium (Section 1.4.2.2). By activating 
NFκB, this induces COX2 production and enhances prostaglandin 
synthesis324,327,328. Thus, by activating the MyD88-dependent signalling pathway, 
LPS can either directly or indirectly propagate inflammatory signals across the 
BBB.  
As these are the most characterised routes of immune-to-brain communication 
following systemic LPS challenge, it is possible that MyD88-dependent signalling 
pathway activation is responsible for the central induction of inflammatory 
target genes. However, as the majority of ISGs upregulated in response to LPS 
can be regulated by type I IFNs (Section 1.4.2.2), it was hypothesised that they 
are being expressed downstream of LPS-induced IFNβ production via the TRIF-
dependent pathway. The secondary aim of this chapter was to explore this 
hypothesis further by establishing whether target gene induction in the brain 
occurred following MyD88-dependent pathway activation in the absence of TRIF-
dependent signalling. C57BL/6 mice were injected intravenously with the TLR2 
ligand, lipoteichoic acid (LTA). TLR2 ligation can only activate NFκB through the 
classical MyD88-dependent signalling pathway (Figure 4.1), thereby eliminating 
the possibility of TRIF-dependent signalling. The expression of target genes in 
the brain was again compared to a vehicle-injected control group using QPCR. In 
summary, the expression levels of microarray target genes were investigated in 
different sterile, and TLR-dependent, models of peripheral inflammation, with 
the aim of investigating the molecular mechanisms governing the modulation of 
these genes in the brain following peripheral LPS injection.  
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Figure 4.1 TLR-induced signalling pathways. 
When activated, toll-like receptors (TLRs) either heterodimerise, such as TLR2 with either TLR1 or 
TLR6, or homodimerise to induce signalling pathway activation. Signalling is regulated by adaptor 
molecules. MyD88 is an adaptor used by all TLRs aside from TLR3. TLR7 recruits MyD88 directly, 
whereas TLR4 and TLR2 recruit MyD88 through bridging adapter TIRAP. MyD88 recruitment 
ultimately leads to the activation of nuclear transcription factor NFκB by releasing the p50 and p65 
subunits from the NFκB inhibitor IκB. Activated NFκB then translocates to the nucleus to induce the 
expression of inflammatory cytokines. An alternative signalling pathway downstream of TLR4 
involves the recruitment of adaptor molecule TRIF through bridging protein TRAM. This ultimately 
leads to activation of IRF3 and subsequent IFNβ induction (Reviewed in Ref 431). 
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4.2 Target gene expression following systemic cytokine-
induced inflammation 
Communication pathways between the immune system and the nervous system 
are often assumed to involve the intermediary action of inflammatory cytokines. 
Therefore, to determine whether elevated inflammatory cytokines were 
sufficient to induce a similar transcriptional profile to systemic LPS, target gene 
induction was assessed following a sterile, cytokine-induced model of systemic 
inflammation. 8 week old, male C57BL/6 mice were challenged intravenously 
with two doses of recombinant murine TNFα (1µg at 0 and 24 hours) or an 
equivalent volume of vehicle (sterile PBS). Mice were terminally anaesthetised, 
and then perfused, 48 hours after initial injection.  
4.2.1 Model validation 
To quantify peripheral inflammation following systemic TNFα challenge, the 
concentration of inflammatory cytokines in the circulation was measured using 
ELISAs. ELISAs were performed on plasma samples isolated from TNFα- and 
vehicle-injected mice; 6 hours, 30 hours and 48 hours following initial injection. 
TNFα and IL-6 were significantly elevated in the circulation 6 hours following a 
single dose of TNFα (Figure 4.2B&C). 6 hours following the second dose of TNFα 
(30 hours), TNFα remained slightly but significantly elevated in the plasma, 
whereas IL-6 had returned to baseline. Surprisingly, no IL-1β was detected in any 
of the samples (Figure 4.2A). Therefore, mice challenged systemically with TNFα 
presented with elevated levels of TNFα and IL-6 in the circulation compared to 
vehicle-injected controls. 
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Figure 4.2 Plasma concentration of inflammatory cytokines following systemic TNFα 
injection 
Mice were injected with 1 µg TNFα (TNF) or an equivalent volume of vehicle at 0 and 24 hours. 
Plasma was isolated from the whole blood of mice; 6 hours, 30 hours and 48 hours following initial 
injection. Concentrations of (A) IL-1β, (B) IL-6 and (C) TNFα (TNF) in the plasma were determined 
using ELISA. Data represent the mean plus or minus SEM. Significance was determined using two-
way ANOVA. n = 4/group. 
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4.2.2 Target gene modulation in the brain, PBL and BM following 
systemic TNFα injection 
In Chapter 3, using both microarrays and QPCR, a number of genes were 
identified as being upregulated in the brain in response to a systemic LPS 
challenge. To establish how these genes were modulated in the brain and 
periphery following TNFα-induced inflammation, SYBR Green QPCR was used to 
compare gene expression in the brains, PBL and bone marrow of TNFα- and 
vehicle-injected mice. Few of the microarray target genes were significantly 
elevated in the brains of the TNFα-challenged mice. Of the ISGs that were 
upregulated in the brain in response to LPS, only Gbp4 was upregulated in the 
brain in response to systemic TNFα (Figure 4.3). Stat1 was also upregulated in 
the brain following intravenous TNFα-injection. Although Stat1 was included in 
the list of target ISGs that, following microarray analysis, were identified as 
being upregulated in the brain in response to systemic LPS (Section 3.3.7), this 
induction was not confirmed using QPCR. None of the genes encoding acute 
phase proteins were significantly elevated in the brain following TNFα-injection 
(Figure 4.4), although there was a trend towards an upregulation of Saa3 (7.9-
fold). Aside from the slight but significant induction of Gbp4 and Stat1 (1.59- 
and 1.26-fold respectively), the only other significantly upregulated genes in the 
brain were immune response genes, Il2rg, Ly6a and Pglyrp1 (Figure 4.5). None of 
these genes were upregulated more than 2-fold. As a result, it was unclear 
whether this mild enhancement of gene expression was biologically meaningful.  
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Figure 4.3 Differential expression of ISGs in the brain, PBL and BM of TNF-treated mice 
compared to vehicle control group. 
Mice were injected with 1 µg TNFα (TNF) or an equivalent volume of vehicle at 0 and 24 hours. 
RNA was then isolated from the brain, peripheral blood leukocytes (PBL) and bone marrow (BM), 
48 hours after initial injection. Gene expression analysis of (A) Ctsc, (B) Cxcl10, (C) Gbp2, (D) 
Gbp3, (E) Gbp4, (F) Ifit1, (G) Ifitm3, (H) Igrm1, (I) Irf7, (J) Lgals3bp, (K) Oasl2, (L) Rtp4, (M) Sp100 
and (N) Stat1 was performed using QPCR and normalised to TBP. Data are expressed as fold 
change in gene expression in the brain, PBL and BM of TNF-injected mice (■) relative to that of 
vehicle-injected controls (□).  Data represent the mean +/- SEM. Significance of each fold change 
was calculated for individual tissues using an unpaired t-test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n 
= 4/group. 
 
Only two genes were significantly upregulated in PBL; those encoding the acute 
phase protein SAA3 and the host defence component, PGLYRP1 (Figure 4.4 & 
Figure 4.5). There was also a trend towards an upregulation of immune response 
gene, Fcgr4. All three of these genes were also significantly upregulated in the 
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bone marrow. Not only were no ISGs induced in the blood, but several ISGs, 
Cxcl10, Gbp2, Gbp3, Gbp4, Sp100 and Stat1 were significantly downregulated 
(Figure 4.3), along with immune components, Apobec3 and C4 (Figure 4.5). 
Overall, elevated levels of circulating TNFα were not sufficient to induce the 
expression of the majority of ISGs, or other target genes, in the brain, PBL or 
bone marrow. Thus, the central induction of target genes following peripheral 
LPS challenge is likely to be more than a mere by-product of elevated TNFα or 
IL-6 in the circulation.  
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Figure 4.4 Differential expression of acute phase response genes in the brain, PBL and BM 
of TNFα-injected mice compared to vehicle control group. 
Mice were injected with 1 µg TNFα (TNF) or an equivalent volume of vehicle at 0 and 24 hours. 
RNA was then isolated from the brain, peripheral blood leukocytes (PBL) and bone marrow (BM), 
48 hours after initial injection. Gene expression analysis of (A) Lcn2, (B) Saa3 and (C) Serpina3n 
was performed using QPCR and normalised to TBP. Data are expressed as fold change in gene 
expression in the brain, PBL and BM of TNF-injected mice (■) relative to that of vehicle-injected 
controls (□). Data represent the mean +/- SEM. Significance of each fold change was calculated for 
individual tissues using an unpaired t-test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 4/group. 
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Figure 4.5 Differential expression of remaining target genes in the brain, PBL and BM of 
TNFα-injected mice compared to vehicle control group. 
Mice were injected with 1 µg TNFα (TNF) or an equivalent volume of vehicle at 0 and 24 hours. 
RNA was then isolated from the brain, peripheral blood leukocytes (PBL) and bone marrow (BM), 
48 hours after initial injection. Gene expression analysis of (A) Apobec3, (B) C4, (C) Fcgr4, (D) 
Il2rg, (E) Ly6a and (F) Pglyrp was performed using QPCR and normalised to TBP. Data are 
expressed as fold change in gene expression in the brain, PBL and BM of TNF-injected mice (■) 
relative to that of vehicle-injected controls (□). Data represent the mean +/- SEM. Significance of 
each fold change was calculated for individual tissues using an unpaired t-test: *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001. n = 4/group. 
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4.3 Temporal target gene expression in PBL and brain 
following repeated LPS challenge  
Although the majority of target genes were not induced in the brain in response 
to systemic TNFα-induced inflammation, the above experiments do not rule out 
the contribution of other inflammatory cytokines which may induce target gene 
expression in the brain. With the aim of establishing the temporal pattern of 
target gene expression in the brain and PBL in the context of endotoxin 
tolerance, when inflammatory cytokine production is known to be ameliorated 
specifically in the periphery but not in the brain429,430,432,433, mice were exposed 
to LPS over a prolonged period of time. Endotoxin tolerance is an important 
defence mechanism designed to protect the host against endotoxic shock. In 
addition to eliciting expression of a number of proinflammatory genes, initial 
cellular exposure to LPS triggers the simultaneous downregulation of TLR 
expression and induction of several inhibitory molecules which negatively 
regulate TLR signalling434. This culminates in a transient inactivation of various 
proinflammatory genes by leukocytes in the periphery, including genes encoding 
the inflammatory cytokines TNFα, IL-1β and IL-6. At the same time, less 
potentially pathogenic genes are primed, such as anti-microbial effectors429. As a 
consequence, repeated exposure to TLR ligands leads to a dampening of the 
proinflammatory milieu without compromising host defence. Conversely, 
cytokine expression has been shown to continue in the brain during endotoxin 
tolerance432,433.To induce endotoxin tolerance, 8 week old, male C57BL/6 mice 
were injected with a single dose of LPS (50 µg i.p.) daily for 2, 5 or 7 
consecutive days. SYBR Green QPCR was then used to determine the expression 
of a selection of target genes in the brains and PBL of LPS challenged mice 
compared to a vehicle injected control group. 
4.3.1 Model validation 
To verify that the concentrations of inflammatory cytokines are ameliorated in 
the circulation following prolonged exposure to systemic LPS, plasma levels of 
IL-1β, IL-6 and TNFα were measured following a single, systemic, injection of 50 
µg LPS and compared to daily administration of the same dose. 6 hours following 
a single, intraperitoneal injection, both IL-1β and IL-6 were significantly 
elevated in the circulation (Figure 4.6A&B). No TNFα was detected at this time 
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point (Figure 4.6C). Concentrations of these cytokines are similar, and only 
slightly lower in magnitude, than what was previously demonstrated following an 
intraperitoneal injection of 100 µg LPS (Section 3.2.1). On day 2, after two doses 
of LPS (on day 0 and day 1) there was still a significant elevation of IL-6 in the 
circulation of LPS challenged mice, although the concentration was reduced by 
more than 6-fold from that observed following a single injection. The 
concentration of IL-6 returned to baseline between days 2 and 5. There was no 
detectable elevation of TNFα or IL-1β following multiple LPS challenges at any of 
the time points analysed. Thus, IL-1β and TNFα are undetectable in the 
circulation following multiple LPS challenges. Whilst IL-6 remained significantly 
elevated after two doses of LPS, it was undetectable for the remainder of the 
model. In keeping with the literature, this suggests that multiple systemic LPS 
challenges induce a state of tolerance that is characterised by reduced 
production of inflammatory cytokines in the periphery. 
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Figure 4.6 Plasma concentration of inflammatory cytokines following acute LPS challenge 
and during endotoxin tolerance. 
(A-C) Concentrations of (A) IL-1β, (B) IL-6 and (C) TNFα (TNF) in the plasma 6 hours after a single 
dose of 50µg LPS. Significance was determined using an unpaired t-test. n = 6/group (Vehicle), n = 
8/group (LPS). (D-E) Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. 
Concentrations of (A) IL-1β, (B) IL-6 and (C) TNFα (TNF) were measured in the plasma 2 days 
(d2), 5 days (d5) and 7 days (d7) following initial injection. Significance was determined using two-
way ANOVA. n = 3/group (Vehicle), n = 5/group (LPS). All concentrations were determined using 
ELISA. Data represent the mean plus or minus SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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4.3.2 Comparing cytokine induction in the brain and PBL during 
endotoxin tolerance 
To establish how inflammatory cytokine induction is effected in the brain during 
endotoxin tolerance, SYBR Green QPCR was performed to compare the 
transcriptional induction of Il1b, Il6 and Tnfa in the brain and matched PBL of 
LPS injected mice compared to vehicle injected controls. Consistent with 
previous reports432,433, Il1b and Tnfa were independently upregulated in the 
brain following multiple LPS challenges (Figure 4.7). Although Il1b expression 
was reduced in the brain between days 2 and 5, Levels of Tnfa transcripts 
remained significantly elevated throughout the model. As anticipated, under 
these conditions, inflammatory cytokine transcripts were not induced in PBL 
(Figure 4.7). Therefore, the brain exhibits a specific cytokine induction in 
response to multiple LPS challenges. This suggests that the brain may not be 
subject to the same regulatory mechanisms that dampen cytokine production in 
the periphery during endotoxin tolerance. 
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Figure 4.7 Cytokine expression in the brain and in the PBL during endotoxin tolerance. 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. RNA was extracted 
from brains and peripheral blood leukocytes (PBL), 2, 5 and 7 days following initial injection. Gene 
expression analysis of (A) Il1b, (B) Il6 and (C) Tnfa was performed using QPCR and normalised to 
TBP. Data are expressed as fold change in gene expression in the brain (■) and PBL (□) of LPS-
injected mice relative to vehicle-injected controls. Data represent the mean +/- SEM. A statistical 
comparison was made, between the fold induction in the brains and PBL of LPS-injected mice and 
that of vehicle-injected controls, using two-way ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 
4/group. 
 
4.3.3 Comparing target gene induction in the brain 
To determine how target ISG induction is affected during endotoxin tolerance, 
expression levels of a selection of ISGs in the brain and PBL of LPS-injected mice 
was compared to those of vehicle-injected mice using SYBR green QPCR. The 
temporal expression of the ISGs was arbitrarily compared to that of Il2rg, a 
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microarray target gene not regulated by IFNs. At day 2, all ISG were significantly 
upregulated in the brains of the LPS-challenged mice (Figure 4.8). At the same 
time point, most ISGs were similarly upregulated in PBL as in brain, with the 
exception of GBP4 which was downregulated. On day 5, ISGs remained induced 
in the brain. All but Cxcl10 were significantly upregulated at this time point. In 
contrast, the same genes were significantly downregulated by PBL. By day 7, ISG 
transcript levels began to return to baseline, with the exception of Irf7 which 
remained significantly induced in the brain. In contrast to the temporal 
expression of ISGs, Il2rg displayed a different pattern of expression. Il2rg was 
significantly upregulated in the brain at all time points. The expression levels of 
this gene did not deviate from baseline in the PBL. These data suggest that 
whilst ISG expression following repeated LPS challenge is dampened in the 
periphery, expression continues in the brain, gradually decreasing in potency 
between days 2 and 7. Subsequently, it would appear that the brain exhibits a 
specific and prolonged response to repeated LPS challenge. Encompassing ISG 
induction, this response is distinct from that of the periphery. Not only does this 
highlight a differential mechanism of gene regulation in the brain from the PBL, 
but it further verifies that ISG and Il2rg expression in the brain is unlikely to be a 
downstream consequence of elevated peripheral inflammatory cytokines. 
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Figure 4.8 Temporal gene expression in the brain and PBL of mice following repeated LPS 
injections 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. RNA was extracted 
from brains and peripheral blood leukocytes (PBL), 2, 5 and 7 days following initial injection. Gene 
expression analysis of (A) Cxcl10, (B) Gbp4, (C) Ifit1, (D) Il2rg, (E) Irf7 and (F) Oasl2 was 
performed using QPCR and normalised to TBP. Data are expressed as fold change in gene 
expression in the brain (■) and PBL (□) of LPS-injected mice relative to vehicle-injected controls.  
Data represent the mean +/- SEM. A statistical comparison was made, between the fold induction 
in the brains and PBL of LPS-injected mice and that of vehicle-injected controls, using two-way 
ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 4/group. 
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4.3.4 Type I IFN induction in the brain 
As shown above, ISGs remained induced specifically in the brain and not in PBL 
following multiple LPS injections. To determine whether this could be a 
downstream effect of IFN production in the brain, TaqMan low density arrays 
(TLDA) were used to assess the transcriptional induction of a selection of type I 
IFNs in the brains of LPS-challenged mice compared to those of vehicle-injected 
controls. On day 2, only Ifnh1 was significantly upregulated (Figure 4.9). 
Transcript levels of the other type I IFN genes remained close to baseline at this 
time point. All IFN transcripts showed a trend towards an upregulation on day 5. 
However, Ifnk was the only gene to be significantly induced. By day 7, Ifnk 
remained induced in the brain, although this was no longer significant. All other 
IFN transcripts had returned to levels statistically comparable to baseline. These 
observations suggest that a mild induction of type I IFNs may occur in the brain 
following repeated LPS challenges. 
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Figure 4.9 Temporal expression of type I IFNs in the brains of mice following repeated LPS 
injections 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. RNA was extracted 
from brains, 2, 5 and 7 days following initial injection. Gene expression analysis of Ifna4, Ifnb1, 
Ifne, Ifnk and Ifnh1 was performed using TaqMan low density arrays and normalised to TBP. Data 
are expressed as fold change in gene expression relative to vehicle-injected control mouse brains. 
Data represent the mean +/- SEM. n = 4-5/group. 
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4.4 Target gene expression following TLR2-induced 
MyD88 activation 
Elevated ISG expression following systemic LPS injection did not appear to be a 
downstream by-product of peripheral inflammatory cytokine production as a 
similar model of sterile inflammation failed to induce the same response. 
Although this lack of response may have been a result of lower levels of 
inflammatory cytokines in the circulation, as demonstrated in Section 4.3, 
expression levels of a selection of target genes remained elevated in the brain 
following daily LPS injections, long after the cytokine response was dampened in 
the periphery. Consequently, it is likely that an alternative mechanism is 
responsible for inducing target gene expression in the brain. 
As described previously, LPS can activate two distinct signalling pathways; the 
MyD88-dependent pathway, or the TRIF-dependent pathway. TLR2 ligand, LTA, 
however, can only activate the MyD88-dependent pathway (Figure 4.1). As a 
result, to determine whether the induction of target genes in the brain occurs 
downstream of TRIF- or MyD88-dependent signalling pathway activation, mice 
were challenged systemically with LTA. 8 week old, male C57BL/6 mice were 
injected intravenously with 2 doses (500µg at 0 and 24 hours) or an equivalent 
volume of vehicle (sterile PBS). Mice were terminally anesthetised, and then 
perfused, 48 hours after initial injection.  
4.4.1 Determining how systemic LTA challenge affects target 
gene expression in the brain, PBL and BM 
To determine whether activation of the MyD88-dependent pathway in the 
periphery was sufficient to induce a similar transcriptional profile in the brain as 
induced by systemic LPS, SYBR Green QPCR was used to compare target gene 
expression in the brains, PBL and bone marrow of mice injected with LTA 
compared to vehicle-injected controls. 
QPCR analysis revealed no significant increase in brain expression of any of the 
genes shown to be upregulated in response to LPS (Figure 4.10, Figure 4.11 & 
Figure 4.12). C4 was the only gene to be significantly upregulated in the brains 
of mice injected with LTA. Again, although C4 was one of the target genes that 
were identified by microarray analysis to be upregulated in the brain in response 
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to LPS (Section 3.3.7), this upregulation could not be verified by QPCR. Thus, 
MyD88-dependent activation of NFκB in the periphery was not sufficient to 
induce the brain inflammation that occurred downstream of LPS-induced TLR4 
activation. 
Similar to both the LPS- and the TNFα-challenged mice, Saa3 was significantly 
induced in PBL. ISGs, Ifitm3 and Lgals3bp and immune response gene Fcgr4 were 
also upregulated by PBL in response to LTA. None of these genes were induced 
to the same extent as they were by PBL following systemic LPS challenge. A 
number of target genes; Cxcl10, Sp100, Lcn2, Saa3 and Pglyrp1 were 
significantly induced in the bone marrow of LTA-challenged mice. Of these 
genes, all but Sp100 were significantly induced in the bone marrow following 
systemic LPS challenge. Taken together, these data suggest that although 
systemic LTA- and LPS-challenge induces the expression of a number of common 
genes in the periphery, only LPS had the capacity to induce target gene 
expression in the brain. 
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Figure 4.10 Differential expression of ISGs in the brain, PBL and BM of LTA-challenged mice 
compared to vehicle control group. 
Mice were injected with 500 µg lipoteichoic acid (LTA) or an equivalent volume of vehicle at 0 and 
24 hours. RNA was then isolated from the brain, peripheral blood leukocytes (PBL) and bone 
marrow (BM), 48 hours after initial injection. Gene expression analysis of (A) Ctsc, (B) Cxcl10, (C) 
Gbp2, (D) Gbp3, (E) Gbp4, (F) Ifit1, (G) Ifitm3, (H) Igrm1, (I) Irf7, (J) Lgals3bp, (K) Oasl2, (L) Rtp4, 
(M) Sp100 and (N) Stat1 was performed using QPCR and normalised to TBP. Data are expressed 
as fold change in gene expression in the brain, PBL and BM of LTA-injected mice (■) relative to 
that of vehicle-injected controls (□).  Data represent the mean +/- SEM. Significance of each fold 
change was calculated for individual tissues using an unpaired t-test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 
0.001. n = 4/group. 
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Figure 4.11 Differential expression of acute phase response genes in the brain, PBL and BM 
of LTA-challenged mice compared to vehicle control group. 
Mice were injected with 500 µg lipoteichoic acid (LTA) or an equivalent volume of vehicle at 0 and 
24 hours. RNA was then isolated from the brain, peripheral blood leukocytes (PBL) and bone 
marrow (BM), 48 hours after initial injection. Gene expression analysis of (A) Lcn2, (B) Saa3 and 
(C) Serpina3n was performed using QPCR and normalised to TBP. Data are expressed as fold 
change in gene expression in the brain, PBL and BM of LTA-injected mice (■) relative to that of 
vehicle-injected controls (□). Data represent the mean +/- SEM. Significance of each fold change 
was calculated for individual tissues using an unpaired t-test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n 
= 4/group. 
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Figure 4.12 Differential expression of remaining target genes in the brain, PBL and BM of 
LTA-challenged mice compared to vehicle control group. 
Mice were injected with 500 µg lipoteichoic acid (LTA) or an equivalent volume of vehicle at 0 and 
24 hours. RNA was then isolated from the brain, peripheral blood leukocytes (PBL) and bone 
marrow (BM), 48 hours after initial injection. Gene expression analysis of (A) Apobec3, (B) C4, (C) 
Fcgr4, (D) Il2rg, (E) Ly6a and (F) Pglyrp was performed using QPCR and normalised to TBP. Data 
are expressed as fold change in gene expression in the brain, PBL and BM of LTA-injected mice 
(■) relative to that of vehicle-injected controls (□). Data represent the mean +/- SEM. Significance 
of each fold change was calculated for individual tissues using an unpaired t-test: *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001. n = 4/group. 
 
 
188 
4.4.2 Detecting peripheral inflammation following LTA injection 
To assess the extent of peripheral inflammation following systemic LTA 
challenge, inflammatory cytokines were measured in the circulation and 
compared to that of a vehicle-injected control group. ELISAs were performed on 
plasma samples isolated from LTA- and vehicle-injected mice; 6 hours, 30 hours 
and 48 hours following initial injection. Unexpectedly, very little inflammation 
was detected in the circulation of mice following systemic LTA challenge. Similar 
to both the LPS and TNFα models, none of the cytokines assayed were 
detectable 48 hours after the initial LTA injection (Figure 4.13). 6 hours 
following initial LTA injection, IL-1β was significantly elevated in the circulation 
(Figure 4.13A), however, levels of TNFα and IL-6 were comparable to baseline 
(Figure 4.13B&C). 30 hours into the model (6 hours after the second injection), 
elevated IL-6 was detectable in the circulation of two of the four LTA-challenged 
mice but this was not significant when compared to the vehicle-treated group. 
These data demonstrate that LTA induces a significant elevation of circulating 
IL-1β which returned to baseline between 6 hours and 30 hours. However, at the 
time points tested, no significant elevation of IL-6 or TNFα could be detected in 
the circulation of mice that were systemically challenged with LTA compared to 
vehicle-injected controls. 
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Figure 4.13 Plasma concentration of inflammatory cytokines following systemic LTA 
injection 
Mice were injected with 500 µg lipoteichoic acid (LTA) or an equivalent volume of vehicle at 0 and 
24 hours. Plasma was isolated from the whole blood of mice; 6hours, 30 hours and 48 hours 
following initial injection. Concentrations of (A) IL-1β, (B) IL-6 and (C) TNFα (TNF) in the plasma 
were determined using ELISA. Data represent the mean plus or minus SEM. Significance was 
determined using two-way ANOVA. n = 4/group. 
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4.5 Discussion and conclusions 
Transcriptional profiling, utilized in Chapter 3, identified an induction of ISGs 
and other immune/inflammatory genes in the brains of mice that had been 
challenged with LPS compared to vehicle-injected controls. To better 
understand the mechanism behind this induction, the ability of different 
inflammatory models to modulate target gene expression in the brain was 
assessed using QPCR.  
One of the characterised mechanisms of immune signal transduction across the 
BBB involves activation of cerebral vascular endothelial cells by circulating 
cytokines, particularly IL-1β and TNFα (Section 1.4.2.2). In order to determine 
whether elevated levels of circulating TNFα were sufficient to induce target 
gene expression in the brain; mice were challenged intravenously with 
recombinant murine TNFα. TNFα is the first inflammatory cytokine to be 
detected in the circulation following systemic LPS challenge and it is thought to 
play a pivotal role in activating the peripheral cytokine cascade414,435,436. Not 
only has TNFα been implicated in the development of depression in patients with 
chronic inflammatory diseases276, but systemic TNFα challenge is known to have 
an impact on the brain of rodents, subsequently triggering a host of sickness 
behaviours266,286,436. Gene expression analysis, 48 hours after initial TNFα 
injection, revealed that, of the genes found to be significantly upregulated 48 
hours after LPS challenge, only one was altered in the brain in response to TNFα. 
These data suggest that target gene induction in the brains of mice injected with 
LPS may be TLR-specific and not a downstream consequence of sterile 
inflammation.  
Another explanation for the lack of target gene modulation in the brain 
following systemic TNFα-injection could be that it failed to induce as high a 
level of systemic inflammation as 100 µg of LPS. Although TNFα is known to 
induce an inflammatory cytokine cascade in the periphery and propagate signals 
across the BBB to induce sickness behaviours, no significant elevation of IL-1β 
was detected in the circulation. This may have been an issue with the dose of 
TNFα used or the time points that were assayed. However, intravenous TNFα 
challenge significantly enhanced levels of circulating TNFα and IL-6, yet target 
gene induction in the brain was negligible. Therefore, the central induction of 
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target genes following LPS challenge is likely to be more than a mere by-product 
of elevated TNFα or IL-6 in the circulation. Furthermore, injecting mice with the 
TLR2 ligand, LTA, induced increased levels of circulating IL-1β. As none of the 
genes that were induced in the brain in response to LPS were also upregulated in 
the brain following LTA challenge, central target gene induction does not appear 
to occur downstream of elevated IL-1β in the circulation. These observations 
suggest that circulating inflammatory cytokines do not appear to play a 
prominent role in inducing ISG transcription, or the expression of other target 
genes, in the brain. Therefore, the neuroinflammation that is induced in 
response to LPS is more likely to be a TLR-specific phenomenon and not a 
generic effect of inflammation. To investigate the role of inflammatory 
cytokines further, the central induction of target genes could be assessed over 
time following several different doses of systemic TNFα or following systemic IL-
1β administration. As cytokines often function in synergy, gene expression in the 
brain could also be measured following the systemic injection of both TNFα and 
IL-1β. Alternatively, target gene expression in the brain following systemic LPS 
injection could be assessed following the neutralisation of TNFα and/or IL-1β in 
the periphery using cytokine-specific monoclonal antibodies or soluble cytokine 
receptors.  
To complement the dataset derived from the systemic TNFα-induced model of 
inflammation, the induction of a selection of target genes, predominantly ISGs, 
was compared in brain and matched PBL samples, in the context of endotoxin 
tolerance. It has been well established that endotoxin tolerance leads to a state 
of hyporesponsiveness in the periphery, characterised by suppression of the 
inflammatory cytokine milieu429,430. This is certainly supported by the ELISA data 
which show an absence of any detectable inflammation in the circulation at day 
5 or day 7. Only IL-6 was elevated in the circulation at day 2. As mentioned 
previously, a number of routes exist to sensitise the brain to inflammation in the 
periphery. As these communication pathways between the immune system and 
the nervous system often involve the intermediary action of inflammatory 
cytokines, such as stimulation of the vagus nerve by IL-1β or endothelium 
activation by IL-1β and TNFα (Section 1.4.2), it seems likely that these routes 
would be impaired in conditions involving endotoxin tolerance. Despite the 
perceived absence of both TNFα and IL-1β, ISGs remain induced in the brain 
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after several peripheral LPS injections. In contrast, the same genes, still induced 
in the periphery by day 2, are downregulated by day 5, with the exception of 
Gbp4 which was downregulated in peripheral blood leukocytes at all time points 
assayed. As GBP expression has been shown to be directly affected by endotoxin 
tolerance437, it is possible that Gbp4 expression would have been silenced after a 
single injection. Analysing Gbp4 expression levels at day 1 after a single 
injection would be required to confirm this. In the periphery, the remaining 
genes, not directly targeted during endotoxin tolerance, must be negatively 
regulated between days 2 and 5 by another, as yet unknown mechanism.  
What is clear from these observations is that a distinct difference in the 
expression kinetics of these genes differentiates the brain from the PBL. As 
mentioned above, previous studies have suggested that the brain continues to 
secrete cytokines in response to repeated challenge with LPS, even though 
cytokine production is negatively regulated in the periphery432,433. In keeping 
with this, QPCR analysis demonstrated a brain-specific induction of Tnfa and Il1b 
following multiple LPS injections. Although Il1b levels were only significantly 
induced after 2 LPS injections, Tnfa remained significantly induced in the brain 
throughout the model. In contrast, the same genes were not induced in matched 
PBL. In addition to Il1b and Tnfa, the QPCR data demonstrated maintained 
induction of other immune response genes in the brain that were negatively 
regulated in the periphery. The mechanism inducing the central induction of 
these genes in the absence of peripheral cytokines remains to be clarified. 
However, it is possible that repeated LPS injection causes a breakdown of the 
BBB allowing LPS to gain access to the brain. Alternatively, phagocytic cells in 
the CVOs may not have the same regulatory mechanisms as their peripheral 
counterparts and may therefore continue to respond to repeated LPS challenge. 
Collectively, these data further imply that circulating inflammatory cytokines 
are not likely to be responsible for the induction of ISGs or Il2rg in the brain 
following LPS injection.  
LPS binds to TLR4 to activate two distinct signalling pathways. IFNβ production is 
a classic hallmark of TLR4-induced IRF3 activation, via the TRIF-dependent 
signalling pathway (Figure 4.1). As the panel of target genes, which were 
induced in the brain in response to systemic LPS administration, was highly 
enriched with type I ISGs (Section 3.3.7), it was hypothesised that a TRIF-
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induced IFNβ response was accountable for their induction in the brain. To 
investigate the involvement of TRIF activation in the neuroinflammation induced 
by systemic LPS injection, mice were challenged with LTA. LTA can only signal 
through the MyD88-dependent signalling pathway (Figure 4.1). Consistent with 
previous reports318, no response was detectable in the brains of mice following 
peripheral LTA injection. This lack of response may be due to the inability of 
TLR2 ligands to stimulate TRIF-dependent signalling and subsequent type I IFN 
production. Conversely, peripheral stimulation with TLR3 ligands is known to 
trigger brain inflammation239,438. Similar to the MyD88-independent pathway 
downstream of TLR4, TLR3 signals through the adaptor molecule TRIF to activate 
IRF3, ultimately triggering IFNβ production431. Subsequently, it would appear 
that IRF activation, whether it occurs in the periphery or the brain, may be a 
requirement of target gene induction in the brain following systemic 
administration of TLR ligands. 
In further support of this hypothesis, a similar study showed that all target genes 
were induced in the brain following topical, cutaneous administration of TLR7/8 
agonist, Imiquimod (Alison McColl, unpublished data). In this study, Imiquimod 
was used to create a psoriasis-like skin pathology. This peripheral inflammatory 
model induced tissue-specific, but not systemic, inflammation and target genes 
were induced specifically in the brain in the absence of detectable inflammatory 
cytokines in the circulation. TLR7- and TLR8-ligation both activate IRF7 which 
then results in the production of IFNα. These findings support the notion that 
TLR-induced type I IFN production, rather than elevated circulating cytokines, is 
responsible for target gene modulation in the brain. 
To conclusively verify the role of TRIF-dependent signalling in inducing the 
expression of ISGs and other target genes in the brain following systemic LPS 
injection, the acute and chronic models of LPS-induced systemic inflammation 
could be repeated using TRIF- or IRF3-deficient mice. Both TRIF and IRF3 are 
required for TLR4-induced IFNβ expression439,440. Therefore, an absence of target 
gene expression in the brains of these mice following LPS injection would 
highlight the importance of MyD88-independent signalling in their induction.  
Although these data imply that a TLR-induced type I IFN response is accountable 
for target gene induction in the brain following systemic LPS challenge, it is still 
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unclear whether type I IFNs are produced in the brain or whether peripherally 
produced IFNs act on the brain in an endocrine manner to trigger ISG induction. 
The TLDA data indicated that transcripts encoding type I IFNs are mildly 
upregulated following multiple LPS challenges. These data are by no means 
conclusive and require further investigation. To establish whether any of the 
observed inductions of type I IFN genes were significant, the TLDA data would 
first have to be validated by QPCR. Even if the data were validated, it is not 
clear whether such a slight induction of IFN transcripts would translate to 
increased protein production. Measuring IFN proteins in brain tissue is 
technically challenging as IFNs are usually produced in low quantities. 
Therefore, rather than quantifying IFN levels in the brain, a useful experiment 
would be to establish whether endotoxin tolerance leads to a dampening of type 
I IFNs in the periphery. One of the genes that are transiently silenced during 
endotoxin tolerance is Ifng430, however, to my knowledge, it is yet to be 
determined how type I IFNs respond to repeated LPS challenges. If it were 
indeed the case that both type I and type II IFNs were silenced in the periphery 
during this model of endotoxin tolerance, by default this would imply that 
centrally produced IFNs are more likely to be responsible for ISG induction in the 
brain than those produced in the periphery. The QPCR data indicate that 
peripheral type I IFN production may well be dampened during endotoxin 
tolerance as, following several LPS injections, ISG expression is silenced in PBL 
but not in the brain. This suggests that type I IFNs may be produced in the brain 
rather than the periphery during endotoxin tolerance. QPCR analysis of IFN 
transcript levels in the brain and PBL at different time points, complemented by 
ELISA assays to quantify protein levels in the brain and blood, would be required 
in order to confirm this. 
In summary, systemic LPS administration induced the transcription of a panel of 
immune/inflammatory genes in the brain. This transcriptional profile was not 
induced by the systemic administration of TNFα, nor did it appear to depend on 
elevated levels of inflammatory cytokines in the circulation. Consequently, the 
observed induction of target genes in the brain may be dependent on TLR-
ligation. In contrast, the same target genes were not induced in the brain 
following systemic administration of the TLR2 ligand, LTA. TLR2 has a signalling 
profile that is distinct from that of TLR4 in that it does not activate IRF3 
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resulting in type I IFN induction. This highlights a potential mechanism of target 
gene induction in the brain which may be dependent on a TLR-induced type I IFN 
response. 
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5 Characterising the chemokine repertoire and 
leukocyte infiltrate present in the brains of LPS-
challenged mice 
197 
5.1 Introduction and aims 
In Chapter 3 it was established that Cxcl10 expression was significantly 
upregulated in the brain following an acute systemic LPS challenge, as was the 
expression of a number of genes involved in leukocyte extravasation. Cxcl10 can 
coordinate the migration of several leukocyte populations, predominantly NK 
cells, Th1 cells, CD8+ cytotoxic T cells and memory T cells99-101,441. It was 
therefore hypothesised that systemic LPS exposure may result in the infiltration 
of these leukocytes to the brain. Current literature suggests that systemic LPS 
injection can result in the recruitment of neutrophils to the cerebral 
vasculature236,237. Although no other chemokine transcripts, including any 
encoding neutrophil chemoattractants, were significantly induced in the brain 
following systemic LPS challenge, transcription was only assessed 48 hours after 
injection. These data provide a mere snapshot of events occurring in the brain 
following an I.P. injection of LPS. Therefore, it remains to be determined how 
systemic LPS exposure modulates the chemokine profile in the brain over time 
and whether the putative chemokine induction results in leukocyte accumulation 
within the brain. 
The primary aim of this chapter was to establish whether systemic exposure to 
LPS culminated in the specific recruitment of inflammatory leukocytes to the 
brain. As there was no way to hypothesise how long leukocytes may take to 
accumulate within the brain, if indeed they do so at all, it was decided that 
leukocyte infiltration would be better investigated over a seven day window 
following daily systemic LPS injections. Although this model leads to LPS 
tolerance in the periphery, it has the advantage that it may better reflect 
physiological conditions, such as bacterial infection or septicaemia, than a single 
dose of LPS. Furthermore, as proof of principle, it was shown in Chapter 4 that 
Cxcl10 remained induced in the brain following daily systemic LPS injections. 
It has been demonstrated in a variety of settings that different leukocyte 
populations infiltrate the brain at different time points. For example, following 
MHV or Semliki Forest virus infection, T cell accumulation in the brain is 
followed by the infiltration of monocytes190,442. This appears to be dependent on 
the temporal induction of chemokines within the brain. Therefore, with the aim 
of assessing which leukocyte populations (if any) were likely to infiltrate the 
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brain following daily systemic LPS injections, TLDA plates were used to 
systematically assess the chemokine repertoire in the brain at different time 
points throughout the LPS model. The induction of chemokine transcripts was 
compared in LPS- and vehicle-injected mice. The accumulation of target 
populations of leukocytes within the brains of LPS-challenged mice was then 
assessed using a combination of immunohistochemistry and flow cytometry. 
5.2 Regulation of chemokine and chemokine receptor 
transcripts following daily systemic LPS injections 
Prior to establishing whether leukocytes infiltrated the brains of mice following 
a series of systemic LPS challenges, gene expression assays were used to assess 
the repertoire of inflammatory chemokine transcripts that were induced in the 
brains of the LPS-treated mice. 8 week old C57BL6 mice were exposed to daily 
injections of LPS (50 µg I.P.) as described in Section 4.3. Mice were culled, and 
perfused, 2 days, 5 days and 7 days after initial LPS challenge.   
5.2.1 Chemokine transcripts are induced in the brain following 
multiple systemic LPS challenges 
To establish how chronic LPS exposure in the periphery regulated chemokine 
transcripts in the brain, TLDA plates were used to systematically screen for the 
transcriptional induction of a panel of 17 inflammatory, or brain-related, 
chemokines in the brains of LPS-injected mice compared to the vehicle-injected 
control group. On day 2, 48 hours after initial LPS injection, CC chemokine 
transcripts Ccl2, Ccl5, Ccl7, Ccl8 and Ccl11 were significantly upregulated, as 
were CXC chemokine transcripts, Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl9, Cxcl10 and 
Cxcl16 (Figure 5.1). Of these, Ccl2, Ccl5, Cxcl1, Cxcl2, Cxcl9 and Cxcl10 were all 
upregulated by at least 10-fold. By day 5, the majority of chemokine transcripts 
did not significantly deviate from baseline, with the exception of Ccl8, Ccl11 and 
Cxcl16. Both Ccl11 and Cxcl16 remained significantly elevated in the brain 
throughout the model. Cx3cl1 was also significantly upregulated by day 7. 
Therefore, several genes encoding inflammatory chemokines are significantly 
induced in the brain following multiple systemic LPS challenges. 
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Figure 5.1 Temporal expression of inflammatory chemokines in the brains of mice following 
repeated LPS injections 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. RNA was extracted 
from brains, 2, 5 and 7 days following initial injection. Gene expression analysis of (A) CC 
chemokines and (B) CXC and CX3C chemokines was performed using TaqMan low density arrays 
and normalised to TBP. Data are expressed as fold change in gene expression relative to vehicle-
injected control mouse brains. Data represent the mean +/- SEM. A statistical comparison was 
made, between the fold induction in the brains of LPS-injected mice and that of vehicle-injected 
controls, using two-way ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 4-5/group. 
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To validate the TLDA data, the induction of the majority of the chemokine 
transcripts that were identified as being upregulated 10-fold or more on day 2 
was additionally assessed using SYBR Green QPCR. Consistent with the TLDA 
data, Ccl5 was significantly upregulated in the brains of LPS-challenged mice on 
day 2 (Figure 5.2A). However, the QPCR data also demonstrated that Ccl5 
remained significantly upregulated until at least day 5. Of all the chemokine 
transcripts assayed, Ccl5 showed the greatest induction in the brains of the LPS-
challenged mice. As a result, attempts were made to confirm this upregulation 
at a protein level using histology. Unfortunately, due to technical difficulties, 
this aim was not achieved (data not shown).  
CCL3 and CCL5 share similar receptors and are often produced concomitantly, 
therefore, the transcriptional regulation of Ccl3 in the brain was also 
determined by QPCR. Although Ccl3 expression was statistically comparable to 
baseline at days 2 and 7, the QPCR data demonstrated that, on day 5, Ccl3 was 
significantly upregulated by approximately 23-fold (Figure 5.2A). 
The induction of genes encoding neutrophil chemoattractants CXCL1 and CXCL2 
was also confirmed for day 2 using QPCR (Figure 5.3A). In addition, Cxcl2 was 
shown to be significantly upregulated in the brain until at least day 5. Although 
the TLDA data demonstrated a significant, approximately 57-fold, induction of 
the gene encoding IFN-inducible CXCL9, this appeared to be below the detection 
limit of the QPCR assay and thus could not be validated (data not shown). The 
significant induction of Cxcl10 at day 2 of the LPS model was previously 
confirmed by QPCR in Figure 4.8A. Attempts were also made to establish 
whether CXCL10 protein was upregulated in the brains of LPS-challenged mice. 
Unfortunately, due to antibody cross-reactivity, this did not prove possible (data 
not shown).  
201 
A
B
i
i
ii
ii
iii
CCL3
d2 d5 d7
0.5
2
4
8
16
32
64 Brain
PBL
*
1
Days
Fo
ld
 C
ha
ng
e
CCL5
d2 d5 d7
4
16
64
256 Brain
PBL
***
*
1
Days
Fo
ld
 C
ha
ng
e
CCR1
d2 d5 d7
0.5
2
4
8
16
Brain
PBL***
***
1
Days
Fo
ld
 C
ha
ng
e
CCR5
d2 d5 d7
2
4
8
16
Brain
PBL
***
1
Days
Fo
ld
 C
ha
ng
e
CCR3
d2 d5 d7
0.125
0.25
0.5
2
4
8
Brain
PBL
1
Days
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
 
Figure 5.2 Temporal expression of CC chemokine and chemokine receptor in the brain and 
PBL of mice following repeated LPS injections 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. RNA was extracted 
from brains and peripheral blood leukocytes (PBL), 2, 5 and 7 days following initial injection. Gene 
expression analysis of (A) CC chemokines, (i) Ccl3 and (ii) CCL5 and (B) CC chemokine receptors, 
(i) Ccr1, (ii) Ccr5 and (iii) Ccr3 was performed using QPCR and normalised to TBP. Data are 
expressed as fold change in gene expression in the brain (■) and PBL (□) of LPS-injected mice 
relative to vehicle-injected controls. Data represent the mean +/- SEM. A statistical comparison 
was made, between the fold induction in the brains and PBL of LPS-injected mice and that of 
vehicle-injected controls, using two-way ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 4/group. 
 
202 
A
B
i ii
C
CXCL1
d2 d5 d7
0.015625
0.0625
0.25
4
16
64
256 Brain
PBL***
1
Days
Fo
ld
 C
ha
ng
e
CXCL2
d2 d5 d7
0.03125
32
1024
1
Brain
PBL*** **
Days
Fo
ld
 C
ha
ng
e
CXCR2
d2 d5 d7
0.25
0.5
2
4
8
16
32
64
128 Brain
PBL
***
1
Days
Fo
ld
 C
ha
ng
e
CXCR3
d2 d5 d7
0.25
0.5
2
4 Brain
PBL
* *
1
Days
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
Fo
ld
 C
ha
ng
e
 
Figure 5.3 Temporal expression of CXC chemokine and chemokine receptor in the brain and 
PBL of mice following repeated LPS injections 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. RNA was extracted 
from brains and peripheral blood leukocytes (PBL), 2, 5 and 7 days following initial injection. Gene 
expression analysis of (A) CXC chemokines, (i) Cxcl1 and (ii) Cxcl2 and CXC chemokine 
receptors, (B) Cxcr2 and (C) Cxcr3 was performed using QPCR and normalised to TBP. Data are 
expressed as fold change in gene expression in the brain (■) and PBL (□) of LPS-injected mice 
relative to vehicle-injected controls. Data represent the mean +/- SEM. A statistical comparison 
was made, between the fold induction in the brains and PBL of LPS-injected mice and that of 
vehicle-injected controls, using two-way ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 4/group. 
 
5.2.2 Chemokines are differentially regulated in the brain and PBL 
Despite the fact that all chemokine transcripts assayed using QPCR were 
upregulated in the brain on at least one of the three time points, none were 
differentially regulated in the PBL of LPS-treated mice (Figure 5.2A & Figure 
5.3A). Thus, chronic exposure to LPS in the periphery triggers a brain-specific 
induction of genes encoding inflammatory chemokines. 
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5.2.3 Chemokine receptor transcripts are differentially induced in 
the brain and PBL 
Having established that chemokine transcripts were induced specifically in the 
brain, QPCR was then performed to determine what impact this series of 
systemic LPS challenges had on the transcriptional modulation of genes encoding 
their cognate chemokine receptors. The relative induction of chemokine 
receptor transcripts was compared in the brain and PBL. In LPS-treated mice at 
day 2, the gene encoding CCR1, one of the two shared receptors for CCL3 and 
CCL5, was significantly upregulated in the brain and PBL by a similar fold change 
(Figure 5.2B). At days 5 and 7, whilst there was a trend towards an upregulation 
in the brain, Ccr1 expression was comparable to baseline in the PBL of LPS-
challenged mice. CCR5, the other shared receptor for CCL3 and CCL5, showed a 
different pattern of transcriptional regulation (Figure 5.2B). Ccr5 was 
significantly upregulated by the PBL of LPS challenged mice on day 2. At days 5 
and 7, whilst there was a trend towards an upregulation in the PBL of the LPS-
treated group, Ccr5 expression did not significantly differ from that of vehicle-
treated controls in either the brain or the PBL. In addition to CCR1 and CCR5, 
CCL5 can bind to CCR3. Unlike Ccr1 and Ccr5, transcript levels of CCR3 were not 
significantly regulated in either the brain or PBL following multiple systemic LPS 
injections (Figure 5.2B). 
Neither of the CXC chemokine receptor transcripts assayed, Cxcr2 or Cxcr3 were 
differentially modulated by the PBL of LPS challenged mice (Figure 5.3B&C). In 
contrast, both genes were significantly upregulated in the brains of the LPS 
treatment group at day 2. In addition, both genes showed a trend towards an 
upregulation in the brain on day 5. By day 7, Cxcr3 was again significantly 
upregulated in the brains of the LPS challenged group.  
These different methods of gene expression analysis collectively demonstrate 
that a panel of inflammatory chemokine transcripts are elevated in the brain 
following several systemic LPS injections. Not only was the induction of these 
chemokine transcripts brain-specific, but it was coupled with an increase in 
mRNA encoding a number of their cognate receptors.  
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5.3 Leukocytes infiltrate the brain in response to chronic 
systemic LPS exposure 
The induction of chemokine receptor transcripts within the brain may be due to 
brain-resident cell populations upregulating their chemokine receptor expression 
in response to peripheral or central TLR ligation. However, as the most 
characterised function of inflammatory chemokines is to recruit leukocytes to 
sites of inflammation, an alternative possibility is that an accumulation of 
leukocytes within the brain is responsible for the elevation in transcript levels. 
To explore this possibility further, mice were again challenged with a single dose 
of LPS (50 µg I.P.) or vehicle daily for 2, 5 or 7 consecutive days. Mice were 
culled and perfused 24 hours after their final injection. Brains were then 
harvested from the mice and analysed by flow cytometry. To control for the 
possibility of blood contamination, whole blood was also harvested from the 
mice and analysed by flow cytometry.   
Prior to surface staining analysis, cells were first gated based on their forward 
scatter (FSC) and side scatter (SSC) (P1 gate). This was followed by the exclusion 
of Draq7+ dead cells (P2 gate). Doublets were then excluded so that only single 
cells (P3 gate) were considered for analysis (Figure 5.4). 
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Figure 5.4 Gating on live, single cells in the brain and PBL 
Representative dot plots showing the gating strategy used to define single live cells amongst total 
events recorded from (A) the brain and (B) whole blood. Cell populations were gated from total 
events based on their FSC and SSC (P1 gate). Dead cells and doublets were excluded (P2 and P3 
gates respectively).  
 
5.3.1 CD45hi cells are increased in the brain following multiple 
systemic LPS challenges 
To determine whether leukocytes infiltrated the brain following chronic systemic 
LPS exposure, the proportions of CD45-expressing cells in the treatment and the 
control groups was first compared using flow cytometry. As microglia 
characteristically express intermediate levels of CD45 on their surface (CD45int), 
it was first necessary to distinguish between CD45int microglia (P4 gate) and 
CD45hi leukocytes (P5 gate) (Figure 5.5A). Having delineated these two 
populations of cells, the proportions of live, single CD45hi leukocytes present in 
LPS-treated mouse brains was compared to that of the vehicle-treated control 
group. At day 2, after 2 doses of LPS, there was a highly significant increase in 
the proportion of CD45hi cells in the brain (6.3-fold) (Figure 5.5B&C). Although 
on day 7 the proportion of CD45hi cells was increased by approximately 2.7-fold, 
this was not statistically significant.  
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Using RNA from an independent experiment, QPCR was performed to determine 
whether there was a similar increase in CD45 transcript levels in the brains of 
LPS-challenged mice. At all time points assayed, there was a significant increase 
in Cd45 mRNA (Figure 5.5D). The fold increase in Cd45 expression in the brain 
was similar to the increase in proportions of CD45hi leukocytes. Collectively, 
these observations suggest that CD45hi cells may accumulate in the brain 
following 2 doses of systemic LPS. 
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Figure 5.5 Proportions of CD45hi cells in the brains of LPS and vehicle-challenged mice 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. Single cell suspensions 
were generated from whole brain tissue at days 2, 5 and 7 following initial LPS- or vehicle-injection. 
(A) Representative dots plots of single live cells (P3 gate, Figure 5.4) from each group. Cells were 
gated based on CD45-expression. P4 gate (■) represents CD45int cells and will therefore contain 
microglial cells. P5 gate (■) represents CD45hi leukocytes. (B) Histograms showing CD45-
expression in LPS-injected (■) and vehicle-injected (shaded) groups over time. (C) Percentages of 
CD45hi leukocytes (P5 gate) in the brain at each time point following injection. (D) Gene expression 
analysis of Cd45 was performed using QPCR and normalised to TBP. mRNA was extracted from 
mouse brains from an independent experiment. Data are expressed as fold change in gene 
expression in the brain of LPS-injected micerelative to that of vehicle-injected controls. Data 
represent the mean +/- SEM. Significance of was calculated for using a two way ANOVA: *P ≤ 
0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 3-4/group. 
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5.3.2 Proportions of microglial cells varied following two doses of 
LPS 
Unexpectedly, at day 2 of the LPS model, there appeared to be a reduction in 
the percentage of live microglial cells following systemic LPS treatment (Figure 
5.5 & Figure 5.6). However, not only were the percentages of microglial cells at 
days 5 and 7 statistically comparable in LPS- and vehicle-injected mice, but they 
were similar to the percentage of microglia observed in LPS-injected mouse 
brains on day 2 (Figure 5.6B). Microglia appeared as one uniform population 
based on their CD11b- and F4/80-expression (Figure 5.6A) and were therefore 
readily identifiable from other cell populations in the brain. The variation in 
their percentages at this early time point could not be explained by an increase 
or decrease in CD45-expression as cells of a similar phenotype could not be 
detected in the CD45hi fraction or the CD45- fraction (data not shown). This 
suggests that there was an increase in the numbers of viable microglial cells 
isolated from the brains of vehicle-injected control mice at day 2. 
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Figure 5.6 Variations in microglial cell numbers 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. Single cell suspensions 
were generated from whole brain tissue at days 2, 5 and 7 following initial LPS- or vehicle-injection. 
(A) Representative dots plots of single live CD45int cells (P4 gate, Figure 5.5) from each group. 
Microglial cells were gated from other CD45int cells based on CD11b- and F4/80-expression. (B) 
Percentages of microglial cells in the brain at each time point following injection. Data represent the 
mean +/- SEM. Significance of was calculated for using a two-way ANOVA: *P ≤ 0.05, **P ≤ 0.01, 
***P ≤ 0.001. n = 3/group. 
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5.3.3 CD11b+ leukocytes infiltrate the brain following multiple 
systemic LPS challenges 
As described above, the proportion of infiltrating CD45hi leukocytes was 
increased in the brains of LPS challenged mice at day 2 of the time course. With 
the aim of identifying which cell populations infiltrated the brain, flow 
cytometry was used to characterise the leukocyte populations present in the 
CD45hi fraction. In the vehicle-treated mouse brains, there was a small 
population of CD45hi leukocytes (Figure 5.5). Further characterisation of these 
cells revealed them to be CD11bhi, F4/80+ cells (Figure 5.7A). As they expressed 
only marginally more of each surface antigen than microglia, these are likely to 
represent brain-resident macrophages, such as PVM. Interestingly, this 
population appeared to be reduced in the brain at day 2 of the LPS time course 
(Figure 5.7A) but had reappeared by day 5 (data not shown). On day 2, 
infiltrating leukocytes in the brains of LPS-challenged mice could be divided into 
two populations based on their level of CD45-expression (P6 and P7 gates, Figure 
5.7A). Not only did these two populations differ in their level of CD11b-
expression, but they also differed from each other, and from CD45int microglial 
cells, in terms of their size and granularity. Both populations of cells were 
CD11b+, F4/80-. However, based on their size, granularity and level of CD11b, 
leukocytes within the P6 gate have been classed as CD11bhi granulocyte-like cells 
whereas those within the P7 gate have been classed as CD11b+ monocyte-like 
cells.  
At day 2 of the LPS model, the proportion of CD11bhi granulocyte-like cells in the 
brains of LPS-challenged mice was significantly increased compared to the 
vehicle-treated control group (Figure 5.7B&D). Although this cell population 
could also be detected in the brains of the LPS-injected group on day 5, there 
was no significant difference at this time point. The percentage of CD11b+ 
monocyte-like cells was also elevated in the brains of LPS challenged mice at 
day 2 (Figure 5.7C&E). Unfortunately, this population was difficult to distinguish 
from other cell populations at day 5 and day 7 and thus could not be quantified 
(data not shown). Taken together, these data suggest that, on day 2, CD11bhi 
granulocyte-like cells and CD11b+ monocyte-like cells may accumulate in the 
brains of LPS challenged mice. 
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Figure 5.7 Characterisation and quantification of CD11b+ leukocyte populations in the 
brains of LPS-challenged mice 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. Single cell suspensions 
were generated from whole brain tissue at days 2, 5 and 7 following initial LPS- or vehicle-injection. 
(A) Representative dot plots from day 2 of the time course. Cells were gated based on level of 
CD45-expression. P4 gate (■) represents CD45int cells. P5 gate (■) represents all CD45hi 
leukocytes. In LPS-injected mice (bottom) there were two distinct populations of CD45hi leukocytes: 
gates P6 (■) and P7 (■). The different populations of CD45-expressing cells from each group were 
overlaid to compare their CD11b- and F4/80-expression and their FSC and SSC. (B & C) 
Representative dots plots of CD45hi leukocytes, P5 gate (■), from (B) each group and (C) day 2 of 
the model. Cells were gated based on CD11b-and F4/80-expression. (D) Percentages of CD11b+ 
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granulocyte-like cells in the brain at each time point following injection. (E) Percentages of CD11b+ 
monocyte-like cells in the brain at day 2 of the model.  Data represent the mean +/- SEM. 
Significance of was calculated for using a two-way ANOVA: *P ≤ 0.05, ***P ≤ 0.001. n = 3/group. 
To establish whether the increased proportions of CD11b+ cell populations in the 
brain were reflected by a similar increase in the peripheral blood, the 
percentage of CD11b+ cells present in matched blood samples was also assessed 
by flow cytometry. The percentage of CD11b+ cells was significantly increased in 
the blood at all time points analysed (Figure 5.8A&B). This did not follow the 
pattern observed in the brain. Although in steady state conditions CD11b+ cells 
could be separated into two different cell populations based on their FSC and 
SSC, using the same parameters these two cell populations were 
indistinguishable from one another following LPS-treatment (Figure 5.8A). 
Furthermore, following LPS-treatment, CD11b+ cells could be separated into two 
different cell populations based on their level of CD45-expression. However, in 
steady-state conditions CD11b-expressing cell populations expressed similar 
levels of CD45. As a result, the specific proportions of granulocyte-like cells and 
monocyte-like cells present in the peripheral blood could not be established 
from this experiment. 
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Figure 5.8 Characterisation and quantification of CD11b+ leukocyte populations in the 
peripheral blood of LPS-challenged mice 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. Single cell suspensions 
were generated from whole brain tissue at days 2, 5 and 7 following initial LPS- or vehicle-injection. 
(A) Representative dot plots from day 2 of the time course. Single live cells were gated based on 
level of CD11b-expression (left). CD11b+ leukocytes were then gated based on their FSC and 
SSC. Different populations of CD11b-expressing cells from each group were overlaid to compare 
their CD45-expression. (B) Percentages of CD11b+ leukocytes in the peripheral blood at each time 
point following injection.  Data represent the mean +/- SEM. Significance of was calculated for 
using a two-way ANOVA: ***P ≤ 0.001. n = 3/group. 
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5.3.4 CD3+ cell populations infiltrate the brain following multiple 
systemic LPS challenges 
As Ccl5 and Cxcl10 were significantly upregulated in the brain, it is possible that 
T cells are recruited to the brain following multiple LPS challenges. This is 
supported by the observation that the chemokine receptor transcripts, Ccr1 and 
Cxcr3, were also upregulated in the brain. To test this hypothesis, flow 
cytometry was used to compare the proportions of CD3+ cell populations in the 
brains of LPS- and vehicle-challenged mice. CD11b+ cells were first excluded 
from CD45hi leukocytes (Figure 5.9A). Within the CD11b-/int faction were two 
distinct populations of CD3+ leukocytes, CD8+ T cells and CD8- T cells. 
Quantification of these two populations revealed no differences in the 
percentage of either population in the brains of LPS-treated mice compared to 
vehicle-treated controls on day 2 or on day 5. However, by day 7, the 
proportions of both CD8+ and CD8- T cell populations were significantly enriched 
in the brains of the LPS-treated animals (Figure 5.9B-D). 
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Figure 5.9 Characterisation and quantification of CD3+ leukocyte populations in the brains 
of LPS-challenged mice 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. Single cell suspensions 
were generated from whole brain tissue at days 2, 5 and 7 following initial LPS- or vehicle-injection. 
(A) Gating strategy. CD45hi leukocytes were gated as described previously. CD11b+ cells were 
then excluded by gating on CD11b-/int cells. (B) Representative contour plots of CD11b-/int cells from 
each group. (C&D) Percentages of (C) CD3+ CD8+ leukocytes and (D) CD3+ CD8- leukocytes in the 
brain at each time point following injection. Data represent the mean +/- SEM. Significance of was 
calculated for using a two way ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 3/group. 
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The percentages of CD3+ T cell populations were also assessed in matched blood 
samples. CD11b+ cells were excluded from CD45+ leukocytes. Again there were 
two distinct populations of CD3+ T cells within the CD11b-/int faction. At all time 
points analysed, there was a highly significant reduction in the percentages of 
both CD8+ and CD8- T cells present in the blood of LPS-treated mice (Figure 
5.10). 
Taken together, these data suggest that chronic exposure to LPS in the periphery 
triggers a substantial increase in the percentage of CD11b+ leukocytes in the 
peripheral blood and a concurrent decrease in the percentage of CD3+ T cells. At 
day 2, following 2 systemic LPS injections, this was coupled with an increase in 
the percentage of both CD11bhi granulocyte-like cells and CD11b+ monocyte-like 
cells in the brain. Unlike the sustained increase in CD11b+ leukocytes that was 
observed in the blood, the elevated proportion of CD11bhi granulocyte-like cells 
in the brain was transient, returning to baseline by day 5. The apparent 
infiltration of CD11b+ leukocytes to the brain was followed by an accumulation 
of both CD8+ and CD8- T cells. 
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Figure 5.10 Characterisation and quantification of CD3+ leukocyte populations in the 
peripheral blood of LPS-challenged mice 
Mice were injected daily with 50µg LPS or an equivalent volume of vehicle. Leukocytes were 
isolated from whole blood at days 2, 5 and 7 following initial LPS- or vehicle-injection. (A) Gating 
strategy. CD45hi leukocytes were gated as described previously. CD11b+ cells were then excluded 
by gating on CD11b-/int cells. (B) Representative contour plots of CD11b-/int cells from each group. 
(C&D) Percentages of (C) CD3+ CD8+ leukocytes and (D) CD3+ CD8- leukocytes in the blood at 
each time point following injection. Data represent the mean +/- SEM. Significance of was 
calculated using a two way ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 3/group. 
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5.4 Identification of infiltrating leukocyte populations in 
the brain using histology 
Although the flow cytometry dataset suggests that CD11b+ and CD3+ leukocyte 
populations may accumulate in the brain when mice are repeatedly challenged 
with LPS in the periphery, it does not indicate where in the brain these 
leukocytes are located. Furthermore, the experiment is limited as the absolute 
numbers of cells in the brain, and the blood, were not quantified due to 
technical constraints. Also, it is possible that the data may be skewed by 
peripheral blood contamination or by the marginalisation of leukocytes to the 
inflamed vasculature. To explore this further, mice were injected with a single 
dose of LPS daily for 2, 5 or 7 consecutive days. Brains were removed from the 
mice 24 hours after their final injection. With the aim of expanding on the data 
derived using flow cytometry, brain tissue was sectioned and stained for markers 
associated with relevant cell populations by immunohistochemistry. Stained 
tissue from the brains of LPS-challenged mice was compared to that of an 
untreated control group (day 0). 
5.4.1 Neutrophil accumulation in the brain 
Based on their size, granularity and high surface expression of CD11b, the 
CD11bhi granulocyte-like cells that were detected in the brains of LPS-treated 
mice at day 2 of the time course are likely to neutrophils. To confirm this 
hypothesis, brain tissue from LPS-challenged mice was stained for the presence 
of the neutrophil granular enzyme myeloperoxidase (MPO). In all LPS challenged 
mice, neutrophils were distributed throughout the brain parenchyma and were 
detectable in the meninges (Figure 5.11A&B). However, the dissemination of 
these cells throughout the brain was sparse by days 5 and 7. On days 2 and 5, 
neutrophils could occasionally be associated with blood vessels (Figure 5.11C). 
This was no longer observed by day 7.  
The absolute cell counts present in whole sections from equivalent brain regions 
were used to quantify the infiltrating neutrophils. Consistent with the flow 
cytometry data, on day 2 there was a significant increase in neutrophil numbers 
within the brains of LPS-challenged mice (Figure 5.12). This was predominantly 
due to the increased numbers of neutrophils infiltrating the parenchyma. 
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Although neutrophils were detected in the brain at the other time points 
following LPS treatment, their increase in numbers was not significant.  
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Figure 5.11 Accumulation of neutrophils in the brain over time 
Mice were injected daily with 50µg LPS. Brain tissue was taken from mice at day 0 (naïve), 2, 5 or 
7 following injection. Tissue was formalin-fixed, embedded in paraffin and cut into 5µm sections 
before being analysed by immunohistochemistry. (A-C) Examples of anti-myeloperoxidase staining 
within (A) the meninges, (B) the parenchyma and (C) blood vessels at each time point. n=3/group. 
221 
Da
y 0
Da
y 2
Da
y 5
Da
y 7
0
200
400
600
800
Meninges
Parenchyma
Blood vessels
Total brain
**
***
C
el
l c
ou
nt
s 
/ s
ec
tio
n
 
Figure 5.12 Relative neutrophil numbers in the brains of LPS-treated mice compared to 
naïve control mice 
Mice were injected daily with 50µg LPS. Brain tissue, taken from mice at day 0, 2, 5 or 7 following 
injection, was formalin-fixed, embedded in paraffin and cut into 5µm sections before being 
analysed by immunohistochemistry. MPO+ cells (Figure 5.11) in the meninges, the parenchyma 
and adhered to blood vessels were quantified. Cells were quantified by counting every MPO+ 
neutrophil in 3 coronal sections from equivalent brain regions of each sample. Cell counts 
represent the mean number of cells per section in each sample. Data are displayed as the mean 
cell count +/- SEM. Significance of was calculated using a two way ANOVA: **P ≤ 0.01, ***P ≤ 
0.001. n = 3/group. 
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5.4.2 CD3+ leukocyte accumulation in the brain 
To confirm that T cells did indeed accumulate in the brain and to establish 
where these cells were localised, brain sections from LPS-treated and control 
mice were stained for T cell surface antigen, CD3. In all LPS-challenged and 
naïve mice, CD3+ cells could be detected in the meninges and in the parenchyma 
(Figure 5.13A&B and Figure 5.14). However, these cells were infrequent in naïve 
mice and in LPS-challenged mice at day 2. By days 5 and 7, there was a 
significant increase in the number of CD3+ cells in the parenchyma of LPS-
challenged mice (Figure 5.13B and Figure 5.14). These cells were distributed 
throughout the parenchyma and were not specifically associated with distinct 
brain regions (data not shown). Despite their accumulation in the parenchyma, 
the numbers of CD3+ cells associated with either the blood vessels or the 
meninges remained statistically comparable to naïve mice throughout the model 
(Figure 5.13 and Figure 5.14).  
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Figure 5.13 Accumulation of T cells in the brain over time 
Mice were injected daily with 50µg LPS. Brain tissue, taken from mice at day 0, 2, 5 or 7 following 
injection, was formalin-fixed, embedded in paraffin and cut into 5µm sections before being 
analysed by immunohistochemistry. (A-C) Examples of anti-CD3 staining within (A) the meninges, 
(B) the parenchyma and (C) blood vessels at each time point. n=3/group. 
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Figure 5.14 Relative T cell numbers in the brains of LPS-treated mice compared to naïve 
control mice 
Mice were injected daily with 50µg LPS. Brain tissue, taken from mice at day 0, 2, 5 or 7 following 
injection, was formalin-fixed, embedded in paraffin and cut into 5µm sections before being 
analysed by immunohistochemistry. CD3+ cells (Figure 5.13) in the meninges, the parenchyma and 
adhered to blood vessels were quantified. Cells were quantified by counting every CD3+ cell in 3 
coronal sections from equivalent brain regions of each sample. Cell counts represent the mean 
number of cells per section in each sample. Data are displayed as the mean cell count +/- SEM. 
Significance of was calculated using a two way ANOVA: **P ≤ 0.01, ***P ≤ 0.001. n = 3/group. 
 
5.4.3 Monocyte accumulation in the brain 
As there was a significant increase in the percentage of CD11b+ monocyte-like 
cells in the brains, brain sections were stained with a MAC387 antibody, specific 
to the macrophage marker calprotectin. No positive staining was detectable in 
the control mice or the LPS-treated mice at either day 2 or day 5. By day 7, 
MAC387+ monocytes were occasionally detected within the cerebral vasculature 
of LPS-treated mice (Figure 5.15A). However, the majority of the positive 
staining was located throughout the parenchyma, particularly in the piriform 
cortex and the thalamus (Figure 5.15C&D). With obvious cytoplasmic 
projections, the MAC387+ cells in the parenchyma morphologically resembled 
macrophages. However, MAC387 can also bind to microglial cells. Due to the lack 
of evidence of monocyte/macrophage infiltration, i.e. perivascular cuffs or 
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clusters of positive cells situated in close proximity to the meninges, it was 
impossible to determine whether monocytes had indeed infiltrated the brain and 
differentiated into macrophages or whether microglial cells had upregulated 
calprotectin in response to systemic LPS. As a result, the MAC387+ cells were not 
quantified. 
In summary, histological characterisation of the leukocyte infiltrate in the brains 
of LPS-challenged mice revealed that by day 2, following two systemic LPS 
injections, neutrophils had accumulated within the brain. This infiltration was 
transient and had returned to a level statistically comparable to that of naïve 
mice by day 5. Consistent with the flow cytometry data, the accumulation of 
neutrophils was followed by the recruitment of CD3+ T cells. However, in this 
experiment T cells entered the brain between days 2 and 5 rather than between 
days 5 and 7. These cells invaded the parenchyma of LPS-challenged mice where 
they remained until at least day 7. Importantly, these data confirm that the 
increased proportions of T cells, and CD11b+ granulocyte-like cells, which were 
detected in the brains of LPS treated mice using flow cytometry, represent a 
genuine increase in absolute cell numbers in the brain. Although there was some 
evidence to suggest that monocytes may also infiltrate the brain and 
differentiate into MAC387+ macrophages between days 5 and 7, this could not 
fully be verified by histology. 
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Figure 5.15 Detection of monocytes/macrophages in the brain over time 
Mice were injected daily with 50µg LPS. Brain tissue was taken from mice at day 0, 2, 5 or 7 
following injection. Tissue was formalin-fixed, embedded in paraffin and cut into 5µm sections 
before being analysed by immunohistochemistry. (A) Examples of anti-calprotectin (MAC387) 
staining on monocytes within blood vessels at day 7 of the LPS model. (B) Examples of isotype 
staining in the piriform cortex (Pir) and the thalamus at day 7 of the LPS model. (C&D) Examples of 
MAC387 staining within (C) the Pir and (D) the thalamus at each time point. n=3/group. 
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5.5 Discussion and conclusions 
In this chapter, a combination of gene expression assays was used to determine 
whether chemokine and/or chemokine receptor transcripts were elevated in the 
brain following chronic exposure to LPS in the periphery. Mice received a single 
I.P. injection of a high dose of LPS, or an equivalent volume of vehicle, daily for 
2, 5 or 7 consecutive days. Many of the chemokine transcripts assayed were 
significantly upregulated in the brains of the LPS challenged mice at day 2, 
following 2 doses of systemic LPS. Although a number remained upregulated 
until at least day 5 of the model, the majority of the chemokine transcripts had 
returned to baseline by this time point. It was previously demonstrated in 
Section 4.3.2 that, as a result of endotoxin tolerance, daily I.P. injections of LPS 
suppressed inflammatory cytokine production in the periphery but not in the 
brain. Interestingly, inflammatory chemokine induction was also brain-specific, 
i.e. was not mirrored by a similar increase by PBL. This is in keeping with a 
previous report by Erickson et al. which demonstrated that protein levels of 
CCL2, CCL3, CCL5 and CXCL1 were significantly increased in the brain, but not 
the serum, of mice following repeated I.P. injections of LPS238. However, the LPS 
model used by Erickson et al. differed somewhat from the model used to 
conduct these studies as, instead of daily LPS challenges, mice received several 
LPS injections within a 24 hour period.  
Amongst the panel of chemokine genes that were highly upregulated in the brain 
following multiple LPS challenges were those encoding the neutrophil 
chemoattractants, CXCL1 and CXCL2. It has previously been demonstrated that, 
following a single I.P injection of LPS, the main source of these chemokines are 
activated endothelial cells443. However, as both chemokines can be expressed by 
reactive astrocytes in models of CNS injury or demyelination444-446, this cell 
population may also express CXCL1 and CXCL2 in response to the prolonged CNS 
inflammation that occurs following multiple injections of LPS. Interestingly, at 
day 2 of the LPS model, the gene encoding CXCR2, the sole receptor for these 
two chemokine ligands, also appeared to be upregulated in the brain. As the 
most characterised function of these chemokines is to recruit CXCR2-expressing 
leukocytes to sites of inflammation, it was hypothesised that the increase in 
Cxcr2 mRNA may have occurred as a result of leukocyte accumulation in the 
brain.  
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In mice, CXCR2 is most prominantly expressed by neutrophils. As a result it has 
previously been used as a surrogate marker to indicate their presence in the 
brain447. However, as it is also expressed in the CNS of both humans and rodents, 
an increase in Cxcr2 mRNA is insufficient to fully determine whether neutrophils 
infiltrate the brains of LPS challenged mice. Flow cytometric analysis of brain 
tissue revealed that the percentage of CD11bhi granulocyte-like cells was 
increased in the brains of LPS-challenged mice at day 2 of the model. Although 
this cell population phenotypically resembled neutrophils, due to the lack of 
surface markers stained, these cells were impossible to fully characterise from 
this experiment alone. However, it was subsequently demonstrated using 
histology that by day 2 of the LPS model, MPO+ neutrophils had invaded the brain 
parenchyma. Surprisingly, the neutrophils did not appear to be localised within 
perivascular cuffs, nor were they significantly enriched in the meninges. It is 
therefore unclear whether they had entered the brain via the BBB or the BCSFB.  
There was occasionally evidence of neutrophils both within and surrounding the 
same blood vessel. Therefore, it seems likely that at least some of the 
neutrophils crossed the BBB and the glia limitans. Histological analysis of brain 
sections at earlier time points would be required in order to establish the 
precise time point these cells entered the brain and their route of entry. Thus by 
day 2 of the LPS model, not only was the induction of Cxcl1 and Cxcl2 in the 
brain accompanied by a transient elevation in Cxcr2 mRNA, but it coincided with 
a transient increase in neutrophil numbers within the brain.  
Although it was difficult to distinguish between CD11+ granulocyte-like cells and 
CD11b+ macrophage-like cells in the blood, the proportion of CD11b+ leukocytes 
present in the circulation of LPS-treated mice was increased throughout the 
model. This is unsurprising as granulocytes and monocytes are rapidly deployed 
from the bone marrow in response to bacterial infection or endotoxin 
administration448-450. Despite an impaired inflammatory cytokine response in the 
periphery, there is one report to suggest that endotoxin-induced granulocyte 
mobilisation from the bone marrow occurs to a similar extent in naïve and 
endotoxin-tolerant mice451. To my knowledge there are no published data 
regarding monocyte mobilisation under these circumstances. Interestingly, the 
transcriptional chemokine receptor transcript data would suggest that, in this 
model, neutrophil numbers are unlikely to be increased to a great extent in the 
229 
peripheral blood, as the levels of Cxcr2 mRNA extracted from PBL remains 
comparable to baseline throughout the time course. It is possible that the 
increased proportion of CD11b+ cells in the blood is predominantly due to an 
elevation in circulating monocyte numbers. A more comprehensive flow 
cytometry staining panel would be required in order to confirm this. In addition, 
as CCR2 signalling is pivotal in triggering monocyte egress from the bone 
marrow, the levels of Ccr2 mRNA could be compared in PBL from LPS- and 
vehicle-treated mice. Thus, the elevated proportions of CD11b+ leukocyte 
populations detectable in the circulation are likely to be due to an increase in 
monocyte and/or granulocyte recruitment from the bone marrow.  
The chemokines CCL3 and CCL5 share the capacity to attract a number of 
different leukocyte populations to the brain. Both chemokines can activate the 
chemokine receptors CCR1 and CCR5. In addition, CCL5 can activate CCR3. The 
leukocyte populations that respond to these chemokines are diverse and include, 
monocytes/macrophages, T cells and NK cells93,95,452,453. As the genes encoding a 
number of other monocyte-associated chemoattractants, namely Ccl2, Ccl7 and 
Ccl8, were significantly upregulated in the brain on day 2 of the LPS model, it 
was hypothesised that this might result in monocyte infiltration. At the same 
time point, there was a significant increase in both Ccr1 mRNA and CD11b+ 
monocyte-like cells in the brain. Although this could be indicative of an influx of 
monocytes, there was no MAC387 staining visible in the brain until day 7.  
An alternative explanation that would also account for the increase in CD11b+ 
leukocytes and Ccr1 mRNA in the brain is a potential infiltration of NK cells at 
day 2 of the LPS model. This would also explain why there was an increase in 
Cxcr3 mRNA in the absence of T cell infiltration at this time point. Attempts 
were made to stain brain sections for NK cells using antibodies specific to NK cell 
marker CD49b (data not shown). Unfortunately, the antibodies reacted non-
specifically to a population of non-haematopoietic cells in the brain and 
therefore could not be used to identify NK cells. Thus, although it is possible 
that NK cells enter the brains of mice following prolonged exposure to LPS in the 
periphery, more work would be required in order to investigate this hypothesis. 
This could be done using either flow cytometry or histology. 
230 
By day 5 of the LPS model, neutrophils were no longer detectable in the brain. 
However, there was a significant increase in the number of CD3+ T cells in the 
brain parenchyma that was detectable only by histology. As there was no 
evidence of T cells within perivascular cuffs or specifically surrounding the 
meninges, their route of entry could not be established. Like neutrophils, T cells 
could be observed within and surrounding the same blood vessels which suggests 
that the BBB was one likely route of entry. It is possible that the T cells entered 
the brain after day 2, giving them time to become fully dispersed throughout the 
parenchyma by day 5. Again, histological examination of brain sections taken at 
different time points between days 2 and 5 would be required to confirm this. By 
day 7, both flow cytometric and histological analysis of brain tissue collectively 
revealed a significant increase in the frequency and absolute numbers of T cells 
in the brain. The majority of infiltrating T cells at this time point expressed CD8. 
However, CD8- T cells, most likely CD4+, were also significantly enriched in the 
brains of LPS-challenged mice on day 7.  
Both CD8+ T cells and CD4+ Th1 cells characteristically express the chemokine 
receptors CCR5 and CXCR3. Therefore, their entry to the brain may be mediated 
by the ligands for one or both of these receptors. In keeping with this 
hypothesis, the genes encoding CXCL9 and CXCL10, the ligands for CXCR3, were 
significantly upregulated in the brain at day 2. Furthermore, transcripts for the 
CCR5 ligands, CCL3 and CCL5, were upregulated until day 5. However, on days 5 
and 7, when T cells were detectable in the brain, there was only a small, but 
significant, increase in Cxcr3 mRNA and slight trend towards an increase in Ccr5 
mRNA. Neither increase was as high as would be expected if the infiltrating T 
cells expressed mRNA for these chemokine receptors. Having said this, CCR5 and 
CXCR3 are both expressed by neurons and glial cells454-457. As the transcriptional 
data have been derived from whole brain homogenate, any differential gene 
expression of Cxcr3 and/or Ccr5 by brain-resident cell populations would bias 
these results. Therefore, although T cells accumulate in the brain following 
multiple systemic LPS injections, it is difficult to define what chemokine 
systems, if any, are responsible for their entry. 
Unlike CD11b+ leukocyte populations, proportions of both CD8+ and CD8- T cells 
were decreased in the blood throughout the LPS model. Rather than a genuine 
decrease in circulating T cell numbers, this is most likely to be a knock-on effect 
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of the increased proportion of CD11b+ leukocytes. Unfortunately the absolute 
cell numbers in the blood were not established. Therefore, if the increased 
proportion of T cells detected in the brain at day 7 was mirrored by a similar 
increase in the peripheral blood, this effect was masked by changes in the 
proportions of other populations of leukocytes. 
At day 7, in addition to CD3+ T cells, MAC387+ cells were detectable in the brain 
parenchyma, particularly in the thalamus and the piriform cortex. As this marker 
can also bind microglia, it was not possible to fully establish whether the 
positive staining represented an influx of monocytes/macrophages to the brain, 
or the induced or upregulated expression of calprotectin by microglial cells in 
response to chronic LPS administration in the periphery. MAC387+ cells could be 
detected within blood vessels; therefore it is likely that at least some of the 
positive staining is attributable to monocyte/macrophage accumulation in the 
brain. Furthermore, although the upregulation of calprotectin by microglia has 
been reported previously in Schizophrenic patients458, to my knowledge it has 
never been reported in response to LPS. These observations indicate that 
monocytes may infiltrate the brain from the periphery in response to prolonged 
exposure to systemic LPS. However, a more detailed histological examination of 
the tissue, with additional macrophage markers, would be required to confirm 
this. 
Taken together, the observations made from this chapter suggest that chronic 
exposure to LPS in the periphery results in the chemokine-mediated recruitment 
of leukocytes to the brain parenchyma. Infiltrating leukocytes include 
neutrophils, T cells and possibly monocytes/macrophages. As described in 
Section 1.3.1.3, neutrophil recruitment to the brain following systemic LPS 
challenge has been previously described236,237. However, to my knowledge, this is 
the first time they have been shown to infiltrate the brain in the context of 
endotoxin tolerance. Furthermore, to my knowledge, this is the first time that 
an accumulation of T cells has been shown in the brains of mice challenged 
systemically with LPS.  
Although intriguing, the data described in this chapter are limited and require 
follow-up studies or repetition. The transcriptional data could be strengthened 
by analysing chemokine and chemokine receptor protein levels. 
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Immunofluorescence staining could be used to determine where in the brain 
these chemokines were expressed and by what cell types. This method could 
also be used to establish whether the relevant chemokine receptors were 
predominantly expressed by infiltrating leukocytes or brain resident cell 
populations. However, as antibodies to chemokines and chemokine receptors are 
often poor, this can prove challenging. In addition, although there was increased 
transcription of numerous chemokine genes in the brain coupled with, or 
followed by, an influx of leukocyte populations, the involvement of chemokines 
in coordinating leukocyte recruitment to the brain under these circumstances 
remains unconfirmed. Follow up studies investigating leukocyte recruitment to 
the brain following treatment with specific chemokine receptor antagonists 
could be used to confirm this.  
At day 5 of the time course, T cells could be detected in the brain by 
immunohistochemical CD3 staining but not by flow cytometry. The reason for 
this discrepancy is unclear. It is possible that T cells begin to infiltrate the brain 
on or around day 5. Although carried out in the same manner, the LPS models 
used for the flow cytometry experiment and the histology staining were 
independent experiments; set up at different times using different litters of 
C57BL6 mice. Therefore a slight variation in the exact time point that T cells 
entered the brain could explain the different results. The flow cytometry data 
described in this chapter have all been derived from a single experiment. To 
gain a better understanding of why T cells were not observed in the brain at day 
5 using flow cytometry, this experiment would have to be repeated.  
Another observation that will require further investigation was the increased 
frequency of microglial cells within the brains of vehicle-treated control mice on 
day 2 of the LPS time course. It is highly unlikely that this reflects a genuine 
decrease in microglial numbers in response to systemic LPS at this time point. 
Not only has nothing similar ever been reported in the literature, but at both of 
the later time points the percentages of microglial cells were similar in LPS- and 
vehicle-treated mice. This suggests that the numbers of microglial cells in the 
brain do not vary. Furthermore, microglial percentages at days 5 and 7, in both 
LPS-treated and control animals were comparable to that of LPS-injected mice 
on day 2. This implies that the increased frequency of microglial cells observed 
in the brains of vehicle-injected control mice at day 2 of the LPS model was 
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most likely to be an anomaly. It is possible that during the preparation of the 
brain tissue for flow cytometry there was reduction in microglial cell death in 
the control brains but there is no obvious reason why this would have happened. 
To fully establish whether the observed differences in microglial cell 
percentages reflected a true phenotype or just an anomaly, the flow cytometry 
experiment would again have to be repeated. 
In summary, repeated injections of LPS in the periphery triggers a transient 
increase in chemokine transcription in the brain. Chemokine induction was 
brain-specific and not mirrored by a similar increase in the peripheral blood. In 
addition, the increased chemokine expression was accompanied with an 
infiltration of neutrophils, followed by the recruitment of T cells and possibly 
monocytes to the brain. Not only did these leukocytes cross either the BBB or 
the BSCB, but they surpassed the glia limitans to become fully dispersed 
throughout the brain parenchyma. Leukocyte infiltration was coupled with an 
increase in mRNA encoding the relative chemokine receptors. Although this 
cannot be fully verified from these data alone, the results outlined in this 
chapter strongly suggest that chronic exposure to LPS in the periphery triggers a 
chemokine-mediated recruitment of inflammatory leukocytes to the brain 
parenchyma. 
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6 Defining the chemokine receptor profile of CNS-
derived pathogenic leukocytes 
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6.1 Introduction and aims 
Having highlighted some of the potential chemokine systems involved in 
facilitating leukocyte entry into the brain following repeated LPS injections, I 
then sought to compare these data to a clinically relevant inflammatory disease. 
MS is a chronic, inflammatory autoimmune disease of the CNS. It is characterised 
by an accumulation of autoreactive and inflammatory leukocytes which form 
demyelinating lesions within the CNS parenchyma. The axonal degeneration that 
ensues can lead to neurological defects such as ataxia, paralysis, loss of vision 
and loss of cognitive function459. Although MS is not a peripheral inflammatory 
disorder, it is a chronic inflammatory disease in which the peripheral immune 
system and the CNS are both intrinsically involved. In addition, routine diagnosis 
of MS involves sampling a patient’s CSF, enabling relatively easy access to a 
population of leukocytes that have crossed the BCSFB.  
Chemokines play a pivotal role in MS. Not only are they associated with the 
trafficking of inflammatory leukocytes to and within the CNS, but they also play 
a role in the migration of regulatory lymphocytes to the CNS and in glial cell 
communication and activation210,228,460-462. Due to their intimate involvement in 
MS pathogenesis, chemokines have been implicated as potential targets for 
therapeutic intervention. As a result, many studies have attempted to analyse 
and interpret the involvement of chemokine systems, i.e. specific 
chemokine/chemokine receptor interactions, in MS pathology. This research has 
been described in more detail in Section 1.3.1.2. Much of our current 
understanding regarding the potentially pathogenic role that specific chemokine 
systems play in MS is derived from studies using genetically manipulated animal 
models. However, knowledge gained from these models does not always 
translate across species. For that reason, more research is required to fully 
characterise the role of chemokine receptors and their respective ligands in 
driving MS pathology. 
In order to establish the specific chemokine systems involved in facilitating 
leukocyte entry to human CNS, CSF and blood samples were to be collected from 
MS patients and a group of patients who were subjected to a lumbar puncture 
but ultimately deemed medically healthy. Patients with MS typically experience 
a massive leukocyte infiltrate across the BCSFB153,156,460. As a result, 1ml of CSF 
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could contain tens of thousands of leukocytes. In contrast, CSF from apparently 
healthy patients, such as those to be used as a control group for this study, 
contains on average 1x103 leukocytes per ml. The aim of this study was 2-fold:  
(1) Due to the limited number of cells that are present in control patient CSF, it 
was necessary to develop a protocol that would generate a sufficient quantity of 
RNA for the relevant downstream gene analyses. 
(2) To use a combination of multiplex gene expression analysis and protein 
assays to systematically characterise the chemokine systems involved in 
governing leukocyte entry to the CNS during MS.  
RNA was to be extracted from CSF-derived leukocytes. By amplifying this RNA 
using IVT, it would be possible to use multiplex gene expression assays such as 
TLDA plates to determine the differential chemokine receptor profile of CSF-
derived leukocytes from MS patients, when compared to that of leukocytes from 
apparently healthy CSF. Additionally, this would allow the expression levels of 
chemokine receptors by CSF- and peripheral blood-derived leukocytes from 
matched patient samples to be examined comparatively. Chemokine levels in 
the residual sera and CSF could then be measured using Luminex® technology, 
identifying any aberrant expression of chemokines in the CSF that may trigger 
the infiltration of inflammatory leukocytes. Thus, providing that a protocol for 
amplifying RNA from low cell numbers could be established, multiplex gene 
expression analysis and protein assays could be employed to characterise the 
specific chemokine systems involved in allowing leukocytes to cross the BCSFB 
during MS. 
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6.2 Optimising RNA extraction and cDNA synthesis 
protocols 
Prior to collection of precious samples, it was necessary to determine whether 
sufficient levels of RNA could be extracted from 1x103 leukocytes; the average 
number expected in control CSF samples. As RNA extraction from such small 
numbers of cells can prove challenging, different RNA extraction methods were 
compared to determine which would generate the greatest yield. In anticipation 
of a low yield of RNA from 103 leukocytes, even after amplification, the 
efficiency of two highly sensitive RT kits was also compared.  
6.2.1 RNA extraction optimisation 
To determine the most effective RNA extraction protocol, RNA was extracted 
from 1x103, 1x104, 1x105 and 5x105 peripheral blood mononuclear cells (PBMCs) 
using different methods. The efficiency of Qiagen columns and Trizol reagent 
were compared, both with, and without, carrier RNA (cRNA). cRNA, derived from 
E. coli transfer RNA was used in an attempt to improve yield by physically 
buffering extracted RNA. A disadvantage of this method is that the extracted 
RNA yield can not be accurately measured using either the nanodrop or the 
Agilent 2100 Bioanalyzer. Additionally, carrier RNA can sometimes interfere with 
downstream reactions. As it is compatible with both protocols, DNase I digestion 
was performed using a DNA-freeTM kit. To test the efficiency of the two 
extraction methods, all of the extracted RNA was converted to cDNA and the 
relative transcript levels of housekeeping gene Gapdh were used as a method of 
comparison following either PCR (Figure 6.1A) or QPCR (Figure 6.1B). As all 
PBMCs originated from the same source, any differences in housekeeping gene 
expression would be due to differences in cDNA level; thus relatively quantifying 
RNA yield. Regardless of the extraction method, enough RNA was extracted from 
103 PBMCs to generate a Gapdh signal when amplified by either PCR or QPCR. 
Both the PCR and QPCR results indicate that Qiagen RNeasy Micro kits are more 
effective than Trizol reagent at extracting RNA from low cell numbers. 
Therefore, subsequent RNA extractions directly from cells were all carried out 
using Qiagen RNeasy columns. cRNA significantly enhanced the yield of RNA 
extracted from 1x104 and 5x105 PBMCs (Figure 6.1B), however, the beneficial 
effect of cRNA seemed variable as it did not improve RNA yield when extracting 
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from either 1x103 or 1x105 PBMCs. In fact, although not deemed significant, its 
use appeared to have a detrimental effect when RNA was extracted from 1x103 
PBMCs. As this was the expected average cell number of control CSF samples, 
the use of E. coli total RNA as a carrier was discontinued. 
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Figure 6.1 Comparison of different methods of RNA extraction 
Relative Gapdh expression. (A) PCR of Gapdh visualized on a 2% agarose gel. cDNA was 
synthesized from RNA extracted from 1x103, 1x104, 1x105 and 5x105 PBMCs using (i) Qiagen kits 
or (ii) Trizol reagent in the presence (+) or absence (-) of E. coli cRNA. (B) Relative Gapdh 
expression was determined using QPCR. cDNA was synthesized from RNA extracted from (i) 
1x103, (ii) 1x104, (iii) 1x105 and (iv) 5x105 PBMCs. Relative transcript expression (RTE) was 
calculated by the equations: RTE = 2χ, where X = CTbaseline - CTmedian. Data represent data +/- SEM. 
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Significance was determined using two-way ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n = 
3/group. 
6.2.1.1 Determining the integrity of RNA extracted from low cell numbers 
The Agilent 2100 Bioanalyzer was used to assess the quality of the RNA from 
1x103, 1x104 and 1x105 PBMCs that was extracted using the Qiagen columns in 
the absence of cRNA. Due to the low yield, RNA was assessed qualitatively using 
the RNA 6000 Pico chip. Each electropherogram below represents one of three 
biological replicates from each group. With 3 distinct peaks and low background, 
RNA extracted from 1x105 cells (Figure 6.2C) closely resembles the example of 
high quality RNA, previously shown in Figure 3.2A. RNA extracted from 1x104 
PBMCs, however, is of inferior quality (Figure 6.2B). Although the 2 peaks 
corresponding to ribosomal subunits 18S and 28S are clearly visible, there is a 
high level of background, indicating a moderate level of degradation. RNA 
extracted from 1x103 cells was undetectable by the Pico chip (Figure 6.2A). As 
the RNA 6000 Pico chip has a range of 50-5000pg/µl, it can be concluded that 
the level of RNA was present in the sample at a concentration of less than 
50pg/µl. These observations imply that, although RNA can be extracted from low 
cell numbers, a threshold may exist, below which RNA begins to lose its 
integrity. In this experiment, RNA began to lose integrity between 1x105 and 
1x104 PBMCs and despite it being of sufficient yield to generate a Gapdh signal 
using PCR, RNA extracted from 1x103 PBMCs was too low to be detected by the 
Bioanalyzer. 
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Figure 6.2 Integrity of RNA samples extracted from 1x103, 1x104 and 1x105 PBMCs 
RNA quality was determined using an Agilent 2100 Bioanalyzer on an RNA 6000 Pico chip. RNA 
was extracted from (A) 1x103, (B) 1x104 and (C) 1x105 PBMCs using Qiagen columns without 
cRNA. Data represent fluorescence intensity (fluorescence units [FU]) measured over time in 
seconds [s]. One representative sample has been shown from each group. n = 3/group. 
6.2.2 cDNA synthesis optimization 
It has been shown above, that extracting RNA from as little at 1x103 leukocytes, 
generates a very low (immeasurable) yield of RNA; detectable only after RT 
followed by PCR amplification. Even after IVT, the level of amplified RNA in 
each sample has the potential to be low. In anticipation of amplifying sufficient 
RNA for multiplex gene expression analysis, a suitably sensitive cDNA synthesis 
kit had to be found that would maximise the cDNA yield. The efficiency of two 
different RT kits was compared. Although the High Capacity RNA-to-cDNA kit is 
recommended for downstream QPCR-based applications, the SuperscriptTM III 
reverse transcription kit is advertised as being more sensitive, and specific, than 
the other RT kits on the market. To test this claim, RNA was extracted from 
1x103, 5x103 and 1x104 PBMCs and converted to cDNA using the two different 
kits. As in Section 6.2.1, the relative transcript levels of Gapdh were used as a 
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method of comparison following QPCR (Figure 6.3). Again, all PBMCs originated 
from the same source. The only variable was the cDNA synthesis kit used and 
therefore, any differences in Gapdh signal could only be due to differences in 
cDNA yield. It is clear from Figure 6.3 that the High Capacity kit is significantly 
more effective than the SuperScriptTM III kit (p<0.0001). cDNA, synthesised using 
this kit, was of a significantly greater yield than that synthesised using the 
SuperScriptTM III kit when using RNA extracted from 5x103 or 1x104 leukocytes as 
a template (Figure 6.3). In addition, there was a trend towards a higher yield 
when RNA from 1x103 leukocytes was converted to cDNA using the High Capacity 
kit. Conclusively, the High Capacity RNA-to-cDNA kit was more effective than 
the SuperScriptTM III RT kit at synthesising cDNA from low levels of RNA.  
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Figure 6.3 Comparison of High Capacity and SuperScriptTM III reverse transcription kits 
Relative Gapdh expression was determined using QPCR. RNA was extracted from 1x103, 5x103 
and 1x104 PBMCs and converted to cDNA using either the High Capacity RNA-to-cDNA kit (HC) or 
the SuperScriptTM III RT kit (SS III). Relative transcript expression (RTE) was calculated by the 
equations: RTE = 2χ where X = CTbaseline - CTmedian . Significance was determined using two-way 
ANOVA: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. n=3/group 
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6.3 Developing a protocol to amplify RNA from low cell 
numbers 
As mentioned, CSF samples, particularly those from control subjects, may 
contain as few as 1x103 leukocytes. To guarantee sufficient levels of cDNA for 
TLDA gene expression analysis, RNA isolated from each sample would first have 
to be subjected to linear amplification using the SuperScriptTM RNA amplification 
kit (Section 2.5.9) before being converted to cDNA. This method, which allows 
for a 1000-fold amplification of available RNA, is optimised to amplify RNA from 
a minimum starting quantity of 100ng. On the basis that each cell expresses 
approximately 50pg of RNA, even if the RNA extraction was 100% efficient, each 
control sample would only contain 50ng of RNA. As this is well below the 
minimum starting quantity defined by the manufacturers, the limitations of the 
RNA amplification kit were tested in order to determine whether RNA could 
successfully be amplified from as little as 1x103 leukocytes. In addition, the 
integrity of the amplified message RNA product (aRNA) was also determined. As 
an additional quality control, SYBR Green QPCR was then used to determine 
whether the transcriptional profile of aRNA accurately represented that of its 
template.  
6.3.1 Testing the efficiency of the RNA amplification kit using 
control HeLa cell RNA 
The SuperScriptTM RNA amplification kit is designed to consistently amplify mRNA 
by at least 1000-fold. As a preliminary quality control mechanism, RNA from 
HeLa cells (provided with the kit) was amplified and the resulting yield 
quantified using a nanodrop. Control amplifications were performed in 
triplicate. The aRNA yield from these IVT reactions is listed in Table 6.1. As 
described by the manufacturers, amplification of 500ng HeLa total RNA should 
generate a minimum of 35µg aRNA. However, in these IVT reactions, a mean of 
only 4.66µg aRNA was transcribed from the control RNA. Therefore, although the 
control HeLa RNA was successfully amplified, the kit appeared to be functioning 
at only a fraction of its suggested capacity.  
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Total RNA Expected 
Yield 
Observed Yield (individual replicates) Mean Yield SEM 
  Control 1 Control 2 Control 3   
500ng ≥35µg 3.03µg 4.61µg 6.34µg 4.66µg 0.96 
Table 6.1 Yield of control amplifications from HeLa RNA 
RNA was amplified from 500ng HeLa RNA as a control reaction in three independent experiments; 
control 1, control 2 and control 3. aRNA quantity was determined using a nanodrop. 
 
6.3.2 Testing the limitations of the IVT kit using different starting 
quantities of template RNA 
The SuperScriptTM RNA amplification kit is designed to amplify RNA from a 
starting quantity of no less than 100 ng. As determined in Section 6.2.1.1, RNA 
extracted from 1x103 leukocytes may contain less than 50 pg/µl. Eluted in 
approximately 12µl, the total yield of RNA extracted from 1x103 leukocytes is 
considerably lower than the starting quantity recommended by the kit. As a 
consequence, before attempting to amplify RNA from precious CSF samples, it 
first had to be determined whether the amplification kit could cope with such 
low levels of starting RNA. To test the limitations of the kit, RNA was extracted 
from PBMCs and serially diluted 2-fold to acquire triplicates of 100 ng, 50 ng, 25 
ng and 12.5 ng of total RNA. RNA amplification from these starting quantities 
yielded a mean of 4.22 µg, 2.34 µg, 1.22 µg and 0.48 µg aRNA respectively 
(Figure 6.4A). As TLDA plates require only 30 ng message RNA, 12.5 ng total RNA 
is an ample starting quantity to provide a sufficient aRNA yield post-
amplification. 
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Figure 6.4 Yield of aRNA from different starting quantities 
RNA was amplified from different starting quantities of template or from RNA extracted from 
different numbers of PBMCs. (A) Yield of aRNA genterated from different starting quantities of 
template RNA. (B) The quantity of RNA extracted from 1x103, 1x104 and 1x105 PBMCs prior to 
amplification. RNA extracted from 1x103 PBMCs was not detectable (ND). (C) Yield of aRNA 
generated from 1x103, 1x104 and 1x105 PBMCs. aRNA yield was quantified using a nanodrop 
whereas unamplified template RNA was quantified using the 2100 Bioanalyzer. Data represent 
mean plus or minus SEM. n = 3/group. 
6.3.3 Testing the limitations of the IVT kit using PBMCs 
Having established that the SuperScriptTM RNA amplification kit could 
successfully amplify RNA from almost one tenth of the minimum starting 
quantity defined by the manufacturers, the kit was then tested using RNA 
extracted from 1x103, 1x104 and 1x105 PBMCs. Extracting RNA from 1x104 and 
1x105 PBMCs yielded a mean of 1.7 ng and 21.7 ng of RNA respectively; as 
determined using an RNA Pico chip (Figure 6.4B). Again, RNA extracted from 
1x103 cells was below the detection limit of the Bioanalyzer. The concentration 
246 
of the amplified product was measured using a nanodrop. Amplification of RNA 
extracted from 1x103, 1x104 and 1x105 PBMCs generated a mean of 34 ng, 367 ng 
and 719 ng of aRNA respectively (Figure 6.4C). Therefore, although the template 
RNA derived from the cells was undetectable, it appears that sufficient RNA for 
TLDA analysis can be amplified from as few as 1x103 leukocytes. 
6.3.4 Determining the transcriptional fidelity of aRNA 
When using amplified RNA to study gene expression, it must accurately represent 
the RNA profile retrieved from the sample. If, for instance, the amplification 
process favours smaller transcripts, then the number of small transcripts, such 
as chemokines, may be disproportionately greater than that of larger 
transcripts, such as chemokine receptors. To determine whether there was any 
bias in the amplification process towards particular transcript lengths, aRNA was 
converted to cDNA using reverse transcriptase. Using cDNA from both amplified 
and unamplified RNA, QPCR was performed to amplify genes with a range of 
different transcript lengths. The CT value, i.e. the number of PCR cycles 
required for the copy number of each transcript to reach an automatically set 
threshold, was used to compare the transcriptional ratios of three genes: Ccl2 
(732bp), Gapdh (1875bp) and Tlr2 (3224bp). The CT value of housekeeping gene 
TBP was used to normalise the results. 
All gene transcripts amplified equally: the ratio between the CT values remaining 
the same regardless of the starting quantity of RNA (Figure 6.5B) or the starting 
number of cells (Figure 6.5D). Only marginal discrepancies were observed when 
comparing aRNA to its template. Tlr2 and Gapdh expression were increased 
slightly in comparison to TBP after amplification (Figure 6.5A&C). As these two 
transcripts are the longest of the target genes amplified, it can be assumed that 
the IVT kit does not favour the amplification of smaller transcripts. The order of 
expression of each transcript was unchanged after amplification indicating that 
amplified RNA exhibits an adequate representation of the gene profile expressed 
by a target cell population. Although amplification from 1x103 cells appeared to 
generate enough aRNA to perform TLDA gene expression analysis (Figure 6.4B), 
transcript levels of the target genes amplified by QPCR were weak to 
undetectable. For that reason the ratios between the target genes were not 
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included in Figure 6.5D. With the exception of RNA amplified from 1x103 cells, 
aRNA reasonably reflects the transcriptional profile of its template. 
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Figure 6.5 Comparison of the transcriptional profile of template RNA and aRNA 
RNA was amplified from different starting quantities and from different numbers of PBMCs. QPCR 
was performed to determine the expression ratio of three genes of different transcript lengths: Ccl2 
(732bp) (●), Gapdh (1875bp) (■) and Tlr2 (3224bp) (▲). The difference between the CT value of 
the target genes and the CT value of housekeeping gene, Tbp, was used as a method of 
comparison (-Δ CT). Comparisons were made between: (A) unamplified template RNA and the 
amplified product (aRNA) generated from 100 ng template, (B) aRNA amplified from 100 ng, 50 ng, 
25 ng and 12.5 ng of template RNA, (C) aRNA from 1x105 PBMCs and unamplified RNA from the 
same PBMC sample, and (D) aRNA amplified from 1x104 and 1x105 PBMCs. Data represents 
mean plus or minus SEM. n = 3 samples/group.  
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6.3.5 Determining the integrity of aRNA generated from different 
starting quantities of template RNA 
Having established that amplifying RNA, from as little as 12.5 ng starting RNA, 
produces enough aRNA output to be used for TLDA analysis; it had then to be 
determined whether the amplified product was of sufficient quality. RNA 
integrity was assessed, before and after amplification, using an Agilent 2100 
Bioanalyzer. The quality of the total RNA that was used as template is shown in 
Figure 6.6A. Although two distinct peaks mark ribosomal subunits 18S and 28S, 
there is a considerable level of background noise indicating partially degraded 
RNA. In spite of this, as will be discussed below, mRNA was amplified 
successfully from different starting quantities of template RNA. Figure 6.6B 
shows an example of high quality aRNA. The electrophoretic trace exhibits a 
broad arch, indicative of a range of sizes of RNA fragments. As only mRNA is 
amplified by IVT, no ribosomal peaks are visible. The most commonly occurring 
fragment length in the sample was 1007 nucleotides long; as determined by 
comparing the speed at which these fragments moved through the microchannel 
(37.26 s) to the standard curve generated from the RNA ladder.  
A representative electropherogram for each of the four groups of amplified RNA 
samples is shown in Figure 6.6. RNA amplified from 50 ng and 100 ng template 
RNA was of a sufficient concentration to be assessed using an RNA Nano chip. 
These were compared on the electropherograms to the RNA ladder (Figure 6.6). 
Considerably reduced in quantity than that of the high quality aRNA, the 
electrophoretic trace of these samples signifies a relatively lower quantity of 
aRNA; which is unsurprising given the low starting quantity. It is the lateral 
position of the peaks that signifies quality. Although the curves on the graphs 
are small, they are also broad, indicating a range of transcript lengths. This 
implies that the amplification was successful; generating aRNA of moderate 
quality. However, amplified RNA contained very few transcripts greater than 
2000bp. Peaking between 200 and 500 nucleotides, the average fragment length 
in RNA, amplified from 100ng, is below half that of the high quality aRNA; 
implying partial degradation. Likewise, aRNA from 50ng of template peaks at 
approximately 500 nucleotides. However, as there is no sharp peak to the left of 
these graphs, a characteristic of high level degradation, the aRNA can be 
considered of satisfactory quality. Too low in concentration to be detected by 
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the Nano chip, RNA amplified from 12.5 ng and 25 ng of template RNA was 
assessed using the RNA Pico chip and evaluated over time. RNA amplified from 
25 ng and 12.5 ng of starting template RNA, again generated a broad curve; 
similar in shape to that of the high quality aRNA (Figure 6.6C&D). However, the 
curves peaked at an earlier time point than the high quality aRNA (Figure 6.6B), 
again indicating a slight shift towards a smaller average transcript length. 
Whether assessed using the Nano chip or the Pico chip, aRNA samples contained 
noticeably less large transcripts than that of the high quality aRNA sample. This 
is a likely indication of partial RNA degradation. Imperfections in the quality of 
the amplified RNA may have arisen due to the poor quality of the starting RNA 
(Figure 6.6A). Taken together, these results show that RNA of a reasonable 
quality can be amplified from as little as 12.5 ng starting RNA, even when 
partially degraded RNA is used as template. 
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Figure 6.6 Integrity of RNA before and after amplification from different RNA starting 
quantities  
Using a SuperScriptTM RNA amplification kit, RNA was amplified from starting concentrations 100 
ng, 50 ng, 25 ng and 12.5 ng of total RNA. The integrity of template RNA and the amplified 
message (aRNA) was determined using an Agilent 2100 Bioanalyzer. Electropherograms display: 
(A) Template RNA, (B) High quality aRNA, peaking at 37.26 seconds [s] and 1007 nucleotides [nt], 
and RNA amplified from (C) 12.5 ng, (D) 25 ng, (E) 50 ng and (F) 100 ng of template RNA. Data 
represent fluorescence intensity (fluorescence units [FU]) measured over time in seconds [s]. (A-D) 
have been compared over time to an RNA marker containing transcripts of known sizes [nt]. (C-F) 
Data shown are one representative sample from each group. n = 3/group. 
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6.3.6 Determining the integrity of aRNA generated from  PBMCs 
Amplifying RNA from 1x103 PBMCs had apparently yielded enough aRNA to 
perform TLDA analysis. To determine why the amplified product did not 
generate sufficient aRNA for QPCR, the integrity of amplified and unamplified 
RNA was assessed; again using the Bioanalyzer. Similar to previous results (Figure 
6.2), RNA extracted from 1x103 leukocytes, was of too low a concentration to be 
detected using the RNA Pico chip (Figure 6.7A).  RNA extracted from 1x104 and 
1x105 PBMCs however, was of high quality (Figure 6.7B&C) suggesting that the 
extraction process itself was successful.  
In contrast to aRNA quantification using the nanodrop, which showed that 
amplifying RNA from 103 PBMCs yielded an average of 34 ng (Figure 6.4), it is 
clear from Figure 6.7A that this amplified product is barely detectable by the 
RNA Pico chip. Only a minute peak is visible on the electropherogram. This 
discrepancy may have arisen because the RNA in these samples is present at too 
low a concentration to be accurately quantified by nanodrop. In addition, the 
little RNA that was detectable in the amplified sample was of poor quality. The 
location of the only peak on the graph, directly adjacent to the RNA marker, is a 
clear indication of sample degradation. As no RNA was detectable in the 
template, it was unclear whether the degradation had occurred prior to, or 
during the amplification process. RNA degradation, in addition to a low starting 
yield preceding IVT, would explain why amplification from 1x103 PBMCs did not 
generate sufficient RNA for QPCR. 
Although clearly containing detectable levels, aRNA samples from 1x104 and 
1x105 PBMCs also appeared to be degraded (Figure 6.7B&C). Electropherograms 
are dominated by a sharp spike at around 27 seconds; implying an enrichment of 
small fragments in the aRNA samples. As there is no indication of the IVT process 
favouring smaller transcripts (Figure 6.5), this is most probably degraded RNA. 
Thus, although it would appear from the nanodrop data that amplifying RNA 
generates a sufficient yield to use for multiplex gene arrays, this RNA is 
degraded. 
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Figure 6.7 Integrity of RNA before and after amplification from different numbers of cells 
RNA was extracted from 1x103, 1x104 and 1x105 PBMCs and amplified using a SuperScriptTM RNA 
amplification kit. The integrity of RNA before and after amplification was determined using an 
Agilent 2100 Bioanalyzer. Electropherograms display: (A) RNA from 1x103 PBMCs (i) before and 
(ii) after amplification. (B) RNA from 1x104 PBMCs (i) before and (ii) after amplification.  (C) RNA 
from 1x105 PBMCs (i) before and (ii) after amplification.  Data represent fluorescence intensity 
(fluorescence units [FU]) measured over time in seconds [s]. Data shown are one representative 
sample from each group. n = 3/group. 
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6.4 Discussion and conclusions 
The initial aim of this study was to develop the most effective protocol for 
extracting RNA from low numbers of cells, amplifying it using IVT and converting 
the amplified product to cDNA. Entirely dependent on the development of this 
protocol, the second aim was to systematically define the chemokine systems 
involved in governing leukocyte infiltration of the CNS during MS. 
Preliminary experiments were set up to compare the efficiency of different 
methods of RNA extraction and different RT kits. Using relative Gapdh transcript 
level as a method of comparison, these experiments highlighted the optimum 
methods of extracting RNA from low cell numbers and of synthesizing cDNA from 
low amounts of template RNA. In addition, it was demonstrated that RNA could 
be extracted from as little as 1x103 leukocytes; the average number expected in 
control CSF samples. Although the yield of RNA was sufficient to generate a 
Gapdh signal using PCR, it was below the detection limit of the RNA Pico chip 
and thus unable to be quantified. As a result, it could not be determined 
whether RNA extraction from 1x103 leukocytes generated a great enough yield of 
template RNA for amplification by IVT. 
To validate the efficiency of the SuperScriptTM RNA Amplification System in the 
proposed study, experiments were set up to test the limitations of the kit. Prior 
to sample collection, the capacity of the kit to amplify RNA from 1x103 
leukocytes had to be demonstrated. RNA was amplified from different starting 
quantities of template RNA and from different starting quantities of leukocytes. 
Encouragingly, the results demonstrate that an adequate amount of aRNA can be 
generated from as little as 12.5 ng of template RNA. Not only was the quantity 
sufficient, but the transcriptional profile of the amplified product, assessed 
using QPCR, was shown to reasonably reflect that of the unamplified template 
RNA from which it was derived. However, a paucity of long transcripts in the 
amplified product suggests that the RNA may have been partially degraded 
during amplification. Another possibility is that the RNA polymerase failed to 
extend the full length of the longer transcripts during amplification. This could 
prove problematic if any of the probe sets used on the TLDA plates are located 
at the 5’ end of a long transcript. As there was no problem amplifying Gapdh, a 
housekeeping gene of comparable transcript length to a chemokine receptor, 
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using primers located in the 5’ region, there is no reason to suggest that 
transcripts of this length might be inaccurately represented. The most likely 
explanation for the lack of long transcripts is the use of partially degraded 
starting RNA. Thus, in this instance it appears that RNA amplification starting 
from only 12.5ng total RNA generates a great enough yield of reasonable quality 
RNA for TLDA gene expression assays. 
Although amplifying from different starting quantities of RNA generated aRNA of 
an adequate quality and quantity, RNA amplification from 1x103 leukocytes was 
not a success. Only a minute level of aRNA generated from 1x103 leukocytes was 
detectable using the Bioanalyzer. This RNA appeared to be degraded and no 
Gapdh, Tlr2 or Ccl2 signal was detectable following QPCR. In Section 6.2.1, it 
was shown that, without any requirement of IVT, QPCR could be successfully 
used to amplify Gapdh when RNA from 103 PBMCs was converted to cDNA. As a 
result, it would appear as if the amplification process deteriorates the quality of 
the RNA; rendering it useless when amplifying from such a low cell number. 
From these data, it is apparent that RNA extracted from 1x103 leukocytes, is 
below the threshold of what is required for amplification.  
A previous report by Baugh et al. demonstrated that RNA could be successfully 
amplified from as little as 2 ng of total RNA463. These aRNA products, however, 
did not perform as well in downstream applications as aRNA generated from over 
10ng of template. Similarly, it has been demonstrated above that RNA can 
successfully be amplified from as little as 1.7ng of template RNA; extracted from 
1x104 PBMCs. Not only was the amplification successful, but it yielded sufficient 
levels of aRNA for subsequent gene expression analysis. In addition, the 
transcription profile of the aRNA product was comparable to the template RNA 
from which it was derived. However, much of the amplified product appeared to 
be degraded and the use of partially degraded RNA for multiplex gene expression 
analysis is ill-advised. Consequently, either new technology or further 
optimisation of the IVT protocol would be required in order to accurately 
determine aberrant chemokine receptor expression in CSF-derived pathogenic 
leukocytes. 
As they have a profoundly higher leukocyte presence in their CSF, an alternative 
approach might be to derive as much information as possible using only MS 
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patient samples. The chemokine receptor profile of leukocytes from diseased 
CSF could simply be compared with that of peripheral blood leukocytes from 
matched patient samples. Although this would not precisely define the particular 
chemokine receptors that are involved in MS pathogenesis, it would highlight any 
receptors that are enriched in the CSF compared to the peripheral blood. As it 
would include the chemokine receptors that are associated with pathogenesis, 
this transcriptional comparison would be beneficial as it would provide a list of 
target receptors to which subsequent gene expression analyses could be 
tailored. However, it was decided that the degree of difficulty involved in 
acquiring the MS patient samples, combined with the expenditure of the 
proposed experiments, outweighed the potential benefits of obtaining this 
information. Thus this work was discontinued. 
A superior method of determining chemokine receptor expression in CSF-derived 
leukocytes might be to use Fluidigm® BioMarkTM dynamic array chips. This 
cutting edge technology uses a series of integrated microchannels to link up 48 
samples with 48 TaqMan® assays. This would allow the relative quantification of 
the expression of 48 genes from each sample. Results are reproducible from 
<100 cells. In addition, the chips negate the need to both extract RNA and 
amplify it using an IVT kit: both processes that could result in RNA degradation. 
Consequently, the relative expression of chemokine receptors by CSF- and 
peripheral blood-derived leukocytes could be examined comparatively using 
BioMarkTM dynamic array chips. Unfortunately, this technology was not available 
at the time of this study. 
The initial aim of this work was to optimise and validate the protocols required 
to extract and amplify RNA: ultimately generating sufficient levels of high-
quality cDNA for TLDA plates. Despite the limitations described by the 
manufacturers of the amplification kit, there have been some preliminary 
successes in amplifying RNA from low starting quantities. However, the amplified 
product often shows signs of degradation, particularly when RNA was amplified 
from low starting numbers of cells. This rendered the aRNA unfit for downstream 
TLDA assays and thus rendered the RNA amplification kit unsuitable for the 
proposed study. As a suitable protocol for amplifying RNA from 1x103 leukocytes 
was not established, the complete chemokine receptor profile of CSF- and 
peripheral blood-derived leukocytes could not be determined. Therefore, the 
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specific chemokine systems involved in governing leukocyte entry to the CSF 
remain to be defined. 
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7 General Discussion 
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7.1 Introduction 
There is now a growing body of evidence to suggest that inflammatory mediators 
can modulate mood and behaviour. Furthermore, prolonged exposure to these 
mediators may be involved in the manifestation of neuropsychiatric symptoms, 
such as depression, anxiety and fatigue. Despite the recent advances in our 
understanding of neuroimmune communication pathways, the molecular 
mechanisms behind these co-morbidities remain unclear. Thus the primary aim 
of this thesis was to establish a better understanding of the bidirectional 
relationship, and communication pathways, that exist between the immune 
system and the brain. 
In Chapter 3, the transmission of inflammatory signals from the periphery to the 
brain was initially investigated using a model of systemic LPS-induced 
inflammation, which is well known for its impact on behaviour. 48 hours after 
intraperitoneal injection, the transcriptional profile in the brains of LPS 
challenged mice was comprehensively interrogated using whole transcriptome 
microarrays. Expression of a number of genes was induced in the brain 48 hours 
following systemic LPS-challenge. A novel comparative approach was then taken 
to explore a potential molecular mechanism behind this induction. Specifically, 
in Chapter 4 of this thesis, the transcriptional modulation of the genes of 
interest was compared in the brain following different sterile, and TLR-
dependent, models of peripheral inflammation. To establish whether target 
genes were induced in the brain in response to elevated circulating 
inflammatory cytokines, gene induction was assessed following systemic TNFα-
induced inflammation. Supplementing the data derived from this study, a model 
of endotoxin tolerance was used to assess the ability of systemic LPS to 
modulate target gene expression in the brain, without the synergistic effects of 
circulating IL-1β, IL-6 or TNFα. Finally, a model of LTA-induced peripheral 
inflammation was used to determine whether activation of the MyD88-dependent 
signalling pathway was sufficient to modulate target gene expression in the 
brain. Therefore, by characterising, and comparing, the gene expression profiles 
in the brains of mice following a number of well-characterised models of 
peripheral inflammation, I have started to investigate the molecular mechanisms 
by which inflammation originating in the periphery can induce neurological 
transcriptional modulation. 
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Chemokine induction, and leukocyte recruitment, to the brain was also assessed 
following systemic LPS challenge. As it may better reflect physiological 
conditions, such as bacterial infection or septicaemia, these studies were 
exclusively performed using a model of endotoxin tolerance, in which mice were 
systemically injected with LPS daily. In Chapter 5 of this thesis, I have 
systematically characterised, for the first time, the transcriptional inflammatory 
chemokine profile in the brain following prolonged exposure to LPS in the 
periphery. In addition, the work in this chapter demonstrates that, in this model 
of endotoxin tolerance, systemic LPS challenge may remotely modulate the 
recruitment of leukocytes to the brain. 
7.2 Characterisation of the transcriptional profile in the 
brains of systemic LPS-challenged mice 
Current literature suggests that systemic LPS itself, and LPS-induced 
inflammatory cytokines, can activate the cerebral vasculature and TLR4-
expressing phagocytic cells resident in CVOs (Section 1.4.2.2). Beginning in the 
CVOs and regions surrounding the blood vessels, the choroid plexus and 
meninges, this triggers a wave of microglial activation that can spread 
throughout the parenchyma via the autocrine and paracrine effects of TNFα and 
IL-1β315,317,318. Not only might these cytokines activate IDO in the brain, which 
can modulate behaviour (Section 1.4.2.2), but IL-1β and inflammation-induced 
secondary messengers, such as PGE2, can stimulate the control circuitry of the 
HPA axis to activate the neuroendocrine system and induce a febrile response 
(Section 1.4.3.1). These central responses to systemic LPS-induced inflammation 
have been well characterised. Activation of the HPA axis is rapid and transient, 
peaking within 1-3 hours of systemic LPS injection464-466. Microglial activation, 
characterised by a robust increase in Cd14, Tlr2 and Il1b mRNA, is similarly 
rapid315,317,318 and evidence of activation in CVOs has been shown as early as 30 
minutes following I.P. injection315,318. Microglial activation in the parenchyma 
then peaks within 8-12 hours of injection and clusters of cells remain activated 
until 24 hours. In contrast, IDO activity in the brain occurs much later, with no 
significant differences in activity detected until 24 hours following systemic LPS 
challenge467. This delay may be due to the time it takes for cytokines to be 
transcribed and translated in the brain. To my knowledge there is currently no 
literature to suggest that any of these characterised central responses last 
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longer than 24 hours following injection. However it was demonstrated in 
Chapter 3 of this thesis, that 48 hours following an acute systemic LPS challenge, 
a number of immune/inflammatory genes were upregulated in the brain. The 
differential transcriptional profile in the brains of LPS-challenged mice was 
markedly enriched with ISGs. This induction appeared to be triggered rapidly 
following systemic LPS administration as a number of ISGs were upregulated in 
the brain by 6 hours post-injection. However, aside from the characterised 
effects described above, there is a paucity of literature describing the impact 
that systemic LPS-induced inflammation has on the brain. This makes it difficult 
to hypothesise what pathways may have been involved in triggering the 
induction of ISGs, and other target genes, in the brain following an acute 
systemic LPS challenge.  
Interestingly, it was demonstrated in Chapter 4 that the majority of microarray 
target genes were not upregulated in the brain following systemic TNFα-induced 
inflammation. Furthermore a selection of target genes, predominantly ISGs, 
remained induced in the brain during endotoxin tolerance, in the absence of a 
detectable inflammatory cytokine response in the periphery. This suggests that, 
rather than being a downstream effect of heightened peripheral inflammation, 
target gene induction in the brain following LPS injection may be a direct 
consequence of LPS-triggered TLR4 signalling either in the periphery, in one of 
the brain’s barriers, or in the brain itself. Importantly, there are few natural 
scenarios that would result in an acute systemic exposure to endotoxin. 
Therefore, prolonged ISG expression in the brain following repeated LPS 
challenge may more accurately reflect what occurs during chronic bacterial 
infection, or sepsis, than a single dose of LPS.  
Despite the hypothesis that LPS-induced ISG modulation was a TLR-specific 
phenomenon, these effects of LPS on the brain were not reproduced by systemic 
administration of the TLR2 ligand, LTA. TLR2 has a signalling profile that is 
distinct from that of TLR4 in that it does not activate IRF3-mediated type I IFN 
induction. Therefore, my results from the LPS experiments could reflect a TLR4-
induced type I IFN response via the non-canonical signalling pathway. This could 
be further investigated by repeating both the acute LPS model, and the 
endotoxin tolerance model, in TRIF-deficient mice or using small molecule 
inhibitors such as Reservatrol, which specifically targets the TRIF-dependent 
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signalling pathway468. As described in Chapter 4, the most characterised routes 
of immune-to-brain communication following systemic LPS challenge involves 
MyD88-dependent signalling pathway activation, or the intermediary actions of 
inflammatory cytokines. Therefore, if ISG induction is triggered in the brain in 
response to a TLR4-mediated IFN response, the data described in this thesis may 
help to broaden perceptions of how inflammatory signals are received by the 
brain. 
Although a TLR-dependent IFN response has been suggested to play a role, it has 
yet to be established how inflammatory signals are transmitted from the 
periphery to the brain in these models to induce ISG expression. This is 
particularly unclear following repeated LPS injections, when the synergistic 
effects of circulating IL-1β, IL-6 or TNFα were lost as a result of endotoxin 
tolerance. Several possible scenarios to account for the observed ISG induction 
in the brain have been described below:  
(1) In addition to being expressed in the periphery, the IFNAR is widely 
expressed in the brain (Figure 7.1). It is possible that circulating type I IFNs 
themselves may have directly accessed the brain to stimulate one of the many 
IFNAR-expressing cell types. As described in Chapter 3, this mechanism of action 
has previously been proposed to account for ISG induction in the brains of mice 
following an I.P. injection of IFNα423. However, it was demonstrated in Chapter 4 
that ISGs remained induced in the brain during endotoxin tolerance, which has 
been shown to inhibit both the classical MyD88-dependent, and the non-
canonical TRIF-dependent, signalling pathways downstream of TLR4469. As a 
consequence, endotoxin tolerance results in impaired type I IFN production. 
Therefore, in these studies, leukocytes in the periphery were unlikely to have 
been the source of the putative type I IFNs that stimulated the brain following 
daily LPS injections. 
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Figure 7.1 Ifnar1 expression in the mouse brain. 
A high-resolution map of Ifnar1 expression in a coronal section of the mouse brain. Expression 
levels were established using in situ hybridisation. Image was downloaded from the Allen Brain 
Atlas (http://www.brain-map.org/). 
(2) In the models described in this thesis, LPS may itself gain access to the brain. 
Although Banks et al. could not detect radio-labelled LPS crossing the BBB of 
mice421, there are reports that LPS can increase BBB permeability310. The 
capacity of LPS to alter BBB integrity may depend on the dose and strain of LPS 
administered and the species and strain of mouse used experimentally. 
Therefore, in the acute model of LPS-mediated systemic inflammation that I 
used in these studies, 100 µg of LPS may have been sufficient to disrupt the 
integrity of the BBB and allow LPS to enter the brain. Due to the potency of LPS, 
only a minute amount would have been required to cross the BBB to elicit a 
detectable response. Breakdown of the BBB is even more likely to have occurred 
during the endotoxin tolerance model, when mice were treated with a high dose 
of LPS daily. To explore this possibility, BBB permeability could be assessed after 
LPS treatment by injecting mice intravenously with visible tracers and screening 
for their presence in the brain. This is commonly done using fluorescently-
labelled dextran amines470, although a more relevant method would be to inject 
mice systemically with fluorescently-labelled LPS and then use confocal imaging 
to establish whether it crossed the BBB. Breaching of the BBB by LPS is certainly 
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worth investigating as a potential mechanism that could account for the 
prolonged ISG induction following repeated LPS challenge. However, to my 
knowledge the occurrence of endotoxin tolerance in the brain has not been 
defined. Therefore, rather than type I IFN production and ISG regulation, chronic 
exposure to LPS in the brain might result in endotoxin tolerance.  
(3) Phagocytic cells resident in the CVOs, and/or cerebral vascular endothelial 
cells, may have responded to circulating LPS by producing type I IFNs. This could 
either have lead to the autocrine induction of ISGs, or the induction of ISG 
expression in adjacent cell populations in a paracrine manner. Due to their 
similarity to peripheral myeloid cells, it might be expected that macrophages 
and microglia in the CVOs would become tolerised in response to repeated LPS 
challenge. However, endotoxin tolerance in cerebral vasculature endothelial 
cells has not been described. Therefore, even if CVO-resident phagocytes do 
become tolerised, it remains possible that cerebral endothelial cells may have 
continued to produce IFNβ during this model. 
Thus, a number of possible mechanisms exist that could account for the 
induction of ISGs in response to systemic LPS, none of which are mutually 
exclusive. Further investigation is required in order to pinpoint the precise mode 
of action behind systemic LPS-induced ISG modulation in the brain.  
Although I did not investigate what impact an LPS-induced IFN response might 
have on brain function and behaviour, there is considerable evidence that 
therapeutic use of type I IFNs in humans can lead to significant neuropsychiatric 
disorders, especially major depression471-473. It has been shown that injecting 
rodents with LPS initiates a number of behavioural adaptations, including 
depression-like behaviours that persevere after other sickness behaviours have 
resolved266. My results suggest that the induction of type I ISGs in the brain in 
response to systemic LPS was likely to be mediated by the action of type I IFNs. 
This indicates that type I IFN production, either in the brain or the periphery, 
may represent a crucial mechanism linking systemic LPS-induced inflammation 
with behavioural changes. 
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7.3 Characterising the chemokine profile and leukocyte 
infiltrate in the brains of LPS-treated mice 
Of the ISGs that were upregulated in the brain in response to acute LPS 
exposure, CXCL10 showed the biggest induction. Moreover, in this LPS model 
there was a significant enrichment of transcripts involved in leukocyte 
extravasation. This prompted me to investigate directly whether systemic LPS 
challenge resulted in leukocyte recruitment to the brain. To better represent 
physiological conditions, and to maximise the chance of detecting infiltrating 
leukocytes, this was investigated over a 7 day window following daily injections 
of LPS. 
First, the inflammatory chemokine repertoire in the brains of LPS treated mice 
was systematically characterised. In addition to Cxcl10, the chemokine 
transcripts that were upregulated in the brains of LPS-challenged mice included 
a number of neutrophil, monocyte and T cell chemoattractants, including Cxcl1, 
Cxcl2, Ccl3, Ccl5, Cxcl9 and Cxcl10. As IFNs are known to increase the expression 
of CXCL9 and CXCL10 in a number of cell types and tissues474-478, there is a strong 
likelihood that these chemokines were upregulated in the brain downstream of 
the systemic LPS-induced IFN response discussed above. The remainder of the 
upregulated chemokine transcripts could have been upregulated in the brain in 
response to TNFα or IL-1β, or were possibly induced directly in response to TLR4 
signalling pathway activation479-484.  
On day 2 of the LPS model, the induction of Cxcl1 and Cxcl2 was associated with 
an early infiltration of neutrophils to the brain and a simultaneous increase in 
Cxcr2 mRNA. Neutrophils are pivotal in mounting a successful response against a 
number of pathogens, but they are also associated with tissue damage485 and 
thus their recruitment to the uninfected brain is likely to be harmful. There are 
many ways in which neutrophils could be damaging to the CNS. Following an 
acute injection of LPS, neutrophil recruitment has been shown to amplify central 
inflammatory processes leading to elevated IL-1β, TNFα and ICAM1 mRNA levels 
in the brain and increased transcription of the genes encoding CXCL1 and 
CXCL2236. This may account for the prolonged expression of IL-1β and TNFα that I 
observed in the brain following daily LPS injections. Neutrophils are also known 
to release toxic agents, such as MPO-derived oxidants, which can have a 
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debilitating effect on BBB integrity486. Therefore, their accumulation in the brain 
may facilitate the entry of circulating LPS, cytokines and/or other leukocytes 
into the brain. Blocking neutrophil entry to the brain using a CXCR2 antagonist 
and performing a BBB permeability assay, would be required in order to confirm 
this. The model that I used to assess neutrophil entry to the brain in this thesis 
differed from those used previously, as mice received daily systemic LPS 
injections. As a result, the neutrophils that were recruited to the brain in this 
model may have been tolerised to LPS in the periphery. However, neutrophils 
may not be as susceptible to endotoxin tolerance as monocytes and 
macrophages487 and it is not known whether they are likely to retain their 
tolerant phenotype after being exposed to the inflamed CNS. Therefore, it is 
unclear to what extent they would contribute to local inflammatory responses in 
the brain following multiple systemic LPS challenges. 
Neutrophil accumulation in the brain was followed by the recruitment of CD8+ 
and CD8- T cells. This may have occurred in response to the enhanced production 
of T cell chemoattractants, such as CCL5, CXCL9 and CXCL10, in the brain. The 
current literature suggests that only activated T cells can enter the brain. As T 
cells do not recognise LPS, those infiltrating the brain were likely to be memory 
cells of various specificities. Although LPS is not presented to T cells, chronic 
inflammatory conditions can result in epitope spreading which could lead to T 
cell activation in the brain488. When stimulated, memory T cells have the 
potential to secrete large amounts of cytokines, such as IFNγ489, which could 
amplify inflammatory responses in the brain and activate IDO, thus resulting in 
depressive behaviours. However, the influx of T cells to the brain could also be 
protective. Chronic exposure to LPS in the periphery may mimic a systemic 
bacterial infection, thus resulting in enhanced T cell immunosurveillance. 
Although not described previously following LPS challenge, increased 
surveillance of the brain by both CD4+ and CD8+ T cells has been reported 
following systemic Listeria monocytogenes infection490,491. However, in these 
reports, the T cells were predominantly situated in the leptomeninges, the 
choroid plexus and in the CSF with few, or none, invading the parenchyma. It 
has been hypothesised that, following systemic L. monocytogenes infection, T 
cell recruitment to the brain is protective against cerebral listeriosis491. T cell 
accumulation in the brain following systemic LPS challenge is a novel observation 
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and it is therefore unclear whether this response contributes to pathogenesis or 
whether T cells are recruited in order to protect the brain from a potential 
infection.  
From the data presented in this thesis, it appeared as if monocytes might have 
infiltrated the brains of LPS-challenged mice and differentiated into 
macrophages or microglia. Further studies would be required in order to confirm 
this. T cell entry to the brain is known to contribute to monocyte recruitment 
during viral infections of the CNS190,442. Furthermore, monocytes are known to 
infiltrate the brain during systemic L. monocytogenes infection492 and during a 
model of hepatic inflammation241. By increasing the production of inflammatory 
cytokines and the brain241 and causing bystander tissue damage493, the 
recruitment of inflammatory monocytes to the brain has the potential to be 
detrimental. As described in Section 1.3.1.1, MHV infection is associated with 
monocyte-mediated inflammation and demyelination. Monocyte-mediated 
damage can also influence behaviour. Following picoronavirus infection, 
monocyte recruitment to the hippocampus resulted in neuronal loss and 
impaired cognitive function493. However, in some settings, the recruitment of 
monocytes to the brain can be beneficial. Following bacterial meningitis, or 
during transgenic models of Alzheimer’s disease, peripheral monocytes 
accumulate in the brain and differentiate into microglia494-496. This has been 
shown to play an important role in the resolution of tissue damage, and in the 
clearance of amyloid deposits, respectively. Thus, whilst it is unclear what role 
they might play in protection or pathology, monocyte recruitment to the brain 
following daily systemic LPS challenges is worth further investigation. 
Although these studies have generated some interesting and novel observations, 
the physiological and pathological implications of leukocytes accumulation in the 
brains of LPS-treated mice have yet to be established. It is possible that 
leukocyte recruitment to the brain is a characteristic response to chronic 
bacterial infection and serves to provide protection against cerebral infection. 
However, by amplifying central inflammatory responses, these responses could 
also cause damage to the brain and perhaps have downstream effects on 
behaviour. 
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7.3.1 Potential brain-specific effects of chemokine induction in 
the inflamed brain 
As well as recruiting inflammatory cells from the bloodstream into the brain, the 
central upregulation of chemokines could have a direct impact on the brain 
itself. As has been described in Section 1.3.2.1, chemokines have been 
postulated to play a neuromodulatory role in the CNS and indeed, all of the 
chemokine receptors that were upregulated in the brain in response to LPS 
treatment are also expressed by neurons and/or glia. Whilst very little is known 
about the role of these receptors or their respective ligands in the brain, a 
variety of theories have been postulated. As will be discussed below, there are 
reports that chemokines can act as neuronal survival factors and 
neuromodulators. Furthermore, they may act on glial cells to modulate the 
extracellular inflammatory milieu. As a result, the upregulation of chemokines 
and their cognate receptors in the brain may modulate brain function and so 
impact on behaviour.  
Interestingly, a number of the chemokines that were induced in the brain in 
response to multiple systemic LPS challenges can directly stimulate a Ca2+ influx 
in cultured neurons via pertussis toxin-sensitive GPCRs497-502. It has been 
suggested that this may allow chemokines to act pre-synaptically to modulate 
the post-synaptic release of neurotransmitters503. However, the evidence for this 
is sparse and at times contradictory (Section 1.3.2.1). There are reports to 
suggest that CCL5 may have the capacity to modulate glutamatergic transmission 
in cultured neurons455,504. Musante et al. demonstrated that CCL5 treatment 
triggered the spontaneous release, but inhibited the potassium-evoked release, 
of glutamate from neurons in the human neocortex455. In contrast to these 
findings, Prisco et al. described a dose-dependent increase in potassium-evoked 
glutamate release when cultured spinal cord neurons were treated with CCL5, 
whilst basal release was unaffected504. This discrepancy may be due to the 
different populations of cultured neurons being used in the two studies and thus 
require further investigation.  
Although CXCR2 expression has also been reported on neurons in the CNS of both 
humans and rodents497,498,505, there has been little published regarding its role in 
neuromodulation. However one report suggests that CXCL1-induced Ca2+ 
268 
mobilisation resulted in increased neurotransmitter release from cerebellar 
Purkinje neurons498. Exposing cultured hippocampal neurons to CXCL10 has been 
shown to induce intracellular Ca2+ mobilisation and so increase both 
spontaneous, and evoked, synaptic transmission506. In addition, 
electrophysiological recordings taken from hippocampal slices have shown that 
acute exposure to exogenous CXCL10 alters synaptic plasticity in wild-type mice 
by inhibiting long term potentiation507. However, in transgenic mice which 
chronically produced CXCL10 under the astrocytic GFAP promotor, there was no 
effect on synaptic plasticity507. This study highlights the confounding data that 
can be derived from acutely exposing neurons to high concentrations of 
inflammatory chemokines and underlies the caution needed in making 
conclusions about the potential impact that LPS-mediated chemokine production 
may have on synaptic plasticity and behavioural responses. 
It has been discussed at various points in this thesis that injecting mice 
systemically with LPS results in the central production of numerous inflammatory 
mediators. This can have a multitude of detrimental effects on the brain and 
may create an environment that is toxic to neurons. There have been reports 
that CXCL1 can inhibit the induced apoptosis of cultured cerebellar granule cells 
by promoting the phosphorylation of extracellular signal-regulated kinase 
(ERK)505,508. Although no mechanism has been proposed, there are several studies 
demonstrating that CCL5 can also act as a survival factor in cultured 
neurons499,502,509. However, in contrast to these reports, CXCL10 has been 
reported to contribute to the apoptosis of primary neurons via caspase 9 
activation456. Consequently, following LPS treatment, the induction of 
chemokines in the brain may either positively, or negatively, influence neuronal 
survival. 
Injecting LPS directly into the CNS results in oligodendrocyte death and the 
subsequent formation of demyelinating lesions510,511. Therefore, in the event 
that LPS does have the capacity to breach the BBB following multiple systemic 
challenges, it could cause demyelination. CXCR2 ligands are thought to play a 
protective role in demyelinating CNS disorders, either by blocking 
oligodendrocyte apoptosis or by attracting oligodendrocyte precursor cells to 
damages sites in the brain to promote tissue repair446,512. As a result, the 
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induction of CXCL1 and CXCL2 may serve to protect the brain from direct LPS-
induced toxicity.  
In addition to potentially modulating neuronal transmission and survival, 
chemokines are known to act as communication molecules between glial cells 
and therefore may influence how these cells respond to systemic LPS challenge. 
Indeed, it has been reported that treating microglia with CCL5 in vitro results in 
a CCR5-dependent dampening of LPS-induced inflammatory cytokine and iNOS 
production513. This suggests that CCR5 signalling may protect the brain from 
microglial neurotoxicity. Conversely, stimulating cultured astrocytes with CCL5 
leads to an increase in the induction of inflammatory cytokine and chemokine 
transcripts, including Ccl3, Ccl5, Cxcl1 and Cxcl2514. Although this effect was 
dependent on pertussis toxin-sensitive GPCRs, it was not attenuated by 
individually knocking out CCL1, CCL3 or CCL5, indicating redundancy of CCR 
usage in this setting. Little has been described regarding the role of CXCL1 or 
CXCL2 in glial cell communication and activation. However, it has been 
suggested that both chemokines can trigger the induction of inflammatory 
cytokines and chemokines, including CCL5 and CXCL10 from primary murine 
astrocytes515. Thus, signalling through glial chemokine receptors may modulate 
the extracellular cytokine and chemokine milieu of the brain during 
inflammation. 
These studies highlight a number of brain-specific responses that may arise 
following chemokine induction in the brain. The chemokines that are most 
upregulated in the brain in response to repeated LPS challenges potentially 
share the capacity to modulate neuronal transmission and survival. By mediating 
communication between, and activation of, glial cells in the brain, they may 
also modulate the extracellular inflammatory environment. There is therefore a 
number of ways in which the chemokines induced in this model might impact on 
behaviour. CCL5 has been shown to modulate glutamate release from nerve 
endings. As described in Chapter 1, aberrant glutamate production has been 
linked to the pathophysiology of depression. In support of a role for CCL5 in 
modulating behaviour, there are some preliminary data, from Kalkonde et al., to 
suggest that CCR5 ligands may impair social recognition in mice516. In addition, a 
report by Lee et al. demonstrated that long-term and spatial memory was 
impaired in CCR5-deficient mice454. However, this was not consistent with the 
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study by Kalkonde et al. who showed that spatial memory was comparable in 
wild-type and CCR5-deficient mice516. In addition to glutamate modulation, 
chemokine induction in the brain may also contribute to behavioural deficits by 
stimulating the production of inflammatory cytokines by glial cells. The impact 
that cytokines can have on behaviour has been described in Chapter 1. In 
summary, based on the current literature regarding their brain-specific effects, 
a role for chemokines in mediating LPS-induced behavioural changes could be 
hypothesised. However, the data available on this subject sparse and often 
contradictory, making this hypothesis highly speculative. 
7.4 Overview and hypotheses 
In order to recognise, and respond to, a viral or bacterial infection, the innate 
immune system utilises a number of different PRRs which specifically recognise 
PAMPs from various sources. LPS is a carbohydrate-rich derivative of bacterial 
cell walls. By interacting with TLR4, LPS alerts the immune system to the 
presence of a bacterial infection, resulting in a potent inflammatory response in 
the periphery. In addition to mobilising the effector arms of the innate immune 
system, LPS-induced inflammation is transmitted to the brain to evoke an 
appropriate behavioural response. The experiments outlined in this thesis 
suggest that systemic LPS may trigger the production of type I IFNs in the brain, 
or that peripherally produced type I IFNs can directly access the brain (Figure 
7.2). The impact that type I IFNs have on behaviour has been well characterised 
and I have therefore hypothesised that systemic LPS-mediated type I IFN 
production, either in the periphery or the brain, may contribute to LPS-induced 
behavioural changes. 
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Figure 7.2 Response in the brain to a single systemic LPS injection: Observations and 
hypotheses 
Systemic LPS is known to interact with TLR4 to activate innate immune cells in the periphery, such 
as neutrophils, macrophages and dendritic cells (DCs). This triggers the enhanced release of 
inflammatory cytokines into the circulation. LPS-induced inflammatory cytokines, and LPS itself, 
can activate the cerebral endothelium, or perivascular macrophages (PVM) in the circumventricular 
organs, which then relay inflammatory signals to the brain via the release of secondary 
messengers. In this thesis, one of the observed effects in the brain following systemic LPS injection 
was the enhanced expression of interferon (IFN) stimulated genes (ISGs). As these ISGs were 
known to be mediated predominantly by type I IFNs, this response may be indicative of enhanced 
type I IFN production. Type I IFNs could be produced by, and/or stimulate ISG expression in, any 
one of the brain-resident immune cells or cerebral vascular endothelial cells. Alternatively, 
peripherally produced IFNs may have a direct effect on the brain. There is a long-established link 
between type I IFNs and depression. Therefore central IFN production is a possible novel link 
between systemic LPS injection and behavioural changes. Of the ISGs induced in the brain in 
response to systemic LPS challenge, Cxcl10 showed the greatest upregulation. In addition, there 
was elevated transcription of Icam1 and Vcam1. This transcriptional response may suggest that the 
brain is being primed for T cell infiltration. 
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Following an acute systemic LPS challenge, transcripts encoding the T cell 
chemoattractant CXCL10, and the cellular adhesion molecules ICAM-1 and VCAM-
1, were elevated in the brain (Figure 7.2). Due to the adversity of a cerebral 
bacterial infection, this transcriptional response may represent a protective 
strategy whereby the brain is being primed for the infiltration of memory T 
cells. Following daily injections of systemic LPS, a number of inflammatory 
chemokine transcripts were induced in the brain. Due to their proposed effects 
on neuronal transmission and survival, these chemokines may directly modulate 
behaviour. However, in this model, chemokine induction was associated with the 
recruitment of neutrophils, and then T cells, to the brain from the periphery 
(Figure 7.3). Both of these cell types have the capacity to amplify local 
inflammatory responses in the brain, which could result in neuronal damage 
and/or have an impact on behaviour. Although this appears counterproductive, 
the effects of repeated LPS injection might mimic the effects of a chronic 
bacterial infection in the periphery, and these leukocytes may confer protection 
against the threat of cerebral infection. Therefore, following a single LPS 
challenge, the brain may become sensitised to LPS-induced inflammation and 
prime itself for leukocyte recruitment. If LPS exposure continues, neutrophils 
and T cells are recruited to the brain, possibly with a principle goal of providing 
protection. 
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Figure 7.3 Response in the brain to daily systemic LPS injections: Observations and 
hypotheses 
Chronic exposure to LPS in the periphery results in endotoxin tolerance, which is associated with a 
downregulation of TLR4 on leukocytes517 and attenuated inflammatory cytokine production in the 
periphery. However, the brain continues to respond to circulating LPS by upregulating inflammatory 
chemokine transcripts. This could be due to the continued response of cerebral endothelial cells to 
circulating LPS, or chronic LPS exposure may increase the permeability of the blood brain barrier 
(BBB) and thus enable LPS to enter the brain. Chemokine induction in the brain was associated 
with the infiltration of leukocytes from the periphery to the brain parenchyma. Neutrophils were 
recruited first, presumably in response to increased CXCL1 and CXCL2. This was followed by an 
accumulation of T cells in the brain. As neutrophils can enhance inflammatory chemokine 
production, and release toxic agents which can disrupt BBB integrity, their recruitment to the brain 
may pave the way for these infiltrating T cells. Leukocyte recruitment may serve to protect the brain 
from the threat of a possible bacterial infection. However, both T cells and monocytes can produce 
inflammatory cytokines which would contribute to the inflammatory milieu of the brain. In addition, 
these cytokines, and LPS-induced inflammatory chemokines, may play a role in modulating brain 
function and behaviour.  
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7.5 Conclusions 
The findings described in this thesis provide novel concepts that demonstrate a 
molecular link between peripheral inflammation and interferon responses in the 
brain. Systemic LPS has the capacity to remotely trigger an immune response in 
the brain. Following acute exposure to LPS in the periphery, the expression of 
ISGs, and other microarray target genes, in the brain was distally modulated in a 
manner that may be dependent on TLR-induced type I IFN production. Whether 
type I IFNs were produced in the brain, or whether peripherally induced IFNs 
directly access the brain to modulate ISG expression, remains open to further 
investigation; as does the downstream effects of central ISG induction. Due to 
the well established link between type I IFNs and depression, TLR-induced IFN 
production is worth investigating as a potential key mechanism linking peripheral 
inflammation with sickness behaviour.  
Repeated injection of LPS in the periphery triggered a transient increase in 
chemokine transcription in the brain. As there are reports to suggest that 
chemokines can modulate neurotransmitter release and the extracellular 
cytokine environment, this chemokine induction could indirectly impact 
behaviour. However, the most characterised function of chemokines is to recruit 
leukocytes to sites of inflammation. Accordingly, chemokine induction in the 
brain during this model was associated with an influx of leukocytes from the 
periphery, and an increase in mRNA encoding the relevant chemokine receptors. 
Thus, whilst their role in modulating brain activity and behaviour cannot be 
excluded, it seems likely that chemokine induction in the brain following daily 
systemic LPS injections mediates the recruitment of leukocytes from the 
periphery. These data highlight a potential protective mechanism that could 
prevent a chronic bacterial infection from spreading from the periphery to the 
brain. 
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7.6 Future directions 
Although the studies described in this thesis have generated some interesting 
and novel data, these data are largely descriptive and would benefit from more 
rigorous testing of the involved mechanisms. There are a number of possible 
experiments that could be done to further explore the potential mechanisms of 
ISG induction in the brain which have been described above. 
As well as being mainly descriptive, the data described in this thesis are limited 
as, instead of focusing on specific brain regions and neuronal cell populations, 
they concentrate on global gene expression occurring throughout the entire 
brain. As described, gene expression was assessed in these studies 48 hours 
following systemic LPS injection. With nothing published, to my knowledge, 
regarding the response in the brain at this time point, taking an unbiased 
approach in terms of which brain regions to focus on was an obvious decision. 
However, it would now be interesting to narrow down on the specific brain 
regions or cell types that respond to peripheral inflammation by upregulating 
ISGs and chemokine transcripts. 
Regional induction of ISGs and chemokine transcripts could be assessed by 
performing gene expression assays on micro-dissected regions of the mouse brain 
following LPS-challenge. However, a more in-depth approach to explore the 
region-specific effects of systemic LPS challenge would be to use fluorescent in 
situ hybridisation (FISH). FISH involves the use of fluorescently-labelled probes, 
specifically designed to bind to transcripts of interest on tissue sections. It can 
be combined with fluorescent immunohistochemistry so that the expression of a 
number of target genes and proteins can be visualised on one section 
simultaneously. Not only would this technique answer the question of which cell 
types respond to peripheral inflammation, but it would facilitate the temporal 
and spatial mapping of target gene expression in the brains of LPS-challenged 
mice. This method could also be used to establish whether IFN transcripts were 
induced in the brain and whether there was any colocalisation between IFN and 
chemokine transcripts that could highlight a potential mechanism of chemokine 
regulation. Moreover, by identifying the expression sites of IFNs, chemokines and 
their respective cognate receptors, hypotheses could be developed as to what 
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potential neurological effects these molecules might have that could impact 
behaviour. 
Although a number of observations have been made from this work, the extent 
to which these are biologically linked remains unclear. Although FISH would help 
to gain a better understanding of the temporal and spatial pattern of events in 
the brain following systemic LPS challenge, it is not sufficient to directly link any 
of the observed responses. As described previously, the involvement of TLR4-
induced non-canonical signalling in inducing ISG expression in the brain could be 
established using TRIF- or IRF3-deficient mice. Similarly, the effect of type I IFNs 
on the induction of chemokines in the brain could be easily investigated using 
IFNAR-deficient mice. In addition, as was described in Chapter 5, the role of 
specific chemokines in recruiting leukocytes to the brain could be verified using 
chemokine receptor antagonists. Therefore, genetically manipulated mice and 
chemokine receptor antagonists could be used to generate a better 
understanding of the pathways linking peripheral inflammation to IFN responses 
and chemokine induction in the brain. 
Finally, whilst it was beyond the scope of this project, the data described in this 
thesis would greatly benefit from an in depth investigation into the possible 
impacts that LPS-induced IFN responses may have on the brain and on behaviour. 
Although behavioural deficits have been reported in mice following peripheral 
LPS or IFNα administration281,282,284,518, there is nothing in the literature to 
suggest that type I IFNs play a role in LPS-induced sickness behaviour. An 
important experiment that could link type I IFNs to LPS-induced behavioural 
changes would be to compare sickness behaviours, and depression-like 
behaviours, in wild-type and IFNAR-deficient mice following systemic LPS 
injection. As LPS-induced ISG induction appears to be a TLR-driven response, this 
may underpin behavioural changes in infectious pathologies. 
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